the assumption of full take @-@ up tends to exagger@@ ate the simulated increase in cas@@ elo@@ ads and fiscal costs of a social policy reform .
if you need more information about your illness or treatment , please read the Pack@@ ager ( also part of the EP@@ AR ) or contact your doctor or pharmac@@ ist .
if you want more information regarding the recommendations of the CH@@ MP , please read the scientific discussion ( also part of the EP@@ AR ) .
it is available as 5 mg , 10 mg and 30 m@@ g. tablets , as 10 mg , 15 mg and 30 m@@ g. of tablets ( tablets , which can rede@@ em in the mouth ) as a solution for inser@@ tion ( 1 mg / ml ) .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; this is the only thing that I have to say , &quot; &quot; &quot; &quot; said , &quot; &quot; &quot; &quot; This is the only thing that I have to do . &quot; &quot; &quot; &quot; &quot; &quot; &quot;
A@@ bili@@ fy is used to treat acute injuries to severe kidney disease and for preventing influ@@ enza in patients who have given the medicine in the past .
the injection solution is applied for quick control of st@@ ei@@ ving dis@@ inf@@ rin@@ gement or behavi@@ our@@ al dys@@ function if the drug intake of medicine is not possible .
in both diseases , the solution can be applied to one or the mel@@ ting furnace in patients who prepar@@ es the swal@@ lowing of tablets .
patients who take the same at the same time as A@@ bili@@ fy should be adjusted as A@@ bili@@ fy should be adjusted to reach A@@ bili@@ fy .
this is a difference between the brain cells by &quot; Neur@@ ot@@ ran@@ sm@@ itter &quot; which allow chemical substances which allow the communication of nerve cells .
Ari@@ pi@@ pra@@ z@@ ol is probably believed to be known as &quot; partially ag@@ ro@@ under &quot; for the recep@@ tors for the neur@@ ot@@ ran@@ sm@@ ates dop@@ amine and 5 @-@ hydro@@ xy@@ cl@@ yp@@ t@@ amine ( also ser@@ ot@@ on@@ in ) .
this means that Ari@@ pi@@ pra@@ z@@ ol is like 5 @-@ hydro@@ xy@@ cl@@ yp@@ t@@ amine and dop@@ amine , but in ger@@ em it works as the ne@@ ot@@ ran@@ sm@@ itter to enable the recep@@ tors .
dop@@ amine and 5 @-@ hydro@@ xy@@ cy@@ to@@ sis in schi@@ z@@ op@@ hr@@ enia and bi@@ polar disorder contributes to norm@@ alize the activity of the brain , whereby psych@@ ot@@ ische or man@@ ic symptoms are reduced and their re@@ occurring occurs .
the effectiveness of A@@ bili@@ fy to prevent the symptoms were examined in three studies over one year .
the eff@@ ic@@ acy of injection solution was compared to 80@@ 5 patients with schi@@ z@@ op@@ hr@@ enia and similar diseases caused by a plac@@ ebo effect on a period of two hours with a plac@@ ebo .
in a further study , A@@ bili@@ fy over twelve weeks of 347 patients with Hal@@ op@@ eri@@ dol , in another study the eff@@ ic@@ acy of A@@ bili@@ fy and plac@@ ebo , which have been stabili@@ zed in 160 patients , where the man@@ ic symptoms have already been stabili@@ zed .
the effectiveness of A@@ bili@@ fy injection solution was compared to 301 patients with bi@@ polar disorder , which was compared with Lor@@ az@@ ep@@ am ( another anti@@ psych@@ ot@@ echni@@ cal ) and plac@@ ebo over a period of two hours .
in all studies the change in the symptoms of patients by a standard sk@@ ala for bi@@ polar disorder or the number of patients who spoke to the treatment .
the company also carried out studies in order to investigate such as the body the mel@@ ting furnace and the solution to remove res@@ ection ( up ) .
in both trials with the injection @-@ injection solution , patients who received A@@ bili@@ fy to D@@ osen from 5.@@ 25 mg , 9,@@ 75 mg or 15 mg , significantly increased significantly reducing the symptoms of im@@ pe@@ al inf@@ erior to patients who had a plac@@ ebo .
the use of bi@@ polar disorder decreased in four of the five curves of studies in four of the five curves of studies man@@ oeu@@ vre as plac@@ ebo .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; in the meantime , however , we need to be more effective than plac@@ ebo . &quot; &quot; &quot; &quot; &quot; &quot; &quot;
A@@ bili@@ fy injection @-@ injection in 10@@ - or 15 @-@ mg fer@@ mentation were also developed as plac@@ ebo the symptoms of im@@ planted ul@@ ness and were similarly effective as Lor@@ az@@ ep@@ am .
the most common side effects of A@@ bili@@ fy to take ( observed at 1 to 10 of 100 patients ) , refra@@ ct@@ ance ( cum@@ ul@@ ence ) , bri@@ mming ( trem@@ bling ) , bri@@ efs ( trem@@ bling ) , ra@@ vin@@ ity ( cum@@ ul@@ ness ) , Ob@@ sti@@ p@@ ation ( con@@ sti@@ p@@ ation ) , fatigue and exhaus@@ tion , ru@@ sty , som@@ ni@@ ness , in@@ som@@ nia ( sleep disorders ) , anxiety disorders , in@@ som@@ nia ( sleep disorders ) and anxiety .
the Committee for Human@@ izing Human Rights ( CH@@ MP ) was directed to the conclusion that the benefits of ap@@ olog@@ y@@ op@@ hr@@ enia and neuro@@ polar bears in Bi@@ polar @-@ I disorder and during the prevention of a new man@@ ic practice at Bi@@ polar @-@ I disorder and during the prevention of a new man@@ ic practice in patients who were able to wei@@ gh the risks associated with Ari@@ pi@@ pra@@ z@@ ol .
in addition , the Committee on the result , that the advantages of injection @-@ injection solution was not suitable for patients with schi@@ z@@ op@@ hr@@ enia , or in patients with man@@ ic@@ op@@ hr@@ enia and patients with man@@ ic@@ op@@ hr@@ enia , if a oral therapy is not suitable to wei@@ gh the risks .
&quot; &quot; &quot; June 2004 the European Commission shared the European Commission of Ot@@ su@@ ka Pharmaceutical Europe Ltd. is an authorization for the transport industry of A@@ bili@@ fy to the entire European Union . &quot; &quot; &quot;
: Audiobook @-@ Review : Mind@@ N@@ apping 2 ( Pan@@ ini ) Audiobook @-@ Review : Geister @-@ Scho@@ cker 9 ( Rom@@ ant@@ ruhe Audio ) : Audiobook @-@ Review : Teufel@@ s@@ bru@@ t ( Musi@@ cal@@ eg@@ enda )
the recommended starting dose for A@@ bili@@ fy amounts to 10 or 15 mg / day at a maintenance dose of 15 mg / day once daily from the meals .
Hemp Info &gt; Hemp fashion ( Cann@@ at@@ rade 04 ) Hemp bri@@ cks H@@ empf@@ la@@ x European Parliament Strasbourg
the recommended starting dose for A@@ bili@@ fy is 15 mg once daily , regardless of the meals as mon@@ otherapy or combination therapy ( see section 5.1 ) .
effectiveness of A@@ bili@@ fy in the treatment of schi@@ z@@ op@@ hr@@ enia and Bi@@ polar @-@ I@@ - disorder in patients ≥ 65 years was not proved .
with regard to the greater sensitivity of this patient group should be taken into consideration when clinical factors are legitimate ( see Section 4.4 ) .
if the CY@@ P@@ 3@@ A4 is set out of the combination therapy , the Ari@@ pi@@ pra@@ z@@ ol dose should be reduced to the recommended dose ( see Section 4.5 ) .
the occurr@@ ence of su@@ peri@@ ority of psych@@ otic disorders and aff@@ ek@@ tive disorders and was reported in some cases after the beginning or after an anti@@ psych@@ otic therapy , even for treatment with Ari@@ pi@@ pra@@ z@@ ol ( see Section 4.8 ) .
results of epide@@ mi@@ ological study showed that patients with bi@@ polar disorder is not an increased force risk of ari@@ pi@@ pra@@ z@@ ol in comparison to other anti@@ psych@@ ot@@ ika .
Ari@@ pi@@ pra@@ z@@ ol should be applied in patients with well @-@ known cardiovascular diseases ( M@@ yo@@ cardi@@ al inf@@ ra or isch@@ emia , hy@@ po@@ vol@@ emia , therapy disorders , hy@@ po@@ vol@@ emia , treatment with blood pressure treatment ) or hyper@@ ton@@ ic ( including ak@@ zel@@ es and MA@@ LIG@@ NE form ) .
3 late dy@@ sk@@ in@@ esia : in clinical studies that a year or less stamina , there were occasional reports about during the treatment with Ari@@ dan@@ pra@@ z@@ ol .
if you treated with A@@ bili@@ fy , patients , symptoms and symptoms of a late dy@@ es should occur in vom@@ iting , the dose should be reduced or to break the treatment .
when a patient is developed signs and symptoms that has been transferred to a M@@ NS or un@@ clear high fever without a additional clinical manifestation of M@@ NS , all anti@@ psych@@ ot@@ ika , including on@@ bili@@ fy .
in fact , Ari@@ pi@@ pra@@ z@@ ol should be applied to patients with cra@@ mp@@ ie@@ ties in the an@@ am@@ n@@ ese or in condition that are used with cra@@ mp@@ ie@@ ties in connection with caution .
56 - 99 years ) with Ari@@ pi@@ pra@@ z@@ ol in patients with Alzheimer &apos;s disease patients had treated patients who were treated with Ari@@ pi@@ pra@@ z@@ ol in comparison to plac@@ ebo .
however , there was a study with fi@@ xer , a significant relationship between the dosage and the response to un@@ desired under@@ eb@@ rov@@ ascular events with Ari@@ pi@@ pra@@ z@@ ol patients .
hyper@@ gl@@ yc@@ emia , in some cases , associated with K@@ eto@@ ile or hyper@@ os@@ mol@@ ar@@ em com@@ a or death , was reported in patients who were treated with at@@ yp@@ ic anti@@ psych@@ ic drug .
there are no precise risk factors for hyper@@ gl@@ yc@@ emia caused by using A@@ bili@@ fy and other at@@ yp@@ ic anti@@ psych@@ ic drug @-@ treated patients who have direct access to the same .
poly@@ di@@ p@@ it , poly@@ ethylene , poly@@ ph@@ ag@@ y and weakness ) are observed and patients with diabetes mel@@ lit@@ us or with risk factors for diabetes mel@@ lit@@ us should be monitored regularly in relation to a deteri@@ oration of glu@@ cose values .
a weight gain is generally known in general in schi@@ z@@ op@@ hr@@ enia , the application of Anti@@ psych@@ ot@@ ika , which is known as a side effect as a side effect is known or an un@@ healthy lifestyle and could lead to serious complications .
due to the primary effect of Ari@@ pi@@ pra@@ z@@ ol in combination with alcohol or other central health medicines , if Ari@@ pi@@ pra@@ z@@ ol is taken in combination with alcohol or other central nervous drugs . ( see Section 4.8 ) .
the H@@ 2 Ant@@ agon@@ ist Fam@@ oti@@ din , a Mag@@ ic acid Blo@@ cker , reduces the res@@ or@@ ption rate of Ari@@ pi@@ pra@@ z@@ ol , but this effect is not relevant as a clinical practice .
in a clinical study with healthy patients suffering a highly effective CY@@ P@@ 2@@ D@@ 6 inhib@@ itor ( Ch@@ ini@@ din ) the AU@@ C of Ari@@ pi@@ pra@@ z@@ ol to 107 % while the C@@ max remained unchanged .
it is expected to expect other highly effective In@@ hi@@ bit@@ ory of CY@@ P@@ 2@@ D@@ 6 , such as Flu@@ ox@@ ia and Par@@ ox@@ et@@ tin , similar effects and therefore should be made similar to similar types of dis@@ rup@@ tions .
at CY@@ P@@ 2@@ D@@ 6 &apos; bad &apos; ( = &quot; &quot; &quot; &quot; big &quot; &quot; &quot; &quot; ) Met@@ aboli@@ sm &quot; &quot; &quot; &quot; Met@@ aboli@@ sm is the common application with high @-@ effective In@@ hi@@ bit@@ rate of CY@@ P@@ 3@@ A4 in higher plasma concent@@ rations of Ari@@ pi@@ pra@@ z@@ ol compared to CY@@ P@@ 2@@ D@@ 6 Exten@@ sive Met@@ aboli@@ sm .
if you want to consider the joint gift of K@@ eto@@ con@@ az@@ ol or other effective CY@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ory users should consider potential risks for the patient .
other highly effective In@@ hi@@ bit@@ ors of CY@@ P@@ 3@@ A4 , such as I@@ tra@@ con@@ az@@ ol and HIV @-@ Prot@@ e@@ as@@ hi@@ bit@@ ory , have similar effects and therefore should be made similar to similar types of dis@@ rup@@ tions .
following the charge of the CY@@ P@@ 2@@ D@@ 6 or 3@@ A4 @-@ inhib@@ itors , the dosage of A@@ bili@@ fy should be adjusted at the start of the accompanying therapy .
Dil@@ ti@@ az@@ em or Esc@@ it@@ op@@ ram ) or CY@@ P@@ 2@@ D@@ 6 together with A@@ bili@@ fy will be administ@@ ered with an average rise of Ari@@ pi@@ pra@@ z@@ ol@@ - concent@@ rations .
deprecated : function ereg _ replace ( ) is deprecated in / www / htdocs / w00cec0c / webEdition / we / include / we _ modules / object / we _ listview _ multiobject.class.php on line 296
patients should be advised to notify their doctor if they are pregnant or pregnancy during treatment with Ari@@ pi@@ pra@@ z@@ ol .
due to the in@@ adequate data transfer to safety reasons and due to the specific needs of the animal studies of the animal conserv@@ atively , this medication may not be applied in pregnancy , unless the potential is justi@@ fiable cause for potential risk .
however , in other anti @-@ psych@@ ot@@ ika , patients should be war@@ med , dangerous goods , including power vehicles , to operate until they are sure that Ari@@ pi@@ pra@@ z@@ ol has no negative impact .
the following side effects were more frequent ( ≥ 1 / 100 ) as possible to plac@@ ebo or were considered possible medical attention ( * ) .
the frequency of the below are defined according to the following criteria : frequently ( &gt; 1 / 100 , &lt; 1 / 10 ) ; occasionally ( &gt; 1 / 100 , &lt; 1 / 100 ) .
schi@@ z@@ op@@ hr@@ enia - In a controlled long @-@ term study about 52 weeks ago , patients who were treated with Ari@@ pi@@ pra@@ z@@ ol , a total of lower inhib@@ itors ( 25.@@ 8 % ) of EPS including Par@@ ent@@ son@@ ism , Ak@@ ath@@ ic and Dy@@ sk@@ in@@ etry , compared with hal@@ op@@ eri@@ dol ( 57,@@ 3 % ) .
in a plac@@ ebo @-@ controlled study about 26 weeks , in@@ significant amounts of EPS 19 % patients suffering from Ari@@ pi@@ pra@@ z@@ ol treatment and 13.@@ 1 % in patients with plac@@ ebo .
in other controlled operation study over 26 weeks , in@@ significant amounts of EPS 14.@@ 8 % was treated with patients who were treated with Ari@@ pi@@ pra@@ z@@ ol and 15.@@ 1 % patients under O@@ ert@@ ap@@ in therapy .
Man@@ ic agent in Bi@@ polar @-@ I @-@ disorder - In a controlled study about 12 weeks was the in@@ trin@@ sic value of EPS 23.@@ 5 % in patients under Ari@@ pi@@ pra@@ z@@ ol@@ - treatment and 5@@ 3.3 % of patients under hal@@ op@@ eri@@ dol treatment .
in a different study over 12 weeks , the tick of EPS 26.@@ 6 % patients came under Ari@@ pi@@ pra@@ z@@ ol treatment and 17.@@ 6 % for those under lithium treatment .
in the long time period of 26 weeks after plac@@ ebo @-@ controlled study was the in@@ vi@@ ction of EPS 18.@@ 2 % for patients under Ari@@ pi@@ pra@@ z@@ ol@@ - treatment and 15.@@ 7 % for plac@@ ebo @-@ treated patients .
a comparison between the patient groups under Ari@@ pi@@ pra@@ z@@ ol and plac@@ ebo , where potential clinical studies were assessed during potential laboratory parameters , there were no medical significant differences .
exhaus@@ tion of C@@ PK ( Kre@@ atine @-@ Ph@@ osp@@ ho@@ kin@@ ase ) , generally temporarily and asy@@ mp@@ tom@@ atic , were observed with 3.5 % of the plac@@ ebo @-@ treated patients , compared with 2.0 % of plac@@ ebo @-@ treated patients .
side effects that may occur in connection with an anti@@ psych@@ otic therapy and above which the occurr@@ ence of rheum@@ ato@@ id syndrome , glau@@ coma , un@@ desired mort@@ ality in older demen@@ tia patients , hyper@@ gl@@ yc@@ emia and Diabetes Mel@@ lit@@ us ( see Section 4.4 ) .
in clinical studies and since the market introduction , in@@ ad@@ vert@@ ent over@@ dos@@ es with Ari@@ pi@@ pra@@ z@@ ol alone in adult patients with estimated dos@@ es of up to 12@@ 60 mg and without death .
there are no information about the eff@@ ic@@ acy of a hem@@ at@@ aly@@ sis with Ari@@ pi@@ pra@@ z@@ ol . however , it is unlikely to be that hem@@ at@@ aly@@ sis in the treatment of a rem@@ apping of benefits as Ari@@ pi@@ pra@@ z@@ ol has a high level of plasma .
it is suspected that the eff@@ ic@@ acy of Ari@@ pi@@ pra@@ z@@ ol in schi@@ z@@ op@@ hr@@ enia and Bi@@ polar @-@ I disorder through the combination of a partial agon@@ ist effect on dop@@ amine D@@ 2- and Ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ Manchester recep@@ tors and a ant@@ agon@@ ist effect on Ser@@ ot@@ on@@ in 5@@ HT@@ 2a recep@@ tors .
in vitro , Ari@@ pi@@ pra@@ z@@ ol showed a high degree of dop@@ amine D@@ 2 and D3 recep@@ tor and the Ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ K and 5@@ HT@@ 2a recep@@ tor and 5@@ HT@@ 7@@ - , for alpha @-@ 1 @-@ ad@@ ren@@ gen and hist@@ amine @-@ H@@ 1@@ recep@@ tor .
with the gift of Ari@@ pi@@ pra@@ z@@ ol in dosing of 0.5 to 30 mg once daily over 2 weeks , the Pos@@ it@@ ans @-@ E@@ missions @-@ Tom@@ ography showed a dos@@ is@@ dependent reduction of 11@@ C @-@ Rac@@ lo@@ pri@@ d , a D2 / D3 recep@@ tor @-@ Lig@@ ne , to Nu@@ cle@@ us cau@@ dat@@ us and the put@@ ty .
in three plac@@ ebo @-@ controlled short time studies ( 4 to 6 weeks ) , patients with positive or negative symptoms showed ari@@ pi@@ pra@@ z@@ ol compared to plac@@ ebo .
in a Hal@@ op@@ eri@@ dol controlled study was 52 % of the overall study published in a Hal@@ op@@ eri@@ z@@ ol 77 % and Hal@@ op@@ eri@@ dol 77 % and Hal@@ op@@ eri@@ dol 73 % ) .
current values from measured values , which were defined as secondary and secondary education , including PAN@@ SS and the Mont@@ gom@@ ery @-@ As@@ berg@@ - Dep@@ res@@ sion rates , showed significantly stronger growth than in Hal@@ op@@ eri@@ dol .
in a plac@@ ebo @-@ controlled study about 26 weeks for stabili@@ zed patients with chronic con@@ iz@@ op@@ hr@@ enia , a significantly higher reduction in return rate , which was 34 % in the Ari@@ pi@@ pra@@ z@@ ol group and 57 % under plac@@ ebo .
in a O@@ ert@@ ap@@ in controlled , multin@@ ational double @-@ blind study by schi@@ z@@ op@@ hr@@ enia ( N = 18 or 13 % of the valuable patient care equipment ) significantly increased by at least 7 % compared to the output value ( i.e. an increase of at least 5.7 kg during an average weight of ca .
in two plac@@ ebo @-@ controlled mon@@ otherapy studies with flexible dosing of 3 weeks with a man@@ ic or mixed lot of bi@@ polar @-@ I disorder , Ari@@ pi@@ pra@@ z@@ ol showed a plac@@ ebo @-@ effectiveness in reduction of symptoms of 3 weeks .
in a plac@@ ebo @-@ controlled mon@@ otherapy study about 3 weeks with fi@@ xer , using a man@@ ic or mixed lot of bi@@ polar @-@ I disorder , Ari@@ pi@@ pra@@ z@@ ol showed no over@@ dosage eff@@ ic@@ acy .
in two plac@@ enta and active mon@@ otherapy studies , a bi@@ polar @-@ I disorder , ari@@ pi@@ pra@@ z@@ ol showed a bi@@ polar @-@ I disorder , with or without mental effects , Ari@@ pi@@ pra@@ z@@ ol showed a lot of plac@@ ebo @-@ effectiveness in week 3 and a hearing effect that was comparable with lithium or Hal@@ op@@ eri@@ dol in week 12 .
Ari@@ pi@@ pra@@ z@@ ol also showed a comparable proportion of patients with the symp@@ tom@@ atic Rem@@ em@@ ology of Man@@ ie , like lithium or Hal@@ op@@ eri@@ dol .
in a plac@@ ebo @-@ controlled study about 6 weeks with a man@@ ic@@ ic @-@ I @-@ disorder , with or without psych@@ otic characteristics , the accompanying medical therapy with Ari@@ pi@@ pra@@ z@@ ol has a excessive effectiveness in the reduction of cardiovascular symptoms in comparison to the mon@@ otherapy with lithium or Val@@ pro@@ at .
10 In a plac@@ ebo @-@ controlled study about 74 weeks , followed by a long @-@ term extension of 74 weeks in man@@ ic@@ acy phase , ari@@ pi@@ pra@@ z@@ ol showed plac@@ ebo effect in respect of the prevention of a bi@@ polar bear , mainly due to the prevention of a bi@@ polar collapse , mainly for prevention of a return in the man@@ ie .
based on in vitro studies the enz@@ y@@ mes CY@@ P@@ 3@@ A4 and CY@@ P@@ 2@@ D@@ 6 is responsible for Deh@@ y@@ dri@@ cal and Hydro@@ xy@@ dness of Ari@@ pi@@ pra@@ z@@ ol , the N @-@ De@@ al@@ ky@@ r is responsible by CY@@ P@@ 3@@ A4 Cat@@ aly@@ sis .
deprecated : function ereg _ replace ( ) is deprecated in / www / htdocs / w00cec0c / webEdition / we / include / we _ modules / object / we _ listview _ multiobject.class.php on line 296
in Ari@@ pi@@ pra@@ z@@ ol there are no differences in the phar@@ yn@@ ok@@ ine@@ tics between male and female healthy subjects , and showed a pharmac@@ ological investigation .
the phar@@ ma @-@ specific evaluation for Phar@@ mak@@ ok@@ ine@@ tics did not have a hint to clinical significant differences in the ethnic origin or the effect of the room on the phar@@ op@@ ok@@ ine@@ tist of Ari@@ pi@@ pra@@ z@@ ol .
the Ph@@ armac@@ ok@@ ine@@ tic properties of Ari@@ pi@@ pra@@ z@@ ol and E@@ ster@@ o @-@ Ari@@ pi@@ pra@@ z@@ ol were similar to patients with severe kidney disorders in comparison to young healthy subjects .
a single dose study on subjects with different gra@@ bs ( Child @-@ Pu@@ gh Class A , B and C ) showed no significant effect regarding the imp@@ air@@ ment of the liver function .
based on conventional studies to safety sp@@ har@@ mac@@ ology , tox@@ icity , and reproduction of re@@ productive instruments , gen@@ oto@@ x@@ iz@@ ations and can@@ ni@@ cal potential , the pre@@ clinical data could not be no particular haz@@ ards for humans .
toxic effects were only observed by dosing or exposure items that exceeded the maximum dosage or exposure when people clearly exceeded , they have no limits for clinical application only limited or no meaning .
the effects of retinal @-@ dependent secondary glau@@ coma ( Li@@ po@@ f@@ us@@ cin pig@@ ment epithel@@ ium and / or Par@@ ench@@ y@@ otic cells ) in rats after 104 mg / kg / day ( corresponds to the recommended dose in female rats ) at 60 mg / kg / day ( corresponds to the recommended dose of people ) at 60 mg / kg / day ( equ@@ als maximum amount of people ) .
in addition a cholesterol lowering of hydr@@ ate con@@ ju@@ g@@ ates of hydro@@ xy@@ - met@@ abo@@ lit@@ es from Ari@@ pi@@ pra@@ z@@ ol in the G@@ alle from A@@ mon@@ ta@@ z@@ ol from 25 to 125 mg / kg / day ( the 1- up to 3@@ fold the recommended dosage dose ( AU@@ C ) at the recommended dosage dose ( AU@@ C ) at the recommended dosage of people based on mg / m2 ) .
due to the highest recommended daily dose of 30 mg sul@@ ph@@ ur concent@@ rations of hydr@@ o con@@ ju@@ gate of hydro@@ xy@@ - Ari@@ pi@@ pra@@ z@@ ol no more than 6 % of the concent@@ rations which were found in the study over 39 weeks in the G@@ alle of A@@ mon@@ g ( 6 % ) in vitro solutions .
in ra@@ bb@@ its , these effects were observed according to dos@@ es , which led to ex@@ positions of 3- and 11@@ 30 of the middle Ste@@ ady @-@ State AU@@ C during the recommended dosage dose .
perfor@@ ated cart@@ on made of aluminium in folding cart@@ ons with 14 x 1 , 28 x 1 , 56 x 1 , 98 x 1 , 98 x 1 tablets .
15 av@@ ro@@ dy@@ es : in clinical studies that a year or less stamina , there were occasional reports about during the treatment with Ari@@ dan@@ pra@@ z@@ ol .
it is suspected that the eff@@ ic@@ acy of Ari@@ pi@@ pra@@ z@@ ol in schi@@ z@@ op@@ hr@@ enia and Bi@@ polar @-@ I disorder through the combination of a partial agon@@ ist effect on dop@@ amine D@@ 2- and Ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ Manchester recep@@ tors and a ant@@ agon@@ ist effect on Ser@@ ot@@ on@@ in 5@@ HT@@ 2a recep@@ tors .
22 In a plac@@ ebo @-@ controlled study about 74 weeks , followed by a long @-@ term extension of 74 weeks in man@@ ic@@ acy phase , ari@@ pi@@ pra@@ z@@ ol showed plac@@ ebo in respect of the prevention of a bi@@ polar bear , mainly for prevention of a bi@@ polar collapse , mainly for prevention of a return in the man@@ ie .
27 late @-@ dy@@ in@@ esia : in clinical studies that a year or less stamina , there were occasional reports about during the treatment with Ari@@ dan@@ pra@@ z@@ ol .
it is suspected that the eff@@ ic@@ acy of Ari@@ pi@@ pra@@ z@@ ol in schi@@ z@@ op@@ hr@@ enia and Bi@@ polar @-@ I disorder through the combination of a partial agon@@ ist effect on dop@@ amine D@@ 2- and Ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ Manchester recep@@ tors and a ant@@ agon@@ ist effect on Ser@@ ot@@ on@@ in 5@@ HT@@ 2a recep@@ tors .
34 In a plac@@ ebo @-@ controlled study about 74 weeks followed by a long @-@ term extension of 74 weeks in man@@ ic@@ acy phase , ari@@ pi@@ pra@@ z@@ ol showed plac@@ ebo in respect of the prevention of a bi@@ polar bear , mainly for prevention of a bi@@ polar collapse , mainly for prevention of a return in the man@@ ie .
39 Car@@ dy@@ sk@@ in@@ esia : in clinical studies that a year or less stamina , there were occasional reports about during the treatment with Ari@@ dan@@ pra@@ z@@ ol .
it is suspected that the eff@@ ic@@ acy of Ari@@ pi@@ pra@@ z@@ ol in schi@@ z@@ op@@ hr@@ enia and Bi@@ polar @-@ I disorder through the combination of a partial agon@@ ist effect on dop@@ amine D@@ 2- and Ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ Manchester recep@@ tors and a ant@@ agon@@ ist effect on Ser@@ ot@@ on@@ in 5@@ HT@@ 2a recep@@ tors .
46 In a plac@@ ebo @-@ controlled study about 74 weeks , followed by a long @-@ loss examination of 74 weeks in man@@ ic@@ acy phase , ari@@ pi@@ pra@@ z@@ ol showed plac@@ ebo in respect of the prevention of a bi@@ polar bear , mainly for prevention of a bi@@ polar collapse , mainly for prevention of a return in the man@@ ie .
the recommended dose for Ari@@ pi@@ pra@@ z@@ ol is 10 or 15 mg / day at a maintenance dose of 15 mg / day once daily from the meals .
patients , the difficulties when swal@@ lowing of A@@ bili@@ fy tablets can take the melt on tablets and take tablets ( see Section 5.2 ) .
the occurr@@ ence of su@@ peri@@ ority of psych@@ otic disorders and aff@@ ective disorder was reported in some cases after the beginning or after an anti@@ psych@@ otic therapy , even for treatment with Ari@@ pi@@ pra@@ z@@ ol ( see Section 4.8 ) .
late dy@@ sk@@ in@@ esia : in clinical studies that a year or less stamina , there were occasional reports about during the treatment with Ari@@ dan@@ pra@@ z@@ ol .
clinical manifest@@ ations of a m@@ NS are high fever , muscle rigi@@ dity , changing consciousness levels and signs of autonomous inst@@ ability ( ir@@ regular pulse or blood pressure , Tach@@ yon , swe@@ ating and heart rhythm ) .
a weight gain is generally known in general in schi@@ z@@ op@@ hr@@ enia , the application of Anti@@ psych@@ ot@@ ika , which is known as a side effect as a side effect is known or an un@@ healthy lifestyle and could lead to serious complications .
patients should be advised to notify their doctor if they are pregnant or pregnancy during treatment with Ari@@ pi@@ pra@@ z@@ ol .
the following side effects were more frequent ( ≥ 1 / 100 ) as possible to plac@@ ebo @-@ relevant side effects of the medicine ( * ) .
in two plac@@ ebo @-@ controlled mon@@ otherapy studies with flexible dosing of 3 weeks with a man@@ ic or mixed lot of bi@@ polar @-@ I disorder , Ari@@ pi@@ pra@@ z@@ ol showed a plac@@ ebo @-@ effectiveness in reduction of symptoms of 3 weeks .
58 In a plac@@ ebo @-@ controlled study about 6 weeks with a man@@ ic@@ ic @-@ I @-@ disorder , with or without psych@@ otic characteristics , the accompanying medical therapy with Ari@@ pi@@ pra@@ z@@ ol has a excessive effectiveness in the reduction of cardiovascular symptoms in comparison to the mon@@ otherapy with lithium or Val@@ pro@@ at .
in a plac@@ ebo @-@ controlled study about 74 weeks followed by a long @-@ term extension of 74 weeks in man@@ ic@@ acy phase , ari@@ pi@@ pra@@ z@@ ol showed plac@@ ebo effect in respect of the prevention of a bi@@ polar bear , mainly for prevention of a bi@@ polar collapse , mainly for prevention of a return in the man@@ ie .
in ra@@ bb@@ its , these effects were produced according to dos@@ es , which were to ex@@ positions of 3- and 11@@ bit of the middle part @-@ state las@@ e @-@ State AU@@ C during the recommended clinical trial
patients , the difficulties when swal@@ lowing of A@@ bili@@ fy tablets can take the melt on tablets and take tablets ( see Section 5.2 ) .
late dy@@ sk@@ in@@ esia : in clinical studies that a year or less stamina , there were occasional reports about during the treatment with Ari@@ dan@@ pra@@ z@@ ol .
71 In a plac@@ ebo @-@ controlled study about 6 weeks with a man@@ ic@@ ic @-@ I @-@ disorder , with or without psych@@ otic characteristics , the accompanying medical therapy with Ari@@ pi@@ pra@@ z@@ ol has a excessive effectiveness in the reduction of cardiovascular symptoms in comparison to the mon@@ otherapy with lithium or Val@@ pro@@ at .
patients , the difficulties when swal@@ lowing of A@@ bili@@ fy tablets can take the melt on tablets and take tablets ( see Section 5.2 ) .
late dy@@ sk@@ in@@ esia : in clinical studies that a year or less stamina , there were occasional reports about during the treatment with Ari@@ dan@@ pra@@ z@@ ol .
84 In a plac@@ ebo @-@ controlled study about 6 weeks with a man@@ ic@@ ic @-@ I @-@ disorder , with or without psych@@ otic characteristics , the accompanying medical therapy with Ari@@ pi@@ pra@@ z@@ ol has a excessive effectiveness in the reduction of cardiovascular symptoms in comparison to the mon@@ otherapy with lithium or Val@@ pro@@ at .
200 mg Fru@@ ct@@ ose each ml 400 mg of meth@@ yl @-@ 4 @-@ hydro@@ xy@@ ben@@ zo@@ at ( E@@ 720 ) each ml 0.2 mg pro@@ yl @-@ 4 @-@ hydro@@ xy@@ ben@@ zo@@ at ( E@@ 27 ) each ml .
the recommended starting dose for A@@ bili@@ fy is 15 mg once daily , regardless of the meals as mon@@ otherapy or combination therapy ( see section 5.1 ) .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; for the prevention of the re@@ occurring medicine in patients who have already received Ari@@ dan@@ pra@@ z@@ ol in order to continue the therapy with the same dose . &quot; &quot; &quot;
late dy@@ sk@@ in@@ esia : in clinical studies that a year or less stamina , there were occasional reports about during the treatment with Ari@@ dan@@ pra@@ z@@ ol .
hyper@@ gl@@ yc@@ emia , in some cases , associated with K@@ eto@@ ile or hyper@@ os@@ mol@@ ar@@ em com@@ a or death , was reported in patients who were treated with at@@ yp@@ ic anti@@ psych@@ ic drug .
there are no precise risk factors for hyper@@ gl@@ yc@@ emia caused by using A@@ bili@@ fy and other at@@ yp@@ ic anti@@ psych@@ ic drug @-@ treated patients who have direct access to the same .
92 in a clinical trial with healthy patients receiving a highly effective CY@@ P@@ 2@@ D@@ 6 inhib@@ itor ( Ch@@ ini@@ din ) the AU@@ C of Ari@@ pi@@ pra@@ z@@ ol to 107 % while the C@@ max remained unchanged .
Dil@@ ti@@ az@@ em or Esc@@ it@@ op@@ ram ) or CY@@ P@@ 2@@ D@@ 6 together with A@@ bili@@ fy will be administ@@ ered with an average rise of Ari@@ pi@@ pra@@ z@@ ol@@ - concent@@ rations .
Man@@ ic@@ acy in Bi@@ polar @-@ I @-@ disorder - In a controlled study about 12 weeks was the in@@ trin@@ sic value of EPS 23.@@ 5 % in patients with Ari@@ pi@@ pra@@ z@@ ol@@ -
it is suspected that the eff@@ ic@@ acy of Ari@@ pi@@ pra@@ z@@ ol in schi@@ z@@ op@@ hr@@ enia and Bi@@ polar @-@ I disorder through the combination of a partial agon@@ ist effect on dop@@ amine D@@ 2- and Ser@@ ot@@ on@@ in 5@@ HT@@ 1@@ Manchester recep@@ tors and a ant@@ agon@@ ist effect on Ser@@ ot@@ on@@ in 5@@ HT@@ 2a recep@@ tors .
in a O@@ ert@@ ap@@ in controlled , multin@@ ational double @-@ blind study by schi@@ z@@ op@@ hr@@ enia ( N = 18 or 13 % of the valuable patient care equipment ) significantly increased by at least 7 % compared to the output value ( i.e. an increase of at least 5.7 kg during an average weight of ca .
97 In a plac@@ ebo @-@ controlled Mon@@ otherapy study about 3 weeks with fi@@ xer , using a man@@ ic or mixed dos@@ es in the Bi@@ polar @-@ I disorder , Ari@@ pi@@ pra@@ z@@ ol showed no over@@ dosage eff@@ ic@@ acy .
in a relative bi@@ polar analysis of 30 mg Ari@@ pi@@ pra@@ z@@ ol is considered a solution to be compared with 30 mg Ari@@ pi@@ pra@@ z@@ ol in tablet form with healthy persons , the ratio between the geomet@@ ric C@@ max -@@ value value and the value of tablets at 122 % ( N = 30 ) .
99 Out of cholesterol caused by the hydr@@ ate con@@ ju@@ g@@ ates of hydro@@ xy@@ - met@@ abo@@ lit@@ es from Ari@@ pi@@ pra@@ z@@ ol in the G@@ alle from A@@ mon@@ ta@@ z@@ ol from 25 to 125 mg / kg / day ( the 1- up to 3@@ fold the recommended dosage dose ( AU@@ C ) at the recommended dosage dose ( AU@@ C ) at the recommended dosage of people based on mg / m2 ) .
in ra@@ bb@@ its , these effects were observed according to dos@@ es , which led to ex@@ positions of 3- and 11@@ 30 of the middle Ste@@ ady @-@ State AU@@ C during the recommended dosage dose .
A@@ bili@@ fy injection solution is applied to rapid control of agi@@ lity and anxiety disorders in patients with schi@@ z@@ op@@ hr@@ enia , or patients with man@@ ic pain of Bi@@ polar @-@ I disorder .
once it is appropriate , the treatment with Ari@@ pi@@ pra@@ z@@ ol injection solution should be finished and with the or@@ ally application of Ari@@ pi@@ pra@@ z@@ ol .
to minimize the res@@ or@@ ption and to minimize the vari@@ ability , a inj@@ ector is recommended in the M. del@@ to@@ im@@ us or deep in the gl@@ ut@@ eus @-@ maxim@@ us muscle , is recommended by adi@@ p@@ ous regions .
a lower dose of 5,@@ 25 mg ( 0.@@ 7 ml ) can be used depending on individual clinical trial period .
in case a leading or@@ ale treatment with Ari@@ pi@@ pra@@ z@@ ol ( see the summary of the medicine by using A@@ bili@@ fy tablets , A@@ bili@@ fy Schmel@@ z@@ entin or A@@ bili@@ fy solution .
there are no exam@@ inations on the eff@@ ic@@ acy of Ari@@ pi@@ pra@@ z@@ ol injection solution in patients with agi@@ lity and behavi@@ our@@ al disorders that causes different from schi@@ z@@ op@@ hr@@ enia and man@@ ic aci@@ ers of Bi@@ polar @-@ I disorder .
if a particle therapy with ben@@ odi@@ zed therapy in addition to the Ari@@ pi@@ pra@@ z@@ ol injection solution , patients should be observed that patients should be observed with a extreme load or blood pressure ( see Section 4.5 ) .
investigations on security and eff@@ ic@@ acy of Ari@@ pi@@ pra@@ z@@ ol injection solution is for patients with alcohol or medicines .
Ari@@ pi@@ pra@@ z@@ ol should be applied in patients with well @-@ known cardiovascular diseases ( M@@ yo@@ cardi@@ al inf@@ ra or isch@@ emia , hy@@ po@@ vol@@ emia , therapy disorders , hy@@ po@@ vol@@ emia , treatment with blood pressure treatment ) or hyper@@ ton@@ ic ( including ak@@ zel@@ es and MA@@ LIG@@ NE form ) .
late dy@@ sk@@ in@@ esia : in clinical studies that a year or less stamina , there were occasional reports about during the treatment with Ari@@ dan@@ pra@@ z@@ ol .
clinical manifest@@ ations of a m@@ NS are high fever , muscle sti@@ ff@@ ness , changing consciousness levels and signs of autonomous inst@@ ability ( ir@@ regular pulse or blood pressure , Tach@@ yon , swe@@ ating and heart rhythm ) .
poly@@ di@@ p@@ it , poly@@ ethylene , poly@@ ph@@ ag@@ y and weakness ) are observed and patients with diabetes mel@@ lit@@ us or with risk factors for diabetes mel@@ lit@@ us should be monitored regularly in terms of gluten @-@ glu@@ cose values .
a weight gain is generally known in schi@@ z@@ op@@ hr@@ enia , the application of Anti@@ psych@@ ot@@ ika , which is known as a side effect as a side effect is known or an un@@ healthy lifestyle and could lead to serious complications .
the intensity of the Sed@@ ation was greater than compared to the long gift of Ari@@ pi@@ pra@@ z@@ ol ( 15 mg dosage ) as an in@@ patient intra@@ mus@@ cular and the same Lor@@ az@@ ep@@ am ( 2 mg dosage ) intra@@ mus@@ cular .
105 The H@@ 2 Ant@@ agon@@ ist Fam@@ oti@@ din , a Mag@@ ic acid Blo@@ cker , reduces the res@@ or@@ ption rate of Ari@@ pi@@ pra@@ z@@ ol , but this effect is not relevant as a clinical practice .
at CY@@ P@@ 2@@ D@@ 6 &apos; bad &apos; ( = &quot; big &quot; ) Met@@ aboli@@ sm , compared to CY@@ P@@ 2@@ D@@ 6 Exten@@ sive Met@@ aboli@@ sm the common application with highly effective use of CY@@ P@@ 3@@ A4 in higher plasma concent@@ rations of Ari@@ pi@@ pra@@ z@@ ol .
other highly effective In@@ hi@@ bit@@ ors of CY@@ P@@ 3@@ A4 , such as I@@ tra@@ con@@ az@@ ol and HI@@ V@@ - Prot@@ e@@ as@@ ein@@ hi@@ bit@@ oren , have similar effects and therefore should be made similar to similar types of dis@@ rup@@ tions .
following the charge of the CY@@ P@@ 2@@ D@@ 6 or 3@@ A4 @-@ inhib@@ itors , the dosage of A@@ bili@@ fy should be adjusted at the start of the accompanying therapy .
106 Lor@@ az@@ ep@@ am ( 2 mg dosage ) intra@@ mus@@ cular , the intensity of the Sed@@ ation was greater than compared to some of the gift of Ari@@ pi@@ pra@@ z@@ ol .
the following side effects were more frequent in clinical studies with Ari@@ pi@@ pra@@ z@@ ol injection solution more often ( ≥ 1 / 100 ) as possible to plac@@ ebo @-@ relevant side effects ( see section 5.1 ) :
the frequency of the below are defined according to the following criteria : frequently ( ≥ 1 / 100 , &lt; 1 / 10 ) ; occasionally ( ≥ 1 / 1.000 , &lt; 1 / 100 ) .
107 The following side effects were more frequently used ( ≥ 1 / 100 ) as possible for plac@@ ebo or were considered possible medical attention ( see section 5.1 ) :
in a plac@@ ebo @-@ controlled study about 26 weeks , in@@ equ@@ ali@@ ation of EPS 19 % in patients with Ari@@ pi@@ pra@@ z@@ ol@@ - treatment and 13.@@ 1 % in patients with plac@@ ebo .
in a different study over 12 weeks , the tick of EPS 26.@@ 6 % patients came under Ari@@ pi@@ pra@@ z@@ ol@@ - treatment and 17.@@ 6 % for those under lithium treatment .
during the long time period of 26 weeks at a plac@@ ebo @-@ controlled study was the in@@ vi@@ ction of EPS 18.@@ 2 % for patients under Ari@@ pi@@ pra@@ z@@ ol treatment and 15.@@ 7 % for plac@@ ebo @-@ treated patients .
a comparison between the patient groups under Ari@@ pi@@ pra@@ z@@ ol and plac@@ ebo , where potential clinical studies were assessed during potential laboratory parameters , there were no medical significant differences .
inf@@ ect of C@@ PK ( Kre@@ at@@ in@@ ph@@ osp@@ ho@@ kin@@ ase ) , generally temporarily and asy@@ mp@@ tom@@ atic , were observed with 3.5 % of the plac@@ ebo @-@ treated patients , compared with 2.0 % of plac@@ ebo @-@ treated patients .
side effects that may occur in connection with an anti@@ psych@@ otic therapy and above which the occurr@@ ence of rheum@@ ato@@ id syndrome , glau@@ coma , un@@ desired mort@@ ality in older demen@@ tia patients , hyper@@ gl@@ yc@@ emia and Diabetes mel@@ lit@@ us ( see Section 4.4 ) .
110 and behavi@@ oral disorders was the Ari@@ pi@@ pra@@ z@@ ol injection solution in statisti@@ cally significant improvements of agi@@ lity and negative dys@@ function associated with plac@@ ebo . was similar to Hal@@ op@@ eri@@ dol .
in a plac@@ ebo @-@ controlled short time study ( 24 h ) with 291 patients with bi@@ polar disorder as well as agi@@ lity and behavi@@ our@@ al disorders , the Ari@@ pi@@ pra@@ z@@ ol injection solution was associated with a statisti@@ cally significant improvement and behavi@@ ors in comparison to plac@@ ebo .
the follow @-@ up mean follow @-@ up from the output value of the PAN@@ SS Exc@@ l Comp@@ onent score with the primary 2 @-@ hour end point was 5,@@ 8 for plac@@ ebo , 9,@@ 6 for Lor@@ az@@ ep@@ am and 8,@@ 7 for Ari@@ dan@@ pra@@ z@@ ol .
in analyses of sub@@ groups in patients with mixed vitamin or patients with severe agi@@ lity , a similar properties in relation to the overall population was observed , but a statistical Sig@@ ni@@ fi@@ kan@@ ers could be detected due to a reduced patient population .
in three plac@@ ebo @-@ controlled short time studies ( 4 to 6 weeks ) , patients with positive or negative symptoms showed ari@@ pi@@ pra@@ z@@ ol ( oral ) compared to plac@@ ebo .
in a Hal@@ op@@ eri@@ dol controlled study was 52 % of the overall study published in a Hal@@ op@@ eri@@ z@@ ol 77 % ( oral ) and Hal@@ op@@ eri@@ dol 73 % ( oral ) and Hal@@ op@@ eri@@ dol 73 % ) .
current values from measured values , which were defined as secondary and secondary education , including PAN@@ SS and the Mont@@ gom@@ ery @-@ As@@ berg &apos;s Dep@@ res@@ sion rates , showed significantly stronger growth than in Hal@@ op@@ eri@@ dol .
in a plac@@ ebo @-@ controlled study about 26 weeks of stabili@@ zed patients with chronic con@@ iz@@ op@@ hr@@ enia ( oral ) showed significantly higher reduction in return rate , which was 34 % in the Ari@@ pi@@ pra@@ z@@ ol@@ - ( oral ) group and 57 % under plac@@ ebo .
in a O@@ ert@@ ap@@ in controlled , multin@@ ational double @-@ blind study by schi@@ z@@ op@@ hr@@ enia ( N = 18 or 13 % of the valuable patient care equipment ) significantly increased by at least 7 % compared to the initial value ( i.e. an increase of at least 5.7 kg during an average weight of ca .
111 In a plac@@ ebo @-@ controlled study about 6 weeks with a man@@ ic@@ ic @-@ I @-@ disorder , with or without psych@@ otic characteristics , the accompanying medical therapy with Ari@@ pi@@ pra@@ z@@ ol has a excessive effectiveness in the reduction of cardiovascular symptoms in comparison to the mon@@ otherapy with lithium or Val@@ pro@@ at .
in a plac@@ ebo @-@ controlled study about 26 weeks followed by a 74 @-@ year study , ari@@ pi@@ pra@@ z@@ ol to plac@@ ebo effect during a stabili@@ zation phase in respect of the prevention of a bi@@ polar bear in respect to the prevention of a bi@@ polar collapse , mainly for prevention of a return in the man@@ ie .
the Ari@@ pi@@ pra@@ z@@ ol AU@@ C is the first 2 hours after intra@@ mus@@ cular injection 90 % greater the AU@@ C according to the same dose as tablets ; the system exposure was similar to the two form@@ ulations .
in 2 studies with healthy subjects , the mean time to reach the maximum Plas@@ mas@@ pi@@ eg@@ els is 1 to 3 hours after application .
the gift of Ari@@ pi@@ pra@@ z@@ ol injection solution was toler@@ ated by rats and mon@@ keys well toler@@ ated and resulting in no direct tox@@ icity of a target group according to a system@@ ic exposure ( AU@@ C ) , the 15@@ - or 5 times over the maximum human@@ ized exposure of 30 mg or mus@@ cular cells .
in studies on the reproduction of intra@@ ven@@ ous application , no safety concerns stem@@ med according to mat@@ ern@@ al exposure , 15@@ - ( rats ) and 29 @-@ times ( rab@@ bit ) and 29 @-@ times ( rab@@ bit ) about the maximum of the therapeutic exposure of 30 mg .
based on conventional studies with Ari@@ pi@@ pra@@ z@@ ol ( oral ) for safety sp@@ har@@ mac@@ ology , tox@@ icity , and re@@ productive instruments , gen@@ oto@@ x@@ iz@@ ations and can@@ ni@@ cal potential , the pre@@ clinical data could not be no particular haz@@ ards for humans .
toxic effects were only observed by dosing or exposure items that exceeded the maximum dosage or exposure when people were clearly exceeded ; so they have no limits for clinical application only limited or no meaning .
the effects caused a dos@@ is@@ tical side @-@ dependent secondary effects ( Li@@ po@@ f@@ us@@ cin pig@@ ment epithel@@ ial and / or Par@@ ench@@ y@@ y rin@@ se rin@@ se rin@@ se vol@@ cano ) in rats after 104 mg / kg / day ( equ@@ ation 10 to 60 mg / kg / day ( the 10 @-@ fold @-@ state @-@ state exposure ) at least 60 mg / kg / day ( the 10 @-@ fold @-@ state @-@ state exposure ( AU@@ C ) at the recommended dose of people ) .
in addition a cholesterol lowering of hydr@@ ate con@@ ju@@ g@@ ates of hydro@@ xy@@ - Met@@ aboli@@ sm of Ari@@ pi@@ pra@@ z@@ ol in the G@@ alle from A@@ ffen after repeated clinical dose of 25 to 125 mg / kg / day ( the 1- to 3 @-@ fold the recommended dose of people based on mg / m2 ) .
in ra@@ bb@@ its , these effects were observed after dosing , which led to ex@@ positions of 3- and 11 bit of the medium @-@ stat@@ s AU@@ C during the recommended intake of the recommended dose .
Pharma@@ ko@@ vi@@ gil@@ ance system is to ensure that the pharmaceutical ko@@ vi@@ gil@@ ance system has to be described before and during the product market , the pharmaceutical ko@@ vi@@ gil@@ ance system is described as in the version 1.0 of module 1.@@ 8.@@ 1. of the author@@ isation .
&quot; &quot; &quot; the &quot; &quot; &quot; &quot; CH@@ MP Gui@@ deline on Risk Management Systems for Medic@@ inal products &quot; &quot; &quot; &quot; must be submitted at the same time with the next peri@@ odic Safety Update report ( PS@@ U ) . &quot; &quot; &quot;
&quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; there is an important risk management plan to be submitted if new information is known , which can be evaluated within 60 days after an important milestone of pharmaceu@@ ko@@ vi@@ gil@@ ance or the measures for risk management was achieved on request of EME@@ A . &quot; &quot; &quot;
the import of far @-@ east goods let PULSA provide an inter@@ sting pri@@ ce@@ - and produc@@ toff@@ ering .
EU / 1 / 04 / 276 / 002 28 x 1 tablets EU / 1 / 04 / 276 / 002 28 x 1 tablets EU / 1 / 04 / 276 / 276 34 x 1 tablets of the EU / 1 / 04 / 276 / 005 98 x 1 tablets
&quot; &quot; &quot; if you want to send us a question about this product , simply complete all the fields marked * and click &quot; &quot; &quot; &quot; Send &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
the report examines all retail channels to provide sector insight .
the report examines all retail channels to provide sector insight .
if one of the remaining side effects are affected or side effects that are not specified in this utility information , please inform your doctor or pharmac@@ ist .
it is applied for the treatment of adults who suffer from a disease that is characterized by symptoms such as the hearing , in case or joining of things which are not present , mis@@ str@@ ust , un@@ related language , in@@ fusion behavi@@ ors , non @-@ dimensional language .
A@@ bili@@ fy will be applied to the treatment of a condition with over@@ sized high este@@ em , feeling a lot less sleep than usually , very fast speech , with quickly changing ideas and sometimes less irrit@@ ability .
high blood sugar or cases of diabetes for diabetes prevention , ir@@ regular muscle movement , in particular in the face of heart or vessel disease , in particular in the face of heart or vessel disease , in particular in the face of heart or vessel disease in the family , stroke or temporary man@@ gel@@ ation of the brain ( tran@@ sit@@ or@@ ic Att@@ achment / TI@@ A ) .
if you suffer as older patient to demen@@ tia ( loss of memory , or other mental abilities ) , you should tell or give a nursing home your doctor if you ever had a stroke or a temporary man@@ ege of the brain .
inform your doctor if you are connected to muscle sti@@ ff@@ ness or sti@@ ff@@ ness with a high fever , swe@@ ating , changing hum@@ ank@@ ind or very tight heart disease .
children and adol@@ esc@@ ents are not able to apply for children and adol@@ esc@@ ents , as it has not been studied at the age of 18 years .
taking advantage of A@@ bili@@ fy with other medicines Please check your doctor or pharmac@@ ist if you have other drugs or supplements , even if it is not interested in prescription drugs .
medicine for treatment of heart rhythm , anti@@ de@@ press@@ ants or herbal medicines used to treat depression treatment and anxiety disorders , treating inflam@@ matory drugs to treat acute inflam@@ matory drugs to treat cancer treatment .
pregnancy and still you should take A@@ bili@@ fy if you are pregnant , unless you are pregnant with your doctor .
they should not be able to go car and do not drive car or machines , until you know how A@@ bili@@ fy will work on you .
please take this medicine after returning to your doctor if you know that you suffer from an int@@ oler@@ ance to certain zu@@ res .
please talk to your doctor or pharmac@@ ist if you have the impression that the effect of atri@@ ots are too strong or weak .
even if you feel better , change or put the daily dose of A@@ bili@@ fy to ask without your doctor before .
if you have taken a bigger amount of A@@ bili@@ fy , you should be advised that you have advised more A@@ bili@@ fy tablets as prescribed by your doctor ( or if anyone else has some of your A@@ bili@@ fy pills ) , please contact your doctor .
if you forget the intake of A@@ bili@@ fy if you forget a dose , take the forgotten dose if you think you do not take a double dose .
frequent side effects ( with more than 1 of 100 , less than 1 of 10 treated ) un@@ controll@@ able movements , head@@ aches , fatigue , vom@@ iting , multip@@ lication , anxiety disorders , anxiety disorders , anxiety disorders , trem@@ bling , trem@@ bling , trem@@ bling , trem@@ bling , trem@@ bling .
side @-@ side effects ( with more than 1 of 100 % less than 1 of 100 treatments ) some individuals can feel at the same time , especially if they are standing out of a sitting position or sitting position .
please inform your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
like A@@ bili@@ fy and contents of the package A@@ bili@@ fy 5 mg tablets are rectangular and blue , with embos@@ sing of A @-@ 007 and 5 on one side .
inform your doctor if you are connected to muscle sti@@ ff@@ ness or sti@@ ff@@ ness with a high fever , swe@@ ating , changing hum@@ ank@@ ind or very tight heart disease .
even if you feel better , change or put the daily dose of A@@ bili@@ fy to ask without your doctor before .
like A@@ bili@@ fy and contents of the package A@@ bili@@ fy 10 mg tablets are rectangular and ro@@ saf@@ ty , with embos@@ sing of A @-@ 008 and 10 on one side .
inform your doctor if you are connected to muscle sti@@ ff@@ ness or sti@@ ff@@ ness with a high fever , swe@@ ating , changing hum@@ ank@@ ind or very tight heart disease .
even if you feel better , change or put the daily dose of A@@ bili@@ fy to ask without your doctor before .
like A@@ bili@@ fy and contents of the package A@@ bili@@ fy 15 mg tablets are round and yellow , with pre@@ face of A @-@ 009 and 15 on one side .
inform your doctor if you are connected to muscle sti@@ ff@@ ness or sti@@ ff@@ ness with a high fever , swe@@ ating , changing hum@@ ank@@ ind or very tight heart disease .
even if you feel better , change or put the daily dose of A@@ bili@@ fy to ask without your doctor before .
how A@@ bili@@ fy and contents of the package A@@ bili@@ fy 30 mg tablets are round and ro@@ saf@@ ty , with pre@@ ference of A @-@ 0@@ 11 and 30 on one side .
171 If you suffer as older patient to demen@@ tia ( loss of memory , or other mental abilities ) , you should tell or give a nursing home your doctor if you ever had a stroke or a temporary man@@ ege of the brain .
inform your doctor if you are connected to muscle sti@@ ff@@ ness or sti@@ ff@@ ness with a high fever , swe@@ ating , changing hum@@ ank@@ ind or very tight heart disease .
important information about certain other ingredients of A@@ bili@@ fy patients who may not take care to phen@@ yl@@ alan@@ in , should be aware that A@@ bili@@ fy enam@@ el may be used as a source of phen@@ yl@@ alan@@ in .
find out immediately after opening the bli@@ ster packaging with dry hands and lay the melt on the whole on the tongue .
even if you feel better , change or put the daily dose of A@@ bili@@ fy to ask without your doctor before .
if you have taken a bigger amount of A@@ bili@@ fy , you should be advised that you have advised more than your doctor if you have been advised by your doctor ( or if someone else has been taken some of your A@@ bili@@ fy Schmel@@ z@@ Mastercard ) , please contact your doctor .
Cal@@ cium tri@@ met@@ asi@@ lic@@ ate , Cro@@ sc@@ li@@ to@@ sis , Cro@@ sc@@ li@@ to@@ l , micro@@ cryst@@ ine Cell@@ ul@@ ose , X@@ y@@ li@@ to@@ l , micro@@ cryst@@ all@@ ine cell@@ ul@@ ose , as@@ es@@ ul@@ f@@ am @-@ cali@@ um , Van@@ ille@@ ul@@ f@@ am @-@ Kali@@ um , Van@@ ille@@ an@@ st@@ ear@@ ate , Iron ( III ) - oxide ( E@@ 172 ) .
how A@@ bili@@ fy looks and content of the package The A@@ bili@@ fy 10 mg mel@@ ting tablets are round and ro@@ saf@@ ty , with embos@@ sing of &quot; A &quot; on one side and &quot; 10 &quot; on the other .
177 If you suffer as older patient to demen@@ tia ( loss of memory , or other mental abilities ) , you should tell or give a nursing home your doctor if you ever had a stroke or a temporary man@@ ege of the brain .
inform your doctor if you are connected to muscle sti@@ ff@@ ness or sti@@ ff@@ ness with a high fever , swe@@ ating , changing hum@@ ank@@ ind or very tight heart disease .
Cal@@ cium tri@@ met@@ asi@@ lic@@ ate , Cro@@ sc@@ li@@ to@@ sis , Cro@@ sc@@ li@@ to@@ l , micro@@ cryst@@ all@@ ine cell@@ ul@@ ose , as@@ es@@ ul@@ f@@ am @-@ cali@@ um , Van@@ ille@@ ul@@ f@@ am @-@ Kali@@ um , Van@@ ille@@ an@@ st@@ ear@@ at , Van@@ ille@@ de@@ st@@ ear@@ ate , Iron ( III ) - hydro@@ xi@@ de @-@ oxide x H2@@ O ( E@@ 172 ) .
&quot; &quot; &quot; how A@@ bili@@ fy and content of the package The A@@ bili@@ fy 15 mg mel@@ ting furnace are about and yellow , with pre@@ face of &quot; &quot; &quot; &quot; A &quot; &quot; &quot; &quot; on one side and &quot; &quot; &quot; &quot; 15 &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
183 If you suffer as older patient to demen@@ tia ( loss of memory , or other mental abilities ) , you should tell or give a nursing home your doctor if you ever had a stroke or a temporary man@@ ege of the brain .
inform your doctor if you are connected to muscle sti@@ ff@@ ness or sti@@ ff@@ ness with a high fever , swe@@ ating , changing hum@@ ank@@ ind or very tight heart disease .
&quot; &quot; &quot; how A@@ bili@@ fy and content of the package The A@@ bili@@ fy 30 mg mel@@ ting furnace are round and ro@@ saf@@ ty , with embos@@ sing of &quot; &quot; &quot; &quot; 6@@ 43 &quot; &quot; &quot; &quot; on one side and &quot; &quot; &quot; &quot; 30 &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
inform your doctor if you are connected to muscle sti@@ ff@@ ness or sti@@ ff@@ ness with a high fever , swe@@ ating , changing hum@@ ank@@ ind or very tight heart disease .
they should not be able to go car and do not drive car or machines , until you know how A@@ bili@@ fy will work on you .
190 Import@@ ant information about certain other ingredients of A@@ bili@@ fy any ml A@@ bili@@ fy solution to take 200 mg Fru@@ ct@@ ose and 400 mg SU@@ CRO@@ SE .
if your doctor says that you suffer from int@@ oler@@ ance to certain zu@@ res , please contact your doctor before you take this medicine .
the dose at A@@ bili@@ fy solution must be measured using the tested measuring cup or the cooled 2 ml Trop@@ ic pi@@ p@@ ette , which are included in the package .
please talk to your doctor or pharmac@@ ist if you have the impression that the effect of atri@@ ots are too strong or weak .
if you have taken a bigger amount of A@@ bili@@ fy , you should consider that you have advised more than your doctor if you have been advised by your doctor ( or if anyone else is differently from your doctor ) , please contact your doctor .
Din@@ os@@ um@@ ed@@ et@@ ate , Fru@@ ct@@ ose , gly@@ cer@@ ol , gly@@ yl @-@ 4@@ - hydro@@ xy@@ ben@@ zo@@ at ( E@@ 720 ) , pro@@ yl @-@ 4 @-@ hydro@@ xy@@ ben@@ zo@@ at ( E@@ 720 ) , so@@ dium hydro@@ xi@@ om , SU@@ CRO@@ SE , ger@@ ated water and natural orange @-@ cream @-@ flavour with other natural flav@@ ours .
how A@@ bili@@ fy looks and content of the package A@@ bili@@ fy 1 mg / ml solution to be a clear , color@@ less to bright liquid in bottles with a cri@@ b of poly@@ prop@@ ylen and at 50 ml , 150 ml or 480 ml
A@@ bili@@ fy injection solution is applied to the rapid treatment of st@@ ei@@ ger@@ ed imm@@ ort@@ al and des@@ perate behavior that are characterized by symptoms such as : the hearing , which are not present , mis@@ str@@ ust , un@@ related language , in@@ coher@@ ent language , non @-@ related behavior .
people with this disease can also be de@@ pressed to feel guilty or acc@@ entu@@ ated . excessive feeling that feel excessive energy to have much less sleep than usually , very fast speech with changing ideas and sometimes less irrit@@ ability .
inform your doctor if you are connected to muscle sti@@ ff@@ ness or sti@@ ff@@ ness with a high fever , swe@@ ating , changing hum@@ ank@@ ind or very tight heart disease .
in application of A@@ bili@@ fy with other medicines please inform your doctor or pharmac@@ ist if you have other drugs or supplements , even if it is not interested in prescription drugs .
medicines for the treatment of heart rhythm , anti@@ de@@ press@@ ants or herbal medicines used to treat depression treatment and anxiety disorders , treating inflam@@ matory drugs to treat acute depression treatment .
196 pregnancy and still hours you should not apply if you are pregnant , unless you are pregnant with your doctor .
you should not be able to go car and do not drive car or machines , if you do not want to use any tools or machines , when applying to the application of A@@ bili@@ fy injection solution .
if you have doubts that you have more ap@@ t injection solution than you do , please do not hesitate to contact your doctor or nursing care practition@@ er .
frequent side effects ( with more than 1 of 100 , less than 1 of 10 treated ) by A@@ bili@@ fy injection solution are ti@@ red@@ ness , vibration , head@@ aches , ru@@ dder and vom@@ iting .
occasional side @-@ side effects ( with more than 1 of 100 % less than 1 of 100 treatments ) some individuals can feel a change of blood pressure , especially when the rest or sitting , or a fast pulse , a dry feeling in the mouth or feel ill .
frequent side effects ( with more than 1 out of 100 , less than 1 of 10 treated ) un@@ controll@@ able movements , head@@ aches , fatigue , fatigue , anxiety disorders , anxiety disorders , anxiety disorders , anxiety disorders , trem@@ bling , trem@@ bling , trem@@ bling and bl@@ urred vision .
if you need more information about your illness or treatment , please read the Pack@@ ager ( also part of the EP@@ AR ) , or contact your doctor or pharmac@@ ist .
Abra@@ x@@ ane should only be applied under the supervision of a qualified On@@ k@@ ologen in the application of Zy@@ to@@ st@@ ati@@ ka ( descent of cells ) specialist departments .
patients may cause certain side effects on blood or the nervous system , the dose is reduced or treatment .
( 44 @-@ 20 ) 74 18 84 23 E @-@ mail : mail @ em@@ e@@ a.@@ europ@@ a.@@ eu e @-@ mail : / / www.@@ em@@ e@@ a.@@ europ@@ a.@@ eu © EME@@ A 2007 Re@@ production and / or distribution of this document , used by Nan@@ op@@ articles .
the eff@@ ic@@ acy of Abra@@ x@@ ane was examined in a major study conducted on 460 women with metast@@ atic breast cancer , of which three quarters were formerly a anth@@ rac@@ y@@ cl@@ in .
the effects of Abra@@ x@@ ane ( in some of some gift or as mon@@ otherapy ) was compared with a conventional pac@@ li@@ ta@@ xel chem@@ otherapy medicine ( given in combination with other medicines for reduced side effects ) .
a overall study of 72 ( 31 % ) of the 228 with Abra@@ x@@ ane treated patients treated to treatment , compared to 37 ( 16 % ) of 225 patients .
in relation to the eff@@ ic@@ acy of the disease , in terms of metast@@ atic breast cancer , there was no difference between the drugs and survival .
on the other hand in patients who had previously received other treatments of their metast@@ atic breast cancer in relation to these indicators that Abra@@ x@@ ane is more effective than conventional pac@@ li@@ ta@@ xel .
it must also be applied in patients who are applied , or prior to the treatment low neutr@@ alisation numbers in the blood .
the European Committee for Human@@ ar@@ z@@ op@@ ers ( CH@@ MP ) showed that Abra@@ x@@ ane in patients who did not treat more harm than conventional pac@@ li@@ ta@@ xel . the medicine was unable to reduce side effects .
January 2008 , the European Commission shared the European Commission of Abra@@ xis Bios@@ ci@@ ence Limited a permit for the transport of Abra@@ x@@ ane in the entire European Union .
Abra@@ x@@ ane @-@ Mon@@ otherapy is indi@@ rectly used for the treatment of metast@@ atic breast cancer in patients with metast@@ atic breast cancer .
patients with severe neutr@@ rop@@ en@@ ie ( Neut@@ ro@@ phil@@ atel@@ ie &lt; 0.50 x 109 / l over a period of a week or longer ) or he@@ avier Neu@@ rop@@ ath@@ ic therapy should be reduced in the subsequent series to 220 mg / m2 .
in sensory neu@@ rop@@ ath@@ ic degree 3 is the treatment to break up to 1 or 2 , and in all the subsequent cycles .
there are currently no sufficient data for the recommendation of D@@ os@@ is@@ adjustable in patients with light up to reduced imp@@ air@@ ment of the liver function ( see Section 4.@@ 4th and 5.2 ) .
no studies have been carried out with a combination of kidney function and there are currently no sufficient data for treatment of D@@ os@@ is@@ adap@@ tations for patients with imp@@ air@@ ment of the kidney function ( see Section 5.2 ) .
for children under 18 years of age , Abra@@ x@@ ane is not recommended for use in children under 18 years .
Abra@@ x@@ ane is a Alb@@ um@@ ine @-@ restricted nan@@ op@@ articles form@@ ulated by Pac@@ li@@ ta@@ xel that could be significantly more pharmac@@ ological features as other form@@ ulations of pac@@ li@@ ta@@ xel . ( see Section 5.1 &amp; 5.2 ) .
if an allergi@@ c reaction should be treated immediately and a symp@@ tom@@ atic treatment should be treated immediately and the patient cannot be treated with pac@@ li@@ ta@@ xel .
in the patients , Abra@@ x@@ ane treatment cycles are applied again to &gt; 1.5 x 109 / l , and the Th@@ rom@@ bo@@ cy@@ ten@@ ders is again on &gt; 100 x 109 / l .
patients with severe liver dys@@ function ( Bi@@ li@@ ru@@ bin &gt; 5 x UL@@ N or AS@@ L / AL@@ T &gt; 10 x UL@@ N ) should not be treated with abrasion .
during a clearly associated with Abra@@ x@@ ane in relation to kar@@ di@@ oto@@ x@@ iz@@ ations , kar@@ di@@ ale deposits are not unusual , especially in patients with older anth@@ rac@@ y@@ cl@@ ine treatment or underlying heart disease or lung disease .
in case of the patients after the gift of abrasion of Abra@@ ms , vom@@ iting and sur@@ render , can be treated with the usual anti@@ em@@ e@@ tika and con@@ sti@@ p@@ ation means .
Abra@@ x@@ ane should not occur at abor@@ tion or at women in bron@@ zing age , which are no effective remedi@@ es , except the treatment of mother with pac@@ li@@ ta@@ xel .
women in fried age should be used during and up to 1 month after treatment with abrasion .
male patients who treated with Abra@@ x@@ ane is treated with abrasion , while and up to six months after the treatment no child .
male patients should be experienced before treating a sper@@ ma@@ ids because of the therapy with Abra@@ x@@ ane the possibility of an ir@@ rever@@ sible in@@ fertility .
Abra@@ x@@ ane can cause side effects as ti@@ red@@ ness ( very often ) and Schwin@@ n ( frequently ) that can act on the transport and the ability to serve equipment .
below are the most common and most important incidents of side effects that were treated with metast@@ atic breast cancer treatment in the pi@@ voting phase III study once all three weeks with 260 mg / m2 Abra@@ ms were treated .
neutr@@ ality was the most striking important stabili@@ sation of the tox@@ icity ( 79 % of the patients reported ) , and was quick to rever@@ sible and dos@@ es ; Leu@@ kop@@ en@@ ie was reported in 71 % of patients .
the sever@@ ity ( H@@ b &lt; 10 g / dl ) was observed with Abra@@ x@@ ane treated patients and was observed in three cases ( H@@ b &lt; 8 g / dl ) .
in Table 1 are the side effects associated with the gift of Abra@@ x@@ ane as mon@@ otherapy at each dose and indications in studies ( N = 183 ) .
most often ( ≥ 1 / 100 , &lt; 1 / 10 ) ; occasionally ( ≥ 1 / 10,000 , &lt; 1 / 100 ) ; rare ( ≥ 1 / 10,000 , &lt; 1 / 10,000 ) ; very rare ( &lt; 1 / 10,000 ) .
occasionally : increased blood pressure , weight gain , increased l@@ act@@ ate hydro@@ gen@@ ase in blood , increased blood sugar , increased blood sugar , increased blood sugar in blood , reduced phosph@@ or@@ us in blood , reduced bone in blood of heart diseases :
Dy@@ sp@@ her@@ ie , blood , dry mouth , elas@@ ticity , dry mouth , elas@@ ticated wai@@ st@@ ness , elas@@ ticity in the mouth , or@@ ale pain , re@@ membran@@ es in the mouth , or@@ ale pain , re@@ membran@@ ce diseases of kid@@ neys and ur@@ ine :
pain in the breast cor@@ al@@ wall , weakness of muscles , gen@@ ome pain , pain relief , muscle sp@@ as@@ iness , pain in the sk@@ el@@ etal mus@@ cul@@ ature , flan@@ k pain , accidents in the streets , muscle tissue , Very frequently :
hel@@ mets 1 The frequency of the over@@ flow reaction is calculated based on a definitive population in one population of 19 patients .
as these events are reported on voluntary basis during clinical practice , no estimate of the actual frequency of frequency and it has been established with these events .
pac@@ li@@ ta@@ xel is a anti @-@ mic@@ rot@@ ator , which promotes the removal of the mic@@ rot@@ ub@@ ules from the tu@@ bular cloth and the mic@@ rot@@ ub@@ ules through inhib@@ itors .
this stabili@@ sation leads to an inhib@@ itor of normal dynamic re@@ organisation of the mi@@ k@@ rot@@ ub@@ ic@@ ular network , which is considerably higher .
it is known that Alb@@ um@@ ina is taught in the Trans@@ cy@@ t@@ ose of Plas@@ ma@@ components in the end@@ othel@@ ial cells and in the context of in @-@ vitro studies , the presence of Alb@@ li@@ ta@@ xel through the end@@ othel@@ ial cells promotes the end@@ othel@@ ial cells .
it is assumed that this improved trans@@ end@@ othel@@ ial transport by the g@@ p @-@ 60 @-@ Alb@@ umin@@ ori is taught in c@@ yst@@ eine ) a pac@@ li@@ ta@@ xel @-@ accumulation in the area of the tum@@ ours .
the application of Abra@@ x@@ ane for metast@@ atic breast car@@ cin@@ oma will be treated by means of 106 patients in two single @-@ mentioned studies and of 454 patients who have been treated in a random@@ ised phase III treatment study .
in a study , 43 patients were treated with metast@@ atic breast cancer with Abra@@ x@@ ane , which was given in form of an in@@ fusion about 30 minutes with a dose of 175 mg / m2 .
in the second study a dose of 300 mg / m2 as in@@ fusion about 30 minutes to 63 patients with metast@@ atic breast car@@ cin@@ oma is used .
these multi@@ lateral study was conducted with metast@@ atic breast cancer patients , who received all 3 weeks a mon@@ otherapy with pac@@ li@@ ta@@ xel 175 mg / m2 as a 3 @-@ hour in@@ fusion for prevention of an allergi@@ c reaction ( N = 225 ) or in the form of abrasion ( N = 229 ) .
in the study , 64 % of patients had an impact of excessive status ( ECO@@ G 1 or 2 ) , 79 % had vis@@ cer@@ ated metast@@ ases and 76 % more than 3 metast@@ as@@ est@@ els .
14 % of the patients had not received any chem@@ otherapy , 27 % had only suffered injuries of chem@@ otherapy , 40 % due to metast@@ asis and 19 % due to metast@@ asis .
9 The results for the general response rate and time to progression in the disease as well as progressive survival and survival for patients who receive the first @-@ line treatment at the bottom .
ne@@ oto@@ x@@ iz@@ an@@ ity opposite pac@@ li@@ ta@@ xel was investigated by improving a degree of patients who were able to evaluate peripheral neu@@ rop@@ ath@@ ic degrees of 3 .
the natural development of peripheral neu@@ rop@@ ath@@ ic for separation on bases on Bas@@ eline due to the cum@@ ulative tox@@ icity of Abra@@ x@@ ane after &gt; 6 treatment curves was still unknown and is still unknown .
the Ph@@ armac@@ ok@@ ine@@ tics of the total pac@@ li@@ ta@@ xel to 30@@ - and 180 @-@ minute in@@ fusion of Abra@@ x@@ ane with a dose of 80 to 375 mg / m2 was calculated in clinical studies .
the active exposure estim@@ ation ( AU@@ C ) has a linear resolution of 26@@ 53 to 16@@ 7@@ 36 n@@ g.@@ h / ml to a dose of 80 to 300 mg / m2 .
10 In intra@@ ven@@ ous tissue of Abra@@ x@@ ane was treated with metast@@ atic breast cancer in the recommended clinical dose of 260 mg / m2 , the pac@@ li@@ ta@@ xel plasma concentration in multi@@ ph@@ as@@ tical way .
the mean distribution volume was 6@@ 32 l / m2 ; the high distribution volume shows up an extensive extra@@ cellular distribution and / or past@@ ures of Pac@@ li@@ ta@@ xel .
in a study with advanced solid tum@@ ors , phar@@ yn@@ ok@@ ine@@ tical properties were evaluated by pac@@ li@@ ta@@ xel to intra@@ ven@@ ous 30 @-@ minute injection of 175 mg / m2 with the values after a 3 @-@ hour injection of 175 mg / m2 with sol@@ dered pac@@ li@@ ta@@ xel .
the Clear@@ ance of Pac@@ li@@ ta@@ xel was higher ( 43 % ) than after a sol@@ dered pac@@ li@@ ta@@ xel injection , and the distribution volume was by Abra@@ x@@ ane considerably ( 53 % ) .
in the published literature on the vitro clinical studies of the human@@ ic cir@@ ca@@ vi@@ li@@ ta@@ xel and two smaller met@@ abo@@ lit@@ es ( 3 &quot; -@@ p @-@ hydro@@ x@@ yp@@ ac@@ li@@ ta@@ xel and 6@@ α -@@ 3 &quot; -@@ p @-@ D@@ ih@@ y@@ dro@@ x@@ yp@@ ac@@ li@@ ta@@ xel ) .
after a 30 @-@ minute in@@ fusion of 260 mg / m2 Abra@@ x@@ ane in patients with metast@@ atic breast cancer was 4 % of the given total dose with fewer than 1 % of Met@@ aboli@@ sm 6@@ α -@@ Hydro@@ x@@ yp@@ ac@@ li@@ ta@@ xel and 3 &quot; -@@ p @-@ hydro@@ x@@ yp@@ ac@@ li@@ ta@@ xel .
however , for patients in the age of over 75 years , however , only a few data available , as only 3 patients of these age group were compiled in pharmac@@ ological analysis .
the chemical and physical stability became possible at 2 ° C - 8 ° C in the original cart@@ on and in front of light light via 8 hours .
Pac@@ li@@ ta@@ xel is a cy@@ tot@@ ox@@ ic medicine and as well as other potential tox@@ ins of toxic substances during dealing with abrasion .
using a ster@@ ile sy@@ ringe is slowly over a period of minimum 1 minute 20 ml of a 9 mg / ml ( 0.@@ 9 % ) Nat@@ ri@@ l@@ oride solution into a abrasion @-@ proof layer .
after full use of the solution should rest at least 5 minutes to rest a good condition of solid material .
then the balance sheet should be slow down for at least 2 minutes and be careful and / or relevant , until a complete re@@ location of the pulse is done .
if possible use or s@@ ine substances have to be visible , the balance sheet has to be adjusted once again in order to obtain a complete res@@ ump@@ tion of the application .
for patients , exact total dos@@ is@@ volume of the 5 @-@ mg / ml @-@ Sus@@ pension is calculated and the corresponding quantity of re@@ acts Abra@@ x@@ ane in an empty , ster@@ ile PV@@ C- or non @-@ PVC in@@ fusion inj@@ ectors .
Pharma@@ ko@@ vi@@ gil@@ ance system The owner of the permission of the Office must ensure that the pharmaceu@@ ko@@ vi@@ gil@@ ance system is presented as defined in version 2.0 and in module 1.@@ 8.@@ 1. the author@@ isation were presented , and works before and during the medicine .
&quot; &quot; &quot; results appear ordered &quot; &quot; &quot; &quot; by relevance &quot; &quot; &quot; &quot; or &quot; &quot; &quot; &quot; by date &quot; &quot; &quot; &quot; or &quot; &quot; &quot; &quot; by date &quot; &quot; &quot; &quot; ( publication date ) , &quot; &quot; &quot;
in accordance with the CH@@ MP Directive on risk management systems , the updated R@@ MP is intended to update the updated R@@ MP at the same time using the next peri@@ odic Safety Update report ( PS@@ BE ) .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; if you want to send us a question about this product , simply complete all the fields marked * and click &quot; &quot; &quot; &quot; Send &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
8 hours in the refrigerator in the tray , if it is kept in the box in the box to protect the content from light .
Abra@@ x@@ ane is used for treatment of breast car@@ cin@@ oma if other therap@@ ies were not successful , but if you are not successful for anth@@ rac@@ y@@ cl@@ in @-@ protein therap@@ ies in question .
Abra@@ x@@ ane should not be applied : • if you are sensitive ( allergi@@ c ) against pac@@ li@@ ta@@ xel or any other components of Abra@@ x@@ ane are • if you protect your white blood cells ( output values for Neut@@ ro@@ phil@@ atel@@ ic number of &lt; 1.5 by 109 / l - your doctor will inform you about it )
special caution when using Abra@@ x@@ ane is required : • If you have an imp@@ air@@ ment of abrasion , Kri@@ s , ting@@ ling , ting@@ ling , feeling of sensitive or muscle tissue occurs • if you have serious liver problems • if you have heart problems
in application of Abra@@ x@@ ane with other medicines please inform the doctor if you may apply other drugs or recently or recently , if it could not cause any prescription drugs .
women in fried age should be used during and up to 1 month after treatment with abrasion .
furthermore , they should be able to advise in the treatment over a sper@@ ma@@ ar treatment , because of the abrasion and the possibility of a male in@@ fertility .
handling of equipment Abra@@ x@@ ane can cause side effects as ti@@ red@@ ness ( very often ) and di@@ agon@@ ist ( often ) that can act on the transport and the ability to serve equipment .
if you also receive other medicine , you should advise you in terms of the driving or loading of machines from your doctor .
22 • an effect on the peripheral ner@@ ves ( pain and de@@ formation of pain ) • pain in one or more joints - pain in the muscles • exercise of pain • vom@@ iting , weakness and fatigue
frequent side effects ( at least 1 of 100 patients reported ) : • skin r@@ ash , dry skin , nail disorders , muscle pain , muscle pain , muscle pain , muscle pain , muscle pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain .
the rare side effects ( at least 1 of 10,000 patients reported ) : • lung infection of the skin reaction to a different substance based on radiation
please inform your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
if it is not used immediately , it can be stored in the deposit box up to 8 hours in the refrigerator ( 2 ° C - 8 ° C ) if this is stored in the box in order to protect the content from light .
every breakthrough of the bottle contains 100 mg Pac@@ li@@ ta@@ xel . • The other component is Alb@@ at@@ ta@@ xel . • The other component is Alb@@ umin@@ ous solution from people ( contains Nat@@ ale , Nat@@ ri@@ um@@ cap@@ ryl@@ ate and N Ac@@ et@@ yl@@ tr@@ yp@@ top@@ han ( Ph.@@ Eur@@ . ) .
precau@@ tionary measures for preparation and application Pac@@ li@@ ta@@ xel is a cy@@ tot@@ ox@@ ic medicine and as well as other potential tox@@ ins of toxic substances during dealing with abrasion .
using a ster@@ ile injection should be slowly over a period of 1 minute 20 ml of a 9 mg / ml ( 0.@@ 9 % ) Nat@@ ri@@ l@@ oride solution into a abrasion @-@ proof layer .
after the through@@ put bottle lasts for at least 2 minutes slowly , careful and / or relevant , until a complete re@@ location of the pul@@ sion is done .
the patients are able to calculate the exact dos@@ is@@ volume of the 5 mg / ml of suspension and the corresponding quantity of re@@ cont@@ acted Abra@@ x@@ ane in an empty , ster@@ ile PVC in@@ fusion system type IV .
in the case of application , Par@@ isi@@ ale pharmaceu@@ ticals should be tested on possible particles and disc@@ ol@@ oration .
stability with abrasion @-@ made bottles with abrasion can be stable up to the packaging of the date on the packing conditions , to protect the contents from light to light .
stability of the re@@ sign@@ ment of suspension spr@@ inkl@@ ed after the initial reconstruction process , the suspension should be filled immediately into an in@@ fusion bucket .
the member states must ensure that the owner of the approval of the approval for the transport of the market launch of the market introduction of the medical specialists in Di@@ aly@@ se@@ atic centers and retail industry of the following information and materials :
• School brochures • summary of the features of the medicine by using ( specialist information ) , lab@@ eling and pack@@ aged products . • With unique aspect of the correct application of the product acci@@ dental cooler boxes for transport by the patient .
&quot; &quot; &quot; this means that Ab@@ se@@ amed a biological medicine is similar to the European Union ( EU ) and it is called &quot; &quot; &quot; &quot; reference &quot; &quot; &quot; &quot; ( also &quot; reference &quot; &quot; &quot; &quot; reference &quot; &quot; &quot; &quot; ) . &quot; &quot; &quot;
it is used for patients with normal blood effects that may occur in connection with a blood trans@@ fusion complications , if before surgery is not possible , and with a blood loss of 900 to 1 800 ml .
the treatment with ab@@ brevi@@ ary must be initiated under the supervision of a doctor that has the experience in treatment of patients with diseases , for which the medicine is shown .
patients with kidney disease and patients who want to carry a blood circulation , is se@@ amed into a v@@ ene .
the injection can also be carried out by the patient or by the doctoral procedure unless they receive an appropriate manual .
patients with chronic kidney disease or patients who receive chem@@ otherapy are always in the recommended area ( between 10 and 12 grams per deci@@ liter of adults or between 9.5 and 11 g / dl in children ) .
the iron values of all patients are prior to control to ensure that no iron defici@@ ency exists , and iron cl@@ ut@@ ches should be administ@@ ered during the entire treatment .
patients who received a chem@@ otherapy or patients with kidney diseases can be caused by an er@@ y@@ thro@@ po@@ i@@ et@@ inal cord , or that the body is not sufficient to body the body &apos;s own er@@ y@@ thro@@ po@@ ie@@ tin .
er@@ y@@ thro@@ po@@ ie@@ tin is also used in operations to increase the number of red blood cells and to reduce the consequences of a blood loss .
it is produced by a cell produced in the gene that a gene ( DNA ) was brought to the formation of epo@@ xy al@@ fa .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; Ab@@ se@@ amed &quot; &quot; &quot; &quot; was implemented as a injection system in a v@@ ene in the framework of a main study with 4@@ 79 patients who were diagnos@@ ed with kidney problems caused by reference treatment . &quot; &quot; &quot;
all of this study involving patients had been at least eight weeks for E@@ pre@@ x / Er@@ yp@@ o in a V@@ ene inj@@ ector , before they were placed either to the se@@ amed or continue to E@@ pre@@ x / Er@@ yp@@ o .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
in addition , the results of a study was to investigate the results of a study conducted under the skin by E@@ pre@@ x / Er@@ yp@@ o for 114 cancer patients who received a chem@@ otherapy .
in the study with patients who were taken on a loss of kidney disease , the hem@@ mo@@ glo@@ bin@@ ocular values were observed in the same extent as with those patients who continue to E@@ pre@@ x / Er@@ yp@@ o .
in comparison , the patients who have received E@@ pre@@ x / Er@@ yp@@ o received an increase of 0.@@ 0@@ 63 g / dl of the initial value of 12.@@ 0 g / dl .
the most common side effect of Ab@@ se@@ amed is a rise of blood pressure , occasionally to symptoms of an enc@@ ephal@@ opath@@ ic therapy ( brain problems ) such as sudden , st@@ ress@@ ful head@@ aches and confusion .
the objective must not be applied to patients who may possibly be sensitive ( allergi@@ c ) against epo@@ xy or one of the other ingredients .
Ab@@ se@@ amed as a Injection under the skin is not recommended for treating N@@ ing@@ problems , since further studies are necessary to ensure that there are no allergi@@ c reactions .
the Committee for Human@@ izing Human Rights ( CH@@ MP ) became an equal opportunity for Ab@@ se@@ amed according to the rules of the European Union , that the drug is a comparable quality , security and eff@@ ic@@ acy profil@@ ers like E@@ pre@@ x / Er@@ yp@@ o .
the company that Ab@@ se@@ amed is , will be prepared for medical specialists in all member states , including information on security of the medicines , including information on security of the drug .
&quot; &quot; &quot; in August 2007 , the European Commission shared the European Commission on Medi@@ ce Store P@@ üt@@ ter GmbH &amp; Co KG an authorization for the transport industry in the entire European Union . &quot; &quot; &quot; &quot; &quot; &quot; &quot;
treatment of an@@ emia and reduction of trans@@ fusion requirements in adults with solid tum@@ ors , mal@@ ign@@ ant ly@@ m@@ ph@@ omas or multi@@ ple@@ m my@@ el@@ om , which is given to chem@@ otherapy and in which the risk of a trans@@ fusion of trans@@ fusion ( e.g. car@@ di@@ ov@@ ask@@ ul@@ ary status , pre@@ dominant an@@ emia at the start of chem@@ otherapy ) .
treatment should not be carried out in patients with medium @-@ severe an@@ emia ( hem@@ mo@@ glob@@ in &#91; H@@ b &#93; 10 - 13 g / dl &#91; 6,@@ 2 - 8,@@ 1 m@@ mo@@ l / l &#93; , no iron defici@@ ency is not available or in@@ adequate , in case of the larger surgical procedures ( 4 or more units blood in men ) .
reduction of foreign blood cannot be applied before a large elect@@ oral surgery on adults without iron defici@@ ency , where a high risk of trans@@ fusion complications are expected to be expected .
HB 10 @-@ 13 g / dl ) and an expected blood loss of 900 @-@ 1800 ml , which can not participate in a aut@@ olog@@ ous blood test programme .
the hem@@ mo@@ global in @-@ target concentration is between 10 and 12 g / dl ( 6,@@ 2 - 7,5 m@@ mo@@ l / l ) , but the hem@@ mo@@ glo@@ omy concentration between 9.5 and 11 g / dl ( 5.@@ 9 - 6.@@ 8 m@@ mo@@ l / l ) .
An@@ ä@@ mi@@ es@@ y@@ mp@@ s and fol@@ lic@@ ations can be different depending on age , gender and overall disease stress , therefore the assessment of the individual clinical trial and disease condition is necessary .
a rise in the hem@@ isph@@ ere to find more than 2 g / dl ( 1.25 m@@ mo@@ l / l ) over a period of four weeks should be avoided .
due to the vari@@ ability between patients , patients can be observed in one patient individual hem@@ mo@@ glo@@ bin@@ s above or under the hem@@ mo@@ glo@@ bin@@ ocular pressure .
in view of this hem@@ mo@@ glo@@ omy is a corresponding D@@ os@@ is@@ Management , the hem@@ mo@@ glob@@ in target concentration of 10 g / dl ( 6,@@ 2 m@@ mo@@ l / l ) to 12 g / dl ( 7.5 m@@ mo@@ l / l ) .
if the hem@@ mo@@ glo@@ bin@@ tie is more than 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month , the epo@@ xy @-@ al@@ fa dose is increased by 25 % .
the patients should be monitored . to ensure that epo@@ xy al@@ fa in the lowest dosage is necessary for control of the an@@ emia and the inf@@ ec@@ ess@@ y@@ mp@@ s is necessary .
the present clinical findings suggest that patients with initially very low H@@ b value ( &lt; 6 g / dl or &lt; 3.@@ 75 m@@ mo@@ l / l ) may require higher levels of maintenance ( H@@ b &gt; 8 g / dl or &gt; 5 m@@ mo@@ l / l ) .
the results of clinical findings suggest that patients with initially very low H@@ b value ( &lt; 6,@@ 8 g / dl or &lt; 4,@@ 25 m@@ mo@@ l / l ) may possibly be higher levels of maintenance ( H@@ b &gt; 6,@@ 8 g / dl or &gt; 4.@@ 25 m@@ mo@@ l / l ) .
starting dose 50 I.@@ U. / kg three times per week via intra@@ ven@@ ous application if necessary with a D@@ os@@ is@@ ature of 25 I.@@ U. / kg ( three times per week ) , until the desired target is achieved ( this should be done in incre@@ ments of at least 4 weeks ) .
An@@ ä@@ mi@@ es@@ y@@ mp@@ s and reports can be different , depending on age , gender and overall disease stress , therefore , the assessment of the individual clinical trial and disease condition is necessary .
in view of this hem@@ mo@@ glo@@ omy is a corresponding D@@ os@@ is@@ Management , the hem@@ mo@@ glob@@ in target concentration of 10 g / dl ( 6,@@ 2 m@@ mo@@ l / l ) to 12 g / dl ( 7.5 m@@ mo@@ l / l ) .
the patients should be monitored . in order to ensure that epo@@ xy al@@ fa in the lowest dosage is necessary for controlling the inf@@ ec@@ ess@@ y@@ mp@@ s is necessary .
when after 4 treatments there is at least 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) or the reproduction of ≥ 40@@ ,000 cells ( 0.@@ 62 m@@ mo@@ l / l ) or the reproduction of ≥ 40@@ ,000 cells , three times per week or 450 I.@@ U. / kg once per week .
when the hem@@ mo@@ glo@@ bin@@ ocular pressure &lt; 1 g / dl ( &lt; 0,@@ 62 m@@ mo@@ l / l ) and re@@ tik@@ u@@ lo@@ cy@@ ten@@ ant &lt; 40@@ ,000 cells / µ@@ l compared to the output value , the dose should be booked on 300 I.@@ U. / kg three times per week .
when after another 4 treatment weeks with 300 I.@@ U. / kg three times a week of the hem@@ mo@@ glo@@ bin@@ s to ≥ 12 g / dl ( ≥ 2.@@ 62 m@@ mo@@ l / l ) or the reproduction of ≥ 40@@ ,000 cells / µ@@ l , should be retained per week .
at the same time the Hä@@ mo@@ glo@@ bin@@ tie is &lt; 1 g / dl ( &lt; 0,@@ 62 m@@ mo@@ l / l ) respectively and the reproduction of &lt; 40@@ ,000 cells / µ@@ l compared to the initial value , is an approach to the epo@@ xy @-@ al@@ fa therapy is unlikely and the treatment should be broken .
patients with light an@@ emia ( hem@@ mat@@ ok@@ rit 33 - 39 % ) , which is required to obtain tests of ≥ 4 blood con@@ dens@@ ation , should be observed twice a week from 600 I.@@ U. / kg body weight twice a week for 3 weeks before surgery .
with the iron sub@@ stitution , such as possible - e.g. some weeks before beginning of the aut@@ olog@@ ous blood sp@@ ouses - it began to be at the start of the se@@ perate therapy of large iron reserves .
6 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
in this case , epo@@ xy @-@ dri@@ lled 300 I.@@ U. / kg , each consecutive days ago , on the day of the intervention as well as 4 days later , on the day of surgery .
alternatively , the injection can be used at the end of the di@@ aly@@ sis over the tube of a F@@ ist@@ el@@ na@@ del , followed by 10 ml is@@ ot@@ on@@ ical cooking solution to rin@@ se the hose and sufficient injection of medicine by means of the circulation .
patients who get infected with any Er@@ y@@ thro@@ po@@ tin ( Pure Red Cell A@@ pl@@ asia , PR@@ CA ) , should not be a se@@ amed or another Er@@ y@@ thro@@ po@@ tin ( see Section 4.4 - Er@@ y@@ thro@@ le@@ stop@@ pers ) .
heart attacks or stroke fall within one month before the treatment , inst@@ ab@@ ile An@@ gina p@@ ect@@ or@@ is , increased risk of deep Ven@@ enth@@ ro@@ mb@@ ones ( e.g. an@@ am@@ nes@@ tically known ven@@ ous th@@ rom@@ bo@@ flav@@ um ) .
in patients who are intended for a larger elect@@ oral surgery , the application of epo@@ ch@@ tin can occur , the application of epo@@ xy cells , peripheral surgery of car@@ cin@@ ogen@@ ic disease , peripheral tum@@ ours or cr@@ eb@@ rov@@ ascular disease ; in patients with recently am@@ mon@@ ary heart attacks or zer@@ eb@@ rov@@ ascular infections .
y@@ thro@@ sis stop@@ en@@ ie ( PR@@ CA ) is rare about the occurr@@ ence of an an@@ tik@@ om@@ ag@@ an PR@@ CA after several years ago and years ago with a sub@@ cut@@ aneous er@@ y@@ thro@@ po@@ tin .
in patients with sudden drug loss , defined as reduction of hem@@ o@@ glo@@ bin@@ ocular values ( 1 - 2 g / dl per month ) with increased need of trans@@ fu@@ sions , the reproduction of vitamin B@@ 12 defici@@ ency is determined and the usual causes for a non @-@ term ( ice , foli@@ c acid or inflammation , blood loss and inflammation ) .
when the Re@@ tik@@ u@@ lo@@ cy@@ ten@@ ants , considering the an@@ emia ( i.e. the reproduction ) ( &lt; 20@@ ,000 / mm@@ 3 or &lt; 20@@ ,000 / mm@@ 3 or &lt; 0.5 % ) , the Th@@ rom@@ bo@@ zy@@ ten@@ - and Leu@@ ko@@ zy@@ ten@@ ants are determined , and if no other reason of an active loss is determined , the anti @-@ Er@@ y@@ thro@@ po@@ etic anti@@ bodies determines a investigation of the bone mar@@ row to diagnosis of PR@@ CA .
the data for immun@@ ity in sub@@ cut@@ aneous use of ab@@ brevi@@ ations in patients with a risk of an@@ tig@@ ated PR@@ CA ( patients with ren@@ ews an@@ emia ) are not sufficient .
&quot; &quot; &quot; 8 &quot; &quot; &quot; &quot; patients with Chr@@ onic kidney disease should not be justified in maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ glob@@ in target zone . &quot; &quot; &quot;
clinical studies were observed in clinical trials and increased risk of serious cardiovascular events when er@@ y@@ thro@@ po@@ ese stimul@@ ates the concentration of over 12 g / dl ( 7.5 m@@ mo@@ l / l ) .
controlled clinical studies have no significant benefit , which is due to the gift of epo@@ xy , if the hem@@ mo@@ glo@@ bin@@ ocular concentration of blood trans@@ fu@@ sions and the avo@@ idance of blood trans@@ fu@@ sions are increased .
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
in case of patients with chronic kidney disease , verb@@ al cor@@ on@@ ary heart diseases or dam in@@ suffici@@ ency should not be passed at maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ glob@@ in target concentration .
after the period of study we have been studied by the treatment of An@@ em@@ ie with epo@@ xy in adults with kidney in@@ suffici@@ ency , which are not yet di@@ aly@@ zed .
in the chem@@ otherapy of chem@@ otherapy , chem@@ otherapy should be taken into account for the assessment of the therapeutic effectiveness of epo@@ xy @-@ al@@ fa therapy and er@@ y@@ thro@@ po@@ etic analysis ( patients who may have been trans@@ duc@@ ed ) .
if the H@@ b increase is greater than 2 g / dl ( 1.@@ 25 m@@ mo@@ l / l ) per month or a h@@ b value of 13 g / dl ( 8,@@ 1 m@@ mo@@ l / l ) must be adjusted to minimize the risk of potential thro@@ mb@@ ot@@ ic events ( see Section 4.2 ) of patients with chem@@ otherapy values between 10 g / dl and 12 g / dl .
the decision for the application re@@ combin@@ ated er@@ y@@ thro@@ po@@ et@@ ine should be considered to be a benefit of risk for the patient &apos;s risk that should also consider the specific clinical practice .
in patients who are intended for a larger elect@@ oral surgery , if possible , before the beginning of the epo@@ xy @-@ al@@ fa therapy the cause of an@@ emia is investigated and treated accordingly .
patients suffering from a larger elect@@ oral surgery , a proper Th@@ ro@@ mb@@ ose@@ proph@@ y@@ la@@ xe , since they have increased risk of thro@@ mb@@ ot@@ opic and v@@ ascular diseases , especially when a lack of cardiovascular disease .
in addition , this may not be excluded in treating with epo@@ xy resin for patients with an output . &gt; 13 g / dl a higher risk of postoperative refra@@ ct@@ ine / v@@ ascular events can consist of .
in several controlled studies in epo@@ et@@ ine , it was not proven to improve tum@@ our patients with symp@@ tom@@ atic anarch@@ y that dimin@@ ish the risk of tumor progression .
4 months in patients with metast@@ atic breast cancer , which was transferred to chem@@ otherapy at 12 - 14 g / dl ( 7.5 - 8,@@ 7 m@@ mo@@ l / l )
in epo@@ xy al@@ fa together with C@@ ic@@ los@@ s , the blood pressure should be modified by C@@ ic@@ los@@ por@@ in and the c@@ ic@@ los@@ por@@ in@@ dose should be adjusted to the increasing hem@@ at@@ ok@@ ie .
&quot; &quot; &quot; in vitro , &quot; &quot; &quot; &quot; in vitro , &quot; &quot; &quot; &quot; or GM @-@ CS@@ F or GM @-@ CS@@ F or GM @-@ CS@@ F or GM @-@ CS@@ F or GM @-@ CS@@ F or GM @-@ CS@@ F as well as &quot; &quot; &quot; &quot; E @-@ CS@@ F or GM @-@ CS@@ F &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
over thro@@ mb@@ ot@@ ische , v@@ ask@@ ul@@ tural events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ sis Th@@ ro@@ mb@@ ones , lung disease , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic glau@@ coma surgery , patients under epo@@ ch@@ tin @-@ treatment , as well as patients under epo@@ ch@@ tin @-@ fa , reports .
the most common side effect during the treatment with epo@@ e@@ tin al@@ fa is a dos@@ is@@ dependent increase in blood pressure or the deteri@@ oration of an existing hyper@@ tension .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
regardless of the Er@@ y@@ thro@@ po@@ tin treatment , it can occur in surgical patients with cardiovascular disease after re@@ vit@@ ating blood sp@@ her@@ ical and v@@ ascular complications .
the gene@@ tically produced epo@@ e@@ tin al@@ fa is identical to the amino acids , and the carbohydrates are identical with the end@@ o@@ gens of the er@@ y@@ thro@@ po@@ tin that was isolated from the ur@@ ine patients .
it could be demonstrated by the help of cultures of human bone fra@@ fa specific to form@@ id@@ thro@@ po@@ ese stimul@@ ates and the Leu@@ kop@@ o@@ ese could not affect the Leu@@ kop@@ o@@ ese .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
in 1895 patients with solid tum@@ ours ( 6@@ 83 Mam@@ ma@@ kar@@ di@@ ol , 260 bronze , tum@@ ours of tum@@ ours , 300 g@@ astro@@ intestinal tum@@ ours and 4@@ 78 other ) and 80@@ 2 patients with hem@@ mo@@ bla@@ st@@ ones .
the progression and tumor progression were examined in five large controlled trials with a total of 28@@ 33 patients ; four of these studies were double @-@ blind plac@@ ebo controlled trials and
no difference in the open study consisted of no difference in the overall survival between the re@@ combin@@ ant human@@ en er@@ y@@ thro@@ po@@ ised patients and the control patients .
in these studies , glau@@ coma patients were treated with re@@ combin@@ ant human@@ en er@@ y@@ thro@@ po@@ etic glau@@ coma patients with an an@@ emia due to various more mal@@ ign@@ ome concent@@ rations , statistical significant mort@@ ality than with controllers .
the overall survival in the studies could not be explained by differences in the instances of Th@@ ro@@ mb@@ ones and associated complications with re@@ combin@@ ant human@@ en er@@ y@@ thro@@ po@@ ster@@ tin @-@ treated patients and with controls .
there is an increased risk of th@@ rom@@ bo@@ lic events in tum@@ our patients who are treated with re@@ combin@@ ant human@@ en er@@ y@@ thro@@ po@@ tin and a negative impact on the overall survival can not be excluded .
it is not clear@@ ed as far as far as far as far as far as these results are treated with chem@@ otherapy which are treated with chem@@ otherapy , which can be treated with chem@@ otherapy at least 13 g / dl , because of a few patients with these characteristics in the tested data were included .
epo@@ xy @-@ al@@ fa determin@@ ants of intra@@ ven@@ ous intra@@ ven@@ ous application showed a half @-@ time period of about 4 hours with healthy plants and a little longer @-@ extended half @-@ time period of about 5 hours in patients with kidney in@@ suffici@@ ency .
after sub@@ cut@@ aneous injection , the Ser@@ um mirror of epo@@ xy is much lower than the servo mirror which can be achieved according to intra@@ ven@@ ous injection .
there are no repeti@@ tion : the ser@@ en@@ sion remain equal , regardless of whether they determined 24 hours after the first gift or 24 hours after the last gift .
the bone fibro@@ sis is a well @-@ known complications of chronic kidney pain in humans and could be caused by a secondary hyper@@ par@@ ath@@ y@@ re@@ o@@ biology or unknown factors .
in a study at hem@@ isph@@ eric pressure , three years ago were treated with epo@@ xy resin treated with di@@ aly@@ se@@ diment , which were not treated with epo@@ ch@@ tin but not increased .
14 In experimental Studies with nearly sevent@@ y of the application for the application of the recommended week dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , a delay of the Os@@ si@@ fication and a rise of death mort@@ ality .
these reports are based on vitro findings with cells from human tum@@ our disease , which are the clinical situation , but of un@@ certain Sig@@ ni@@ fi@@ kan@@ ets .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
the sy@@ ring@@ es are shown with a gradu@@ ating valve and the filling volume is shown so that if necessary , the dimension of particles is possible .
the treatment with ab@@ brevi@@ ary must be initiated under supervision of doctors , experience in the treatment of patients with the above mentioned indication .
21 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
23 For patients with Chr@@ onic kidney disease should not be passed at maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ global in @-@ target concentration .
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
over thro@@ mb@@ ot@@ ische , v@@ ask@@ ul@@ tural events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ tic Th@@ ro@@ mb@@ ones , hem@@ angi@@ ogen@@ ic attack , lung disease , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic glau@@ coma surgery , patients under epo@@ ch@@ tin @-@ treatment , so also patients under epo@@ ch@@ tin @-@ fa drugs .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
29 In experimental Studies with nearly sevent@@ y of the application for the application of the recommended week dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , a delay of the Os@@ si@@ fication and a rise of death mort@@ ality .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
36 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
38 of patients with chronic kidney disease should be observed at maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ global in @-@ target concentration .
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
over thro@@ mb@@ ot@@ ische , v@@ ask@@ ul@@ tural events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ tic Th@@ ro@@ mb@@ ones , lung disease , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic glau@@ coma surgery , patients under epo@@ ch@@ tin @-@ treatment , so also patients under epo@@ ch@@ tin @-@ fa drugs .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
44 In experimental studies with nearly sevent@@ y of the application for the application of man recommended weekday dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , to a delay of the Os@@ si@@ fication and a rise of death mort@@ ality .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
51 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , which once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
furthermore , patients with chronic kidney disease should be observed at maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ global in @-@ target concentration .
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
over thro@@ mb@@ ot@@ ische , v@@ ask@@ ul@@ tural events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ tic Th@@ ro@@ mb@@ ones , lung disease , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks and 56 hem@@ angi@@ op@@ ium treatment , so also patient under epo@@ ch@@ tin @-@ treatment , so also patients under epo@@ ch@@ tin @-@ fa drugs .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
59 In the experimental studies of approximately 20@@ ,000 of the application for the application of man recommended weekday dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , to a delay of the Os@@ si@@ fication and a rise of death mort@@ ality .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
66 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
68 In patients with Chr@@ onic kidney pain due to maintenance therapy , which cannot be exceeded by section 4.2 for the lower limit of the hem@@ mo@@ global in @-@ target concentration .
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
over thro@@ mb@@ ot@@ ische , v@@ ask@@ ul@@ tural events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ sis Th@@ ro@@ mb@@ ones , lung disease , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic glau@@ coma surgery , patients under epo@@ ch@@ tin @-@ treatment , so also patients under epo@@ ch@@ tin @-@ fa drugs .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
74 In experimental studies with nearly the 20@@ ,000 of the application for the application of the recommended week dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , a delay of the Os@@ si@@ fication and a rise of f@@ etal mort@@ ality .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
81 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
83 . patients with chronic kidney disease should not be passed at maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ global in @-@ target concentration .
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
over thro@@ mb@@ ot@@ ische , v@@ ask@@ ul@@ tural events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ tic Th@@ ro@@ mb@@ ones , lung disease , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic glau@@ coma surgery , patients under epo@@ ch@@ tin @-@ treatment , so also patients under epo@@ ch@@ tin @-@ fa drugs .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
89 in experimental studies with nearly sevent@@ y of the application for the use of man recommended weekday dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , a delay of the Os@@ si@@ fication and a rise of death mort@@ ality .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
96 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
98 For patients with Chr@@ onic kidney disease should not be passed at maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ global in @-@ target concentration .
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
over thro@@ mb@@ ot@@ ische , v@@ ask@@ ul@@ tural events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ tic Th@@ ro@@ mb@@ ones , lung disease , Ret@@ inal Th@@ ro@@ mb@@ ones , angi@@ ogen@@ ic Att@@ achment , Ret@@ inal Th@@ ro@@ mb@@ ones , rheum@@ atic glau@@ coma surgery , glau@@ coma surgery , patients under epo@@ ch@@ tin @-@ treatment , so also patients under epo@@ ch@@ tin @-@ fa , reports .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
104 In the experimental studies with nearly the 20@@ ,000 of the application for the application of the recommended week dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , a delay of the Os@@ si@@ fication and a rise of death mort@@ ality .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
111 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
113 For patients with Chr@@ onic kidney disease should not be passed at maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ global in @-@ target concentration .
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
over thro@@ mb@@ ot@@ ische , v@@ ask@@ ul@@ tural events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ tic Th@@ ro@@ mb@@ ones , lung disease , Ret@@ inal Th@@ ro@@ mb@@ ones , angi@@ ogen@@ ic Att@@ achment , Ret@@ inal Th@@ ro@@ mb@@ ones , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks and 116 hem@@ angi@@ op@@ ium treatment , as well as patients under epo@@ xy al@@ fa , reports .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
119 In experimental studies with nearly the 20@@ ,000 of the application for the application of the recommended week dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , a delay of the Os@@ si@@ fication and a rise of death mort@@ ality .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
126 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , which once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
if patients with chronic kidney disease should be observed at maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ global in @-@ target concentration .
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
over thro@@ mb@@ ot@@ ische , v@@ ask@@ ul@@ tural events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ tic Th@@ ro@@ mb@@ ones , hem@@ angi@@ ogen@@ ic attack , lung disease , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ os@@ yn@@ em@@ ic treatment , so also patient under epo@@ ch@@ tin @-@ treatment , so also patients under epo@@ ch@@ tin @-@ fa drugs .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
134 in experimental studies with nearly sevent@@ y of the application for the use of man recommended weekday dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , a delay of the Os@@ si@@ fication and a rise of death mort@@ ality .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
141 The recommended dosage is 600 I.@@ U. / kg epo@@ xy , which once weekly once weekly on three weeks ( day 21 , 14 and 7 ) before surgery and on the day of surgery ( day 0 ) .
&quot; &quot; &quot; 143 &quot; &quot; &quot; &quot; if patients with Chr@@ onic kidney disease should be justified in maintenance therapy under section 4.2 for the lower limit of the hem@@ mo@@ global in @-@ target concentration . &quot; &quot; &quot;
the hem@@ mo@@ glo@@ bin@@ es should amount to approximately 1 g / dl ( 0.@@ 62 m@@ mo@@ l / l ) per month , and should not exceed 2 g / dl ( 1.25 m@@ mo@@ l / l ) per month to minimize the risk of an increase of high blood pressure .
over thro@@ mb@@ otic , v@@ ascular events like m@@ yo@@ cardi@@ di@@ ale I@@ ri@@ ms , M@@ yo@@ cardi@@ al attacks , paraly@@ sis Th@@ ro@@ mb@@ ones , lung disease , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic attacks , retin@@ opath@@ ic glau@@ coma surgery , patients under epo@@ ch@@ tin @-@ treatment , so also patients under epo@@ ch@@ tin @-@ fa drugs .
a higher intra@@ ocular th@@ rom@@ bo@@ v@@ ascular events ( see Section 4.4 and Section 4.8 - General ) was observed in patients under the treatment with er@@ y@@ thro@@ po@@ et@@ ines .
9 patients with hem@@ mo@@ bla@@ st@@ es ( 221 , my@@ el@@ oma , 144 non @-@ Ho@@ d@@ g@@ kin@@ - ly@@ m@@ ph@@ oma and 24 other hem@@ mo@@ bla@@ st@@ ones ) and 332 patients with solid tum@@ ours ( 172 breast cancer , 22 pro@@ state cancer , 21 g@@ astro@@ intestinal car@@ cin@@ oma and 30 other ) .
149 in experimental studies with nearly the 20@@ ,000 of the application for the use of man recommended weekday dose , epo@@ xy al@@ fa is reduced in epo@@ xy body weight , to a delay of the Os@@ si@@ fication and a rise of death mort@@ ality .
as part of the out@@ patient application , the patient can store the patient closed for a period of three days outside of the cooling water and not over 25 ° C .
the propri@@ et@@ or of the owner of approval for the in@@ traffic , the member of the member states , the member of the member states , member of the member of the member states to provide the information and materials to provide the following information and materials : • Schul@@ ungs@@ brochure with the following information and materials . • Equi@@ pping the product handling of correct cooling modules for transport by the patient .
the owner of the permission of the permission of the Federal Office will ensure that in the 3.0 3.0 and in module 1.@@ 8.@@ 1. of the author@@ isation , pharmaceu@@ ko@@ vi@@ gil@@ ance system is carried out and functional before the medicine will be applied in traffic .
the owner of the approval for the in@@ traffic is obliged to comply with the risk management plan ( R@@ MP ) as well as in version 5 of the author@@ isation for the risk management plan ( R@@ MP ) as well as according to each subsequent through the CH@@ MP certificate of the Risk Management Plan .
&quot; &quot; &quot; a updated R@@ MP should be provided according to the &quot; CH@@ MP Gui@@ deline on Risk Management Systems for Medic@@ inal products &quot; &quot; &quot; &quot; at the same time with the next updated report on the in@@ concei@@ vable effect of the drug using ( peri@@ odic Safety Update Report , PS@@ UR ) .
in addition , a updated R@@ MP should be submitted to the latest security requirements ( Safety Speci@@ fication ) , the pharmaceutical ko@@ vi@@ gil@@ ance , or the measures for risk reduction . • within 60 days after reaching an important ( the pharmaceu@@ ko@@ vi@@ gil@@ ance or risk reduction )
• within a month before your treatment a heart attack or stroke , if you have a heart attack or stroke loss in the v@@ eins , the risk of a blood cell formation in the v@@ eins ( deep Ven@@ tim@@ ents ) exists - if you have joined the risk of such blood rop@@ es .
they had serious blood circulation in the heart ( cor@@ on@@ ary heart disease ) , the ar@@ ter@@ ies of legs or arms ( peripheral vision disorder ) or the brain ( zer@@ eb@@ rov@@ ascular disease ) .
during the treatment with Ab@@ se@@ amed it can occur within the norm@@ ative to an easy dos@@ is@@ tive increase in the blood pressure , which is back to another treatment .
their doctor will perform regular blood tests , to control the number of blood vessels during the first 8 weeks of treatment regularly .
iron defici@@ ency , resolution of red blood cells ( H@@ äm@@ oly@@ sis ) , blood loss , vitamin @-@ B@@ 12@@ - or consequ@@ aci@@ dity , should be taken into account and before the start of therapy with discharge .
it is very rarely seen by the occurr@@ ence of an int@@ oler@@ ab@@ y@@ thro@@ sis stop@@ en@@ y after several years after years after years , y@@ thro@@ po@@ etic effects were reported .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; if you suffer under er@@ y@@ thro@@ sis stop@@ en@@ ie , he will suffer your treatment with se@@ amed and set , as your an@@ emia is best . &quot; &quot; &quot; &quot; &quot; &quot; &quot;
this must be observed by injection molding into a v@@ ene ( intra@@ ven@@ ous ) if you are treated because of a kidney disease due to kidney disease .
at the same time the risk for problems with the heart or blood vessels are increased and the mort@@ ality could be increased .
in increased or increasing the pot@@ ency , your doctor may contribute to an inter@@ ruption of the treatment with discharge in consideration until the pot@@ assi@@ um values are again in the norm@@ alities .
if you suffer from chronic kidney disease and clinical reason@@ ing through in@@ sufficient heart performance , your doctor will ensure that your hem@@ mo@@ glo@@ bin@@ dings will not exceed certain value .
according to the present findings , the treatment of blood diseases caused by chronic kidney disease ( N@@ ing@@ in@@ suffici@@ ency ) , which are not yet di@@ aly@@ zed the progression of the kidney disease .
&quot; &quot; &quot; results appear ordered &quot; &quot; &quot; &quot; by relevance &quot; &quot; &quot; &quot; or &quot; &quot; &quot; &quot; by date &quot; &quot; &quot; &quot; ( publication date ) , &quot; &quot; &quot;
200 your doctor will determine your values of the red blood color ( hem@@ mo@@ glob@@ in ) and your query dose according to adapt the risk of a blood vessel formation ( thro@@ mb@@ ot@@ opic event ) as low as possible .
this risk should be treated carefully , especially if you have an increased risk of thro@@ mb@@ otic v@@ ascular events , e.g. if you have an increased risk of thro@@ mb@@ ot@@ ical v@@ ascular events ( e.g. a deep Ven@@ tim@@ ents or lung disease ) .
in case of cancer patients , remember that Ab@@ se@@ amed like a growth factor for blood pollution and under certain circumstances the tum@@ ors can affect the tum@@ ors .
if you have a greater orthop@@ a@@ edic surgery , the treatment should be investigated prior to the treatment of your an@@ emia and to be treated accordingly .
if your values of red blood color ( hem@@ mo@@ glob@@ in ) should be high , you should not get off when an increased risk of ble@@ eding formation after surgery .
please inform your doctor or pharmac@@ ist if you take other drugs or have taken this medication even if it is not authorised to prescription drugs .
if you take C@@ ic@@ los@@ s ( means for the oppression of the immune system ) during your therapy with Ab@@ se@@ amed , your doctor will arrange a certain blood tests to measure the blood level of C@@ ic@@ los@@ s to measure the blood level of C@@ ic@@ los@@ s .
laboratory tests have no exchange effect between epo@@ xy and G @-@ CS@@ F or GM @-@ CS@@ F ( G @-@ CS@@ F and GM @-@ CS@@ F are required to build the immune system , for example in cancer - chem@@ otherapy or HIV ) .
depending on how your blood pul@@ ley ( an@@ emia ) treatment can be adjusted for all four weeks until your state is under control .
your doctor will replace regular blood tests to verify the success and make sure that the medicine is really effective and your hem@@ mo@@ glo@@ bin@@ tie value .
as soon as you arrive well , you get regular cra@@ ckers from se@@ amed between 25 and 50 I.@@ E. / kg twice a week , distributed on two large inj@@ ections .
your doctor will arrange to include regular blood tests to verify the success rate and make sure your hem@@ mo@@ glo@@ bin@@ tie value a certain value .
depending on how the an@@ emia is said to treatment , the dose can be adjusted around all four weeks until the condition is under control .
in order to ensure this and make sure that the hem@@ mo@@ glo@@ bin@@ ocular value does not exceed a certain value , the treat@@ ment@@ ing doctor will perform regular blood tests .
if it is necessary to reduce the treatment period before surgery , a dose of 300 I.@@ E. / kg on 10 consecutive days prior to surgery , on day of surgery , and further 4 days after surgery .
however , you can also learn if your doctor may also be appropriate for your doctor , even how you use se@@ perate yourself under the skin .
heart disease , heart disease , brain blood , temporary in@@ tox@@ ins , hem@@ angi@@ ogen@@ ic disorders , lung cancer , corneal surgery ( an@@ eur@@ ial ) , Th@@ ro@@ mb@@ ones of the ret@@ ina and blood cl@@ esi@@ ons in artificial kidney were reported in patients with Er@@ y@@ thro@@ po@@ tin treatment .
an eye @-@ eye and the lips ( qu@@ ine @-@ eye ) and shock @-@ allergi@@ c reactions with symptoms such as Kri@@ s , Rö@@ der , Ju@@ ck@@ rei@@ z , Hit@@ ze@@ ep and acceler@@ ated pulse were reported in rare cases .
er@@ y@@ thro@@ sis stop@@ en@@ ie means that no more sufficient red blood cells can be formed ( see Section &quot; Special Features in the application of Ab@@ se@@ amed ) . &quot;
after repeated blood sp@@ ends it is independent of the treatment with discharge - to a blood vessel formation ( thro@@ mb@@ ot@@ ical v@@ ascular events ) .
the treatment with Ab@@ se@@ amed may be compared with the increased risk of blood pro@@ p formation after surgery ( postoperative refra@@ ct@@ otic v@@ ascular events ) when your source code is too high
inform your doctor or pharmac@@ ist when one of the remaining side effects you considerably affected or if you notice side effects that are not specified in this utility information .
if a spray can be taken out of the fridge and room temperature ( up to 25 ° C ) , it has to be used either within 3 days or yet .
Ac@@ tu@@ a is applied for the treatment of the following diseases : • Oste@@ op@@ or@@ osis ( a disease that makes bones spr@@ ing@@ le ) both in women after their exchange years as well as men .
patients with a high risk risk ( bone fra@@ is ) applied , including patients who recently have a slightly trau@@ mati@@ sm of hi@@ ring such as the disease , a disease that changes the normal course of bone growth .
in addition , patients with Mor@@ bus Pa@@ get at least 500 mg of calcium is twice daily for at least 10 days after the treatment ; patients with hi@@ ps should get a large dose of vitamin D ( 50 000 to 125 000 IE ) oral or injection in a muscle .
the administration of par@@ acet@@ am@@ ol or I@@ bu@@ pro@@ fen ( remedy against inflammation ) just after the application of acet@@ one can significantly reduce muscle pain , such as fever , muscle pain , gri@@ ps similar symptoms , joint pain and head@@ aches .
for the treatment of the Mor@@ bus Pa@@ get may only be prescribed by doctors that have experience in the treatment of this disease .
since the active ingredient in Ac@@ tu@@ a is the same as in Z@@ omet@@ a , a portion of the data material was used for zinc to valuation of acet@@ one .
in the first study nearly 8 000 older women were involved in ost@@ e@@ op@@ or@@ osis , and the number of vert@@ eb@@ ral and hip fra@@ c@@ tures were examined over a period of three years .
the second study included 2 127 men and women with ost@@ e@@ op@@ or@@ osis over 50 years that had recently been a hip fra@@ cture ; it was investigated the number of cargo ships over a period of up to five years .
with Mor@@ bus Pa@@ get was tested in two studies in a total of 357 patients and six months long with ris@@ ed@@ ron@@ at ( another bis@@ phosph@@ on@@ at ) .
main indicators for the effectiveness , whether the content of alkal@@ ine phosph@@ ate in ser@@ um ( an enz@@ yme , the bone sub@@ strate ) in the blood , norm@@ alized or at least 75 % compared to the output value .
in the study with older women , the risk of flu@@ ids in Ac@@ tu@@ a ( without other Oste@@ op@@ or@@ os@@ em@@ edi@@ ans ) was reduced by a period of three years in comparison to the plac@@ ebo .
in comparison of all patients in Ac@@ tu@@ a ( with or without other Oste@@ op@@ or@@ os@@ em@@ edi@@ ans ) with those under plac@@ ebo the risk of hi@@ ps was reduced by 41 % .
in the study with men and women with hi@@ ps , 9 % of the patients had a fra@@ cture ( 92 of 1 0@@ 65 ) compared to 13 % of the patients under plac@@ ebo ( 139 from 1 0@@ 62 ) .
most side effects of Ac@@ tu@@ a are left within the first three days after in@@ fusion and are less frequent .
Ac@@ tu@@ a must not be applied to patients who may have sensitive ( allergi@@ c ) against z@@ ol@@ ed@@ ron@@ ic acid or other bis@@ phosph@@ on@@ ate or any other ingredients .
like with all bis@@ phosph@@ on@@ ates , patients are subject to the risk of kidney , reactions to in@@ fu@@ sion@@ ary interface and ost@@ e@@ ek@@ rose ( de@@ die by bone tissue ) in the jaw .
the manufacturer of Ac@@ tu@@ a presents awareness material for doctors who use Ac@@ tu@@ a for treatment of ost@@ e@@ op@@ or@@ osis , as well as such material for patients who should contact the medicine by taking care of the medicine .
in April 2005 , the European Commission divided the European Commission of Nov@@ arti@@ s Euro@@ ph@@ arm Limited for the transport of acet@@ one in the entire European Union .
conditions A restrictions regarding the safe AND EQU@@ IP@@ MENT OF Drug Policy , implement SIN@@ D • BE@@ DIN@@ G@@ ITI@@ ONS OR MORE AC@@ COUN@@ TRY OF THE DE@@ CI@@ ATION OF THE DO@@ CU@@ MENT OF THE DO@@ CU@@ MENT OF THE DO@@ CU@@ MENT HERE
treatment of ost@@ e@@ op@@ or@@ osis in post@@ men@@ op@@ aus@@ al women and men with an increased risk of fra@@ c@@ tures , including patients with a recently er@@ lit@@ t@@ ted low @-@ trau@@ mati@@ sm .
the patient information sheets are provided and the following core groups include : • The Pack@@ ages of cal@@ ci@@ um and vitamin D , appropriate physical activity , non @-@ smo@@ kers and vitamin D , appropriate signs and symptoms of serious adverse events • Los@@ ing to medical or care aid
treatment of ost@@ e@@ op@@ or@@ osis • at post@@ men@@ op@@ aus@@ al women in men with an increased risk of fra@@ c@@ tures , including patients with a recently er@@ lit@@ t@@ ted low @-@ trau@@ mati@@ sm .
for treatment of post@@ men@@ op@@ aus@@ al Oste@@ op@@ or@@ osis and ost@@ e@@ op@@ or@@ osis in men an intra@@ ven@@ ous in@@ fusion of 5 mg acet@@ one once annually .
in patients with a low @-@ trau@@ mati@@ cally hip fra@@ ction , the administration of in@@ fusion of acet@@ one two or more weeks after operating supply of the hip fra@@ ction ( see Section 5.1 ) .
for the treatment of Mor@@ bus Pa@@ get should be prescribed by doctors , the experience in the treatment of Mor@@ bus Pa@@ get .
after a treatment of the Mor@@ bus Pa@@ get with Ac@@ tu@@ a , a long remote period was observed in patients that have been marked on the therapy ( see section 5.1 ) .
in addition , it is advis@@ able to ensure sufficient intake of calcium , according to twice daily at least 500 mg of elem@@ entary calcium , for at least 10 days after the gift of acet@@ one . ( see Section 4.4 ) .
patients with a recently er@@ lit@@ t@@ ted low @-@ trau@@ mati@@ sm is recommended for a initial dose of 50,000 to 125@@ ,000 I.@@ E. orange or intra@@ mus@@ cular vitamin D before the first Ac@@ tu@@ a in@@ fusion .
the frequency of symptoms associated within the first three days after the administration of acet@@ am@@ ol or I@@ bu@@ pro@@ fen may be reduced shortly after the application of acet@@ am@@ ol .
patients with kidney dys@@ function ( see Section 4.4 ) In patients with a Kre@@ at@@ in@@ in @-@ Clear@@ ance &lt; 35 ml / min will not recommended , as limited clinical experiences for this patient group are free .
older patients ( ≥ 65 years ) A d@@ os@@ is@@ cation is not necessary because the bi@@ polar tra@@ ce@@ ability , distribution and Eli@@ min@@ ation at older patients similar to younger ones .
children and adol@@ esc@@ ents are not recommended for use in children and adol@@ esc@@ ents under 18 years of age , because data is missing and eff@@ ort@@ less .
Ac@@ tu@@ a is not recommended for patients with severe kidney disease ( Kre@@ at@@ in@@ in @-@ Clear@@ ance &lt; 35 ml / min ) for this patient population only limited clinical experiences .
an existing Hy@@ po@@ kal@@ zä@@ m stands before the beginning of the therapy with acet@@ one by means of sufficient intake of calcium and vitamin D ( see Section 4.3 ) .
due to the rapid inclusion of the use of z@@ ol@@ ed@@ ron@@ ic acid to the bone structure is a temporary , sometimes the symp@@ tom@@ atic hy@@ po@@ pot@@ ency is normally used within the first 10 days after the in@@ fusion of Ac@@ tu@@ a occurs ( see Section 4.8 ) .
in addition , it is advis@@ able to ensure sufficient intake of calcium , according to twice daily at least 500 mg of elem@@ entary calcium , for at least 10 days after the gift of acet@@ one . ( see section 4.2 ) .
cancer treatment , chem@@ otherapy , treatment with cor@@ on@@ ero@@ ids , bad oral hygiene ) should be applied after a application of bis@@ phosph@@ on@@ ates with appropriate preventive det@@ erg@@ ents .
for patients who need medicines , no data is available , whether the inter@@ ruption of the treatment with bis@@ phosph@@ on@@ ates is reduced to the risk of ost@@ omy in the jaw area .
clinical evaluation by the treatment procedure should be basis for treatment plan of each patient and based on an individual benefit risk assessment .
the frequency of symptoms which may occur within the first three days after the use of acet@@ am@@ ol or I@@ bu@@ pro@@ fen for the application of acet@@ am@@ ol or I@@ bu@@ pro@@ fen for the application of Ac@@ tu@@ a ( see section 4.2 ) .
the frequency is reported as a serious side effect on patients , the Ac@@ tu@@ a were increased ( 1,3 % ) ( 51 % ) ( 51 % ) ( 51 % ) ( 22 % ) ( 22 % ) ( 22 % ) ( 22 % ) .
XHTML 1.1 plus Math@@ ML 2.0 XHTML 1.1 plus Math@@ ML 2.0 XHTML 1.1 plus Math@@ ML 2.0 XHTML 1.1 plus Math@@ ML 2.0 plus SVG 1.1 Math@@ ML 2.0 SVG 1.0 SVG 1.1 SVG 1.1 SVG 1.1 Tiny SVG 1.1 Basic S@@ MIL 1.0 S@@ MIL 2.0 Root Element : HTML
very frequent ( ≥ 1 / 100 , &lt; 1 / 10 ) , occasional ( ≥ 1 / 1000 , &lt; 1 / 100 ) , rare ( ≥ 1 / 10,000 , &lt; 1 / 1,000 ) un@@ desired pharmaceutical effects are listed in the table 1 .
kidney dys@@ function of Z@@ ol@@ ed@@ ron@@ ic acid has been infected with kidney dys@@ function ( i.e. a decrease of the ser@@ um @-@ cre@@ at@@ in@@ into ) and rare cases than acute rej@@ ection .
the change of creation of cre@@ at@@ in@@ in @-@ Clear@@ ance ( annually before the administration @-@ related ) and the occurr@@ ence of kidney dys@@ function as well as a limited N@@ ing@@ function were comparable to ost@@ e@@ op@@ or@@ osis over three years between the Ac@@ la@@ sta@@ - and the plac@@ ebo group .
a tran@@ script to increase the Ser@@ um cre@@ at@@ in@@ ins within 10 days after injection was treated with 1.8 % of acet@@ ate treated patients compared to 0.8 % of plac@@ ebo @-@ treated patients .
based on the rating of the Labor@@ atories , the current asy@@ mp@@ tom@@ atic Kal@@ zi@@ um values , which are below the normal balance sheet ( less than 2,@@ 10 m@@ mo@@ l / l ) , by 2.3 % of acet@@ one in a large clinical study treated patients in the Mor@@ bus / Pa@@ get trials treat patients .
all patients received additional amounts of vitamin D and calcium in the study for post@@ men@@ op@@ aus@@ al Oste@@ op@@ or@@ osis in the study for preventing clinical fra@@ c@@ tures after a hip fra@@ ction and in the Mor@@ bus @-@ Pa@@ get @-@ studies ( see Section 4.2 ) .
in the study for the prevention of clinical trials after a recently er@@ lit@@ t@@ ous hip fra@@ ction , the vitamin D mirrors were not rout@@ inely measured , however , the majority of the patient received a initi@@ al@@ dose vitamin D prior to the administration of Ac@@ tu@@ a ( see Section 4.2 ) .
local reactions after the administration of Z@@ ol@@ ed@@ ron@@ ic acid in a large clinical trial was published on local reactions in the in@@ fusion zone , such as tubes , sw@@ elling and / or pain , reports ( 7 % ) .
Oste@@ on@@ ek@@ ro@@ sis in the jaw area , above all , especially for cancer patients , ost@@ omy in cancer patients , which were treated with bis@@ phosph@@ on@@ ate , including Z@@ ol@@ ed@@ ron@@ ic acid , including Z@@ ol@@ ed@@ ron@@ ic acid ) .
many of these patients had signs for local infections including ost@@ om@@ yel@@ i@@ tis , and the majority of reports refers to cancer patients after dental extract or other dental allo@@ ys .
7 study with 7.@@ 7@@ 36 patients came in ost@@ omy in treatment with acet@@ one and in a plac@@ ebo @-@ treated patients .
in case of over@@ dosing , which leads to a clinical @-@ relevant hypo@@ po@@ m , can be achieved through the gift of or@@ ical calcium and / or intra@@ ven@@ ous in@@ fusion of calcium glu@@ con@@ at .
clinical effectiveness in treatment of post@@ men@@ op@@ aus@@ al Oste@@ op@@ or@@ osis ( PFT ) The eff@@ ic@@ acy and safety of acet@@ one 5 mg once annually for 3 consecutive years at post@@ men@@ op@@ aus@@ al women ( BM@@ D ) -@@ T @-@ Score for the Sch@@ enk@@ el@@ h@@ as ≤ 0.1 or more or a medium hard @-@ treated lung function .
effects on morph@@ omet@@ ric vert@@ enti@@ re@@ signs were significantly higher than a period of three years as well as after a year the frequency of one or more new spine fra@@ c@@ tures ( see table 2 ) .
Ac@@ tu@@ a @-@ treated patients in 75 years and older than 60 % lower risk of vert@@ ine defects compared with plac@@ ebo @-@ patients ( p &lt; 0,@@ 0001 ) .
effects on hip fra@@ c@@ tures of hi@@ bis@@ a showed a constant effect on three years , which resulted in one of 41 % ( 95 % CI , 17 % up to 58 % ) reduced risk for hip fra@@ c@@ tures .
effect on the bone density ( BM@@ D ) Ac@@ tu@@ a increased the bone density of cy@@ cl@@ er@@ foli@@ c acid , and at dist@@ al radi@@ us compared with the plac@@ ebo @-@ treatment significantly in all times ( 6 , 12 , 24 and 36 months ) .
9 increase the bone density of the lungs in order to cut 6.@@ 7 % , the whole tri@@ mmed is 5,@@ 1 % , the difference between 5,@@ 1 % and the dist@@ al radi@@ us around 3.2 % .
bone hist@@ ology with 152 post@@ men@@ op@@ aus@@ al cancer , which were treated with acet@@ one ( N = 82 ) or plac@@ ebo ( N = 70 ) or plac@@ ebo ( N = 70 ) or plac@@ ebo ( N = 70 ) .
a micro@@ computer tom@@ echan@@ ics ( µ@@ CT ) analysis showed an increase of intra@@ ocular bone volum@@ etric methods and maintaining the tra@@ cker bone structure .
bone @-@ specific alkal@@ ine cancer immun@@ os@@ ase ( B@@ SAP ) , the N @-@ terminal Pro@@ sper@@ ti@@ d of Typ @-@ I@@ - Koll@@ agen ( P@@ 1@@ NP ) in Ser@@ um and the beta @-@ C @-@ Tel@@ op@@ ep@@ ti@@ d ( b @-@ C@@ TX ) in Ser@@ um and the beta @-@ C @-@ Tel@@ op@@ ep@@ ti@@ d ( b @-@ C@@ TX ) were determined during the study of 5@@ 17 to 1.@@ 246 patients in peri@@ o@@ dic@@ als during the study .
treatment with a yearly 5 @-@ mg dosage of acet@@ one reduced B@@ SAP to 12 months increased by 30 % compared to the output value and was held at 28 % below the output value up to 36 months .
P@@ 1@@ NP was significantly reduced by 61 % below the output value after 12 months and increased by 52 % under the output value up to 36 months .
B @-@ C@@ TX was significantly reduced by 61 % below the output value to 12 months and was kept at 55 % below the output value up to 36 months .
the vitamin D mirrors were not rout@@ inely measured , but the majority of the patients received a suspended dose vitamin D ( 50,000 to 125@@ 0,000 I.@@ U. oral or intra@@ mus@@ cular ) 2 weeks before in@@ fusion .
the total population was 10 % ( 101 patients ) in the plac@@ ebo group compared with 13 % ( 141 patients ) in the plac@@ ebo group .
effect on the bone mineral density ( BM@@ D ) In the H@@ ORI@@ Z@@ ON @-@ study increased the Ac@@ ry@@ a treatment compared to plac@@ ebo @-@ treatment the BM@@ D to the total hardness and shot points on all time points .
Ac@@ tu@@ a treatment led by 24 months in comparison to plac@@ ebo @-@ treatment to increase the BM@@ D by 5,@@ 4 % on the total hardness and 4.@@ 3 % at Sch@@ enk@@ el@@ h@@ als .
clinical effectiveness in men in H@@ ORI@@ Z@@ ON @-@ r@@ ft study were published by 508 men random@@ ised and at 185 patients the BM@@ D were assessed according to 24 months .
the study was not designed to show a reduction of the clinical symptoms in males ; the frequency of clinical fra@@ c@@ tures was 7.5 % at Ac@@ ry@@ a @-@ treated men compared to 8.8 % in plac@@ ebo .
Euromonitor International has over 40 years &apos; experience of publishing market research reports , business reference books and online information systems .
clinical effectiveness of the treatment at Mor@@ bus Pa@@ get the bone was investigated by patient in patients and patients in the age of 30 years ago with radi@@ ological tum@@ ours ( mean Ser@@ um mirror of the alkal@@ ine mirror of alkal@@ ine phosph@@ ate in accordance with the 2,@@ 6@@ 1.7 to 3,@@ 0@@ fold @-@ specific upper levels in the study ) .
11 The effectiveness of an in@@ fusion of 5 mg Z@@ ol@@ ed@@ ron@@ ic acid compared to intake 30 mg ris@@ ed@@ ron@@ at once daily during 2 months in two se@@ k studies of studies .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
&quot; &quot; &quot; &quot; &quot; &quot; &quot; well @-@ being &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot;
of the 143 with Ac@@ tu@@ a and the 107 with Ris@@ ed@@ ron@@ at treat@@ able study , the therapeutic approach could be compared with Ac@@ tu@@ a , compared to 71 of with cracks at the treated patients , in a middle duration of the follow @-@ up phase of 18 months after application .
unique and multi @-@ fold 5 and 15 minutes of in@@ fusion In@@ fusion of 2 , 4 , 8 and 16 mg Z@@ ol@@ ed@@ ron@@ ic acid in 64 patients receiving the following pharmac@@ ological data that have proven itself as dos@@ is@@ independent .
after that , plasma levels quickly took up to &lt; 10 % of the maximum quality after 4 h and &lt; 1 % after 24 h , followed by a long lasting phase very little concentration , no more than 0.1 % of the maximum .
ras@@ cal bi@@ ph@@ as@@ sic dis@@ appearance of the large circulation , with half @-@ hole times t ½ -@@ 0.@@ 24 and t ½ &#124; 1,@@ 87 hours , followed by a long sh@@ min@@ ation phase with a terminal Eli@@ min@@ ation@@ sh@@ al@@ bs@@ age t ½ , 146 hours .
the early distribution phases ( α and β , with the above t ½ -@@ values ) , the fast res@@ or@@ ption into the bones and the dis@@ advantages over the kid@@ neys .
in the first 24 hours , 39 ± 16 % of the permitted dose in Ur@@ in , while the rest is primarily bound to bone tissue .
the total body @-@ Clear@@ ance is independent of the dose 5,@@ 04 ± 2.5 l / h and remains un@@ affected by gender , age , race or body weight .
an extension of the in@@ fusion period of 5 to 15 minutes led to decrease of the z@@ ol@@ ed@@ ron@@ re@@ - concentration in 30 % at the end of in@@ fusion , but had no effect on the surface below the curve ( plasma concentration against time ) .
a decreased relative risk of Cy@@ to@@ chrome @-@ P@@ 450 @-@ En@@ z@@ ym@@ ogen@@ ic substances is unlikely , because Z@@ ol@@ ed@@ ron@@ ic acid is not suspected because they are a weak or no direct and / or Ir@@ rever@@ sible , hydrogen in@@ hibition of the P@@ 450@@ -
special Pati@@ ents groups ( see Section 4.2 ) The ren@@ ale Clear@@ ance of the Z@@ ol@@ ed@@ ron@@ ic cor@@ related with the Kre@@ at@@ in@@ in @-@ Clear@@ ance , namely 75 ± 29 ml / min ( range 22 to 143 ml / min ) .
it follows that a light ( cl@@ c@@ r = 50@@ - 80 ml / min ) and excessive kidney dys@@ function calls up to 35 ml / min ( no D@@ os@@ is@@ cation of the Z@@ ol@@ ed@@ ron@@ ic acid ) .
as for severe kidney dys@@ function ( Kre@@ at@@ in@@ ine Clear@@ ance &lt; 30 ml / min ) only limited data , are not limited to these conditions .
acute tox@@ icity The highest non @-@ recur@@ rence intra@@ ven@@ ous single dose was 10 mg / kg body weight and in rats 0.@@ 6 mg / kg body weight .
for studies of dogs , single d@@ ots of 1.0 mg / kg ( based on AU@@ C the 6@@ fold of the recommended therapeu@@ tic exposure ) , given a period of 15 minutes , well and without ren@@ al imp@@ air@@ ment .
for chronic pain and chronic tox@@ icity in rats with intra@@ ven@@ ous application , a total of 6 mg / kg , a total of 6 @-@ times ( cum@@ ulative dose , related to the AU@@ C ) , a total of 6 @-@ times ( cum@@ ulative dose , related to the AU@@ C , corresponds to the AU@@ C ) .
in long @-@ term studies with repeated instruments which exceeded the maximum of the intended Human @-@ exposure , the toxic effects of other organs , including the guest of the patient , and the liver , as well as intra@@ ven@@ ous injection systems .
the most common results and studies with repeti@@ tive application was a prolifer@@ ating Spon@@ gi@@ osa in the met@@ ap@@ hy@@ se of the long bone in the growth phase with almost all dos@@ es , a way which reflects the pharmac@@ ological , anti@@ res@@ or@@ tive effect of the substance .
a Ter@@ at@@ ogen@@ esis of 0.2 mg / kg than external and inner ( vis@@ cer@@ al ) ab@@ norm@@ alities and such el@@ sk@@ el@@ eton .
in ra@@ bb@@ its , no Ter@@ ato@@ id effects or embr@@ yo @-@ ton@@ al effects were observed , although the fi@@ xation of the tox@@ icity of 0.1 mg / kg resulted in the lowest Ser@@ um @-@ calcium @-@ mirror .
if the medicine is not used immediately , the user is responsible for storage time according to preparation and conditions before application ; usually should not exceed 24 h at 2 ° C to 8 ° C .
Ac@@ tu@@ a is delivered as a package with a bottle of packing unit or as a bund@@ led package consisting of 5 pack@@ ets which included a bottle .
treatment of ost@@ e@@ op@@ or@@ osis in post@@ men@@ op@@ aus@@ al women and men with an increased risk of fra@@ c@@ tures , including patients with a recently er@@ lit@@ t@@ ted low @-@ trau@@ mati@@ sm .
the patient information sheets are provided and the following core groups include : • The Pack@@ ages of cal@@ ci@@ um and vitamin D , appropriate physical activity , the non @-@ smo@@ kers and vitamin D , appropriate signs and symptoms of serious adverse events • To attack medical or care aid
July 2007 , supple@@ mented by 29 September 2006 , in the module 1.@@ 8.1 of author@@ isation contract , pharmaceu@@ ko@@ vi@@ gil@@ ance system is working in force and works before and during the product .
Ris@@ ko Management Plan The owner of approval for the in@@ traffic is obliged to perform the studies and additional activities to the pharmaceu@@ ko@@ vi@@ gil@@ ance plan , which are placed in the pharmaceu@@ ticals management plan ( R@@ MP ) in module 1.@@ 8.2 of author@@ isation and all the following by the CH@@ MP authorized versions of the R@@ MP .
Euromonitor International has over 40 years &apos; experience of publishing market research reports , business reference books and online information systems .
• If new information is known , the current statements concerning safety , the pharmaceutical ko@@ vi@@ gil@@ ance plan or activities to minimize risk of risk . • Within half of 60 days when an important milestone ( for pharmaceu@@ ko@@ vi@@ gil@@ ance or risk management ) was achieved . • On request the EME@@ A requirement requirements .
Z@@ ol@@ ed@@ ron@@ ic is a representative of a sub@@ st@@ amping class which is called ic@@ phosph@@ on@@ ate , and is used to treat cancer treatment in post@@ men@@ op@@ aus@@ al women who used ost@@ e@@ op@@ or@@ osis in men and the Mor@@ bus Pa@@ get of the garlic .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; a few weeks ago , &quot; &quot; &quot; &quot; he said , &quot; &quot; &quot; &quot; he said , &quot; &quot; &quot; &quot; he said , &quot; &quot; &quot; &quot; he said , &quot; &quot; &quot; &quot; he said , &quot; &quot; &quot; &quot; he said . &quot; &quot; &quot;
while the Mor@@ bus Pa@@ get is done , the bone structure is progres@@ sed quickly , and new bone material is un@@ usable , which makes the bone material weaker than normal .
Ac@@ tu@@ a acts , using the bone structure the bone structure has norm@@ alized , a normal bone formation , and thus reducing the bone strength .
if you are in dental treatment or dental surgery , please inform your doctor that you are treated with Ac@@ tu@@ a .
for application of acet@@ one with other medicines Please check your doctor , pharmac@@ ies or health care if you have other drugs or have recently taken this medication even if it is not authorised to prescription drugs .
for your doctor , it is particularly important to know if you are taking the medicine .
with application of Ac@@ tu@@ a with food and drinks you may worry about that you have sufficient liquid in accordance with the instructions of your doctor before and after treatment with Ac@@ tu@@ a .
Oste@@ op@@ or@@ osis The normal dose is 5 mg once per year that is administ@@ ered by your doctor or patient care as in@@ fusion in a v@@ ene .
if you have broken , it is recommended to use the administration of Ac@@ tu@@ a two or more weeks after the operational supply of the hip bru@@ it .
Mor@@ bus Pa@@ get The normal dose is 5 mg , which is administ@@ ered by your doctor or patient care as in@@ fusion in a v@@ ene .
since Ac@@ tu@@ a has a long time , you will need a additional dose for a year or longer .
it is important to follow these instructions to follow the cal@@ ci@@ um mirror in your blood in time after in@@ fusion .
with Mor@@ bus Pa@@ get can work for a longer than a year , and your doctor will inform you when you need an extended treatment .
if the administration of Ac@@ tu@@ a has been applied , you will contact your doctor or hospital to arrange a new appointment .
before the end of the therapy with Ac@@ cre@@ a Falls you will take the end of the treatment with Ac@@ tu@@ a , please take your next doctor and talk about this with your doctor .
adverse events related to the first in@@ fusion of in@@ fusion ( more than 30 % of the patients ) are often frequent after the subsequent in@@ fusion .
fever and ch@@ iller , muscle - or joint pain and head@@ aches , occur within the first three days after the administration of acet@@ one .
currently it is un@@ clear whether Ac@@ tu@@ a usually causes this ir@@ regular heart stick , but you should report your doctor if you received such symptoms after you received Ac@@ tu@@ a .
enter multiple addresses separated by comm@@ as and / or different lines .
flu , pl@@ ess@@ ness , ti@@ red@@ ness , ti@@ red@@ ness , im@@ pregn@@ ation , im@@ pregn@@ ation , im@@ pregn@@ ation , facial cum@@ ulus , facial cum@@ ulus , facial cum@@ ulus , facial cum@@ ber , facial cum@@ ber , arom@@ atic , red@@ ness , red@@ ness , red@@ ness , red@@ ness , red@@ ness , red@@ ness , red@@ ness , red@@ ness , red@@ ness and Dur@@ st .
persistent pain and / or not healing wo@@ unds in the mouth or on the jaw were treated especially for patients who were treated with bis@@ phosph@@ on@@ ates due to other diseases .
over allergi@@ c reactions , including rare cases of breathing problems , N@@ ath@@ ing and An@@ gi@@ o@@ ops ( such as sw@@ elling in the face , the tongue or in Ra@@ chen ) , was reported .
please inform your doctor , pharmac@@ ies or health care if one of the remaining side effects are considerably affected or no side effects that are not listed in this utility information .
if the medicine is not used immediately , the user is responsible for the bearing time and conditions until application ; usually should not exceed 24 h at 2 ° C to 8 ° C .
patients with a recently treated low @-@ trau@@ matic hip fra@@ ction is recommended to increase the in@@ fusion of acet@@ one two or more weeks after the operative supply of the hip fra@@ ction .
before and after the administration of Ac@@ tu@@ a , patients must obtain sufficient liquid with liquid ; this is especially important in patients who obtain a di@@ ure@@ tic treatment .
due to the rapid inclusion of the use of z@@ ol@@ ed@@ ron@@ ic acid to the bone structure can develop a temporary , sometimes symp@@ tom@@ atic po@@ inter of hy@@ po@@ kal@@ f@@ c acid , which occurs usually within the first 10 days after the in@@ fusion of acet@@ one .
in addition , it is advis@@ able to ensure sufficient intake of calcium , according to at least twice daily 500 mg of elem@@ entary calcium , for at least 10 days after the gift of acet@@ one .
patients with one recently discovered low @-@ trau@@ mati@@ sm is an initial dose of 50,000 to 125@@ ,000 I.@@ E. orange or intra@@ mus@@ cular vitamin D in in@@ fusion of acet@@ one .
if you need more information about your illness or treatment , please read the Pack@@ ager ( also part of the EP@@ AR ) or contact your doctor or pharmac@@ ist .
A@@ comp@@ lia is also applied to a diet and exercise for adult patients who suffer from o@@ bes@@ ity ( body fat ) of 30 kg / m ² or above or the above mentioned ( BM@@ I of 27 kg / m ² or above ) and furthermore , or more
in addition , four studies were conducted on 7 000 patients in which A@@ comp@@ lia had been used in comparison to a plac@@ ebo .
&quot; &quot; &quot; results appear ordered &quot; &quot; &quot; &quot; by relevance &quot; &quot; &quot; &quot; or &quot; &quot; &quot; &quot; by date &quot; &quot; &quot; &quot; ( publication date ) , &quot; &quot; &quot;
which risk is associated with A@@ comp@@ lia ? it is the most common side effects of A@@ comp@@ lia that were observed during the studies ( observed in more than 1 of 10 patients ) , NA@@ US@@ EA ( Ü@@ bel@@ ess ) and infections of the upper resp@@ ir@@ . ng The complete list of the side effects are found in connection with A@@ comp@@ lia &apos;s side effects .
it may also be applied to patients who suffer from severe depression or anti@@ de@@ press@@ ants , as there are risk of depression and among other things in a small minority of patients .
caution is offered at the same application of A@@ comp@@ lia with medicines such as K@@ eto@@ con@@ az@@ ol or I@@ tra@@ con@@ az@@ ol ( medicine against fung@@ al infections ) , ritu@@ als for use at HI@@ V@@ - infection ) , Tel@@ i@@ thro@@ my@@ cin or Clari@@ fying my@@ cin ( antibiotics ) . LN
pdf @-@ Datei per E @-@ Mail , Enter@@ pris@@ e@@ wide Price ( Global Site License ) * * * , versandkostenfrei
medicine is applied to patients who need it from health and not from cosmetic reasons ( by providing services for patients and doctors ) , and around the ar@@ z
it also applies to diet and exercise for treating a o@@ bes@@ ity ( BM@@ I ≥ 30 kg / m ² ) or over@@ estimated patients ( BM@@ I &gt; 27 kg / m ² ) , which also include a or more risk factors like type @-@ 2 diabetes or dy@@ sli@@ pi@@ d@@ emia .
A@@ comp@@ lia is not recommended for use in children and adol@@ esc@@ ents under 18 years of the absence of absence of data for effectiveness and in@@ contin@@ ence .
the dep@@ res@@ sive strength or tuning changes with depres@@ sive symptoms were received by up to 10 % of the patients who were reported to 1 % of the patients , the Rim@@ on@@ ab@@ ant reported ( see Section 4.8 ) .
medical and de@@ press@@ ant disorders may not be applied , however , unless the benefits of treatment in individual cases the risk ( see Section 4.3 and 6.@@ 4.8 ) .
it also applies to patients who are present - apart from o@@ bes@@ ity - no recogni@@ z@@ able risks , de@@ press@@ ants can occur .
stocks or other obvious persons ) are to be added to realize that it is necessary to monitor the symptoms of such symptoms and get rid of medical advice if these symptoms occur .
• Grin@@ ding patients The eff@@ ic@@ acy and in@@ tox@@ ins of fluor@@ on@@ ab@@ ant at the treatment of patients over 75 years were not sufficient .
patients with a cardiovascular event ( M@@ yo@@ cardi@@ al inf@@ ra or stroke , etc . ) were less than 6 months of studies with Rim@@ on@@ ab@@ ant .
ri@@ f@@ amp@@ ic@@ in , phen@@ y@@ to@@ in , phen@@ y@@ to@@ sis , phen@@ y@@ to@@ sis ) , is assumed that the simultaneous amount of pot@@ ent CY@@ P@@ 3@@ A4 In@@ du@@ sters the plasma concentration of Rim@@ on@@ ab@@ ant
according to patients with a o@@ bes@@ ity , patients receiving patients with a o@@ bes@@ ity and moreover , in addition to 38@@ 00 patients in other indications .
the following table ( table 1 ) shows the un@@ desired effect of un@@ desired effect in the plac@@ ebo @-@ controlled trials in patients that were treated to weight reduction and due to increased met@@ abolic disease .
he was significantly higher than the correspon@@ d@@ inal plac@@ eb@@ rows ( for un@@ desirable effects of ≥ 1 % ) or if it relevant ( for un@@ desired effect &lt; 1 % ) .
often ( ≥ 10 % ) ; frequent ( ≥ 12 , &lt; 1 % ) ; rare ( ≥ 0.@@ 01 , &lt; 0.1 % ) ; very t l@@ ä
in a homo@@ geneous case study , in which a limited number of persons were administ@@ ered by up to 300 mg , only slight symptoms .
the patients had a BM@@ I ≥ 30 kg / m ² or BM@@ I &gt; 27 kg / m ² and an simultaneously with hyper@@ ton@@ ic and / or dy@@ sli@@ pi@@ d@@ emia .
n weight reduction after one year was for A@@ comp@@ lia 20 mg 6,5 kg , related to the initial value , compared to 1.6 kg for placement , compared to 1.6 kg for placement ( differential -@@ 4.1 kg CI@@ 95 % -@@ 5,@@ 3 , p &lt; 0,@@ 001 ) .
the patients who were treated with A@@ comp@@ lia 20 mg were treated , and 1,2 kg in the placement group ( differential -@@ 3.7 kg ; CI@@ 95 % -@@ 4.4 , -@@ 3.3 ; p &lt; 0,@@ 001 ) .
after 2 years the difference in the overall weight reduction between A@@ comp@@ lia and plac@@ ebo -@@ 4.1 kg ( CI@@ 95 % -@@ 5.0 % ; -@@ 3.@@ 4 , p &lt; 0,@@ 001 ) . E@@ IM
9 Weight reduction and additional risk factors in patients with patients without diabetes , in which a mixed population of patients with patients
&quot; &quot; &quot; from Rim@@ on@@ ab@@ ant 20 mg &quot; &quot; &quot; &quot; U@@ gl@@ yc@@ etes successfully &quot; &quot; &quot; &quot; ( output value Tri@@ gl@@ yc@@ etes 1,@@ 62 m@@ mo@@ l / l ) compared to a rise of 5.6 %
in a second study in patients with a o@@ bes@@ ity and with a significant type @-@ 2- diabetes ( ser@@ en@@ ade ) , the absolute change of H@@ b@@ A@@ 1@@ c value ( with a output value of 7,@@ 9 % for both groups ) after 6 months -@@ 0,8 for Rim@@ on@@ ab@@ ant 20 mg and -@@ 0,3 . plac@@ ebo
the pro@@ gen@@ u@@ ale proportion of patients who reached a H@@ b@@ A@@ 1@@ c@@ - value of &lt; 7 % reached , was 51 % in the plac@@ ebo group and 35 % in the plac@@ ebo group .
differences between the middle weight change between the 20 MG@@ - and the plac@@ ebo group was 3,@@ 8 kg ( CI@@ 95 % -@@ 5,0 , -@@ 2.@@ 6 p &lt; 0,@@ 001 ) . LN
improvement of the H@@ b@@ A@@ 1@@ c value in patients who had been taken over 20 % by direct effects of Rim@@ on@@ ab@@ ant , about 50 % by the weight reduction .
2 hours , Ste@@ ady state plasma levels were achieved after 13 days ( C@@ max = 196 ± 28,@@ 1 ng / ml ; C@@ t@@ pin = 9@@ 1,6 ± 14.@@ 1 ng / ml ; AU@@ C@@ 0 @-@ 24 = 29@@ 60 ± 268 m@@ g.@@ h / ml ) .
influence of food : he subjects , pow@@ dered jack@@ on@@ ab@@ ant either in the case of food received by 67 % increased by 67 % higher C@@ max or around 48 % increased from AU@@ C .
patients with black skin color can be lower up to 31 % lower C@@ max and a 43 % lower AU@@ C have developed a patient &apos;s patients of other ethnic Alban@@ ians .
most popular analysis ( age range 18@@ - 81 years ) is estimated that a 75@@ - year patient is increased to 21 % higher C@@ max and a 27 % higher AU@@ C than a 40 @-@ year period .
5.3 Cross @-@ clinical data for safety he had been observed , which were not observed in clinical trials , but were not relevant for clinical trials as possibly relevant for clinical application :
in some cases , however , not in all cases the beginning of the vul@@ can@@ es must be connected with a resol@@ ute @-@ condition stress as the handling of animals .
Rim@@ on@@ ab@@ ant was given over a longer period prior to the pa@@ ar@@ ung ( 9 weeks ) which suffered a recovery from the initi@@ als of Rim@@ on@@ ab@@ ant , so did not un@@ desired effects on fer@@ mentation or Zy@@ kl@@ us@@ ine disorders .
the influence of Rim@@ on@@ ab@@ ant on pre@@ - and post@@ nat@@ al development was examined at the rat@@ te in dosing of up to 10 mg / kg / day .
in a study on rats and post@@ nat@@ al development caused a exposition with Rim@@ on@@ ab@@ ant in u@@ ter@@ o and by l@@ act@@ ating no changes in learning behaviour or memory .
detailed information on this drug is available on the website of the European Healthcare Agency ( EME@@ A ) htt@@ p : / / www.@@ em@@ e@@ a.@@ europ@@ a.@@ eu / item com@@ pr@@ enti@@ s ger@@ ar@@ z
La On the Pack@@ ages of the medicine by means of name and address of the manufacturer which are responsible for the release of the certi@@ fications .
the analysis particularly foc@@ usses on the hetero@@ geneity of regional dynamics and the spati@@ ally structured inter@@ dependency between locations . IAB @-@ Bibliothek 354 Archive
accordingly , if the symptoms of a depression ( see below ) during treatment with A@@ comp@@ lia , please contact your doctor and break the treatment .
di@@ zz@@ iness , dro@@ pping , anxiety , it@@ ching , excessive swe@@ ating , inclin@@ ation , bl@@ ending toler@@ ances , bl@@ ending toler@@ ances ( cum@@ ini@@ tis ) , memory loss ( cum@@ ulus ) , memory loss ( cum@@ ulus ) , down@@ ward , gri@@ pping technique ( cum@@ ulus ) .
find information in your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
the assumption of full take @-@ up tends to exagger@@ ate the simulated increase in cas@@ elo@@ ads and fiscal costs of a social policy reform .
Ac@@ tos will applied for the treatment of type 2 diabetes ( also known as non ins@@ ul@@ in@@ dependent diabetes ) . • It can be applied only ( mono therapy ) in patients ( especially important patients ) . • It can be applied together with another Di@@ ab@@ et@@ es@@ medi@@ kam@@ ent ( Dual@@ therapy ) .
it can also be applied to met@@ aph@@ or in patients ( especially in important patients ) which can not be used by metals alone in the highest possible dose .
in combination with an Sul@@ ph@@ yl@@ res@@ ol or ins@@ ulin , the amount of ins@@ ulin and ins@@ ulin is reduced to patients with Hy@@ po@@ gl@@ yc@@ emia ( low blood sugar ) ; here should the dose of sul@@ ph@@ yl@@ ur@@ ine or ins@@ ulin may be reduced .
this means that the physical ins@@ ulin is better utili@@ zed and the blood sugar level may cause blood sugar , causing type 2 diabetes .
in more than 1 400 patients the eff@@ ic@@ acy of Ac@@ tos in Tri@@ ple@@ therapy was examined ; in addition , patients received a combination of metals in combination with an Sul@@ ph@@ yl@@ res@@ ol , in addition to them up to 3.5 years ago or plac@@ ebo .
in the studies the concentration of a substance in the blood ( gly@@ co@@ li@@ li@@ ated hem@@ mo@@ glob@@ in , H@@ b@@ A@@ 1@@ c ) which shows how well the blood sugar is set .
Ac@@ tions led to a drop of H@@ b@@ A@@ 1@@ c value , indicating that the blood glu@@ cose values are reduced by 15 mg , 30 mg and 45 mg .
at the end of the tri@@ ple@@ therapy study , the effect of additional gift of Ac@@ tos for existing treatment with metast@@ able and an Sul@@ ph@@ yl@@ res@@ ol in a drop of H@@ b@@ A@@ 1@@ c values at 0.@@ 94 % while the additional gift of plac@@ ebo will lead to a drop of 0.@@ 35 % .
in a small study , in which the combination of Ac@@ tos and ins@@ ulin at 289 patients , the patients , the Ac@@ tos were also examined for ins@@ ulin , a drop of H@@ b@@ A@@ 1@@ c values ranging from 0.@@ 69 % to 6 months , compared with 0.@@ 14 % in patients , which in addition to plac@@ ebo .
most common side effects in connection with Ac@@ tos were visual disorders , infections of the upper resp@@ ir@@ atory infections , weight gain and hy@@ po@@ ol@@ emia ( reduced sensitivity to friction ) .
Ac@@ tos may not be applied to patients with liver problems , the heart failure of Pi@@ og@@ li@@ ta@@ xis or any other components , even in patients with liver problems , heart failure or di@@ abe@@ tic c@@ eto@@ ile ( high k@@ et@@ on@@ mirror - in blood ) .
it was decided to serve Ac@@ tos during a mono therapy ( using the all@@ number of use ) as an alternative to the standard treatment with metast@@ able in patients when met@@ form@@ in is not shown .
October 2000 , European Commission shared the European Commission of Tak@@ eda Europe R &amp; D Centre Limited for the transport of Ac@@ tos at the entire European Union .
&quot; &quot; &quot; the tablets are white to be white , round , curved and wear on one side the marking &quot; &quot; &quot; &quot; 15 &quot; &quot; &quot; &quot; on the other side the wording &quot; &quot; &quot; &quot; AC@@ TOS &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
ins@@ ulin is also indicated in combination with ins@@ ulin in patients with type 2 diabetes mel@@ lit@@ us , their blood sugar with ins@@ ulin and in@@ compatible with ins@@ ulin ( see Section 4.4 ) .
the application of Pi@@ og@@ li@@ ta@@ xis in patients under 18 years have no data available , therefore the application is not recommended in this age group .
patients suffering from intra@@ ocular heart rate ( e.g. earlier cardi@@ al heart attack or symp@@ tom@@ atic cor@@ on@@ ary heart disease ) , the doctor should begin the treatment with the lowest available dose and increase the dose increased .
patients should be observed on signs and symptoms of a heart failure , weight gain or o@@ bes@@ e@@ wers , especially those with reduced noise reserves .
patients should be observed on signs and symptoms of a heart failure , weight gain and Ö@@ de@@ ms , if pi@@ og@@ li@@ ta@@ k is applied in combination with ins@@ ulin .
a cardi@@ ov@@ arian Out@@ come study with pi@@ og@@ li@@ ta@@ xis in patients under 75 years ago with type 2 diabetes mel@@ lit@@ us and pre @-@ existing metast@@ atic disease was performed .
&quot; &quot; &quot; in this study , an increase in reports on heart failure , however , does not lead to an increase in the rise in the study . &quot; &quot; &quot; &quot; &quot; &quot; &quot;
for patients with increased cir@@ rho@@ sis ( AL@@ T &gt; 2.5 x upper limit of the norm@@ zone ) or with other signs of liver disease may not be used .
if the AL@@ T mirror is increased until 3 @-@ fold the upper limit of the standard area , the liver enz@@ ym@@ phs are as soon as possible .
if a patient has developed symptoms that indicate a hep@@ atic dys@@ function , such as imper@@ ative evil , vom@@ iting , appetite , appetite , appetite and / or dark har@@ n , are the liver enz@@ ym@@ ity values .
the decision whether the treatment of the patients with pi@@ og@@ li@@ f@@ ow@@ l should be continued until pre@@ defined the laboratory parameters of clinical assessment .
in clinical studies with pi@@ og@@ li@@ ta@@ xis was treated with dos@@ is@@ tive weight gain , which can be eaten by fat deposits and in some cases with a fluid bed .
as a consequence of hem@@ odi@@ lution under the therapy with pi@@ og@@ li@@ ta@@ k , a low reduction in the medium hem@@ or@@ ph@@ atic values ( relative reduction by 4 % ) and the hem@@ at@@ oc@@ r@@ its ( relative reduction by 4.1 % ) .
similar changes were observed with comparable controlled trials with pi@@ v@@ li@@ tis at 3 @-@ 4 % and the hem@@ at@@ oc@@ r@@ its around 3.4 @-@ 4 % and the hem@@ at@@ oc@@ r@@ its for 1 @-@ 2 % and the hem@@ at@@ ok@@ r@@ its to 1 @-@ 3.2 % ) .
as a result of the increased ins@@ ulin @-@ sensitivity in patients , the pi@@ og@@ li@@ ta@@ xis as or@@ ale two @-@ phase combination therapy with ins@@ ulin or two @-@ purpose therapy with ins@@ ulin , the risk of dos@@ is@@ able hy@@ po@@ gl@@ yc@@ emia .
after the launch of the launch of Thi@@ az@@ oli@@ d@@ der@@ ons , including Pi@@ og@@ li@@ ta@@ xis , including Pi@@ og@@ li@@ ta@@ xis , above a occurr@@ ence or a deteri@@ oration of an di@@ abe@@ tic mac@@ ular de@@ ms with a reduction of visual acuity .
it is un@@ clear whether there is a direct connection between the intake of Pi@@ og@@ li@@ ta@@ xis and the occurr@@ ence of mac@@ ul@@ a@@ ö@@ de@@ ms are aware of the possibility of mac@@ ul@@ a@@ ö@@ de@@ ms , if patients should be able to look at distur@@ b@@ ance of visual acuity , a suitable oph@@ thalm@@ ological examination should be taken into consideration .
in a summary analysis of research @-@ desirable events with random@@ ised controlled trials , controlled , double @-@ blind trial studies have been treated with more than 8.@@ 100 patients who were treated with pi@@ og@@ li@@ ta@@ xis .
the intra@@ ocular pressure was treated by 1.9 pounds per 100 patient years with pi@@ og@@ li@@ ta@@ xis treated women and 1.1 potenti@@ als per 100 patient years in women who were treated with a comparative medi@@ ation .
in the Pro@@ active Study , a study over 3.5 years to study of cardiovascular events , the fra@@ c@@ als at 44 / 870 ( 5.1 % ; 1.0 Fra@@ ction per 100 patient @-@ years ) were treated with patients with a comparison of comparison of patients .
patients should be aware of the possibility of pregnancy or if a patient may wish to take a pregnancy or this time , the treatment is treated ( see Section 4.6 ) .
studies have shown that Pi@@ og@@ li@@ ta@@ xis are no relevant effects on the phar@@ yn@@ ok@@ ine@@ tics or pharmaceutical pot@@ ency of di@@ ox@@ in , war@@ far@@ es , phen@@ yl@@ ou@@ mon and metals .
inter@@ changeable effects with medicines created by these enz@@ y@@ mes , e.g. or@@ ale contra@@ cep@@ tiva , CY@@ CLO@@ SPOR@@ IN , cal@@ ci@@ um@@ kan@@ al@@ blo@@ cker and H@@ MG@@ Co@@ A @-@ reduc@@ er are not expected .
the simultaneous application of Pi@@ og@@ li@@ ta@@ xis with a cy@@ to@@ chrome P@@ 450 2@@ C@@ 8@@ - inhib@@ itor is resulting in an increase of AU@@ C by Pi@@ og@@ li@@ ta@@ k - 3 times .
the simultaneous application of Pi@@ og@@ li@@ ta@@ k with ri@@ f@@ amp@@ ic@@ in ( a Cy@@ to@@ chrome P@@ 450 2@@ C@@ 8 @-@ In@@ duc@@ er ) resulting in a drop of AU@@ C by Pi@@ og@@ li@@ ta@@ k at 54 % .
this is due to treatment with pi@@ og@@ li@@ ta@@ xis that reduce hyper@@ ins@@ ul@@ in@@ emia and increased ins@@ ulin defici@@ ency of the parent . thereby the availability of the sample rate is reduced .
very often &gt; 1 / 10 ; often &gt; 1 / 100 , &lt; 1 / 10 ; rare &gt; 1 / 1000 , &lt; 1 / 1000 ; very rare &lt; 1 / 10000 , individual cases : unknown ( available from actual data is not available ) .
this lead to a temporary change of the Tur@@ g@@ ors and B@@ rech@@ ari@@ zation of the lens as they can also be observed with other hypo@@ aller@@ genic ingredients .
in clinical studies with pi@@ og@@ li@@ ta@@ xis , AL@@ T @-@ An@@ sti@@ ege were often frequently used as in plac@@ ebo , however less than in comparison groups under met@@ aph@@ or or Sul@@ ph@@ yl@@ har@@ n@@ é .
in a Out@@ come study in patients with pre @-@ existing low @-@ Croatian disease , the frequency of a severe heart failure rate is 1.6 % higher than under plac@@ ebo .
since the launch of the launch of a heart failure in Pi@@ og@@ li@@ ta@@ xis , however , more often , if pi@@ og@@ li@@ ta@@ xis is applied in combination with ins@@ ulin or patients with heart failure in the An@@ am@@ n@@ ese .
the analysis particularly foc@@ usses on the hetero@@ geneity of regional dynamics and the spati@@ ally structured inter@@ dependency between locations . IAB @-@ Bibliothek 354 Archive Info@@ bereich . online Survey of the IAB web presence 29 July 2015
in the above a period of 3.5 years of current Pro@@ active study , Fra@@ c@@ als at 44 / 870 ( 5.1 % ) were treated using pi@@ og@@ li@@ ta@@ xis treated patients , compared with 23 / 90@@ 5 ( 2.5 % ) in patients with a comparison of comparison .
when taking the maximum dose of 120 mg / day over four days , then 180 mg / day over seven days , no symptoms .
Pi@@ og@@ li@@ ta@@ xis seems to work a activation of specific nuclear incidents ( Per@@ ox@@ is@@ ome Pro@@ lifer@@ ator Activ@@ ated Rec@@ ep@@ tor methods ) , which leads to an elevated in@@ sensitivity of liver , fat and sk@@ el@@ etal mus@@ cular cells .
it could be shown that Pi@@ og@@ li@@ ta@@ xis was reduced in the liver and increases the peripheral gluten in case of ins@@ ulin resistance .
clinical trial with pi@@ og@@ li@@ ta@@ ve versus G@@ lic@@ la@@ zi@@ d as mon@@ otherapy was continuing over two years to investigate the time to the therapeutic effects ( defined as H@@ b@@ A@@ 1@@ c ≥ 8,0 % after the first 6 treatments ) .
at the time after two years after the beginning of the therapy a blood sugar control ( defined as H@@ b@@ A@@ 1@@ c &lt; 8.0 % ) due to pi@@ og@@ li@@ ta@@ xis in 69 % of the treated patients ( compared to 50 % of patients under G@@ lic@@ la@@ zi@@ d ) .
in a plac@@ ebo @-@ controlled study about 12 months , patients , whose blood sugar is in@@ adequate despite three mon@@ oun@@ cing optim@@ ising phase with ins@@ ulin .
in patients with pi@@ og@@ li@@ ta@@ xis , the mean H@@ b@@ A@@ 1@@ c value increased to 0.@@ 45 % compared with the patients who continue to use ins@@ ulin at the pi@@ og@@ li@@ ta@@ k @-@ treated group .
clinical studies over a year showed a statisti@@ cally significant reduction of the Alb@@ um@@ in / Kre@@ at@@ in@@ in @-@ Qu@@ oti@@ ators compared to the initial values .
the effect of pi@@ og@@ li@@ ta@@ xis ( mon@@ otherapy with 45 mg of hard Pla@@ z@@ ebo ) was checked in a small , on 18 weeks of study on type @-@ 2 di@@ abe@@ tic .
in most cases of clinical studies were observed in comparison to plac@@ ebo a reduction in the total of plasma tri@@ angles , and a rise of HD@@ L@@ - cholesterol levels and a increase in HD@@ L@@ - cholesterol levels .
in clinical studies over a period of up to two years reduced Pi@@ og@@ li@@ ta@@ k in comparison to Pla@@ z@@ ebo , Met@@ form@@ in or G@@ lic@@ la@@ zi@@ d the total absorption capacity and increased the HD@@ L cholesterol levels .
in comparison to Pla@@ z@@ ebo , there was no statistical significant increase in L@@ DL @-@ cholesterol , while the metast@@ atic and G@@ lic@@ la@@ zi@@ d decreased values .
in a study over 20 weeks reduced Pi@@ og@@ li@@ ta@@ xis not only the N@@ ü@@ ber @-@ Tri@@ gl@@ yc@@ eri@@ des , but improved also the post@@ erior Tri@@ gl@@ yc@@ eri@@ ous levels , this is both a effect on the Tri@@ lateral Tri@@ lli@@ d absorption .
in the Pro@@ active study , a cardi@@ ov@@ arian Out@@ come study , 5@@ 238 patients with type 2 diabetes mel@@ lit@@ us and pre @-@ existing metast@@ atic disease in groups described above a period of up to 3.5 years in addition to existing anti@@ di@@ abe@@ tic and cardiovascular disease .
depending on the application , Pi@@ og@@ li@@ ta@@ k is quickly res@@ or@@ b@@ ished , the highest concent@@ rations of un@@ modified Pi@@ og@@ li@@ ta@@ xis in plasma is usually 2 hours after application .
based on this basis , the contribution of M @-@ IV contributes to the effectiveness of M @-@ IV effectiveness , whereas the relative effectiveness of M @-@ II is minim@@ ised to the relative effectiveness of M @-@ II .
in Inter@@ disciplinary Studies , Pi@@ og@@ li@@ ta@@ xis was not relevant to the phar@@ yn@@ ok@@ ine@@ tics or pharmaceutical generation of di@@ ox@@ in , war@@ far@@ es , phen@@ yl@@ mon and metals .
the simultaneous application of Pi@@ og@@ li@@ ta@@ xis with a cy@@ to@@ chrome P@@ 450 2@@ C@@ 8@@ - in@@ hibition ) or with ri@@ f@@ amp@@ ic@@ in ( a cy@@ to@@ chrome P@@ 450 2@@ C@@ 8 @-@ In@@ duc@@ er ) and lowers the plasma concentration of Pi@@ og@@ li@@ ta@@ k ( see section 4.5 ) .
following orange application of radioactive decay in humans , the Mar@@ ker was mainly found in the fan ( 55 % ) and a lower degree in har@@ n ( 45 % ) .
the mean plasma @-@ Eli@@ min@@ ation@@ sh@@ rou@@ wer@@ ed by un@@ modified Pi@@ og@@ li@@ ta@@ xis amounts to humans 5 @-@ 6 hours , and the whole active met@@ abo@@ lit@@ es is 16 - 23 hours .
the plasma concent@@ rations of Pi@@ og@@ li@@ ta@@ xis and its met@@ abo@@ lit@@ es are lower than in healthy subjects , whereas the ration@@ ale of the or@@ alen mat@@ urity of the mother &apos;s sub@@ mar@@ es are similar .
in tox@@ ic@@ ological studies of mice , rats , dogs , dogs and monkey agreements with hem@@ isph@@ eric , an@@ emia , and rever@@ sible heart hyper@@ tro@@ phy .
this is due to treatment with pi@@ og@@ li@@ ta@@ xis that decreased hyper@@ ins@@ ul@@ in@@ emia and increased ins@@ ulin resistance of the wom@@ b and consequently the availability of the sample rate for the f@@ öt@@ ting growth is reduced .
in long @-@ term studies ( up to 2 years ) were induced by Hyper@@ pl@@ aque ( with male and female rats ) and tum@@ ors ( with male rats ) of ur@@ inary corneal epithel@@ ium .
in a animal model of the famili@@ al treatment of the famili@@ al poly@@ posi@@ s ( FA@@ P ) led the treatment with two other Thi@@ ac@@ oli@@ d@@ der@@ ons into an increased frequency of colli@@ sions .
the tablets are white up to white , round , flat and wear on one side the button &quot; &quot; &quot; &quot; 30 &quot; &quot; &quot; &quot; on the other side the wording &quot; &quot; &quot; &quot; AC@@ TOS &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
the intra@@ ocular pressure was treated by 1.9 pounds per 100 patient years with pi@@ og@@ li@@ ta@@ xis treated women and 1.1 potenti@@ als per 100 patient years in women who were treated with a comparative medi@@ ation .
in the Pro@@ active Study , a study over 3.5 years to study of cardiovascular events , the fra@@ c@@ als at 44 / 870 ( 5.1 % ; 1.0 Fra@@ ction per 100 patient @-@ years ) were treated with patients with a comparison of comparison of patients .
in a further study over two years , the effects of a combination therapy of metals produced by Pi@@ og@@ li@@ ta@@ xis or G@@ lic@@ la@@ zi@@ d were examined .
clinical studies over 1 year showed a statisti@@ cally significant significant reduction of the Alb@@ um@@ in / Kre@@ at@@ in@@ in Qu@@ oti@@ ds compared to the initial values .
in a study over 20 weeks reduced Pi@@ og@@ li@@ ta@@ xis not only the N@@ ü@@ ber @-@ Tri@@ gl@@ yc@@ eri@@ des , but improved beyond a effect on the tr@@ y@@ gly@@ z@@ eri@@ d absorption than also on the tr@@ y@@ gly@@ z@@ eri@@ d synthesis .
although the study aims to assess the goal of its primary end@@ point , causing a combination of total injuries , non @-@ fatal cor@@ on@@ ary ar@@ thritis , stroke , acute cor@@ on@@ ary syndrome , the results close to the intake of pi@@ og@@ li@@ ta@@ xis no kar@@ di@@ ov@@ arian regimes .
the tablets are white up to white , round , flat and wear on one side the button &quot; &quot; &quot; &quot; AC@@ TOS &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
in a summary analysis of reports made from random@@ ised , controlled , double @-@ blind trial studies have been treated with more than 8.@@ 100 patients who were treated with pi@@ og@@ li@@ ta@@ via and over 7.@@ 400 patients , the comparative study of bone fra@@ c@@ ers were treated with women .
in the Pro@@ active Study , a study over 3.5 years to study of cardiovascular events , the fra@@ c@@ als at 44 / 870 ( 5.1 % ; 1.0 Fra@@ ction per 100 patient @-@ years ) were treated with patients with a comparison of comparison of patients .
in a study over 20 weeks reduced Pi@@ og@@ li@@ ta@@ xis not only the N@@ ü@@ ber @-@ Tri@@ gl@@ yc@@ eri@@ des , but also improved the post@@ erior Tri@@ gl@@ yc@@ eri@@ ous levels , this is both a effect on the Tri@@ lateral Tri@@ lli@@ d absorption .
on the Pack@@ ages of the medicine by means of name and address of the manufacturer , which is responsible for the release of the train@@ ee .
the pharmaceutical company is in September 2005 an additional 6 month peri@@ odic Safety update report ( PS@@ UR ) and subsequently annual PS@@ UR@@ s are enough to reach a different level of CH@@ MP .
it must be a updated risk management plan according to CH@@ MP gui@@ deline on Risk Management Systems for Medic@@ inal Products for Human Use .
if you are aware of type 2 diabetes care , Ac@@ tos 15 mg tablets the control of your blood glu@@ cose , creating a better breakdown of body ins@@ ulin .
if you are known that you suffer from sugar int@@ oler@@ ance , please contact Ac@@ tos 15@@ mg tablets for your doctor .
please inform your doctor or pharmac@@ ist if you have more medicines or until recently , even if it is not authorised to prescription drugs .
if you take Ac@@ tos 15 mg tablets in combination with other medicines for treatment of diabetes ( such as ins@@ ulin , chlor@@ meth@@ acryl@@ amide , G@@ lic@@ la@@ zi@@ d , Tol@@ but@@ yl ) , your doctor will inform you if you have to reduce the dose of your medicines .
some patients with long @-@ risk type 2 diabetes mel@@ lit@@ us and heart disease , which were treated with Ac@@ tos and ins@@ ulin .
in clinical studies , Pi@@ og@@ li@@ ta@@ xis ( other or@@ ally anti@@ di@@ abe@@ tic or plac@@ ebo ( more effective tablets ) was compared to women ( but not in men ) , the Pi@@ og@@ li@@ ta@@ k showed a higher number of bone br@@ anded .
if you have taken a number of tablets , or if another or a child has taken your medicines , you have to contact your doctor or pharmac@@ ist .
like Ac@@ tos and content of Ac@@ tos 15 mg tablets are white to white , round , curved tablets with the marking &quot; 15 &quot; on one side and the wording &quot; AC@@ TOS &quot; on the other side .
if you are aware of type 2 diabetes care , Ac@@ tos 30 mg tablets the control of your blood glu@@ cose , creating a better breakdown of body ins@@ ulin .
if you are known that you suffer from sugar int@@ oler@@ ance , please contact the intake of Ac@@ tos 30@@ mg tablets for your doctor .
if you take Ac@@ tos 30 mg tablets in combination with other medicines for treatment of diabetes ( such as ins@@ ulin , chlor@@ meth@@ acryl@@ amide , G@@ lic@@ la@@ zi@@ d , Tol@@ but@@ yl ) , your doctor will inform you if you have to reduce the dose of your medicines .
61 Inform@@ ing you as soon as possible your doctor if you find signs of a heart failure , like unusual brief or rapid weight gain or local sw@@ ings ( Ö@@ de@@ ma ) .
in clinical studies , Pi@@ og@@ li@@ ta@@ xis ( other or@@ ally anti@@ di@@ abe@@ tic or plac@@ ebo ( more effective tablets ) was compared to women ( but not in men ) , the Pi@@ og@@ li@@ ta@@ k showed a higher number of bone br@@ anded .
like Ac@@ tos and content of Ac@@ tos 30 mg tablets are white , white , flat tray with the marking &quot; 30 &quot; on one side and the wording &quot; AC@@ TOS &quot; on the other side .
if you are aware of type 2 diabetes care , Ac@@ tos 45 mg tablets the control of your blood glu@@ cose , creating a better breakdown of body ins@@ ulin .
please contact Ac@@ tos 45@@ mg tablets for your doctor .
if you take Ac@@ tos 45 mg tablets in combination with other medicines for treatment of diabetes ( such as ins@@ ulin , chlor@@ inated iron , G@@ lic@@ la@@ zi@@ d , Tol@@ but@@ yl , G@@ lic@@ la@@ zi@@ d , Tol@@ but@@ yl ) , your doctor will have to reduce your dose if you need to reduce the dose of your medicines .
66 In a number of patients with long @-@ risk type 2 diabetes mel@@ lit@@ us and heart disease , which were treated with Ac@@ tos and ins@@ ulin .
inform yourself as soon as possible your doctor if you find signs of a heart failure , like unusual brief or rapid weight gain or local sw@@ ings ( Ö@@ de@@ ma ) .
in clinical studies , Pi@@ og@@ li@@ ta@@ xis ( other or@@ ally anti@@ di@@ abe@@ tic or plac@@ ebo ( more effective tablets ) was compared to women ( but not in men ) , the Pi@@ og@@ li@@ ta@@ k showed a higher number of bone br@@ anded .
67 If one of the specified side effects are affected or no side effects that are not specified in this use information , please refer to your doctor or pharmac@@ ist .
like Ac@@ tos and content of Ac@@ tos 300 mg tablets are white , white , flat tray with the marking &quot; 45 &quot; on one side and the wording &quot; AC@@ TOS &quot; on the other side .
the assumption of full take @-@ up tends to exagger@@ ate the simulated increase in cas@@ elo@@ ads and fiscal costs of a social policy reform .
if you need more information about your medical condition or treatment of your illness , please read the Pack@@ ager ( also part of the EP@@ AR ) or contact your doctor or pharmac@@ ist .
if you want more information on the recommendations of the CH@@ MP , please read the scientific discussion ( which also part of the EP@@ AR ) .
Ac@@ tra@@ ph@@ ane 10 : sol@@ uble ins@@ ulin 20 % and Is@@ oph@@ an ins@@ ulin 20 % acet@@ ate ins@@ ulin 20 % acet@@ ate ins@@ ulin 40 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ph@@ ane 50 % Ac@@ tra@@ ct @-@ ins@@ ulin 50 % and is@@ oph@@ an ins@@ ulin 50 %
Ac@@ tra@@ ph@@ ane is usually used once or twice a day when a rapid effect together with a longer lasting effect is desired .
( 44 @-@ 20 ) 74 18 86 00 Fax ( 44 @-@ 20 ) 74 18 86 68 E @-@ mail : mail @ em@@ e@@ a.@@ eu@@ .@@ int © EME@@ A 2006 Re@@ production and / or distribution of this document is used for non @-@ profit organization ( r@@ DNA ) , using the procedure of so @-@ called &quot; re@@ combin@@ ant technology .
Ac@@ tra@@ ph@@ ane was found in a total of 294 patients with type 1 diabetes that can not produce ins@@ ulin , and type 2 diabetes , where the body is not able to use ins@@ ulin effectively .
in the study after 12 weeks the concentration of a substance ( gly@@ co@@ graph@@ ite hem@@ mo@@ glob@@ in ( H@@ b@@ A@@ 1@@ c ) was measured in the study , as well as the blood sugar is set .
Ac@@ tra@@ ph@@ ane led to a decrease of the H@@ b@@ A@@ 1@@ c Spi@@ eg@@ els that showed that the blood sugar level is similar to similar as with other ins@@ ulin .
Ac@@ tra@@ ph@@ ane should not be applied to patients who possibly have sensitive ( allergi@@ c ) to Human@@ ins@@ ulin ( r@@ DNA ) or one of the other ingredients .
in addition , the dos@@ es of Ac@@ tra@@ ol could possibly be adjusted if it is administ@@ ered together with a number of other medicines which can be applied to blood sugar ( the full list is of pack@@ aged packages ) .
the Committee for Human@@ izing Human Behavi@@ or ( CH@@ MP ) became the conclusion that the benefits of Ac@@ tra@@ ocular pressure during treatment of diabetes due to risks .
October 2002 , the European Commission shared the European Commission to Nov@@ o Nor@@ disk A / S authorization for the transport of Ac@@ tra@@ ffi@@ ane in the entire European Union .
pre@@ mixed salad products are usually used once or twice a day when a rapid effect together with a longer lasting effect is desired .
injection needle must be transported at least 6 seconds under the skin to ensure that the whole dose was inj@@ ected .
patients , whose blood glu@@ cose is significantly improved by an intensive use of ins@@ ulin therapy , the hy@@ po@@ gl@@ yc@@ emia could be changed and should be considered to be supported .
any alter@@ ation regarding strength , brand ( manufacturers ) , ins@@ ulin type ( fast reaction to ins@@ ulin , long @-@ ins@@ ulin @-@ ins@@ ulin ) , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin ,
in case of change to Ac@@ tra@@ pe@@ ane for patients a D@@ os@@ is@@ cation is required , this can be necessary during the first dose or months after the special treatment .
some patients , hypo@@ aller@@ yc@@ em@@ ic reactions after a change of animal in@@ ins@@ ulin , reported that the early warning blocks of a hy@@ po@@ gl@@ yc@@ emia is less pronounced than in their previous ins@@ ulin .
before travelling to go through several time zones , the patient should be advised to obtain the advice of his doctor because such trips can be applied for ins@@ ulin and meals .
the doctor must therefore consider a possible risk of interactions in therapy and to ask them to other medicines for other medicines .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; one of the most serious diseases caused by hyper@@ gl@@ yc@@ emia , which may occur with non @-@ sufficient sealing therapy , increase the risk of ab@@ norm@@ alities and fruit to@@ d in u@@ ter@@ o . &quot; &quot; &quot;
heavy metals can lead to awareness of awareness and / or cra@@ mp@@ ho@@ ists and by temporary or permanent distur@@ ban@@ ces of the brain function and even death .
diseases of the nervous system - a rapid growth of Neu@@ rop@@ ath@@ ic A rapid growth of blood sugar control may be associated with complaints , which are referred to as acute painful re@@ rop@@ athy and usually rever@@ sible .
5 A intensive use of ins@@ ulin therapy with a ab@@ rup@@ tible improvement of blood glu@@ cose however , however , can be associated with a temporary deteri@@ oration of di@@ abe@@ tic retin@@ opathy .
diseases of the skin and of the skin cell phone - Li@@ pod@@ yst@@ rop@@ hi@@ e An der Injection station can be a li@@ ve@@ yst@@ rop@@ hi@@ e when switching to injection holes within the injection system .
general disorders and complaints on the appointment of money - Local Contra@@ cts protection at the Injection station While the ins@@ ulin therapy may cause local over@@ flow reactions ( Romans , sw@@ elling , it@@ ching , it@@ ching , it@@ ching , pain and hem@@ at@@ om at the inj@@ ector ) .
diseases of the immune system Gel@@ o@@ form - Ur@@ tic@@ aria , Ex@@ an@@ ensis essential , rare - An@@ ap@@ hy@@ l@@ act@@ ate reactions , including gener@@ ated skin disorder , ju@@ cks , swe@@ ating , resp@@ ect@@ omy , resp@@ ir@@ atory disorders , resp@@ ir@@ atory disorders , heart attack , low blood pressure , and emotion .
a Hy@@ po@@ gl@@ yc@@ ie can be continuously developing : • Lei@@ ght Hy@@ po@@ is@@ ins drainage tube can be treated with glu@@ cose or glu@@ cose food .
Di@@ abe@@ tics should always have mat@@ urity , swe@@ ets , bis@@ cuits or zu@@ cker@@ ate fruit juice are treated with an intra@@ mus@@ cular or sub@@ cut@@ aneous injection of glu@@ c@@ agon ( 0.5 to 1.0 mg ) of glu@@ cose or sub@@ cut@@ aneous injection of glu@@ c@@ agon ( 0.5 to 1.0 mg ) .
the effect begins within half an hour , the active ingredient is reached within 2 to 8 hours and the total duration is up to 24 hours .
Res@@ or@@ ption of Res@@ or@@ tive profiles is that there is a mixture of ins@@ ulin products with faster or delayed res@@ or@@ ption .
a series of split@@ ting ( hydro@@ ly@@ sis ) places in agriculture , ins@@ ul@@ ates ; none of the split by the met@@ abo@@ ard is active .
based on the conventional studies on safety sp@@ har@@ mac@@ ology , tox@@ icity and recur@@ rence of the cardi@@ ac disease , the cardi@@ ac potential and re@@ productive data are no particular haz@@ ards for humans .
the temperature of the ins@@ ulin at room temperature ( not over 25 ° C ) , the temperature of ins@@ ulin at room temperature ( not above 25 ° C ) , before it is used for the first use res@@ us@@ hing .
some patients , hypo@@ aller@@ yc@@ em@@ ic reactions after a change of animal in@@ ins@@ ulin , reported that the early warning blocks of a hy@@ po@@ gl@@ yc@@ emia is less pronounced than in their previous ins@@ ulin .
the doctor must therefore consider a possible risk of interactions in therapy and to ask them to other medicines for other medicines .
&quot; &quot; &quot; 12 &quot; &quot; &quot; &quot; the g@@ gl@@ yc@@ emia caused by hyper@@ gl@@ yc@@ emia , which may occur with non @-@ sufficient sealing therapy , increase the risk of ab@@ norm@@ alities and fruit to@@ d in u@@ ter@@ o . &quot; &quot; &quot;
13 A intensive use of ins@@ ulin therapy with a ab@@ rup@@ tible improvement of blood glu@@ cose however , however , can be associated with a temporary deteri@@ oration of di@@ abe@@ tic retin@@ opathy .
the termin@@ ale half @-@ time ( t ½ ) is therefore more a measure of Res@@ or@@ ption for ins@@ ulin from the ins@@ ulin from the plasma ( ins@@ ulin in the blood circulation ) .
the temperature of the ins@@ ulin at room temperature ( not over 25 ° C ) , the temperature of ins@@ ulin at room temperature ( not above 25 ° C ) , before it is used for the first use res@@ us@@ hing .
some patients , hypo@@ aller@@ yc@@ em@@ ic reactions after a change of animal in@@ ins@@ ulin , reported that the early warning blocks of a hy@@ po@@ gl@@ yc@@ emia is less pronounced than in their previous ins@@ ulin .
20 S@@ event@@ s.@@ Hy@@ po@@ gl@@ yc@@ emia caused by hyper@@ gl@@ yc@@ emia , which may occur in a sufficiently controlled di@@ ab@@ ject therapy , increase the risk of ab@@ norm@@ alities and fruit @-@ to@@ d in u@@ ter@@ o .
21 A intensive use of ins@@ ulin therapy with a ab@@ rup@@ tible improvement of blood glu@@ cose however , however , can be associated with a temporary deteri@@ oration of di@@ abe@@ tic retin@@ opathy .
diseases of the immune system Gel@@ o@@ form - Ur@@ tic@@ aria , Ex@@ an@@ ensis essential , rare - An@@ ap@@ hy@@ l@@ act@@ ate reactions , including gener@@ ated skin disorder , ju@@ cks , swe@@ ating , resp@@ ect@@ omy , resp@@ ir@@ atory disorders , resp@@ ir@@ atory disorders , heart attack , low blood pressure , and emotion .
cartridges can only be used together with products that guarantee the quality and effective function of the cartridge .
it is recommended - after Ac@@ tra@@ pe@@ ane Pen@@ alty from the refrigerator - the temperature of ins@@ ulin at room temperature ( not above 25 ° C ) before it is used according to the manual for the first use res@@ us@@ hing .
some patients , hypo@@ aller@@ yc@@ em@@ ic reactions after a change of animal in@@ ins@@ ulin , reported that the early warning blocks of a hy@@ po@@ gl@@ yc@@ emia is less pronounced than in their previous ins@@ ulin .
&quot; &quot; &quot; 28 &quot; &quot; &quot; &quot; the hypo@@ cris@@ y of hypo@@ aller@@ emia , which may occur in a sufficiently controlled di@@ ab@@ effect therapy , increase the risk of ab@@ norm@@ alities and fruit to@@ d in u@@ ter@@ o . &quot; &quot; &quot;
29 A Inten@@ si@@ fication of the ins@@ ulin therapy with an ab@@ rup@@ tible improvement of blood glu@@ cose however , however , can be associated with a temporary deteri@@ oration of di@@ abe@@ tic retin@@ opathy .
some patients , hypo@@ aller@@ yc@@ em@@ ic reactions after a change of animal in@@ ins@@ ulin , reported that the early warning blocks of a hy@@ po@@ gl@@ yc@@ emia is less pronounced than in their previous ins@@ ulin .
the g@@ gl@@ yc@@ emia caused by hyper@@ gl@@ yc@@ emia , which may occur in a sufficiently controlled di@@ ab@@ ject therapy , increase the risk of ab@@ norm@@ alities and fruit @-@ to@@ d in u@@ ter@@ o .
37 A intensive use of ins@@ ulin therapy with a ab@@ rup@@ tible improvement of blood glu@@ cose however , however , can be associated with a temporary deteri@@ oration of di@@ abe@@ tic retin@@ opathy .
&quot; &quot; &quot; 44 &quot; &quot; &quot; &quot; the g@@ gl@@ yc@@ emia caused by hyper@@ gl@@ yc@@ emia , which may occur in a sufficiently controlled sealing therapy that may increase the risk of ab@@ norm@@ alities and fruit to@@ d in u@@ ter@@ o . &quot; &quot; &quot;
45 A intensive care of ins@@ ulin therapy with an ab@@ rup@@ tible improvement of blood glu@@ cose however , however , can be associated with a temporary deteri@@ oration of di@@ abe@@ tic retin@@ opathy .
some patients , hypo@@ aller@@ yc@@ em@@ ic reactions after a change of animal in@@ ins@@ ulin , reported that the early warning blocks of a hy@@ po@@ gl@@ yc@@ emia is less pronounced than in their previous ins@@ ulin .
&quot; &quot; &quot; 52 &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot;
53 A intensive use of ins@@ ulin therapy with a ab@@ rup@@ tible improvement of blood glu@@ cose however , however , can be associated with a temporary deteri@@ oration of di@@ abe@@ tic retin@@ opathy .
injection devices must be prepared prior to the injection so that the D@@ os@@ is@@ regulator appears to zero back and an ins@@ int@@ rop@@ fen at the top of the injection needle .
59 patients , whose blood glu@@ cose is significantly improved by an intensive use of ins@@ ulin therapy , the hy@@ po@@ gl@@ yc@@ emia could be changed and should be considered to be considered to be investigated .
both hy@@ po@@ dr@@ emia , as well as hyper@@ gl@@ yc@@ emia , which may occur in a sufficiently controlled Di@@ ab@@ ject therapy , increase the risk of ab@@ norm@@ alities and fruit bars in u@@ ter@@ o .
an intensive use of ins@@ ulin therapy with a ab@@ rup@@ tible improvement of blood glu@@ cose however , however , can be associated with a temporary deteri@@ oration of di@@ abe@@ tic retin@@ opathy .
diseases of the immune system Gel@@ o@@ form - Ur@@ tic@@ aria , Ex@@ an@@ ensis essential , rare - An@@ ap@@ hy@@ l@@ act@@ ate reactions , including gener@@ ated skin disorder , ju@@ cks , swe@@ ating , resp@@ ect@@ omy , resp@@ ir@@ atory disorders , resp@@ ir@@ atory disorders , heart attack , low blood pressure , and emotion .
Fisher auctions can be used only together with products that guarantee a safe and effective function of the finished product .
it is recommended - after Ac@@ tra@@ pe@@ ane Nov@@ o@@ uns from the refrigerator - the temperature of ins@@ ulin at room temperature ( not over 25 ° C ) before it is used according to the manual for the first use res@@ us@@ hing .
67 patients , whose blood glu@@ cose is significantly improved by an intensi@@ fied ins@@ ulin therapy , the hy@@ po@@ dr@@ yc@@ emia could be changed and should be assessed accordingly .
75 patients , whose blood glu@@ cose is significantly improved by an intensi@@ fied ins@@ ulin therapy , the hy@@ po@@ dr@@ yc@@ emia could be changed and should be assessed accordingly .
83 patients , whose blood glu@@ cose is significantly improved by an intensi@@ fied ins@@ ulin therapy , the hy@@ po@@ dr@@ yc@@ emia could be changed and should be considered to be considered to be investigated .
91 patients , whose blood glu@@ cose is significantly improved by an intensi@@ fied ins@@ ulin therapy , the hy@@ po@@ dr@@ yc@@ emia could be changed and should be assessed accordingly .
99 patients , whose blood glu@@ cose is significantly improved by an intensive use of ins@@ ulin therapy , the hy@@ po@@ gl@@ yc@@ emia could be changed and should be considered to be considered to be investigated .
any alter@@ ation regarding strength , brand ( manufacturers ) , ins@@ ulin type ( fast reaction , bi@@ ph@@ as@@ sic , long @-@ ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin ) and / or branches ( through re@@ combin@@ ant DNA to ins@@ ulin , ins@@ ulin ) and / or manufacturing method ( due to re@@ combin@@ ant DNA ) to ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@ ulin , ins@@
it is recommended - after Ac@@ tra@@ pe@@ ane In@@ no@@ ix was removed from the refrigerator - the temperature of ins@@ ulin at room temperature ( not over 25 ° C ) before it is used for the first use res@@ us@@ hing .
it is recommended - after Ac@@ tra@@ pe@@ ane Flex@@ Pen from the refrigerator - the temperature of ins@@ ulin at room temperature ( not above 25 ° C ) before it is used according to the manual for the first use res@@ us@@ hing .
on the Pack@@ ages of the medicine by means of name and address of the manufacturer , which is responsible for the release of the train@@ ee .
store in the refrigerator ( 2 FI@@ C - 8 DRO@@ C ) Not @-@ freeze the through@@ put bottle in the box to protect the content from light to protect : not in the refrigerator or over 25 ° C .
sub@@ cut@@ aneous application Pen@@ alty cartridges are intended for use with ins@@ ulin orient@@ ated equipment from Nov@@ o Nor@@ disk available . Ac@@ tu@@ ph@@ ane 10 pen@@ fill may only be used by a person
store in the refrigerator ( 2 PEN@@ C - 8 PEN@@ C ) non @-@ freeze the cartridge in the box to protect the content from light to protect : not in the refrigerator or over 30 ° C .
sub@@ cut@@ aneous application Pen@@ alty cartridges are intended for use with ins@@ ulin processing units from Nov@@ o Nor@@ disk supplied , Ac@@ tra@@ pe@@ ane 20 Pen@@ sion@@ ers may only be used by a person
sub@@ cut@@ aneous application Pen@@ alty cartridges are intended for use with ins@@ ulin orient@@ ated equipment from Nov@@ o Nor@@ disk available . Ac@@ tu@@ ph@@ ane 30 Pen@@ sion@@ ers may only be used by a person
sub@@ cut@@ aneous application Pen@@ alty cartridges are intended for use with ins@@ ulin processing units from Nov@@ o Nor@@ disk supplied , Ac@@ tra@@ pe@@ ane 40 pen@@ fill can only be used only by one person
sub@@ cut@@ aneous application Pen@@ alty cartridges are intended for use with ins@@ ulin processing units from Nov@@ o Nor@@ disk available , Ac@@ tu@@ ph@@ ane 50 pen@@ fill can only be used by a person
sub@@ cut@@ aneous use for use with Ac@@ tra@@ pe@@ ane 10 Nov@@ o@@ Nit@@ ro , Nov@@ o@@ Fine injection nad@@ eln , Ac@@ tra@@ pe@@ ane 10 Nov@@ o@@ das may be used only by a person
store in the refrigerator ( 2 PEN@@ C - 8 DRO@@ C ) Not @-@ freeze the light of the light : not in the refrigerator or over 30 ° C .
sub@@ cut@@ aneous items may be used with Ac@@ tra@@ pe@@ ane 20 Nov@@ o@@ flex , Nov@@ o@@ Fine injection nad@@ eln , Ac@@ tra@@ pe@@ ane 20 Nov@@ o@@ cked may only be used by a person .
sub@@ cut@@ aneous use for use with Ac@@ tra@@ pe@@ ane 30 Nov@@ o@@ uns are provided Nov@@ o@@ Fine injection nad@@ eln , Ac@@ tra@@ pe@@ ane 30 Nov@@ o@@ cked may only be used by a person
sub@@ cut@@ aneous use for use with Ac@@ tra@@ pe@@ ane 40 Nov@@ o@@ uns are provided Nov@@ o@@ Fine injection nad@@ eln , Ac@@ tra@@ pe@@ ane 40 Nov@@ o@@ cked may only be used by a person
sub@@ cut@@ aneous use for use with Ac@@ tra@@ pe@@ ane 50 Nov@@ o@@ uns are provided Nov@@ o@@ Fine injection nad@@ eln , Ac@@ tra@@ pe@@ ane 50 Nov@@ o@@ cked may only be used by a person
sub@@ cut@@ aneous use for use with Ac@@ tra@@ pe@@ ane 30 In@@ no@@ uns are provided Nov@@ o@@ Fine S injection nad@@ eln , Ac@@ tra@@ pe@@ ane 30 In@@ no@@ k may only be used by a person
this means that about half an hour after you have applied to decrease your blood sugar , and that the effect is about 24 hours .
you are allergi@@ c ( sensitive ) to this ins@@ ulin product , Met@@ ac@@ res@@ ol or any other components ( see Section 7 more information ) .
make the symptoms of an all@@ ergy if you feel first signs of a hypo@@ cris@@ sc@@ yc@@ ie ( symptoms of a sub@@ strate ) .
if your doctor has a change of ins@@ ulin or a stamp to another type , it might have to be adjusted by your doctor .
► check the label on the label whether it is the right ins@@ int@@ et type ► dis@@ inf@@ ect the rubber membrane with a medical T@@ up@@ le .
if this is not completely unnecessary if you get the through@@ change to your pharmacy , if it has not been approved or frozen ( see 6 How is Ac@@ tra@@ pe@@ ane treatment ? ) ► when it is not known for the res@@ us@@ ement .
use the injection moulding technology that is recommended to your doctor or your di@@ ab@@ et@@ es@@ ber@@ ate in ► the injection needle at least 6 seconds for your skin to make sure that the complete dose was inj@@ ected .
the warning signs of a submission can suddenly occur and may be : k@@ old sweat , cold spirits , heart pain , heart pain , heart disease , anxiety disorders , anxiety disorders , anxiety , anxiety or trem@@ or , anxiety , confusion , concentration of difficulties .
tell your relatives , friends and tight labour , that they should bring you in case of awareness into the stable side situation and immediately reco@@ gnis@@ es a doctor .
you may not eat anything or drink , because you may not be treated to you or even to death . ► If a heavy sub@@ strate cannot be treated , this may cause a loss of consciousness , or even to death , if you have a sub@@ stitution of consciousness , or even when they occur with consciousness , consult your doctor .
you can gain the consciousness faster when you get the hormone glu@@ c@@ agon from one person , which is familiar with the gift .
this can happen : • If you have too much ins@@ ulin and if you eat too little meal if you eat more than otherwise physically .
strengthened Har@@ n@@ d@@ rank , Dur@@ st , App@@ e@@ pl@@ ess@@ ness , Ü@@ eber@@ ry or vom@@ iting , did dry skin , mouth dry , and fru@@ ity ( after acet@@ one ) ri@@ pen@@ ing breath .
• You have to forget an ins@@ ulator of ins@@ ulin and less ins@@ ulin than you need to have infection or fever • more food than usual • less physical exercise than usual .
if you often give rise to a inj@@ uri@@ ous at the same place , the skin tissue can shrink ( Li@@ ev@@ rop@@ hi@@ e ) or side ( Lip@@ oh@@ y@@ per@@ tro@@ phy ) .
in case you are developing or thick@@ ening your skin to the inj@@ ections , report your doctor or di@@ ab@@ et@@ es@@ ber@@ ing in this case , as these reactions can em@@ li@@ fy or adjust your ins@@ ulin if you inj@@ ure into such a way .
if you are looking for a doctor if the symptoms of allergi@@ es to other parts of the body , or • if you suddenly feel un@@ comfortable and you get wel@@ ve bur@@ dens , wick@@ edness ( vom@@ iting ) , resp@@ ir@@ atory you are di@@ arr@@ ho@@ ea or you have the impression of re@@ vit@@ ality .
you probably may have a very rare heavy @-@ allergi@@ c reaction to Ac@@ tra@@ pe@@ ane or one of its components ( such as a given system@@ ic reaction ) .
if one of the remaining side effects are affected or side effects that are not specified in this utility information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
what Ac@@ tra@@ pe@@ ane 30 contains - The active ingredient is caused by re@@ combin@@ ant DNA technology ( 30 % as sol@@ uble ins@@ ulin and 70 % as Is@@ oph@@ an @-@ ins@@ ulin ) .
like Ac@@ tra@@ pe@@ ane &apos;s content and contents of the package A injection suspension is delivered as an ingredient , white , wat@@ ery suspension to pack@@ aged 10 ml or a bund@@ les of 5 ml or a bund@@ le with 5 to 10 ml .
use the injection moulding technology that is recommended to your doctor or your di@@ ab@@ et@@ es@@ ber@@ ate in ► the injection needle at least 6 seconds for your skin to make sure that the complete dose was inj@@ ected .
it is recommended - after they removed from the refrigerator - the temperature of the through@@ put on room temperature before the ins@@ ulin is used according to the instructions for the first use res@@ us@@ hing .
like Ac@@ tra@@ pe@@ ane &apos;s content and contents of the package A injection suspension is delivered as an ingredient , white , wat@@ ery suspension to pack@@ aged 10 ml or a bund@@ les of 5 ml or a bund@@ le with 5 to 10 ml .
► check the label you can see if there is the right ins@@ int@@ yp bist - check the pen@@ fill cartridge including the rubber band ( plug ) .
use it not to see if any damage is visible or a gap between the rubber ring and the white ribbon of the label is visible .
for further information , please refer to the manual transmission of your ins@@ in@@ ing@@ ual membrane using a medical T@@ up@@ le . ► Do you always use a new injection needle to avoid contamination .
the use of ins@@ ulin or the device that contains the Pen@@ alty or the device that has been damaged or cr@@ ushed , is the danger of ins@@ ulin or ins@@ ulin .
if you are treated with Ac@@ tra@@ pe@@ ane 10 Pen@@ alty and other ins@@ ulin in Pen@@ alty cartridges , you should use two ins@@ ulin in@@ ject systems , depending on the ins@@ ulin type .
before you use the cartridge into the ins@@ ulin system , they move at least 20 times between positions a and b ( see picture ) , so that the glass ball is moving from one end of the cartridge to the other .
use the injection moulding technology that is recommended to remove your doctor or your di@@ ab@@ et@@ es@@ ber@@ ing in the form of your injection system , the injection needle has at least 6 seconds with your skin to ensure that the inj@@ ections was to remove and keep the injection needle without turning moul@@ ded injection holes .
183 Get your relatives , friends , and close friends , that they should bring you in case of consciousness in the stable side situation and immediately reco@@ gnis@@ es a doctor in case of consciousness .
• You have to forget an ins@@ ulator of ins@@ ulin and less ins@@ ulin than you need to have infection or fever • more food than usual • less physical exercise than usual .
if one of the remaining side effects are affected or side effects that are not specified in this utility information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
it is recommended - after they removed from the refrigerator - the temperature of the pen@@ fill cartridge to room temperature before the ins@@ ulin is used according to the instructions for the first use res@@ us@@ hing .
185 keep the cartridges always in the box if you don &apos;t use it to protect them from light .
what Ac@@ tra@@ pe@@ ane 10 contains - The active ingredient is caused by re@@ combin@@ ant DNA technology ( 10 % as sol@@ uble ins@@ ulin and 90 % as Is@@ man@@ an ins@@ ulin ) .
like Ac@@ tra@@ pe@@ ane &apos;s content and contents of the package A injection suspension is delivered as low , white , wat@@ ery sus@@ pen@@ sions in packages with 1 , 5 or 10 cartridges to each 3 ml .
for further information , please refer to the manual transmission of your ins@@ in@@ ing@@ ual membrane using a medical T@@ up@@ le . ► Do you always use a new injection needle to avoid contamination .
if you are treated with Ac@@ tra@@ pe@@ ane 20 Pen@@ alty and other ins@@ ulin in Pen@@ alty cartridges , you should use two ins@@ ulin in@@ ject systems , depending on the ins@@ ulin type .
189 Be sure to put your relatives , friends and close friends , that they should bring you in case of consciousness in the stable side and immediately to get a doctor .
if one of the remaining side effects are affected or side effects that are not specified in this utility information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
&quot; &quot; &quot; 191 do not store the cartridges in the box if you don &apos;t use it to protect them from light . &quot; &quot; &quot;
what Ac@@ tra@@ pe@@ ane 20 contains - The active ingredient is caused by re@@ combin@@ ant DNA technology ( 20 % as sol@@ uble ins@@ ulin and 80 % as Is@@ oph@@ an @-@ ins@@ ulin ) .
like Ac@@ tra@@ pe@@ ane &apos;s content and contents of the package A injection suspension is delivered as low , white , wat@@ ery sus@@ pen@@ sions in packages with 1 , 5 or 10 cartridges to each 3 ml .
for further information , please refer to the manual transmission of your ins@@ in@@ ing@@ ual membrane using a medical T@@ up@@ le . ► Do you always use a new injection needle to avoid contamination .
if you are treated with Ac@@ tra@@ pe@@ ane 30 Pen@@ alty and other ins@@ ulin in Pen@@ alty cartridges , you should use two ins@@ ulin in@@ ject systems , depending on the ins@@ ulin type .
learn your relatives , friends and close co @-@ work , that they should bring you in case of awareness into the stable side situation and immediately reco@@ gnis@@ es a doctor .
if one of the remaining side effects are affected or side effects that are not specified in this utility information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
197 keep the cartridges always in the box if you don &apos;t use it to protect them from light .
manufacturers of the manufacturer can be printed by the Char@@ ging name which is identified at the bottom of the panel and on the label :
if at the second and third place of the charter number the character sets W@@ 5 , S@@ 6 , P@@ 5 , K@@ 7 or ZF appears , the manufacturer Nov@@ o Nor@@ disk A / S , Nov@@ o All@@ é , DK@@ - 28@@ 80 Bag@@ sv@@ aer@@ d , Denmark
if at the second and third place of the char@@ gen name the character combination of H@@ 7 or T@@ 6 is the manufacturer Nov@@ o Nor@@ disk Production SAS , 45 , Avenue d &apos;@@ Or@@ lé@@ ans , F @-@ 28@@ 002 Ch@@ art@@ res , France .
for more information , please refer to the manual transmission of your In@@ sul in@@ in@@ object system . ► Rescue is always a new injection needle to avoid contamination .
if you are treated with Ac@@ tra@@ pe@@ ane 40 pen@@ fill and other ins@@ ulin in Pen@@ alty cartridges , you should use two ins@@ ulin in@@ ject systems , depending on the ins@@ ulin type .
201 Be sure to put your relatives , friends and close friends , that they should bring you in case of awareness into the stable side situation and to get a physician .
if one of the remaining side effects are affected or side effects that are not specified in this utility information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
203 . store the cartridges always in the box if you don &apos;t use it to protect them from light .
what Ac@@ tra@@ pe@@ ane 40 contains - The active ingredient is caused by re@@ combin@@ ant DNA technology ( 40 % as sol@@ uble ins@@ ulin and 60 % as Is@@ oph@@ an @-@ ins@@ ulin ) .
for more information , please refer to the manual transmission of your In@@ sul in@@ in@@ object system . ► Rescue is always a new injection needle to avoid contamination .
if you are treated with Ac@@ tra@@ pe@@ ane 50 Pen@@ alty and other ins@@ ulin in Pen@@ alty cartridges , you should use two ins@@ ulin in@@ ject systems , depending on the ins@@ ulin type .
before you use the s@@ fill cartridge into the ins@@ ulin system , they move at least 20 times between positions a and b ( see picture ) , so that the glass ball is moving from one end of the cartridge to the other .
207 S@@ ages you make your relatives , friends , and tight labour , that they should bring you in case of awareness into the stable side situation and immediately reco@@ gnis@@ es a doctor .
if one of the remaining side effects are affected or side effects that are not specified in this utility information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
209 keep the cartridges always in the box if you don &apos;t use it to protect them from light .
what Ac@@ tra@@ pe@@ ane 50 contains - The active ingredient is caused by re@@ combin@@ ant DNA technology ( 50 % as sol@@ uble ins@@ ulin and 50 % as Is@@ oph@@ an @-@ ins@@ ulin ) .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
► Self @-@ check on the label whether it is the right In@@ sul type - ► Ben@@ eath you for each injection a new injection needle to avoid contamination .
but in ins@@ ulin in@@ fusion of ins@@ ulin , the risk of ins@@ ulin must be damaged or cr@@ ushed , the danger of ins@@ ulin defici@@ ency is not been approved or frozen ( see 6 How is Ac@@ tra@@ pe@@ ane ) is not consistent with the res@@ ump@@ tion of ins@@ ulin .
the warning signs of a submission can suddenly occur and may be : k@@ old sweat , cold spirits , heart pain , heart pain , heart disease , anxiety disorders , anxiety disorders , anxiety , anxiety or trem@@ or , anxiety , confusion , concentration of difficulties .
214 If one of the specified side effects you are affected or side effects that are not specified in this use information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
in use of Nov@@ o@@ qu@@ ay repair and such that are used in short @-@ term or used as replacement , are not store in the refrigerator .
it is recommended - after having taken out from the refrigerator - the temperature of the Nov@@ o@@ Let &apos;s start to reach room temperature before the ins@@ ulin is set in accordance with the manual for the first use res@@ us@@ hing .
set the applied folder of your Nov@@ o@@ Part completion if Nov@@ o@@ don &apos;t be used in use to protect the ins@@ ulin in front of light .
as Ac@@ tra@@ pe@@ ane &apos;s content and contents of the package A injection suspension is delivered as an ingredient , white , wat@@ ery suspension to pack@@ ets with 5 or 10 skills .
before each injection • check whether still at least 12 units of ins@@ ulin in the cartridge , so that a uniform mixture is ensured .
go to it to avoid the injection of air and to ensure correct dosage : • H@@ old you Ac@@ tra@@ pe@@ ane 10 Nov@@ o@@ ops with the injection needle after top • Klo@@ os with the fingers slightly against the cartridge .
if air bub@@ bles are present at the top in the cartridge • While you hold Ac@@ tra@@ pe@@ ane 10 Nov@@ o@@ das , you turn the cartridge to hold a click in the direction of the arrow ( Figure C ) • And you need to keep the pat@@ rone in the direction of the injection needle .
• Support cor@@ rup@@ ts back to the completion that the digit 0 compared to the met@@ ering stream is shown ( figure E ) • checks whether the pressure button is completely ste@@ ered .
if not , turn off the connection folder , until the print button is quite sti@@ ff@@ ered , • H@@ ull your Ac@@ tra@@ pe@@ ane 10 Nov@@ o@@ ops wa@@ ager@@ echt .
when the pressure knob is not freely accessible to outside , ins@@ ulin is de@@ pressed from the Injection pin , the scale is showing 0 , 2 , 4 , 6 , 8 , 12 , 16 , 16 and 18 units .
the push button is moving forward to the outside while you turn off the seal on the back button and shows 20 , 40 and 60 units .
check the amount of dose you can see the number on con@@ sol@@ vents • Emergency you can see the highest number you can see on the compres@@ sible dose • If you have a wrong dose , turn right or back@@ wards until you have the right number of units .
otherwise , ins@@ ulin is done from the injection needle and the set dosage is not correctly correctly • If you want to adjust the dose of more than 78 units , take the following steps :
please enter the connection folder and put it back to , that the 0 of the met@@ ering stamp is opposite .
be careful only during the injection pressure on the pressure button . • H@@ old you pass the pressure button to the injection , until the injection holes from the skin was pulled out of the skin .
if not , turn off the cl@@ amps as well as the pressure button is completely ste@@ ered , and then drive them as in the use of using the pressure shiel@@ ding a cli@@ pping device .
it may possibly be in@@ accurate • You cannot set any dose that is higher than the number of remaining in the cartridge of units • You can use the remain@@ der amount to cut as much ins@@ ulin still remains .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
224 If one of the remaining side effects are affected or no side effects that are not specified in this use information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
226 Before each injection • check whether still at least 12 units of ins@@ ulin in the cartridge , so that a uniform mixture is ensured .
go to it to avoid the injection of air and to ensure correct dosage : • H@@ old you Ac@@ tra@@ pe@@ ane 20 Nov@@ o@@ ops with the injection needle after top • Klo@@ os with the fingers slightly against the cartridge .
if air bub@@ bles are present at the top of the cartridge • While you hold Ac@@ tra@@ pe@@ ane 20 Nov@@ o@@ uns , you turn the cartridge to hold a click in the direction of the arrow ( Figure C ) • And you need to keep the pat@@ rone in the direction of the injection needle .
if not , turn off the connection folder , up to the print button , it is inserted to your Ac@@ tra@@ pe@@ ane 20 Nov@@ o@@ cks wa@@ ager@@ echt .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
234 If one of the remaining side effects are affected or side effects that are not specified in this use information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
236 Before each injection • check whether still at least 12 units of ins@@ ulin in the cartridge , so that a uniform mixture is ensured .
go to this type to avoid injection of air and to ensure correct dosage : • H@@ old you Ac@@ tra@@ pe@@ ane 30 Nov@@ o@@ ops with the injection needle after top • Klo@@ p@@ pling with the fingers slightly against the cartridge .
if air bub@@ bles are present at the top of the cartridge • While you hold Ac@@ tra@@ pe@@ ane 30 Nov@@ o@@ uns , you turn the cartridge to hold a click in the direction of the arrow ( Figure C ) • And you need to keep the pat@@ rone in the direction of the injection needle .
if not , turn off the connection folder , until the print button is completely inserted , • H@@ ull your Ac@@ tra@@ pe@@ ane 30 Nov@@ o@@ cks wa@@ ager@@ echt .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
244 If one of the remaining side effects are affected or side effects that are not specified in this use information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
246 Di@@ ce of each injection • check whether still at least 12 units of ins@@ ulin in the cartridge , so that a uniform mixture is ensured .
go to this type to avoid injection of air and to ensure correct dosage : • H@@ old you Ac@@ tra@@ pe@@ ane 40 Nov@@ o@@ ops with the injection needle after top • Klo@@ p@@ pling with the fingers slightly against the cartridge .
if air bub@@ bles are present at the top of the cartridge • While you hold Ac@@ tra@@ pe@@ ane 40 Nov@@ o@@ uns , you turn the cartridge to hold a click in the direction of the arrow ( Figure C ) • And you need to keep the pat@@ rone in the direction of the injection needle .
if not , turn off the connection folder , up to the print button , it is inserted to your Ac@@ tra@@ pe@@ ane 40 Nov@@ o@@ cks wa@@ ager@@ echt .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
254 For one of these side effects are affected or no side effects that are not specified in this use information , please refer to your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
it is recommended - after having taken out from the refrigerator - the temperature of the Nov@@ o@@ Let &apos;s start to reach room temperature before the ins@@ ulin is set in accordance with the manual for the first use res@@ us@@ hing .
&quot; &quot; &quot; 256 in each injection • check whether still at least 12 units of ins@@ ulin in the cartridge , so that a uniform mixture is ensured . &quot; &quot; &quot;
go to this type to avoid injection of air and to ensure correct dosage : • H@@ old you Ac@@ tra@@ pe@@ ane 50 Nov@@ o@@ ops with the injection needle after top • Klo@@ sters with the fingers slightly against the cartridge .
if air bub@@ bles are present at the top in the cartridge • While you hold Ac@@ tra@@ pe@@ ane 50 Nov@@ o@@ uns , you turn the cartridge to hold a click in the direction of the arrow ( Figure C ) • And you need to keep the pat@@ rone in the direction of the injection needle .
if not , turn off the connection folder , until the print button is quite sti@@ ff@@ ered , • H@@ ull your Ac@@ tra@@ pe@@ ane 50 Nov@@ o@@ cks wa@@ ager@@ echt .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
but in ins@@ ulin in@@ fusion of ins@@ ulin , the risk of ins@@ ulin is damaged or dis@@ ks , is the danger of ins@@ ulin or ins@@ ulin .
the warning signs of a submission can suddenly occur and may be : k@@ old sweat , cold spirits , heart pain , heart pain , heart disease , anxiety disorders , anxiety disorders , anxiety , anxiety or trem@@ or , anxiety , confusion , concentration of difficulties .
264 If one of the remaining side effects are affected or no side effects that are not specified in this use information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
in use of in@@ no@@ vial separation and such that are used in short @-@ term or as replacement , are not store in the refrigerator .
it is recommended - after having taken out from the refrigerator - the temperature of the in@@ no@@ vial is delivered to room temperature before the ins@@ ulin is applied in accordance with the manual for the first use res@@ us@@ hing .
set the connection kit of your in@@ no@@ vial is always set if In@@ no@@ Mani@@ pul@@ ates is not stored in use to protect the ins@@ ulin in front of light .
as Ac@@ tra@@ pe@@ ane &apos;s content and contents of the package A injection suspension is delivered as an ingredient , white , wat@@ ery suspension to pack@@ ets with 1 , 5 or 10 ( 10 ) .
the movement needs to be repeated until the liquid is equal to the fluid , and then look at all the following steps of the injection without delay .
• Des@@ in@@ ates the rubber mixing with a medical T@@ up@@ le • Ben@@ ies you always use a new injection needle to avoid a contamination of a Nov@@ o@@ del@@ S injection needle , which is straight and firmly on Ac@@ tra@@ pe@@ ane 30 in@@ no@@ zzles ( Figure 1@@ B ) • Zi@@ pped the large external injection molding tools and the internal inj@@ ector liner .
• check whether the pressure button is fully loaded and the D@@ os@@ is@@ regulator on zero , • Make the number of units you have to inj@@ ected by using the D@@ os@@ is@@ regulator in the clo@@ ck@@ wise ( figure 2 ) .
do not use the resi@@ dual scale to measure your ins@@ ulin dose • you listen to each individually available unit .
perform the injection technology that will show you your doctor • G@@ eben take the dose by pressing the pressure button ( Figure 3 ) .
the D@@ os@@ is@@ regulator is set to zero back and you listen to zero @-@ noise • The injection holes should not block at least 6 seconds while the injection holes should not block at least 6 seconds while the injection holes should not be set to zero when the inj@@ ector can be set to zero .
medical staff , family members as well as other care for the removal measures for removal and disposal of injection moulding may be observed in order to avoid un@@ avo@@ id@@ able bul@@ lets with the injection needle .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
but in ins@@ ulin in@@ fusion of ins@@ ulin , the risk of ins@@ ulin must be damaged or cr@@ ushed , the danger of ins@@ ulin is not kept correctly or frozen ( see 6 How is Ac@@ tra@@ pe@@ ane ) is not consistent with respect to the res@@ ump@@ y .
in case you are developing or thick@@ ening your skin to the inj@@ ections , report your doctor or di@@ ab@@ et@@ es@@ ber@@ ing in this case , as these reactions can em@@ li@@ fy or adjust your ins@@ ulin if you inj@@ ure into such a way .
274 If one of the remaining side effects are affected or no side effects that are not specified in this use information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
in use of preventive det@@ erg@@ ents and such that are used in short @-@ term or substitute , are not used in the refrigerator .
it is recommended - after having been taken out from the refrigerator - the temperature of fle@@ R is delivered to room temperature before the ins@@ ulin is set in accordance with the manual for the first use res@@ us@@ hing .
in case you have set the connection folder of your fle@@ ece container , when fle@@ x@@ Pen is not used in use to protect ins@@ ulin in front of light .
as Ac@@ tra@@ pe@@ ane &apos;s content and contents of the package A injection suspension is delivered as an ingredient , white , wat@@ ery suspension to pack@@ ets with 1 , 5 or 10 ( 10 ) .
manufacturers of the manufacturer can be printed by the Char@@ ging name which is identified at the bottom of the panel and on the label :
275 • If the second and third place of the char@@ gen name the character sets W@@ 5 , S@@ 6 , P@@ 5 , K@@ 7 or ZF appears , the manufacturer Nov@@ o Nor@@ disk Production SAS , 45 , Avenue d &apos;@@ Or@@ lé@@ ans , F@@ - 28@@ 002 Ch@@ art@@ res , France .
B Move the completion between positions 1 and 2 t@@ mal , and so that the glass ball is moving from one end of the cartridge to the other .
move the completion of at least 10 times between positions 1 and 2 and up to the liquid once and appears .
• To reduce the risk of un@@ intended way to reduce the inner cover again to the injection needle after you have taken once again .
279 G H@@ old you comb the fle@@ ece with the injection pin after top and kno@@ ck up a few times with the finger easily against the cartridge , so that the existing air bub@@ bles appear above the cartridge .
the dose can be adjusted both on top and down at the bottom by using the D@@ os@@ is@@ vor@@ m button in the appropriate direction , until correct dose compared to the marking of the display .
the assumption of full take @-@ up tends to exagger@@ ate the simulated increase in cas@@ elo@@ ads and fiscal costs of a social policy reform .
the in@@ comprehen@@ sible part of Ac@@ tra@@ pi@@ d , ins@@ ulin ( r@@ DNA ) will be established with the procedure of so @-@ called &quot; re@@ combin@@ ant technology . &quot;
( 44 @-@ 20 ) 74 18 86 00 Fax ( 44 @-@ 20 ) 74 18 86 68 E @-@ mail : mail @ em@@ e@@ a.@@ o. htt@@ p : / / www.@@ em@@ e@@ a.@@ europ@@ a.@@ eu
Ac@@ tra@@ pi@@ d may not be applied to patients who may possibly be sensitive to ins@@ ulin ( r@@ DNA ) or one of the other ingredients .
in addition , the dos@@ es of Ac@@ tra@@ pi@@ d may have to be adjusted if it is administ@@ ered together with a number of other medicines .
October 2002 , the European Commission shared the European Commission to Nov@@ o Nor@@ disk A / S authorization for the transport of Ac@@ tra@@ pi@@ d in the entire European Union .
if two types of ins@@ ulin is mixed , first , the amount of ins@@ ulin is glu@@ ed to the amount of ins@@ ulin ins@@ ulin , then the amount of ins@@ ulin is glu@@ ed to the amount of ins@@ ulin .
3 . when changing to Ac@@ tra@@ pi@@ d when patients do not require a D@@ os@@ is@@ cation is necessary , this can be necessary during the first dose or months after the special treatment .
before travelling to go through several time zones , the patient should be advised to obtain the advice of his doctor because such trips can be applied for ins@@ ulin and meals .
5 General diseases and complaints on the appointment of money - Local Contra@@ cts reaction in the inj@@ uri@@ ous reaction of the ins@@ ulin therapy may cause local over@@ flow reactions ( Romans , sw@@ elling , it@@ ching , it@@ ching , it@@ ching , pain and hem@@ at@@ om at the inj@@ ector ) .
Di@@ abe@@ tics should always have mat@@ urity , swe@@ ets , bis@@ cuits or zu@@ cker@@ ate fruit juice are treated with an intra@@ mus@@ cular or sub@@ cut@@ aneous injection of glu@@ c@@ agon ( 0.5 to 1.0 mg ) of glu@@ cose or sub@@ cut@@ aneous injection of glu@@ c@@ agon ( 0.5 to 1.0 mg ) .
a clinical trial in a intensive brief@@ ing at the treatment of hyper@@ gl@@ yc@@ emia ( blood sugar through 10 m@@ mo@@ l / l ) with 204 di@@ abe@@ tic and 13@@ 44 non @-@ di@@ abe@@ tic patients with intra@@ ven@@ ous acet@@ yl@@ emia ( blood sugar 4,@@ 4 - 6,@@ 1 m@@ mo@@ l / l )
the effect begins within half an hour , the active ingredient is reached within 1.5 to 3.5 hours and the total efficiency amounts to approximately 7 to 8 hours .
children and adol@@ esc@@ ents The phar@@ yn@@ ok@@ ine@@ tic profile of Ac@@ tra@@ pi@@ d was studied at a smaller number ( n = 18 ) di@@ abe@@ tic children ( aged between 6 and 12 years ) and youth ( at the age between 13 and 17 years ) .
the data is limited , however , however , that the pharmac@@ ological profile of children and adol@@ esc@@ ents is similar to adults and adol@@ esc@@ ents .
in@@ fusion systems with Ac@@ tra@@ pi@@ d in concent@@ rations 0,@@ 05 I.@@ U. / ml - 1.0 I.@@ U. / ml ins@@ ulin in the in@@ fusion fluid flow 0,@@ 9 % Nat@@ ri@@ um chl@@ oride , 5 % D @-@ glu@@ cose concent@@ rations of polypropylene at room temperature 24 hours long .
11 If the change to Ac@@ tra@@ pi@@ d in the case of a D@@ os@@ is@@ cation is necessary , this can be necessary during the first dose or months after the special treatment .
before travelling to go through several time zones , the patient should be advised to obtain the advice of his doctor because such trips can be applied for ins@@ ulin and meals .
13 General diseases and complaints on the appointment of money - Local Contra@@ cts reaction in the inj@@ uri@@ ous reaction of the ins@@ ulin therapy may cause local over@@ flow reactions ( Romans , sw@@ elling , it@@ ching , it@@ ching , it@@ ching , pain and hem@@ at@@ om at the inj@@ ector ) .
Di@@ abe@@ tics should always have mat@@ urity , swe@@ ets , bis@@ cuits or zu@@ cker@@ ate fruit juice are treated with an intra@@ mus@@ cular or sub@@ cut@@ aneous injection of glu@@ c@@ agon ( 0.5 to 1.0 mg ) of glu@@ cose or sub@@ cut@@ aneous injection of glu@@ c@@ agon ( 0.5 to 1.0 mg ) .
children and adol@@ esc@@ ents The phar@@ yn@@ ok@@ ine@@ tic profile of Ac@@ tra@@ pi@@ d was studied at a smaller number ( n = 18 ) di@@ abe@@ tic children ( aged between 6 and 12 years ) and youth ( at the age between 13 and 17 years ) .
intra@@ ven@@ ous application of Ac@@ tra@@ pi@@ d made out of completion or cartridges should be used in situations where no penetration are available .
if you need to change to Ac@@ tra@@ pi@@ d in the case of change to Ac@@ tra@@ pi@@ d , this can be necessary during the first dose or months after switching to Ac@@ tra@@ pi@@ d .
21 disorders of the skin and of the skin cell - Li@@ pod@@ yst@@ rop@@ hi@@ e An der Injection station can develop a Li@@ pod@@ yst@@ rop@@ hi@@ e when switching to injection holes within the injection system .
children and adol@@ esc@@ ents The phar@@ yn@@ ok@@ ine@@ tic profile of Ac@@ tra@@ pi@@ d was studied at a smaller number ( n = 18 ) di@@ abe@@ tic children ( aged between 6 and 12 years ) and youth ( at the age between 13 and 17 years ) .
29 diseases of the skin and the basement of the skin tissue - Li@@ pod@@ yst@@ rop@@ hi@@ e An der Injection station can be a li@@ ve@@ yst@@ rop@@ hi@@ e when switching to injection holes within the injection system .
diseases of the immune system Gel@@ o@@ form - Ur@@ tic@@ aria , Ex@@ an@@ ensis essential , rare - An@@ ap@@ hy@@ l@@ act@@ ate reactions , including gener@@ ated skin disorder , ju@@ cks , swe@@ ating , resp@@ ect@@ omy , resp@@ ir@@ atory disorders , resp@@ ir@@ atory disorders , heart attack , low blood pressure , and emotion .
children and adol@@ esc@@ ents The phar@@ yn@@ ok@@ ine@@ tic profile of Ac@@ tra@@ pi@@ d was studied at a smaller number ( n = 18 ) di@@ abe@@ tic children ( aged between 6 and 12 years ) and youth ( at the age between 13 and 17 years ) .
diseases of the immune system Gel@@ o@@ form - Ur@@ tic@@ aria , Ex@@ an@@ ensis essential , rare - An@@ ap@@ hy@@ l@@ act@@ ate reactions , including gener@@ ated skin disorder , ju@@ cks , swe@@ ating , resp@@ ect@@ omy , resp@@ ir@@ atory disorders , resp@@ ir@@ atory disorders , heart attack , low blood pressure , and emotion .
38 A clinical trial in a intensive procedure for treatment of hyper@@ gl@@ yc@@ emia ( blood sugar through 10 m@@ mo@@ l / l ) with 204 di@@ abe@@ tic and 13@@ 44 non @-@ di@@ abe@@ tic patients with intra@@ ven@@ ous acet@@ yl@@ emia ( blood sugar 4,@@ 4 - 6,@@ 1 m@@ mo@@ l / l )
diseases of the immune system Gel@@ o@@ form - Ur@@ tic@@ aria , Ex@@ an@@ ensis essential , rare - An@@ ap@@ hy@@ l@@ act@@ ate reactions , including gener@@ ated skin disorder , ju@@ cks , swe@@ ating , resp@@ ect@@ omy , resp@@ ir@@ atory disorders , resp@@ ir@@ atory disorders , heart attack , low blood pressure , and emotion .
46 A clinical trial in a intensive procedure for treatment of hyper@@ gl@@ yc@@ emia ( blood sugar through 10 m@@ mo@@ l / l ) with 204 di@@ abe@@ tic and 13@@ 44 non @-@ di@@ abe@@ tic patients with intra@@ ven@@ ous acet@@ yl@@ emia ( blood sugar 4,@@ 4 - 6,@@ 1 m@@ mo@@ l / l )
store in the refrigerator ( 2 ° C - 8 ° C ) Not to freeze the through@@ put bottle in the box to protect the content from light to protect : not in the refrigerator or over 25 ° C .
sub@@ cut@@ aneous application Pen@@ alty cartridges are used for use with Nov@@ o Nor@@ disk In@@ tra@@ d injection systems , Ac@@ tra@@ pi@@ d Pen@@ alty can only be used by a person
store in the refrigerator ( 2 ° C - 8 ° C ) non @-@ freeze the cartridge in the box to protect the content from light to protect : not in the refrigerator or over 30 ° C .
sub@@ cut@@ aneous use for use with Ac@@ tra@@ pi@@ d Nov@@ o@@ uns are provided Nov@@ o@@ Fine injection nad@@ eln , Ac@@ tra@@ pi@@ d Nov@@ o@@ strich can only be used by a person
store in the refrigerator ( 2 ° C - 8 ° C ) non @-@ freeze on light after light : not in the refrigerator or over 30 ° C .
sub@@ cut@@ aneous use for use with Ac@@ tra@@ pi@@ d In@@ no@@ ck , Nov@@ o@@ Fine S injection nad@@ eln , Ac@@ tra@@ pi@@ d In@@ no@@ k may only be used by a person
this means that about half an hour after you have applied to decrease your blood sugar , and that the effect is about 8 hours .
► check the label on the label whether it is the right ins@@ int@@ et type . ► dis@@ inf@@ ect the rubber membrane with a medical T@@ up@@ le .
if this doesn &apos;t fully proceed if you get the through@@ change to your pharmacy , if it was not properly kept correctly or frozen ( see 6 How is Ac@@ tra@@ pi@@ d ? ) ► when it is not clear as water and colour@@ less .
use the injection moulding technology that is recommended to your doctor or your di@@ ab@@ et@@ es@@ ber@@ ate in ► the injection needle at least 6 seconds for your skin to make sure that the complete dose was inj@@ ected .
83 S@@ ages you make your relatives , friends and tight labour , that they should bring you in case of awareness into the stable side situation and immediately reco@@ gnis@@ es a doctor in case of consciousness .
you probably may have a very rare heavy all@@ erg@@ ent reaction to Ac@@ tra@@ pi@@ d or a part of its components ( such as &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; system@@ ic reaction &quot; ) . &quot; &quot; &quot;
the injection solution is delivered as a clear , color@@ less , wat@@ ery solution in packages with 1 or 5 holes on each 10 ml or a bund@@ led chim@@ es with 5 to 10 ml .
89 With@@ draw@@ al your relatives , friends and close co @-@ work , that they should bring you in case of consciousness in the stable side situation and immediately reco@@ gnis@@ es a doctor in case of consciousness .
you can check the label on the label whether it is the right ins@@ int@@ et type , you always check the cartridge including the rubber band ( plug ) .
the ins@@ ulin or the device that contains the Pen@@ alty or the device that has been damaged or cr@@ ushed ; it is the danger of ins@@ ulin or ins@@ ulin .
if you are treated with Ac@@ tra@@ pi@@ d Pen@@ alty and other ins@@ ulin in Pen@@ alty cartridges , you should use two ins@@ ulin in@@ ject systems , depending on ins@@ ulin type .
use the injection moulding technology that is recommended to remove your doctor or di@@ ab@@ et@@ es@@ ber@@ ate , but the injection needle has at least 6 seconds with your skin to ensure that the inj@@ uri@@ ous injection was to remove and keep the injection needle without turning moul@@ ded injection holes .
• If the second and third place of the char@@ gen name the character sets W@@ 5 , S@@ 6 , P@@ 5 , K@@ 7 or ZF appears , the manufacturer Nov@@ o Nor@@ disk A / S , Nov@@ o All@@ é , D@@ K @-@ 28@@ 80 Bag@@ sv@@ aer@@ d , Denmark
• If the second and third place of the char@@ gen name the character combination of H@@ 7 or T@@ 6 is the manufacturer Nov@@ o Nor@@ disk Production SAS , 45 , Avenue d &apos;@@ Or@@ lé@@ ans , F@@ - 28@@ 002 Ch@@ art@@ res , France .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
► Self @-@ check on the label whether it is the right ins@@ int@@ yp : ► Do you always use new injection needle to avoid contamination .
in ins@@ ulin in@@ fusion pumps , if the Nov@@ o@@ uns was left , damaged or cr@@ ushed ; it is the danger of ins@@ ulin in ► when it was not properly kept correctly or frozen ( see 6 How is Ac@@ tra@@ pi@@ d ? ) ► when it &apos;s not clear to water and colour@@ less .
this can happen : • If you have too much ins@@ ulin and if you eat too little meal if you eat more than otherwise physically .
in order to set the applied folder of your Nov@@ o@@ Part , it is always set if it is not used in use to protect it from light .
• Des@@ in@@ ates the rubber membrane with a medical T@@ up@@ le • Ben@@ ies you always use a new injection needle to avoid a contamination of a Nov@@ o@@ flex injection needle , which is straight and firmly on Ac@@ tra@@ pi@@ d Nov@@ o@@ strich ( figure A ) • Zi@@ pped the large external cap of the injection needle and the inner cap of the injection needle .
to ensure the injection of air to avoid and to ensure correct dosage : • H@@ old you acet@@ ate Ac@@ tra@@ pi@@ d Nov@@ o@@ uns with the injection needle after top • Klo@@ p@@ pling with the fingers slightly against the cartridge .
if air bub@@ bles are present at the top in the cartridge • While you continue the injection needle , turn the cartridge to a click in the direction of the arrow ( Figure B ) • And the injection pin can easily be positioned in the direction of the injection needle .
• Support cor@@ rup@@ ts back to the completion that the digit 0 compared to the met@@ ering brand ( figure D ) • checks whether the pressure button is completely ste@@ ered .
if the pressure is not move freely , ins@@ ulin is de@@ pressed from the Injection pin , the scale is showing 0 , 2 , 4 , 6 , 8 , 12 , 16 , 16 and 18 units .
the push button moves to the outside while you turn off the wiring diagram • The scale under the pressure button ( push button valve ) shows 20 , 40 and 60 units .
&quot; &quot; &quot; 107 &quot; &quot; &quot; &quot; you can see the highest number you can see the two numbers to obtain the suggested dose • If you have a wrong dose , turn right or back@@ wards until you have the right number of units . &quot; &quot; &quot;
turn them until the push button is down below and you feel a resistance for the connection , and put it back to , that the 0 of the met@@ ering stamp is opposite .
be sure to press the pressure on the pressure button and press the pressure button to press the pressure to the injection , until the injection holes from the skin was pulled out of the skin .
it may possibly be in@@ accurate • You can use any dose that is higher than the number of remaining in the cartridge of units • You can use the Rest@@ ore sk@@ ala to figure out how much ins@@ ulin is still left , but you can &apos;t use it to adjust your dose .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
but if the in@@ no@@ vial is left , the risk of ins@@ ulin is reduced or cr@@ ushed ; it is the danger of ins@@ ulin in ► when it was not properly kept correctly or frozen ( see 6 How is Ac@@ tra@@ pi@@ d ? ) ► when it &apos;s not clear to water and colour@@ less .
in case you have set the connection folder of your in@@ no@@ vial is always set if he is not able to protect it from light to light .
• Des@@ in@@ ates the rubber ra@@ gm with a medical T@@ up@@ le • Ben@@ eath the protective layer of a Nov@@ o@@ del@@ S injection needle , which is straight and firmly on Ac@@ tra@@ pi@@ d In@@ no@@ k ( Figure 1A ) • Zi@@ pped the big outer cap of the injection needle and the inner cap of the injection needle .
the D@@ os@@ is@@ regulator is set to zero back and you listen to zero @-@ noise • The inj@@ ector is not to block at least 6 seconds while the inj@@ ector is not block to zero .
neur@@ or@@ ale Anti@@ di@@ abe@@ tic ( for one ) , mon@@ o@@ am@@ ino@@ xi@@ th@@ ic acid ( MA@@ O inhib@@ itors ) , an@@ aes@@ th@@ ogen@@ ic acid ( ACE ) -@@ inhib@@ itors , an@@ odi@@ aly@@ ath@@ om@@ im@@ e@@ ogen@@ ic , growth hormone , hormone synthesis .
121 ► when it was not stored correctly or frozen ( see 6 How is Ac@@ tra@@ pi@@ d preserve ? ) ► does not clear as water and colour@@ less .
if one of the remaining side effects are affected or side effects that are not specified in this utility information , please inform your doctor , your di@@ ab@@ et@@ es@@ ber@@ ater@@ in or your pharmac@@ ist .
in addition , the adap@@ tor of your fle@@ x@@ Pen is always set if it is not used in use to protect it from light .
F H@@ old you fle@@ e the fle@@ ece with the injection pin after top and kno@@ ck a few times with the finger easily against the cartridge , so that the existing air bub@@ bles appear above the cartridge .
the dose can be adjusted both on top and down at the bottom by using the D@@ os@@ is@@ ion@@ er button to the appropriate dose compared to the marking of the D@@ os@@ is@@ indicator .
A@@ den@@ ur@@ ic is applied to patients who have already use the signs of cryst@@ all@@ ine values , including ar@@ thritis ( pain and inflammation in the ser@@ rations ) or plaster layer ( &quot; stones &quot; ) of ur@@ ine cryst@@ all@@ ine , which can lead to the joint and bone damage .
if the ur@@ inary reaction rate after two or four weeks is still over 6 mg per deci@@ liter , the dose can be increased once daily 120 mg .
during the first treatment of treatments , there is therefore recommended that patients can take at least during the first six months under treatment with A@@ den@@ ur@@ ic even further drugs to the prevention of plaster waste .
the medicine is not recommended for children and in patients who had a organ transplan@@ tation since it was not investigated for these groups .
in the first study at the 1 0@@ 72 patients , the eff@@ ic@@ acy of three A@@ den@@ ur@@ ic dosage ( once daily 80 , 120 and 240 mg ) was compared with a plac@@ ebo ( head@@ medicine ) and allo@@ pur@@ in@@ ol ( another medication for hyper@@ ur@@ ic@@ emia ) .
in the second study two dos@@ ages of A@@ den@@ ur@@ ic ( once daily 80 and 120 mg ) were compared with allo@@ pur@@ in@@ ol compared with allo@@ pur@@ in@@ ol .
in both studies , allo@@ pur@@ in@@ ol was applied in a dose of daily 300 mg ; patients with kidney results were only 100 mg per day .
the basic agent for the effectiveness was the number of patients , their ur@@ ative disorders in the blood at the last three measurements below 6 mg / dl .
in the first study 48 % ( 126 of 262 ) of the patients who took A@@ den@@ ur@@ ic in a dose of 80 mg per day , and 65 % ( 175 of 269 ) patients who took a daily 120 mg in the blood of 6 mg / dl .
in comparison , this was at 22 % ( 60 of 268 ) of the patients under allo@@ pur@@ in@@ ol and not of the 134 patients under plac@@ ebo .
the most common side effects of A@@ den@@ ur@@ ic ( observed at 1 to 10 of 100 patients ) are head@@ aches , di@@ arr@@ ho@@ ea ( NA@@ US@@ EA ) , skin r@@ ash and normal liver values .
in particular in patients with heart claims , there may also be an increased risk of specific side effects that affect the heart and the blood vessels .
&quot; &quot; &quot; the Committee for Human@@ izing Human Rights ( CH@@ MP ) came to the conclusion that A@@ den@@ ur@@ ic was more effective in the blood of ur@@ alism in the blood , but also a higher risk of side effects in connection with the heart and the blood vessel . &quot; &quot; &quot;
treatment of chronic hyper@@ ur@@ ic@@ emia in diseases caused by ur@@ ination of ur@@ ination ( including one from the hospital &apos;s history ) or relevant Gi@@ cht@@ ar@@ thritis ) .
if the Ser@@ um@@ har@@ ass@@ ess@@ ation rate after 2 @-@ 4 weeks still &gt; 6 mg / dl ( 357 µ@@ mo@@ l / l ) , it can be considered to be taken into consideration by AD@@ EN@@ UR@@ IC 120 mg 1 x day .
in patients with severe kidney dys@@ function , effectiveness and security are not fully examined ( Kre@@ at@@ in@@ arian Clear@@ ance &lt; 30 ml / min , see Section 5.2 ) .
children and adol@@ esc@@ ents have no experiences yet in children and adol@@ esc@@ ents are not recommended in this patient group .
organ transplan@@ ts have no experiences yet , the application of Feb@@ u@@ ost@@ at is not recommended ( see Section 5.1 ) .
cardiovascular disease in patients with chronic heart disease or de@@ compens@@ ated heart failure , the treatment with Feb@@ el@@ ost@@ ate is not recommended ( see Section 4.8 ) .
as with other har@@ ms of medicines , it may come to a acute gi@@ dium case because of the reduction of the Ser@@ b har@@ ass@@ ess@@ ation of ur@@ inary tis@@ sues within the tis@@ sues .
B. in mal@@ evol@@ ent diseases and their treatment , Les@@ ch@@ - Ny@@ han @-@ Syndrome ) is the absolute concentration of X@@ an@@ thin in rare cases in rare cases , so far that it comes to a shift in har@@ n@@ tra@@ ct .
liver disease as the clinical studies of the phase 3 were easy removal of the liver dys@@ function values with Feb@@ el@@ ost@@ at treated patients ( 3.5 % ) .
it is therefore recommended to perform the beginning of the Feb@@ u@@ ary @-@ treatment and in the further course of clinical findings and a liver functional test ( see Section 5.1 ) .
the@@ ophy@@ ll@@ ine was performed , but it is known that the X@@ O inhib@@ itor can lead to a rise in the the@@ ophy@@ ll@@ ation of the@@ ophy@@ ll@@ ation of the@@ ophy@@ ll@@ ine , also for other X@@ O inhib@@ itors .
in study , the simultaneous evaluation of Feb@@ el@@ ost@@ at and Nap@@ ro@@ xen 250 mg 2 x day with a rise of Feb@@ tel exposure estim@@ ation ( C@@ max 28 % , AU@@ C 41 % and t@@ 1 / 2 26 % ) .
in clinical studies , the application of Nap@@ ro@@ xen or other N@@ SA@@ R / Co@@ x @-@ 2 inhib@@ itors aren &apos;t in connection with a clinical significant significant contribution .
Col@@ ch@@ ic@@ in / In@@ dom@@ et@@ ac@@ in / Hydro@@ chlor@@ othi@@ azi@@ d / War@@ mb@@ in Feb@@ . ux@@ ost@@ at can be applied together with Col@@ ch@@ ic@@ in or In@@ dom@@ et@@ ac@@ in , without any other active ingredient .
in a study with subjects aged 120 mg AD@@ EN@@ UR@@ IC 1 , a mean 22 % increase in the AU@@ C of Des@@ i@@ pra@@ min , an CY@@ P@@ 2@@ D@@ 6 sub@@ strate , which indicates a possible weak in@@ hi@@ bit@@ ory effects of Feb@@ u@@ ost@@ at on the CY@@ P@@ 2@@ D@@ 6 @-@ enz@@ yme in vivo .
An@@ ta@@ zi@@ da It could be shown that the simultaneous intake of a stimulus is delayed , the magn@@ esium hydro@@ xi@@ de and aluminium hydro@@ x@@ id recep@@ tors ( around 1 hour ) delayed and a decrease of C@@ max is 32 % , but not a significant change of AU@@ C .
pregnancy data about a very limited number of exp@@ on@@ ated pregnancy , not on side effects of Feb@@ el@@ ost@@ at on the pregnancy or health of fo@@ etus / new@@ born .
the experimental studies cannot be found on direct or indirect effects on pregnancy , embr@@ y@@ onic / f@@ ale development or birth ( see Section 5.3 ) .
patients should be careful to be careful with machines or when exercising of dangerous actions until they are sure to be sure that AD@@ EN@@ UR@@ IC does not affect their performance .
compared to the allo@@ pur@@ in@@ ol group , the phase 3 ( 1.3 versus 0.@@ 7 events per 100 patient years ) and in long @-@ term studies ( 1.4 versus 0.@@ 7 events per 100 patient years ) are observed , although no statistical significant differences were found .
in this case the risk factors were a ar@@ teri@@ os@@ kl@@ ine slave disease and / or a M@@ yo@@ cardi@@ al inf@@ ra or a de@@ compens@@ ated heart failure in the hospital .
frequently ( ≥ 1 / 100 to &lt; 1 / 10 ) , occasional ( ≥ 1 / 1,000 up to &lt; 1 / 100 ) and rare ( ≥ 1 / 120 mg / 1,000 ) side effects that were reported in the treatment groups with 80 mg / 120 mg .
patients , exercise and vom@@ iting are more common in patients who were treated with Col@@ ch@@ ic@@ in . * * In the clinical studies were no serious injuries or severe floo@@ ds .
7 : long @-@ term @-@ term studies in open @-@ long @-@ term studies , participation in open @-@ long @-@ term studies were posted up to 1 year long , 2 patients up to 2 years and 53 patients up to 3 years with Feb@@ r / 120 mg / 120 mg .
during the long @-@ term studies of the term studies of the treated events were similar to the studies of the phase 3 reports ( see table 1 ) .
the following treatments have been reported in all @-@ tem@@ ost@@ at@@ - treatment groups and more than once reports and went into long @-@ term studies ( up to 4 years in long @-@ term period ) ( up to 4 years with an ex@@ posi@@ tional period of &gt; 1.@@ 900 patient years ) , according to information .
the following treatment results were not reported in the circumstances of the circumstances of the phase 3 for these dos@@ es either not reported or with a l@@ act@@ ness :
diabetes , hyper@@ cholester@@ ol@@ emia , sle@@ e@@ pl@@ ess@@ ness , skin disorders , skin irrit@@ ations , skin irrit@@ ations , skin irrit@@ ations , skin irrit@@ ations , skin irrit@@ ation , er@@ ec@@ tile dys@@ function , increase in blood concent@@ rations in blood , decline of ly@@ mp@@ ho@@ cy@@ ten@@ ants , decrease in the number of white blood cells .
active mechanism of har@@ n@@ acid is used in humans the final product of the Pur@@ in@@ Journal and is created in the framework of the re@@ ac@@ ic hy@@ po@@ x@@ an@@ thin → X@@ an@@ thin → Har@@ n@@ c acid .
Feb@@ el@@ ost@@ at is an effective , not Pur@@ ine sel@@ ective inhib@@ itor of X@@ O ( NP @-@ SI@@ X@@ O ) with a Ki value for those in vitro inhib@@ itors , which is below the nan@@ om@@ ol@@ ar area .
clinical study results The effectiveness of AD@@ EN@@ UR@@ IC has been described in two Pi@@ eter studies of the phase 3 ( AP@@ EX study and F@@ act study as described below ) that were performed with hyper@@ ur@@ ic@@ emia and gyp@@ sy .
the primary target point was present in each study of the patients , in which the last three month of certain ser@@ um acid is &lt; 6,0 mg / dl ( 357 µ@@ mo@@ l / l ) .
plac@@ ebo ( n = 134 ) , AD@@ EN@@ UR@@ IC 80 mg 1 x daily ( n = 134 ) , AD@@ EN@@ UR@@ IC 240 mg 1 x daily ( n = 134 ) or allo@@ pur@@ in@@ ol 300 mg 1 x day ( n = 134 ) or allo@@ pur@@ in@@ ol 300 mg 1 per day ( n = 10 ) for patients with a ser@@ um kre@@ at@@ in@@ in@@ worth
the AP@@ EX study showed the statisti@@ cally significant reduction of treatment with AD@@ EN@@ UR@@ IC 80 mg 1 x 1 per day as well as with AD@@ EN@@ UR@@ IC 80 mg 1 per day as well as with AD@@ EN@@ UR@@ IC 120 mg ( n = 258 ) / 100 mg ( n = 10 ) .
the F@@ act report showed the long @-@ term reduction of the Ser@@ um@@ har@@ n@@ ect@@ or@@ eg@@ els under 6 mg / dl ( 357 µ@@ mo@@ l / l ) the statistical significant reduction of the treatment with AD@@ EN@@ UR@@ IC 80 mg 1 per day as well as with AD@@ EN@@ UR@@ IC 120 mg 1 per day compared to the treatment with the conventional dosage of allo@@ pur@@ in@@ ol 300 mg .
patients with ser@@ um car@@ at@@ in@@ ine values &lt; 1.5 and ≤ 2.0 mg / dl ) or 300 mg 1 x day ( n = 509 ) were compiled for the analysis . * p &lt; 0,@@ 001 &#93; allo@@ pur@@ in@@ ol , # p &lt; 0,@@ 001 : 80 mg
the reduction of the servo drive system is &lt; 6,0 mg / dl ( 357 µ@@ mo@@ l / l ) , at the doctor &apos;s visit in week 2 and permanently remove the overall treatment .
the allo@@ pur@@ in@@ ol 300 mg 1 x 1 per day ; 10 patients with ser@@ um kre@@ at@@ in@@ ite &gt; 1.5 and &lt; 2.0 mg / dl were 100 mg 1 x day .
a primary end@@ point in the sub @-@ group of patients with kidney dys@@ function restri@@ ction The AP@@ EX study analyses the effectiveness of 40 patients with kidney dys@@ function ( d. h ) .
with AD@@ EN@@ UR@@ IC , the primary target point is 44 % ( 80 mg 1 x daily ) , 45 % ( 120 mg 1 x day ) and 60 % ( 240 mg 1 x day ) .
the assumption of full take @-@ up tends to exagger@@ ate the simulated increase in cas@@ elo@@ ads and fiscal costs of a social policy reform .
a primary end@@ point in the sub @-@ group of patients with ser@@ en@@ har@@ ma concent@@ rations ≥ 10 mg / dl Et@@ wa 40 % of patients ( AP@@ EX@@ - and F@@ act study ) had a ser@@ um concentration of ≥ 10 mg / dl .
the assumption of full take @-@ up tends to exagger@@ ate the simulated increase in cas@@ elo@@ ads and fiscal costs of a social policy reform .
this was associated with a reduction of gyp@@ sum size , which in 54 % of the patients had a complete dis@@ appearance of the plaster and the month 24 to 24 .
increased T@@ SH@@ - Values ( &gt; 5.5 µ@@ S / ml ) were observed with patients who received a long @-@ term treatment with Feb@@ el@@ ost@@ at ( 5.0 % ) and also with patients who received allo@@ pur@@ in@@ ol ( 5.@@ 8 % ) in the open @-@ time extensions ( see Section 4.4 ) .
in healthy persons the maximum plasma concent@@ rations ( C@@ max ) and the area under Plas@@ ma@@ concentrated time curve ( AU@@ C ) from Feb@@ r to 120 mg up to 120 mg dos@@ is@@ is proportional .
for dos@@ es between 120 mg and 300 mg will observe a rise of AU@@ C that is greater than the dos@@ is@@ proportional increase .
depending on the intake of or multi @-@ cou@@ pler boxes of 80 and 120 mg 1 x day , the C@@ max contains 2.8 / 3.2 µ@@ g / ml and 5,0 @-@ 5.6 µ@@ g / ml .
however , no clin@@ ically significant change was observed in pro@@ centric caus@@ tic retin@@ opathy , if this was checked ( multiple dos@@ es of 80 mg ) .
distribution The apparent ste@@ e @-@ state distribution volume ( V@@ ss / F ) of Feb@@ ux@@ ost@@ at is located in the area of 29 to 75 l after taking dose of 10 @-@ 300 mg .
the plasma marking is about 9@@ 9.@@ 2 % ( primary binding to Alb@@ um@@ in ) and is achieved through the concentration width that is reached with dos@@ es of 80 and 120 mg .
in vitro studies , the oxid@@ ative met@@ abo@@ lit@@ es are mainly produced by CY@@ P@@ 1@@ A1 , CY@@ P@@ 2@@ A2 , CY@@ P@@ 2@@ C@@ 8 or CY@@ P@@ 2@@ C@@ 9 , and that there is the glu@@ cose @-@ glu@@ cur@@ on@@ id primarily due to U@@ GT 1@@ a@@ 1 , 1@@ A@@ 8 and 1@@ A@@ 9 .
after taking a 80 mg dosage of 14@@ C @-@ mark@@ eted Feb@@ u@@ ost@@ at about 49 % of the dose in Ur@@ in as un@@ modified phar@@ yn@@ ost@@ at ( 3 % ) , acet@@ yl@@ meth@@ acryl@@ ate and their con@@ ju@@ gate ( 13 % ) , as well as other unknown met@@ abo@@ lit@@ es ( 3 % ) .
the report examines all retail channels to provide sector insight . data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
special patient groups N@@ ing@@ in@@ suffici@@ ency After the intake of multi@@ pl@@ ers of 80 mg AD@@ EN@@ UR@@ IC in patients with light , moderate or severe kidney failure , the C@@ max of Feb@@ u@@ ost@@ at does not change in relation to patients with normal kidney function .
the mean total length of AU@@ C from Feb@@ u@@ ost@@ at around the 1.8 @-@ fold of 7.5 g / ml / ml in the group with regular nuts on 13.@@ 2 , g / ml in the group with severe kidney function .
&quot; &quot; &quot; 12 &quot; &quot; &quot; &quot; T @-@ Pu@@ gh @-@ Classification &quot; &quot; &quot; &quot; is intended for patients with light ( Chil@@ dr@@ ona Pu@@ gh @-@ Classification 36@@ A ) or medium @-@ severe ( A @-@ Pu@@ gh @-@ Klassifikation B ) . &quot; &quot; &quot;
at the age of age there were no significant changes in terms of AU@@ C of Feb@@ el@@ ost@@ at or its Met@@ aboli@@ sm after taking vitamin EN@@ UR@@ IC in older patients compared to younger patients .
car@@ cin@@ ogen@@ esis , mut@@ agen@@ esis , imp@@ air@@ ment of fer@@ mentation in the male rats - a statistical significant reduction of hard@@ bladder ( transi@@ tional pap@@ ill@@ ous and car@@ cin@@ oma ) are found in connection with x@@ an@@ thin stones in the highly @-@ do@@ omed @-@ treated group , at about the 11 @-@ inch of exposure in humans .
this findings may be seen as a consequence of a specialist @-@ specific Pur@@ in@@ ence and ur@@ in@@ aries and for clinical application as not relevant .
it has been established that there were no effect on the fer@@ tile and reproduction performance of male and female rats .
at high dos@@ es , which were about 4,@@ 3 of the human@@ ized exposure rates , joined forces with a drop of th@@ rust performance and an develop@@ mental delay during the desc@@ endants of rats .
Ter@@ at@@ ological studies in tra@@ il@@ ateral rats with ex@@ positions , which are about 4,@@ 3 @-@ fold @-@ fold ra@@ bb@@ its with ex@@ positions that have no effect on the 13 @-@ fold of human therapeutic effects .
Col@@ ch@@ ic@@ in / In@@ dom@@ et@@ ac@@ in / Hydro@@ chlor@@ othi@@ azi@@ d / War@@ mb@@ in Feb@@ . ux@@ ost@@ at can be applied together with Col@@ ch@@ ic@@ in or In@@ dom@@ et@@ ac@@ in , without any other active ingredient .
patients , exercise and vom@@ iting are more common in patients who were treated with Col@@ ch@@ ic@@ in . * * In the clinical studies were no serious injuries or severe floo@@ ds .
in the open @-@ long period of studies there were 2 patients until 1 year long , 2 patients up to 2 years ago , 57 patients up to 3 years long and 53 patients up to 4 years with Feb@@ el@@ ost@@ at 80 mg / 120 mg .
the primary target point was present in each study of the patients , in which the last three month of certain ser@@ um acid is &lt; 6,0 mg / dl ( 357 µ@@ mo@@ l / l ) .
the assumption of full take @-@ up tends to exagger@@ ate the simulated increase in cas@@ elo@@ ads and fiscal costs of a social policy reform .
the report provides detailed comparative data on the number of deals and their value categ@@ orized into deal types , sub @-@ sector and regions .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; this is the result of a liver failure . &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; this is the result of a liver failure . &quot; &quot; &quot; &quot; &quot; &quot; &quot;
car@@ cin@@ ogen@@ esis , mut@@ agen@@ esis , imp@@ air@@ ment of fer@@ mentation in the male rats - a statistical significant reduction of hard@@ bladder ( transi@@ tional pap@@ ill@@ ous and car@@ cin@@ oma ) are found in connection with x@@ an@@ thin stones in the highly @-@ do@@ omed @-@ treated group , at about the 11 @-@ inch of exposure in humans .
the owner of the permission of the author@@ isation to ensure that a pharmaceutical ko@@ vi@@ gil@@ ance system is described as defined in version 2.0 module 1.@@ 8.1 of the author@@ isation before the medicine is brought into circulation .
a updated R@@ MP is based on the CH@@ MP gui@@ deline to risk management systems for Human@@ izing take @-@ up with the next peri@@ odic Safety Update report ( PS@@ UR ) .
in addition , one entry of the R@@ MP is required • if new information is expected , which have a influence on security data , the pharmaceu@@ ko@@ vi@@ gil@@ ance or activities for risk management • within 60 days after completion of major revenues ( pharmaceu@@ ko@@ vi@@ gil@@ ance or risk management ) • on request of EME@@ A
in some people , Har@@ n@@ foli@@ c acid can reach concent@@ rations in blood and can concentrate on concent@@ rations which is so high that Har@@ n@@ acid is in@@ sol@@ uble .
the cryst@@ all@@ ine concentration of the 1 x daily intake of AD@@ EN@@ UR@@ IC is low , the cryst@@ all@@ ine formation prevent dis@@ comfort .
AD@@ EN@@ UR@@ IC may not be taken if you are sensitive ( allergi@@ c ) against the active vacc@@ ination or one of the other components of AD@@ EN@@ UR@@ IC .
inform your doctor before you have a heart attack , if you have a heart rate or had a heart attack , or if you have a heart attack or an other heart problem . if you have a heart attack or an other heart problem , if you are treated with a high dosage disease or the Les@@ ch @-@ Ny@@ han @-@ Syn@@ dro@@ ms ( a rare con@@ gen@@ ital disease , which is treated to a lot of ur@@ onic acid in blood ) .
when you have a gi@@ cht@@ an@@ case ( sudden occurr@@ ence of heavy pain , pressure sensitivity , gra@@ ding , heat recovery and joint sw@@ elling ) , wait for the treatment with AD@@ EN@@ UR@@ IC .
this must not be done at any time , but in particular , in particular during the first treatment weeks or - mon@@ ate , if you take AD@@ EN@@ UR@@ IC .
your doctor will cause you to prevent other drugs to prevent a plaster attack or to treat the associated symptoms ( such as pain and joints ) .
please inform your doctor or pharmac@@ ist if you take other drugs or have taken this medication even if it is not authorised to prescription drugs .
it is especially important for you to take your doctor or pharmac@@ ist if you are taking a medicine if you may take medication . • Az@@ ath@@ i@@ op@@ rin ( for treatment of cancer ) • Az@@ ath@@ i@@ op@@ rin ( for treatment of as@@ th@@ ma ) • war@@ far@@ in ( for treatment of as@@ th@@ ma )
no studies on the effects of AD@@ EN@@ UR@@ IC on the traffic flow and the ability to serve machines are carried out .
please use AD@@ EN@@ UR@@ IC only after return to your doctor if you know that you suffer from an int@@ oler@@ ance to certain zu@@ res .
on the back of the bli@@ ster@@ pack@@ ers , the individual weekday editions are printed , so that you can have taken a tablet , if you have taken a tablet , and can be taken with or without food .
if you have taken an over@@ dose , please contact your doctor or to the closest hospital .
if you forget the intake of AD@@ EN@@ UR@@ IC you will forget it as soon as possible , unless the next intake is short before .
if you are taking the intake of AD@@ EN@@ UR@@ IC requests , your ur@@ ring concentration has re@@ tains , and your complaints can f@@ end up , because new material can be found in your ser@@ ops and kid@@ neys as well as their surroundings .
frequent side @-@ effects ( more than 1 of 100 treatments , but less than 1 of 10 treated ) : • collecting results • de@@ bit • nu@@ de • skin r@@ umen
rare side effects ( more than 1 of 10,000 patients , but less than 1 of 1,000 treated ) : • weakness • Nerv@@ ousness • Dur@@ st@@ resses
please inform your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
AD@@ EN@@ UR@@ IC is available in 2 Bli@@ ster@@ pack@@ ings with 14 tablets ( Pack of 28 tablets ) or in 6 tablets ( Pack of 84 pills ) .
&quot; &quot; &quot; if you want to send us a question about this product , simply complete all the fields marked * and click &quot; &quot; &quot; &quot; Send &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
Dan@@ mark , Nor@@ ge , Su@@ omi / Finland , Dan@@ omi / Finland , Ru@@ d@@ land Institute of the Syn@@ th@@ è@@ se ( IP@@ SEN ) AB K@@ ista Education Tower Col@@ our@@ se at 33 SE - 164 K@@ ista n / Ru@@ ot@@ si / Sv@@ í@@ lÄ j@@ ó@@ ð Tel / T@@ l@@ f / S@@ í@@ mi : + 46 8 5@@ 88 370 70
AD@@ RO@@ VAN@@ CE is used for treatment of ost@@ op@@ or@@ osis ( a disease in which the bones are used to be used with women after men@@ op@@ ause ) at women after men@@ op@@ ause .
the patient must take the tablet with a full glass of water ( no mineral water ) at least 30 minutes before the food , drinking or another other drug ( including An@@ ta@@ zi@@ da , calcium and vit@@ amine ) .
to avoid an irrit@@ ation of the food intake , the patient may take place after the first food intake of the day , the earliest at the earliest 30 minutes after taking the tablet .
since Al@@ end@@ ron@@ at and Vitamin D3 already used separately from other medicines used in the European Union , the company moved from earlier studies and published literature .
the company also introduced a study with 35 men and 6@@ 82 post@@ men@@ op@@ aus@@ al women with ost@@ e@@ op@@ or@@ osis to reflect the effectiveness of AD@@ RO@@ VAN@@ CE in terms of increasing vitamin D Spi@@ eg@@ els .
after a 15 @-@ day treatment the proportion of patients with low vitamin D mirrors were treated with the patients who were treated with AD@@ RO@@ LL@@ CE ( 32 % ) compared to those who were exclusively Al@@ end@@ ron@@ at ( 32 % ) .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
the most common side effects ( observed at 1 to 10 of 100 patients ) are head@@ aches , pain of the movement of motion ( muscles , bone , or joints ) , in@@ sti@@ p@@ ation , di@@ arr@@ ho@@ e ( swal@@ lowing ) , in@@ sti@@ p@@ ity ( swal@@ lowing ) , wor@@ sen@@ ed de@@ dom@@ y ( swal@@ lowing stomach ) and sau@@ cer .
for patients with et@@ ching high sensitivity ( all@@ ergy ) against Al@@ end@@ ron@@ at , vitamin D3 or one of the other components must not be applied to AD@@ RO@@ VAN@@ CE .
there must not be applied in diseases of the food waste , patients with Hy@@ po@@ cal@@ c@@ emia ( minor calcium ) or in patients that are not at least 30 minutes or sit at least 30 minutes .
Hemp Info Hemp fashion ( Cann@@ at@@ rade 04 ) Hemp bri@@ cks H@@ empf@@ la@@ x European Parliament Strasbourg
&quot; &quot; &quot; &quot; &quot; &quot; &quot; white , white until large white tablets , marked with the shape of a garlic on one side and &quot; &quot; &quot; &quot; on the other side . &quot; &quot; &quot;
AD@@ RO@@ VAN@@ CE is only available with water ( not with mineral water ) at least 30 minutes before the first food , drink or deposits of medicines ( including An@@ ta@@ zi@@ da , calcium and vitamin defici@@ ency ) for the day .
the following hints are exactly to follow the risk of mal@@ op@@ ha@@ ale irrit@@ ations and thus dimin@@ ish side effects ( see Section 4.4 ) :
• AD@@ RO@@ VAN@@ CE is to be done according to the day of the day only with a full glass of water ( at least 200 ml ) , because a risk of or@@ op@@ har@@ yn@@ ge@@ al Ul@@ timo exists . • The patients should not take place before the first food intake of the day , take place at the earliest 30 minutes after taking the tablet .
B. mi@@ onic Ul@@ an , active g@@ astro@@ intestinal ble@@ eding or surgical intervention in the upper ro@@ omy therapy , only among particular caution ( see Section 4.3 ) .
you can also find the most important source of your data , you can also use the data to be processed correctly . if your company is not yet listed , you need to add the vat of 19 % . shipping to a german destination is 7 euros . &#91; ... &#93;
the doctor is therefore atten@@ tive to all signs and symptoms that are considered to be possible to investigate the occurr@@ ence of symptoms such as Dy@@ sp@@ her@@ y , pain when swal@@ lowing or equ@@ ali@@ ation , pain during swal@@ lowing or equ@@ ali@@ ation So@@ d@@ burn the medicine and medical advice ( see Section 4.8 ) .
3 The risk of severe mal@@ ign@@ yl @-@ side effects seems to be increased in patients that the medicines does not fit correctly and / or after the occurr@@ ence of symptoms that take on a mal@@ op@@ ha@@ ale Ir@@ rit@@ ation .
it is very important that all persons need to be passed on the patient and understood by patients ( see Section 4.2 ) .
during large @-@ scale clinical studies with Al@@ end@@ ron@@ at no increased risk has been discovered ( after market introduction ) Mag@@ ical and Du@@ o@@ den@@ al@@ ul@@ ators , among others , some severe conflicts and complications , reported ( see Section 4.8 ) .
ost@@ e@@ op@@ sis of the Ki@@ ef@@ ers , usually reported in connection with a denti@@ tion and / or local infection ( including ost@@ om@@ yel@@ i@@ tis ) , cancer patients reported in cancer patients with cancer patients .
no data is available to ensure the use of a bis@@ phosph@@ on@@ at@@ therapy in patients who need a ki@@ os@@ sing surgical procedure , the risk of ost@@ e@@ op@@ sis of the Ki@@ ef@@ ers .
the clinical estim@@ ation by the treat@@ ment@@ ing doctor is responsible for treatment planning in each patient based on a individual benefit risk assessment .
patients should consider that they should take a dose of dose from AD@@ RO@@ VAN@@ CE to take the tablet at the next morning after they have noticed their failure .
they should not take two tablets on the same day , but taking care of a tablet per week as originally planned on the planned day .
other diseases caused by the mineral change ( such as vitamin D defici@@ ency and hyp@@ op@@ ar@@ ath@@ y@@ re@@ o@@ gens ) , should be treated appropri@@ ated before the start of the therapy with AD@@ RO@@ VAN@@ CE .
Al@@ end@@ ron@@ ate foods and beverages ( including mineral water ) , calcium supplements , An@@ ta@@ zi@@ da and some or@@ ale pharmaceu@@ ticals can affect the Res@@ or@@ ption of Al@@ end@@ ron@@ at when they have taken the same time .
therefore , patients should wait at least 30 minutes before they take other drugs ( see Sec@@ tion@@ 4.2 and 5.2 ) .
although specific interaction studies were not carried out , Al@@ end@@ ron@@ at was taken in clinical studies together with a variety of usually pro@@ filed medicines .
AD@@ RO@@ VAN@@ CE is intended for use in post@@ men@@ op@@ aus@@ al women and is therefore not to apply either during pregnancy or nursing women .
animal studies with Al@@ end@@ ron@@ at can be no reference to directly disc@@ arded effects of the pregnancy , the embr@@ y@@ onic / fatty or post@@ nat@@ al development .
ost@@ e@@ op@@ sis of the Ki@@ ef@@ ers was reported in patients with bis@@ phosph@@ on@@ ates ; most reports come from cancer patients but also reported in ost@@ e@@ op@@ or@@ os@@ ep@@ ati@@ sm .
nevertheless , the ser@@ um @-@ Cal@@ ci@@ ums occurred to &lt; 8.0 mg / dl ( 2.0 m@@ mo@@ l / l ) and the Ser@@ um - phosph@@ ate from ≤ 2.0 mg / dl ( 0.@@ 65 m@@ mo@@ l / l ) in both treatment groups with similar quantity .
Al@@ end@@ ron@@ at In@@ struction of a oral over@@ dose may occur in Hy@@ po@@ cal@@ c@@ äm@@ y , hyp@@ oph@@ osph@@ at@@ emia , and side @-@ effects in the top of the limb@@ o , so@@ d@@ burn , Ö@@ kon@@ tis or Ul@@ ou@@ tis .
col@@ ec@@ al@@ ci@@ fer@@ ol ( vitamin D3 ) vitamin D3 is produced in the skin by UV light above the conversion of 7 @-@ stretch of vitamin D3 .
the main effect of 1,@@ 25 @-@ D@@ ih@@ y@@ dro@@ i D3 is the increase of calcium loss of calcium and phosph@@ ate as well as the regulation of ser@@ um Cal@@ cium , the ren@@ al dis@@ advantages of calcium , the bone structure and bone res@@ ection .
in severe cases , a lack of secondary hyper@@ par@@ ath@@ y@@ re@@ o@@ biology , Hyp@@ oph@@ osph@@ at@@ emia , weakness of the sec@@ ular muscles and ost@@ e@@ al@@ az@@ y and so on a further increased risk for stor@@ ms and bone bur@@ sts at ost@@ e@@ op@@ or@@ ot@@ esque persons .
the weight bench can be adjusted to the normal temperature of the normal temperature of the bone density and the bone density of a normal , young population , or imp@@ urities of the bone density as a result of a particular path@@ ological fra@@ cture .
patients received AD@@ RO@@ VAN@@ CE in the lower thickness ( 70 mg / 2.@@ 800 I.@@ E. ) ( n = 350 ) or Fos@@ am@@ ax ( Al@@ end@@ ron@@ at ) 70 mg once weekly ( n = 332 ) ; additional vitamin D supplements were prohibited .
after 15 @-@ weekly treatment there were significantly higher ( 26 % ) in the group under AD@@ RO@@ VAN@@ CE ( 70 m@@ mo@@ l / l &#91; 23 ng / ml &#93; ) than in the group under Al@@ end@@ ron@@ at alone ( 46 n@@ mo@@ l / l &#91; 18.@@ 2 ng / ml &#93; ) .
AD@@ RO@@ VAN@@ CE ( 70 mg / 2.@@ 800 I.@@ E. ) significantly higher than 15 weeks the share of patients with vitamin D in@@ suffici@@ ency ( Ser@@ um@@ ming from 25 @-@ hydro@@ xy@@ vitamin D &lt; 3@@ 7,5 n@@ mo@@ l / l &#91; &lt; 33 ng / ml &#93; ) around 6@@ 2.5 % compared to Al@@ end@@ ron@@ at alone ( 12 % ) .
studies of Al@@ end@@ ron@@ at once a week 70 mg ( n = 5@@ 19 ) and Al@@ end@@ ron@@ at 10 mg daily ( n = 370 ) was found in post@@ men@@ op@@ aus@@ al women with ost@@ op@@ or@@ osis .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
in the phase III studies in the mid @-@ III studies , the BM@@ D with Al@@ end@@ ron@@ at 10 mg / day in relation to plac@@ ebo after 3 years 8,@@ 8 % at the spine , 5,@@ 9 % on pi@@ qu@@ al@@ as and 7,@@ 8 % at Tro@@ ch@@ anter .
in combination with the plac@@ ebo group , a reduction of 48 % ( al@@ end@@ ron@@ at 3.2 % compared to Pla@@ z@@ ebo 6.@@ 2 % ) in the number of patients who have one or more flu@@ ids .
in the two year extension these studies held the asc@@ ents of the BM@@ D of spine and Tro@@ ch@@ anter ; also the BM@@ D of Fem@@ ini@@ um and the whole body was stopped .
fit for two pl@@ az@@ ebo@@ ards controlled trials with which Al@@ end@@ ron@@ at daily ( 5 mg daily over 2 years and then 10 mg daily : 1 or 2 years ) are taken into account :
in this study , daily gift of Al@@ end@@ ron@@ at present the appearance of at least a new spine between 47 % ( Al@@ end@@ ron@@ at 7,@@ 9 % compared to Pla@@ z@@ ebo 15,@@ 0 % ) .
Res@@ or@@ ption based on an intra@@ ven@@ ous reference dose was the mean shift of algae between 5 and 70 mg after noc@@ turn@@ al fast@@ ing and two hours before intake of a standardis@@ ed breakfast .
the bi@@ polar tra@@ ce@@ ability had been taken according to about 0,@@ 46 % and 0.@@ 39 % when Al@@ end@@ ron@@ at one or half an hour before a standardis@@ ed breakfast .
in ost@@ e@@ op@@ or@@ osis , Al@@ end@@ ron@@ at has been effective if there was at least 30 minutes before the first meal or drinking of the day .
in healthy plants , the gift of or@@ ical Pre@@ d@@ nis@@ on ( 20 mg ) three times a day of so@@ lit@@ ary change in the oral Bi@@ over@@ dose of Al@@ end@@ ron@@ at ( increase in the range of 20 % to 44 % ) .
9 * I have found that Al@@ end@@ ron@@ at took place after intra@@ ven@@ ous gift of 1 mg / kg temporarily in past@@ ure , but then turn off into the bone .
ex@@ ile after intra@@ ven@@ ous tissue of a single dose of 14@@ C @-@ Al@@ end@@ ron@@ at about 50 % of radioactive decay within 72 hours with the ur@@ ine rose and little or no radio@@ activity was restored in the subjects .
after intra@@ ven@@ ous tissue of a individual dose of 10 mg , the ren@@ ale Clear@@ ance of Al@@ end@@ ron@@ at 71 ml / min and the system@@ ic hem@@ ance will not exceed 200 ml / min .
Al@@ end@@ ron@@ at is not in rats with rats or bas@@ ische conveying system of the kid@@ neys , and therefore , it is not accepted that people have influenced the dis@@ sem@@ ination of other drugs by this transport systems .
Res@@ or@@ ption In healthy adult patients ( women and men ) , after the gift of AD@@ RO@@ VAN@@ CE after noc@@ turn@@ al surface ( AU@@ C@@ 0 @-@ 120 h ) for vitamin D3 29@@ 6,@@ 4 ng • h / ml ( without consideration end@@ ogen@@ ous vitamin @-@ D3 @-@ mirror ) .
the mean maximum concentration in ser@@ um ( C@@ max ) of Vitamin D3 was 5,@@ 9 ng / ml and the medium @-@ time lasts up to the end of the maximum static concentration ( T@@ max ) 12 hours .
the vitamin D3 supports the liver swi@@ ft@@ ly to 25 @-@ hydro@@ xy@@ vitamin D3 hydro@@ xy@@ ges and then in the kid@@ neys to 1.@@ 25 @-@ D@@ ih@@ y@@ dro@@ xy@@ vitamin D3 , the organic active form .
ex@@ foli@@ ation of radioactive decay in vitamin D3 supports healthy patients , the mean increase in radio@@ activity in ur@@ ine to 48 hours 2,4 % , in the subjects after 4 days 4,@@ 9 % .
characteristics in patients with clinical trials have shown that the proportion of Al@@ end@@ ron@@ ate is depos@@ ited in bone .
although no clinical data is part of it , nevertheless , the ren@@ al Eli@@ min@@ ation of Al@@ end@@ ron@@ at will be reduced to patients with limited N@@ ing@@ function .
therefore , patients with limited N@@ ing@@ function is expected to be expected in the bone of Al@@ end@@ ron@@ at ( see Section 4.2 ) .
Al@@ end@@ ron@@ at Not @-@ clinical data on the basis of conventional studies to safety sp@@ har@@ mac@@ ology , for chronic tox@@ icity , for the chronic tox@@ icity , and that are no particular haz@@ ards for humans .
studies on rats showed that the gift of Al@@ end@@ ron@@ at was caused by the occurr@@ ence of D@@ yst@@ oc@@ ie with the occurr@@ ence of D@@ yst@@ oc@@ emia caused by the occurr@@ ence of D@@ yst@@ oc@@ emia .
Micro@@ crystal cryst@@ all@@ ine Cell@@ ul@@ ose ( E 460 ) L@@ act@@ ose int@@ ric@@ ates Sili@@ cium L@@ act@@ um@@ di@@ cion@@ ate SU@@ CRO@@ SE high @-@ disper@@ sed silicon t@@ ear@@ ate ( Ph.@@ Eur@@ . ) ( E 5@@ 72 ) but@@ yl hydro@@ x@@ yt@@ ol@@ u@@ ol ( Ph.@@ Eur@@ . ) ( E 5@@ 72 ) , may ( E 5@@ 72 )
E@@ tu@@ i with sealed aluminium / aluminium mirror packs with 2 tablets ) , 4 ( 1 E@@ tu@@ is with 2 tablets ) , 6 ( 3 t@@ tu@@ is with 4 tray ) , 12 ( 3 t@@ tu@@ is with 4 tray ) tablets .
the import of far @-@ east goods let PULSA provide an inter@@ sting pri@@ ce@@ - and produc@@ toff@@ ering .
rectangular , white until large white tablets , marked with the shape of a garlic on one side and &quot; 270 &quot; on the other side .
13 • The patients should not apply to intake AD@@ RO@@ VAN@@ CE at least 30 minutes . • AD@@ RO@@ VAN@@ CE shall not be taken before bed@@ time or before the first place of the day .
the risk of severe mal@@ ign@@ yl @-@ side effects seems to be increased in patients that the medicines does not fit correctly and / or after the occurr@@ ence of symptoms that take on a mal@@ op@@ ha@@ ale Ir@@ rit@@ ation .
during large @-@ scale clinical studies with Al@@ end@@ ron@@ at no increased risk has been discovered ( after market introduction ) Mag@@ ical and Du@@ o@@ den@@ al@@ ul@@ ators , among others , some severe conflicts and complications , reported ( see Section 4.8 ) .
18 Col@@ ec@@ al@@ ci@@ fer@@ ol ( Vitamin D3 ) vitamin D3 is produced in the skin by UV light above the conversion of 7 @-@ ri@@ y@@ dro@@ pp@@ ies to vitamin D3 .
patients received AD@@ RO@@ VAN@@ CE in the lower thickness ( 70 mg / 2.@@ 800 I.@@ E. ) ( n = 350 ) or Fos@@ am@@ ax ( Al@@ end@@ ron@@ at ) 70 mg once weekly ( n = 332 ) ; additional vitamin D supplements were prohibited .
vitamin D3 ( the amount of vitamin D3 at the higher dose of AD@@ RO@@ VAN@@ CE ) once a week , has been shown in a 24 @-@ week trial study with ost@@ e@@ op@@ op@@ aus@@ al women with ost@@ op@@ or@@ osis .
after 24 @-@ weekly treatment were significantly higher in the 5.@@ 600 @-@ I.@@ E@@ .-@@ vitamin @-@ D3 Group ( 69 n@@ mo@@ l / l &#91; 27.@@ 6 ng / ml &#93; ) as in the 2.@@ 800 @-@ I.@@ E@@ .-@@ vitamin @-@ D3 @-@ Gruppe ( 64 n@@ mo@@ l / l &#91; 25.@@ 5 ng / ml &#93; ) .
the assumption of full take @-@ up tends to exagger@@ ate the simulated increase in cas@@ elo@@ ads and fiscal costs of a social policy reform .
3.@@ 1 % of the entire head in the group with 70 mg once weekly or in the group with 10 mg daily .
in this study , daily gift of Al@@ end@@ ron@@ at present the appearance of at least a new spine between 47 % ( Al@@ end@@ ron@@ at 7,@@ 9 % compared to Pla@@ z@@ ebo 15,@@ 0 % ) .
the bi@@ polar tra@@ ce@@ ability took part in about 0,@@ 46 % and 0.@@ 39 % when Al@@ end@@ ron@@ at one or half an hour before a standardis@@ ed breakfast
enter multiple addresses separated by comm@@ as and / or different lines .
Res@@ or@@ ption With healthy adults ( women and men ) , after the gift of AD@@ RO@@ VAN@@ CE ( 70 mg / 5.@@ 600 I.@@ E. ) after buff@@ ers and two hours prior to a meal the middle area under the Ser@@ um concentration time curve ( AU@@ C@@ 0 @-@ 80 h ) for vitamin D3 49@@ 0,2 ng • h / ml ( without consideration end@@ ogen@@ ous vitamin @-@ D3 @-@ mirror ) .
the mean maximum concentration in ser@@ um ( C@@ max ) of Vitamin D3 was 12.@@ 2 ng / ml and the medium @-@ time lasts up to the end of the maximum static concentration ( T@@ max ) 10.5 hours .
smaller quantities are saved in fat and muscle tissue , and are stored as a vitamin D3 to get later in the circulation .
21 Vitamin D3 becomes swi@@ ft@@ ly fast to 25 @-@ hydro@@ xy@@ id D3 hydro@@ xy@@ .dll and then in the kid@@ neys to 1.@@ 25 @-@ D@@ ih@@ y@@ dro@@ xy@@ vitamin D3 , the organic active form .
none of them were found on a loss of the cure &apos;s long @-@ term degra@@ dation of cum@@ ul@@ ative intra@@ ven@@ ous in@@ ven@@ ous dos@@ es up to 35 mg / kg with animals .
E@@ tu@@ i with sealed aluminium / aluminium mirror packs with 2 tablets ) , 4 ( 1 E@@ tu@@ is with 4 tablets ) , 12 ( 1 E@@ tu@@ is with 4 tablets ) or 40 ( 10 tablet ) tablets .
Pharma@@ ko@@ vi@@ gil@@ ance system The owner of the permission of the Office has been prepared to ensure that a pharmaceutical ko@@ vi@@ gil@@ ance system is described as in version 2 module 1.@@ 8.1 of the admission examination before the medicine is brought into circulation .
the risk management plan of the owner of approval for the transport , studies and other pharmaceutical ko@@ vi@@ gil@@ ance activities , which are described in the risk management plan ( R@@ MP ) and its corresponding actu@@ ations according to version 1 module 1.@@ 8.2 of author@@ isation in detail are described in detail .
a updated R@@ MP is based on the CH@@ MP gui@@ deline to risk management systems for Human@@ izing lin@@ ers with the next peri@@ odic Saf@@ t@@ ey Update report ( PS@@ UR ) .
in addition , one entry of the R@@ MP is required in order to determine a influence on security data , pharmaceu@@ ko@@ vi@@ gil@@ ance or activities to risk management - within 60 days after developing an important milestone ( pharmaceu@@ ko@@ vi@@ gil@@ ance or risk management ) - in requirement from EME@@ A
take an AD@@ RO@@ VAN@@ CE tablets according to you as well as before the first food and drinking and taking care of any other drugs by taking the tablet with a full glass of water ( not cut with mineral water ) .
if you have any questions , please contact your doctor or pharmac@@ ist . if you have any further questions please contact your doctor or pharmac@@ ist .
in exchange years , the ov@@ aries produce no female hormon@@ es , o@@ est@@ rogen , more which help to get the sk@@ el@@ ett of women healthy .
the fra@@ cture arise at the tip , the spine or the wrist and can not only cause pain , but also considerable problems such as prevented attitude ( &quot; weather forecast &quot; ) and a loss of mobility .
AD@@ RO@@ VAN@@ CE prevents loss to loss of bone mass , but also contributes to decrease the bone loss again and dimin@@ ish the risk of fluid and hi@@ ps .
if your doctor has observed , it is possible to sit at least 30 minutes ahead or stand ( 4 ) if your doctor has found that your cal@@ ci@@ alis is reduced in blood .
40 • if you have problems while travelling or with di@@ gestion , • if you have cancer , • if you have cancer , • if you have a chem@@ otherapy or radi@@ otherapy treatment , • if you are not routine , if you are not rout@@ inely to denti@@ stry .
these complaints may occur in particular , if the patient can take the AD@@ RO@@ VAN@@ CE tablets with a full glass of water and take care of 30 minutes after taking taking place .
taking advantage of AD@@ RO@@ VAN@@ CE with other medicines , An@@ ta@@ zi@@ da and some other medicines can take the effectiveness of AD@@ RO@@ VAN@@ CE at equal intake .
certain drugs or food additives can be able to use the vitamin D in the body &apos;s body , including artificial fla@@ vors , mineral oils , or@@ list@@ at and the cholesterol , cholesterol , or@@ list@@ at and the cholesterol of cholesterol .
please inform your doctor or pharmac@@ ist if you have other drugs or supplements , even if it is not interested in prescription drugs .
please take this medicine after returning to your doctor if you know that you suffer from an int@@ oler@@ ance to certain zu@@ res .
please follow the announcement 2 ) , 3 ) , 4 ) and 5 ) to facilitate the transport of AD@@ RO@@ VAN@@ CE tablets into the stomach and to reduce the potential irrit@@ ation of the raw materials ( Ö@@ SCH ) to reduce your mouth with the stomach .
take the AD@@ RO@@ VAN@@ CE tablets after the first drop and take away from any other medicines or beverages , as well as with mineral water ( at least 200 ml ) water ( not with mineral water ) . • Not with mineral water ( with or without carbon@@ ic acid ) . • Not available with coffee or tea . • Not available with juice or milk .
( 3 ) Go to you - remain completely upright ( in the sitting , standing or standing ) - at least 30 minutes after taking the tablet .
( 5 ) If you have difficulties or pain during swal@@ lowing , pain behind the breast , re@@ fresh@@ ness or allergi@@ es to you , use AD@@ RO@@ VAN@@ CE , and look for your doctor .
( 6 ) On the swal@@ lowing of your AD@@ RO@@ VAN@@ CE tablets at least 30 minutes before you take care of your first food , drinks or other medicines such as An@@ ta@@ zi@@ da ( mag@@ nific@@ ant medicine ) , cal@@ ci@@ um@@ - or vitamin defici@@ ency of this day .
if you have taken a lot of tablets on once , drink a full glass of milk and please contact your doctor .
if you have the intake of a tablet , take a tablet to the next morning after you have noticed your failure .
usually : • sau@@ ces , swal@@ lowing , pain when swal@@ lowing ; the pain which cause your mouth with your stomach . ) , pain in the breast basket , so@@ d@@ burn and pain or dis@@ infection occurs , • bone , muscle , and / or joint pain , • bone strength ; in@@ sti@@ p@@ ation ; se@@ pul@@ ses , • head@@ aches , • head@@ aches , • head@@ aches , • head@@ aches .
occasionally : • Fe@@ el ; vom@@ iting , • irrit@@ ations and inflammation of the food ( ov@@ ens ) - the tubes that connects your mouth with your stomach ( ov@@ ens ) or the stomach loop , • black or te@@ er@@ ous throne , • skin r@@ ash ; it@@ ching skin .
after market introduction , the following side effects were not known ) : • ( rot@@ ational ) Schwin@@ n , • joint pain , • ti@@ red@@ ness , • ti@@ red@@ ness , • ti@@ red@@ ness and infections , often after cur@@ ing of teeth , • sw@@ elling at hands or legs .
43 D@@ ab@@ ei is helpful if you not@@ ices , which complaints they had started , and how long they held them .
the other components are micro@@ cryst@@ ine Cell@@ ul@@ ose ( E 460 ) , L@@ act@@ ose , hyper@@ disper@@ ses silicon , gel@@ atine , Cro@@ sc@@ um@@ bi@@ osis , magn@@ esium hydro@@ xi@@ de ( Ph.@@ Eur@@ . ) ( E 5@@ 72 ) , but@@ yl hydro@@ x@@ yt@@ ol@@ u@@ ol ( Ph.@@ Eur@@ . ) ( E 5@@ 72 ) , thickness , modified ( corn ) , and aluminum nat@@ ri@@ um@@ si@@ lic@@ ate ( E 5@@ 54 ) .
the tablets are available in E@@ tu@@ is with sealed aluminium / aluminium bli@@ sters in the following package sizes : • 2 tablets ( 1 E@@ tu@@ is with 2 tablets in aluminum bli@@ ster@@ pack@@ ers ) • 12 tablets ( 1 E@@ tu@@ is with 4 tablets in aluminum bli@@ ster@@ pack@@ ers ) • 30 pills ( 10 pills in aluminum bli@@ ster@@ pack@@ ers )
in exchange years , the ov@@ aries produce no female hormon@@ es , o@@ est@@ rogen , more which help to get the sk@@ el@@ ett of women healthy .
48 • If you have problems with allergi@@ es , • if you have problems with di@@ arr@@ ho@@ ea , • if you have cancer , • if you are cancer , • if you have a chem@@ otherapy or radi@@ otherapy treatment , • if you are not routine , if you are not rout@@ inely to denti@@ stry .
taking advantage of AD@@ RO@@ VAN@@ CE with other medicines , An@@ ta@@ zi@@ da and some other medicines can take the effectiveness of AD@@ RO@@ VAN@@ CE at equal intake .
2 ) Take the AD@@ RO@@ VAN@@ CE tablets according to the first stand and take away from any other medicines or beverages , as well as with mineral water ( at least 200 ml ) water ( not with mineral water ) . • Not with mineral water ( or without carbon@@ ic acid ) . • Not with coffee or tea . • Not available with juice or milk .
3 ) Go to you - remain completely upright ( in the sitting , standing or standing ) - at least 30 minutes after taking the tablet .
5 ) If you have difficulties or pain during swal@@ lowing , pain behind the breast , re@@ fresh@@ ness or allergi@@ es to you , use AD@@ RO@@ VAN@@ CE , and look for your doctor .
6 ) On the swal@@ lowing of your AD@@ RO@@ VAN@@ CE tablets at least 30 minutes before you take care of your first food , drinks or other medicines such as An@@ ta@@ zi@@ da ( mag@@ nific@@ ant medicine ) , cal@@ ci@@ um@@ - or vitamin defici@@ ency of this day .
• ( rot@@ ational ) Schwin@@ n , • joint pain , • ti@@ red@@ ness , • hair loss , • pine problems ( ost@@ e@@ ek@@ rose ) in connection with delay and infections , often after cur@@ ing of teeth , • sw@@ elling at hands or legs .
tablets are available as rectangular , white until large white tablets , marked with the shape of a garlic on one side and &quot; 270 &quot; on the other side .
C@@ agra@@ ph is administ@@ ered adult patients to prevent a kidney or liver transplan@@ tation to prevent a recovery of the transplan@@ tation through the immune system .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
furthermore , the results of a clinical trial was presented to 6@@ 68 patients with kidney transplan@@ tation , whereby the application of an app@@ agra@@ f with Progra@@ f / Progra@@ ft or C@@ ic@@ los@@ s were compared .
most indi@@ ces of the eff@@ ic@@ acy was the number of patients , where the transplan@@ tation were needed after a treatment duration of a year ago ( by example , as often a new organ transplan@@ tation or a re@@ recording of the di@@ aly@@ sis was required ) .
patients with liver transplan@@ tation and 129 patients were performed with liver transplan@@ t and 129 patients with liver transplan@@ t and the treatment of the body .
Tre@@ vor ( cit@@ tern ) , head@@ aches , exercise disorders ( hyper@@ gl@@ yc@@ emia ) , kidney disease ( hyper@@ gl@@ yc@@ emia ) , diabetes , increased pot@@ ency of blood ( hyper@@ cholester@@ ol@@ emia ) , hyper@@ tension ( hyper@@ cholester@@ ol@@ emia ) , hyper@@ tension ( hyper@@ cholester@@ ol@@ emia ) .
for patients with et@@ ching over@@ sensitivity ( all@@ ergy ) against Tac@@ ro@@ li@@ m , macro@@ lid @-@ antibiotics ( such as er@@ y@@ thro@@ my@@ cin ) or one of the other ingredients may not be applied .
patients and doctors need to be careful if other ( especially some herbal ) medicines simultaneously be taken simultaneously with an app@@ agra@@ f dosage or the dosage of the same medication must be adjusted accordingly .
hard r@@ att@@ les , ret@@ ardi@@ um yellow @-@ orange gel@@ atine , printed in red ink on the bright yellow embos@@ sed part with &quot; 20@@ mg &quot; and on the orange clay part with &quot; &quot; &quot; 6@@ 47 &quot; ; it contains white powder .
only doctors who are familiar with immun@@ os@@ upp@@ res@@ sive therapy and treatment of transplan@@ t patients should be able to arrange this medicine or changes in immun@@ os@@ res@@ sive therapy .
due to clinical differences in the system@@ ic exposure of Tac@@ ro@@ li@@ m , this can lead to Tran@@ splan@@ ting or to an increased intra@@ ocular side effects , including sub @-@ level or immun@@ ity .
patients should always be the same Tac@@ ro@@ li@@ m form@@ ulation and the corresponding dosage forms ; provisions of the form@@ ulation or of the regime should only be performed under the eng@@ aging control of one in the transplan@@ tation ( see Sec@@ ond@@ 4.4 and 5.7 ) .
in a consequence of an extension to an alternative form@@ ulation , a therapeutic drug monitoring and corresponding D@@ os@@ is@@ ks must be carried out to ensure that the system@@ ic exposure of Tac@@ ro@@ li@@ m remains preserved .
the dosage of an app@@ agra@@ ve should be applied in the first line of the clinical assessment of abor@@ tion and transi@@ ence in the individual case and on blood circulation ( see below &quot; recommendations
after conversion from Progra@@ f to Adv@@ ance , the Tac@@ ro@@ li@@ m valley should be controlled by the conversion and over two weeks after conversion .
on day 4 was the system@@ ic exposure , measured as a talents , with both form@@ ulations and even in le@@ ber@@ transplan@@ t patients .
careful and repeated controls of the Tac@@ ro@@ li@@ m Tal@@ ents are recommended during the first two weeks after transplan@@ t under Man@@ agra@@ t to ensure proper substance exposure in the immediate therapeutic phase .
because Tac@@ ro@@ li@@ m is a substance with low bal@@ ance , an adaptation of the scal@@ pel has reached several days until the Ste@@ ady State is reached .
if the condition of the patient is permitted in the first post@@ operative phase no or@@ ale intake of medicines , the Tac@@ ro@@ li@@ m treatment intra@@ ven@@ ous ( Progra@@ f 5 mg / ml concentrate on the production of an in@@ fusion solution ) with a dose of ca .
for this reason , there is no translation for this news @-@ article . we kindly ask you to take about ten minutes to take part in this Online Survey . online Survey Information for survey participants
recommendations for transplan@@ tation proph@@ y@@ la@@ xis of the Tran@@ splan@@ t treatment should begin with 0.@@ 20 - 0,@@ 30 mg / kg / day as once daily gift at the morning .
further os@@ ome adjustments can later be necessary because the phar@@ yn@@ ok@@ ine@@ tics of Tac@@ ro@@ li@@ m can change in the course of stabili@@ zation of the patients after transplan@@ tation .
D@@ os@@ is@@ recommendations - liver transplan@@ t proph@@ y@@ la@@ xis of Tran@@ splan@@ ting The or@@ ale Adv@@ ance therapy should begin with 0.@@ 10 - 0,@@ 20 mg / kg / day as once daily gift at the morning .
optimization of Progra@@ f to Cai@@ ro@@ f Is a tran@@ spo@@ iled dosage of twice daily dose of Progra@@ f capsules at an once daily intake of cookies , so it has to be done according to an daily dose of 1 : 1 ( mg : mg ) , especially for the entire daily dose .
N@@ ier@@ - and liver transplan@@ tation after an imp@@ air@@ ment of other immun@@ os@@ upp@@ res@@ si@@ va treatment , the treatment must begin in kidney and liver transplan@@ tation with each patient in kidney and liver transplan@@ tation .
heart transplan@@ tation In adult patients who are placed on Cai@@ ro@@ f is a or@@ ale initi@@ al@@ dose of 0.@@ 15 mg / kg / day daily once in the morning .
other transplan@@ ts have no clinical experience with C@@ agra@@ ph in lung , p@@ ank@@ re@@ as@@ - and dar@@ transplan@@ t patients in a or@@ ally initi@@ al@@ dose of 0.2 mg / kg / day and when bow@@ ling transplan@@ t patients in a oral Initi@@ al dose of 0,3 mg / kg / day .
mut@@ ations in specific patient groups patients with limited risk of blood cells in the aspi@@ ration field , patients with severe liver dys@@ function may be necessary with severe liver dys@@ function disorders .
patients with limited N@@ ing@@ function , the kidney function does not affect the phar@@ op@@ ok@@ ine@@ tics of Tac@@ ro@@ li@@ m , may it be assumed that a dys@@ function is not required .
because of the ne@@ ph@@ oto@@ x@@ ic potenti@@ als of Tac@@ ro@@ li@@ m , however , a careful observation of the kidney function ( including a regular determination of ser@@ um cancer ) , a calculation of creation of creation of creation of creation of creation of creation .
conversion from c@@ ic@@ los@@ por@@ in to Cai@@ agra@@ f in the location of a C@@ ic@@ los@@ sum of the conversion of a C@@ ic@@ los@@ sum @-@ based therapy is caution ( see Sec@@ ond@@ 4.4 and 4.5 ) .
recommendations for talents in thorou@@ gh@@ b@@ ness The dose should take place in the first line on clinical assessment of recovery and prevention in the individual case under normal blood @-@ Tac@@ ro@@ li@@ m Tal@@ ents in the individual case .
it is recommended that Tac@@ ro@@ li@@ m Tal@@ ents during the first two weeks after transplan@@ tation , followed by peri@@ odic Assessment during the maintenance therapy .
blood test mirror of Tac@@ ro@@ li@@ m should also change after conversion of Progra@@ f , D@@ os@@ is@@ cation , changes of immun@@ os@@ upp@@ res@@ sive therapy or at equal application of substances which could change the Tac@@ ro@@ li@@ m full circulation ( see Section 4.5 ) .
since an dec@@ agra@@ t has been a pharmaceutical company with a low Clear@@ ance you can take off several days up to the Ste@@ ady State .
the data in clinical studies indicate that a successful treatment is possible in most cases , when the talent is in blood 20 ng / ml .
in the clinical practice there are the talents of Tac@@ ro@@ li@@ m in the blood blood in full blood in the first time according to liver transplan@@ t in the field of 5 - 20 ng / ml and pe@@ eled after 10 - 20 ng / ml .
during the rep@@ aired maintenance of the liver , kidney and heart transplan@@ ts were usually used in blood concent@@ rations in the range of 5 - 15 ng / ml .
this has led to serious unwanted events including transplan@@ ts or other side effects that may occur in a consequence of Tac@@ ro@@ li@@ m , or over@@ exposure estim@@ ation .
patients should always be the same Tac@@ ro@@ li@@ m form@@ ulation and the corresponding dosage forms ; provisions of the form@@ ulation or of the regime should only be performed under the eng@@ aging control of one in the transplan@@ tation ( see Figure 4.2 and 4.8 ) .
5 . for the treatment of adult patients with transplan@@ tation which proved to be proved no clinical data for the ret@@ ard@@ ent wording and as@@ agra@@ f .
for proph@@ y@@ la@@ xis of the transplan@@ tation in adult heart transplan@@ ts and transplan@@ ts are still no clinical data for the ret@@ ardi@@ ate form@@ ulation .
due to the potential effects that can lead to a decrease of Tac@@ ro@@ li@@ mus@@ nes ( hyper@@ ic@@ um perfor@@ atum ) , the intake of herbal supplements , the cur@@ is@@ her@@ b ( hyper@@ ic@@ um perfor@@ atum ) , or other plant agents during pregnancy ( see Section 4.5 ) .
patients with di@@ arr@@ ho@@ ea is a particularly thorough monitoring of Tac@@ ro@@ li@@ mus@@ cular concent@@ rations in blood , as the Tac@@ ro@@ li@@ m blood level under such circumstances .
in rare cases , Progra@@ f was identified as car@@ di@@ om@@ y@@ opath@@ ie in aqu@@ eous or sep@@ sis @-@ hyper@@ tro@@ phy , which may also occur in an app@@ agra@@ t .
other factors which increase the risk of such enz@@ yme distur@@ ban@@ ces , a treatment with cor@@ ti@@ cl@@ ero@@ ids , hyper@@ tension , kidney or liver dys@@ function , infections , liquid over@@ load and o@@ bes@@ ity .
like other immun@@ os@@ res@@ si@@ va , the effect of sunlight or UV light due to the possible risk of mal@@ ign@@ ant skin alter@@ ations through appropriate clothing or use of a solar protection thanks to a high protection factor .
if patients , the Tac@@ ro@@ li@@ m should take symptoms for PRE@@ S such as head@@ aches , mut@@ ually state of consciousness , acting and visual disorders , should be a radi@@ ological investigation ( e.g. B ) .
since ref@@ usal , ret@@ ard@@ ants , act@@ ose , L@@ act@@ ose is contained in patients with the rare her@@ edit@@ ary Gal@@ act@@ ose int@@ oler@@ ant , L@@ act@@ ose defect or glu@@ cose Gal@@ act@@ ose @-@ Mal@@ etes .
the simultaneous application of medicines or herbal remedi@@ es which are known as Hem@@ mer or In@@ duc@@ tors from CY@@ P@@ 3@@ A4 , the metabolism of Tac@@ ro@@ li@@ m can increase the metabolism of Tac@@ ro@@ li@@ m and reduce the blood values of Tac@@ ro@@ li@@ m .
it is recommended to change the Tac@@ ro@@ li@@ mus@@ - blood level with equal gift of substances that can change the CY@@ P@@ 3A met@@ abolic type to maintain uniform concent@@ rations ( see Figure 4.2 and 4.4 ) .
a pronounced impact effect was influenced by an@@ tim@@ icro@@ bi@@ al such as K@@ eto@@ con@@ az@@ ol , Flu@@ con@@ az@@ ol , I@@ tra@@ con@@ az@@ ol and V@@ ori@@ con@@ az@@ ol , and with the Macro@@ lid anti@@ biotic an@@ y@@ thro@@ my@@ cin and HIV @-@ Prot@@ e@@ as@@ tics ( z .
Ph@@ armac@@ ok@@ ine@@ tic studies indicate that the increase in blood levels mainly of the elevated bi@@ polar bi@@ odiversity loss of Tac@@ ro@@ li@@ m , caused by inhib@@ itor of g@@ astro@@ intestinal bacteria .
high do@@ si@@ cal Pre@@ d@@ nis@@ ol@@ on or meth@@ yl@@ pre@@ d@@ nis@@ ol@@ on , as it is used in acute risk reactions , the concentration of Tac@@ ro@@ li@@ m can increase or reduce the concentration of Tac@@ ro@@ li@@ m .
effect of Tac@@ ro@@ li@@ m is known as CY@@ P@@ 3@@ A4 inhib@@ itor that is known as CY@@ P@@ 3@@ A4 inhib@@ itors . therefore , the simultaneous application of Tac@@ ro@@ li@@ m with medicines , which is affected by CY@@ P@@ 3@@ A4 .
in Tac@@ ro@@ li@@ m the Clear@@ ance of mort@@ ality contra@@ cep@@ tiva and thus increase the hormon@@ al exposure , is especially useful for decisions regarding their recep@@ tions .
the results of animal tests have shown that Tac@@ ro@@ li@@ m is possible to reduce the clearing of the gran@@ ob@@ sc@@ ital and phen@@ az@@ on and their semi @-@ value .
results of a large number of studies on Tran@@ splan@@ t patients are no reference to other immun@@ os@@ res@@ si@@ va compared to other immun@@ os@@ res@@ si@@ va compared to other immun@@ os@@ res@@ si@@ va compared to other immun@@ os@@ res@@ si@@ va .
in u@@ ter@@ o exposure , a monitoring of the new@@ born on possible harmful effects of Tac@@ ro@@ li@@ m ( especially regarding its effect on the kid@@ neys ) .
there is the risk of a premature birth ( &lt; week 37 ) and a hyper@@ k@@ ali@@ emia of the new@@ born ( In@@ zi@@ ps 8 of 111 Neu@@ born , i.e. :
the exc@@ use profile of immun@@ os@@ res@@ si@@ va often can often find out due to the retinal diseases of the patient and even further treatment with a variety of other medicines .
( ≥ 1 / 100 , ≤ 1 / 10 ) , occasionally ( ≥ 1 / 100 , ≤ 1 / 100 ) , occasionally ( ≥ 1 / 10,000 , ≤ 1 / 100 ) , rare ( ≥ 1 / 10,000 , ≤ 1 / 1000 ) , very rare ( ≥ 1 / 10,000 , ≤ 1 / 1000 ) , very rare ( ≥ 1 / 10,000 , ≤ 1 / 1000 ) .
ultr@@ asonic dis@@ rup@@ tive disorders of the cardi@@ ac surgery , Tach@@ y@@ kar@@ di@@ opath@@ ie , M@@ yo@@ cardi@@ di@@ opath@@ ie , Chamber of hyper@@ tro@@ phy , pal@@ eness of ar@@ rhyth@@ ms , an@@ om@@ ali@@ es in EC@@ G , ab@@ nor@@ ma heart rate and pulse frequency
di@@ arr@@ ho@@ eal disease , stomach cancer , stomach infections , stomach p@@ ains , blood vessels , blood vessels , blood flow , blood flow , blood flow , blood flow , blood flow , blood flow , blood flow , blood flow , and paraly@@ sis , character and symptoms in g@@ astro@@ intestinal flora - area
infections and paras@@ ite disorders How well @-@ known immun@@ os@@ upp@@ res@@ si@@ va is treated with patients who are treated with Tac@@ ro@@ li@@ m ( viral , bacterial , my@@ kot@@ ical , prot@@ o@@ zo@@ ale ) .
cases of BK @-@ virus @-@ associated N@@ eph@@ rop@@ ath@@ ie and J@@ C virus associated with immun@@ os@@ enc@@ ephal@@ opathy ( P@@ ML ) were reported at patients under immun@@ os@@ upp@@ ression therapy , including treatment with Cai@@ agra@@ f .
it was reported about credi@@ ble or b@@ ös@@ zed fung@@ i , including EB@@ V@@ - associated ly@@ m@@ ph@@ opro@@ jection and skin @-@ tum@@ ors in conjunction with Tac@@ ro@@ li@@ m .
due to its high molecular weight , its low water sol@@ uble and the high frequency to er@@ y@@ thro@@ cy@@ tes and plasma spheres are accepted that Tac@@ ro@@ li@@ m is not di@@ aly@@ zed .
active mechanism and phar@@ ma@@ co@@ dynamic effects on molecular level the effects of Tac@@ ro@@ li@@ m is responsible for molecular diagnostics ( F@@ KB@@ P@@ 12 ) , which is responsible for the enrich@@ ment of the connection in the cell .
this leads to a cal@@ ci@@ ously controlled inhib@@ itor of signal trans@@ duc@@ tors because of the T cells and prevents the tran@@ scrip@@ tion of a certain number of ly@@ mp@@ ho@@ kin @-@ g@@ enen .
in the form of intra@@ ocular pressure , the intra@@ ocular inflammation of the brain cells ( such as inter@@ leu@@ kin @-@ 2 , inter@@ leu@@ kin @-@ 3 and intra@@ vit@@ on ) as well as the expression of inter@@ leu@@ kin @-@ 2 recep@@ tors .
12 replies from the K@@ agra@@ f group ( N = 237 ) 32.@@ 6 % and the Progra@@ f group ( N = 232 ) 29.@@ 3 % .
&quot; &quot; &quot; the patients &quot; &quot; &quot; &quot; patients &quot; &quot; &quot; &quot; for 12 months and 9@@ 0.8 % for Progra@@ f and 9@@ 0,8 % for Progra@@ f ; in the right @-@ arm 24 ( 14 women , 11 men ) and the Progra@@ f @-@ Arm 24 ( 5 women , 19 men ) deaths . &quot; &quot; &quot;
transplan@@ tation The effectiveness and security of the C@@ agra@@ f and Progra@@ f was compared with my@@ cop@@ hen@@ ol@@ at@@ mo@@ fe@@ til ( MM@@ F ) and cor@@ on@@ ero@@ ids in combination with my@@ cop@@ hen@@ ol@@ at@@ mo@@ fe@@ til ( MM@@ F ) and cor@@ tical transplan@@ ts .
the patients &quot; survival rates according to 12 months of 9@@ 6.@@ 9 % for the purchase of 9@@ 6.@@ 9 % for Progra@@ f ; in the Adv@@ ance Arm , 10 ( 3 women , 7 men ) and the Progra@@ f @-@ arm 8 ( 3 women , 5 men ) deaths .
the eff@@ ic@@ acy and safety of Progra@@ f , C@@ ic@@ los@@ por@@ in and Adv@@ ance , respectively , in combination with Basi@@ lic@@ o therapeu@@ tics , MM@@ F and cor@@ on@@ ero@@ ids , at 6@@ 38 de nov@@ o kidney transplan@@ ts .
after 12 months ( defined as death , transplan@@ tation loss , Bi@@ op@@ her approved removal or lack of retri@@ ev@@ - data ) was 14.@@ 0 % in the purchase group ( N = 214 ) and 17.@@ 0 % in the C@@ ic@@ los@@ por@@ in group ( N = 212 ) .
the treatment difference was -@@ 3.0 % ( Cai@@ agra@@ f@@ - C@@ ic@@ los@@ por@@ in ) ( 9@@ 5,@@ 2 % , 4.0 % &#93; ) for ref@@ agra@@ f vs C@@ ic@@ los@@ por@@ in and -@@ 1.9 % ( Progra@@ f @-@ C@@ ic@@ los@@ s ) ( 9@@ 5.2 % , 5.6 % &#93; ) for Progra@@ f vs C@@ ic@@ los@@ s .
in an dec@@ agra@@ t arm , 3 ( men ) , in the Progra@@ f @-@ arm 10 ( 3 women , 7 men ) and in C@@ ic@@ los@@ i @-@ Arm 6 ( 3 women , 3 men ) deaths .
published results of primary immun@@ otherapy with Tac@@ ro@@ li@@ m in the form of twice daily re@@ treated patients with other primary immune diseases associated with pan@@ cre@@ as@@ - , lung and intestinal tra@@ ffi@@ ckers .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; the patients &quot; &quot; &quot; &quot; transplan@@ t patients &quot; &quot; &quot; &quot; patients who tested an pan@@ cre@@ atic transplan@@ tation were used in 630 cases after an intestinal transplan@@ t as a pri@@ esth@@ esia immun@@ os@@ upp@@ res@@ sive medicines . &quot; &quot; &quot;
in a total , the safety profile of or@@ ical Progra@@ f in these published studies were published in the major studies in which Progra@@ f involving liver , N@@ ier@@ - and heart transplan@@ tation to primary immune disorders .
XHTML 1.1 plus Math@@ ML 2.0 XHTML 1.1 plus Math@@ ML 2.0 XHTML 1.1 plus Math@@ ML 2.0 plus SVG 1.1 Math@@ ML 2.0 SVG 1.0 SVG 1.1 SVG 1.1 SVG 1.1 Tiny SVG 1.1 Basic S@@ MIL 1.0 S@@ MIL 2.0 Root Element : HTML
during the first year after transplan@@ t , the Bron@@ chi@@ tis Syndrome Association ( 2.7 % versus 8.@@ 57 % ) was in the first year after transplan@@ tation ( 2.7 % versus 8.@@ 57 % ) .
the rate of life after a year was 8@@ 0,8 % in the Tac@@ ro@@ li@@ mus@@ cular and 83 % in the C@@ ic@@ los@@ por@@ a group ( Tre@@ ede et al . , 3rd IC@@ I San Diego , USA , 2004 ; Abstract 22 ) .
with Tac@@ ro@@ li@@ m treated patients came in 21.@@ 7 % of the cases in the formation of a bronze med@@ i ob@@ liter@@ ans compared to 38.@@ 0 % under C@@ ic@@ los@@ por@@ in ( p = 0.0@@ 25 ) .
the number of cases where C@@ ic@@ los@@ s had to be moved into Tac@@ ro@@ li@@ m ( n = 13 ) as the number of patients who were set by Tac@@ ro@@ li@@ m on C@@ ic@@ los@@ por@@ in ( n = 2 ) ( Ke@@ en@@ an et al . , Ann @-@ ac@@ ic Sur@@ g 1995 ; 60 : 580 ) .
the number of cases , in which it came to no acute tran@@ spon@@ ser@@ ment , after 6 months ( 57,@@ 7 % versus 9,@@ 3 % ) and after 1 year ( 50 % versus 33,@@ 3 % ) and after 1 year ( Tre@@ ede et al . , J Heart L@@ ung Tran@@ splan@@ t 2001 ; 20 : 511 ) .
in a study the frequency of a bronze statue was significantly lower with Tac@@ ro@@ li@@ m therapy by Tac@@ ro@@ li@@ m treated patients .
pan@@ cre@@ atic immun@@ otherap@@ ies A multi @-@ centralized study with or@@ ical Progra@@ f was carried out at the same time a pan@@ cre@@ atic and kidney transplan@@ tation which were given after a random@@ ised procedure of Tac@@ ro@@ li@@ m ( n = 102 ) or C@@ ic@@ los@@ por@@ in ( n = 102 ) .
the or@@ ale initi@@ al@@ dose ( per Protocol ) of Tac@@ ro@@ li@@ m was 0.2 mg / kg / day and was then re@@ covering the valley of 8 to 15 ng / ml on 5 .
bow@@ ling transplan@@ t The published clinical findings of a mon@@ o@@ centric study with or@@ es@@ oph@@ thal@@ ate patients showed a updated survival rate of 75 % after 1 year , 5 % after 5 years and 42 % after 10 years .
methods for early detection of ep@@ stein @-@ Bar@@ r ( EB@@ V ) and C@@ MV infections , bone draw@@ cord , additional gift of Inter@@ leu@@ kin @-@ 2 @-@ Ant@@ ag@@ os D@@ ac@@ liz@@ um@@ ab , lower starting point of Tac@@ ro@@ li@@ m ( Abu @-@ El@@ mag@@ ne et al . , Ann Sor@@ g 2001 ; 234 : 404 ) .
factors like a low Hä@@ mat@@ ok@@ rit@@ es and low protein concent@@ rations which may lead to a increase in the increase of in@@ tox@@ icity from Tac@@ ro@@ li@@ m , or treatment with cor@@ on@@ oids from the met@@ abolic disease should be responsible for the transplan@@ tation .
this can be eff@@ ected that Tac@@ ro@@ li@@ m is almost completely ob@@ struct@@ ed , whereby the ex@@ cre@@ tion is mainly carried out over the units .
for stable patients that were set by Progra@@ f ( twice daily ) to Adv@@ ance ( twice daily ) in relation to 1 : 1 ( mg : mg ) , the system@@ ic exposure of Tac@@ ro@@ li@@ m ( AU@@ C@@ 0 @-@ 24 ) was lower than 10 % lower than under Progra@@ f .
it is recommended that Tac@@ ro@@ li@@ m Tal@@ ents during the first two weeks after transplan@@ tation , followed by peri@@ odic Assessment during the maintenance therapy .
21 . for the treatment of adult patients with transplan@@ tation which proved to be proved no clinical data for the ret@@ ard@@ ent wording and as@@ agra@@ f .
other factors which increase the risk of such enz@@ yme distur@@ ban@@ ces , a treatment with cor@@ ti@@ cl@@ ero@@ ids , hyper@@ tension , kidney or liver dys@@ function , infections , liquid over@@ load and o@@ bes@@ ity .
28 approved of the re@@ alism was within the first 24 weeks in the C@@ agra@@ f group ( N = 237 ) 32.@@ 6 % and in the Progra@@ f group ( N = 232 ) 29.@@ 3 % .
the eff@@ ic@@ acy and safety of Progra@@ f , C@@ ic@@ los@@ por@@ in and Adv@@ ance , respectively , in combination with Basi@@ lic@@ o therapeu@@ tics , MM@@ F and cor@@ on@@ ero@@ ids , at 6@@ 38 de nov@@ o kidney transplan@@ ts .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; fl@@ att@@ les , ret@@ ard@@ ust red @-@ orange gel@@ atine , printed in red ink on the gr@@ ated red cap top with &quot; &quot; &quot; &quot; 6@@ 87 &quot; &quot; &quot; &quot; with &quot; &quot; &quot; &quot; 6@@ 87 &quot; &quot; &quot; &quot; they contain white pow@@ ders . &quot; &quot; &quot;
it is recommended that Tac@@ ro@@ li@@ m Tal@@ ents during the first two weeks after transplan@@ tation , followed by peri@@ odic Assessment during the maintenance therapy .
37 For the treatment of adult patients with transplan@@ tation which proved to be proved no clinical data for the ret@@ ard@@ ent wording and as@@ agra@@ f .
other factors which increase the risk of such enz@@ yme distur@@ ban@@ ces , a treatment with cor@@ ti@@ cl@@ ero@@ ids , hyper@@ tension , kidney or liver dys@@ function , infections , liquid over@@ load and o@@ bes@@ ity .
44 approved in the C@@ agra@@ f group ( N = 237 ) 32.@@ 6 % and the Progra@@ f group ( N = 232 ) 29.@@ 3 % .
the eff@@ ic@@ acy and safety of Progra@@ f , C@@ ic@@ los@@ por@@ in and Adv@@ ance , respectively , in combination with Basi@@ lic@@ o therapeu@@ tics , MM@@ F and cor@@ on@@ ero@@ ids , at 6@@ 38 de nov@@ o kidney transplan@@ ts .
a total of 34 patients were set up in Tac@@ ro@@ li@@ m in Tac@@ ro@@ li@@ m while only 6 Tac@@ ro@@ li@@ m @-@ patients another therapy ( B@@ ech@@ stein et al . , Tran@@ splan@@ tation 2004 ; 77 : 12@@ 21 ) .
bow@@ ling transplan@@ t The published clinical findings of a mon@@ o@@ centric study with or@@ es@@ oph@@ thal@@ ate patients showed a updated survival rate of 75 % after 1 year , 5 % after 5 years and 42 % after 10 years .
this can be eff@@ ected that Tac@@ ro@@ li@@ m is almost completely ob@@ struct@@ ed , whereby the ex@@ cre@@ tion is mainly carried out over the units .
risk management plan The owner of approval for the transport of approval , which are accepted in the pharmaceu@@ ko@@ vi@@ gil@@ ance plan , as described in version 3.2 of the risk management plan ( R@@ MP ) , as well as all further insp@@ ections of the R@@ MP , which are approved by CH@@ MP .
according to the CH@@ MP gui@@ deline to the risk management systems for drug use , the updated R@@ MP has to be submitted with the next peri@@ odic security report ( peri@@ odic Safety Update Report , PS@@ BE ) .
perhaps you receive an authorization of your liver , kidney or heart transplan@@ t or heart transplan@@ t or any other transplan@@ tation .
taking your doctor or pharmac@@ ist if you take any medicine or pharmac@@ ist if you have other drugs or pharmac@@ ist if you are not interested in prescription drugs or herbal remedi@@ es .
am@@ il@@ ori@@ d , Tri@@ am@@ less or Spir@@ on@@ ol@@ ac@@ ton ) , certain pain remedi@@ es ( so non ster@@ o@@ id@@ al anti @-@ log@@ is@@ omet@@ ry such as I@@ bu@@ pro@@ fen ) , anti@@ o@@ ag@@ ul@@ ants or medicine for treatment of diabetes mel@@ lit@@ us .
pregnancy and down@@ time when a pregnancy is planned or already exists , ask before taking care of your doctor or pharmac@@ ist to advice .
if you are interested in transportation or machines , you must contact the tax of a vehicle or use tools if you are taking taking care of an adap@@ tive or relevant touch .
important information on certain other ingredients of C@@ agra@@ f Please take an end to your doctor if you know if you suffer from an int@@ oler@@ ance to certain zu@@ res .
ensure that you will always receive the same Tac@@ ro@@ li@@ m medication if you may rede@@ em your prescription , unless your specialist is expressly agreed to change the Tac@@ ro@@ li@@ m Association .
if you get a medicine where you can find a medication , which can be changed or the dosing instructions , please do so quickly as possible with your treat@@ ment@@ ing doctor or pharmac@@ ist , so that you can get the correct medicine .
this allows your doctor to determine the right amount of time and time to time , it has to perform a regular blood tests .
if you have taken a bigger amount of C@@ agra@@ f when you have taken a bigger amount of Cai@@ ro@@ f you will search for your doctor or the emergency department of the nearest hospital .
if you forget the intake of an app@@ agra@@ f you have forgotten if you have forgotten the capsules you get at the same day at the earliest possible time .
if you reduce the intake of ref@@ agra@@ ph in the end of the treatment with an dec@@ agra@@ ph , the risk of recovery of your tran@@ spon@@ der may increase .
the P@@ agra@@ f 0.5 mg hard r@@ att@@ les , which are hard @-@ coloured , are hard to be printed with &quot; 0.5 mg &quot; and their or@@ ang@@ es lower part with &quot; &quot; &quot; 6@@ 47 &quot; and their or@@ ang@@ es lower part with &quot; &quot; &quot; &quot; 6@@ 47 &quot; &quot; &quot; &quot; are filled with white powder . &quot; &quot; &quot;
&quot; &quot; &quot; best @-@ to @-@ use search interface in English , &quot; &quot; &quot; &quot; Tools , Internet Options , Security &quot; &quot; &quot; &quot; and &quot; &quot; &quot; &quot; Tools , Internet Options , Security &quot; &quot; &quot; &quot; and &quot; &quot; &quot; &quot; Tools , Internet Options , Privacy &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
&quot; &quot; &quot; best @-@ to @-@ use search interface in English , &quot; &quot; &quot; &quot; Tools , Internet Options , Security &quot; &quot; &quot; &quot; and &quot; &quot; &quot; &quot; Tools , Internet Options , Security &quot; &quot; &quot; &quot; and &quot; &quot; &quot; &quot; Tools , Internet Options , Privacy &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
P@@ â@@ nia A@@ stell@@ as Pharma dor@@ a@@ ţ Det@@ ali@@ i de Age p@@ entr@@ u Rom@@ â@@ nia , ose@@ au@@ a Bu@@ cu@@ re@@ anal@@ ti @-@ P@@ lo@@ ie@@ vi@@ ata 42 @-@ 44 , Cl@@ ă di@@ re 1 , par@@ ter , 0@@ 13@@ 6@@ 96 @-@ Bu@@ cu@@ re@@ aks ti Tel : + 40 ( 0 ) 21 361 04@@ 95
Slov@@ ens@@ k@@ á republi@@ ka A@@ stell@@ as Pharma s.r.@@ o. , K@@ č z@@ lo@@ ž . Gal@@ á@@ ni@@ ho 15 / C SK@@ I@@ 8@@ 21 04 Bratislava 2 Tel : + 421 2 44@@ 44 2@@ 157
Adv@@ ance is used for treatment and prevention of blood tests in patients with hem@@ ophi@@ lia A ( one due to the lack of factor ) , due to the lack of factor VIII .
the dosage and frequency of the application takes on whether E@@ ate for treatment of ble@@ eding or treatment of ble@@ eding during surgery .
patients with h@@ amm@@ ophi@@ lia A suffer from a factor VIII defici@@ ency , causing blood cl@@ esi@@ as@@ ound problems such as ble@@ eding in joints , muscles or internal organs .
Oc@@ to@@ co@@ g al@@ fa is not extra@@ cted from human Plasma , but after a method that is called &quot; re@@ combin@@ ant DNA technology . &quot;
PSYNDEX is the most comprehensive abstract database ( not full @-@ text ) of psychological literature , audiovisual media , intervention programs , and tests from the German @-@ speaking countries .
Man@@ ate is one of the other in the European Union called Rec@@ om@@ bin@@ ate , similar to that , however , it is possible to produce proteins and animal origin in the European Union .
in three additional studies of patients with severe to moderate H@@ äm@@ bach A , among them a study with 53 children under six years , the application of drug treatment was investigated by treatment in blood tests and surgical intervention .
in the main study , C@@ ate has been equ@@ alled the eff@@ ic@@ acy of blood tests in 86 % of 510 new blood vessels with &quot; excellent &quot; or &quot; well . &quot;
the most common side effects of Adv@@ ance ( observed at 1 to 10 of 100 patients ) are Schwin@@ n , head@@ aches , py@@ re@@ x@@ ie ( fever ) and the formation of anti@@ bodies .
Adv@@ ant@@ ages may not be applied to patients who may have sensitive ( allergi@@ c ) against the human interference factor VIII , mouse or Ham@@ ster@@ ones or other ingredients .
March 2004 , the European Commission divided the European Commission for an authorization for the use of supplements in the entire European Union .
dosage the dosage and duration of the sub@@ stitution treatment , according to the sword of the factor VIII @-@ Man@@ age , according to the location and extent of the blood and the clinical state of the patient .
in the following ap@@ pr@@ or@@ rh@@ ag@@ ical events , the factor of VIII activity is not affected by the specified plasma levels ( in % of the standard or in I.@@ E. / dl ) .
injection all 12 @-@ 24 hours ( 8 @-@ 24 hours with patients under 6 years ) for 3 @-@ 4 days or longer , until the pain and the acute imp@@ air@@ ment of imp@@ air@@ ment .
injection all 8 @-@ 24 hours ( 6 @-@ 12 hours at patients under 6 years ) , until the risk for the patient is pre @-@ operative .
during the treatment , the reduction of the factor and the frequency of the inj@@ ections are an adequate determination of the factor VIII @-@ plasma spheres .
individual patients can be distinguished in their reaction to factor VIII , different in vivo Recovery and different semi @-@ value times .
3 proph@@ y@@ la@@ xis for long term proph@@ y@@ la@@ xis of ble@@ eding in patients with severe hem@@ ophi@@ lia A should be given between 20 and 40 I.@@ E. from factor VIII per kg body weight in distance of 2 @-@ 3 days .
if the expected factor of VIII @-@ plasma activities should not be reached , or if the blood is not limited to a reasonable dose , it must be carried out to reflect an inhib@@ itor in order to see an inhib@@ itor .
in patients with high in@@ hi@@ bit@@ ory values , it is possible that the factor VIII therapy is not effective , so that other therapeutic measures need to be discussed .
the administration speed is to be granted according to the patient , whereby a maximum injection rate of 10 ml / min should not be exceeded .
the formation of neutr@@ alisation ( in@@ hi@@ bit@@ ory ) against the factor VIII is a well @-@ known compensation for patients with hem@@ ophi@@ lia A .
these in@@ hi@@ bit@@ ory activities are always against the pro@@ co@@ ag@@ ul@@ atory activity of factor VIII @-@ Ig@@ G immun@@ og@@ lob@@ ul@@ ine that are quanti@@ fied in Be@@ thes@@ da units ( B.@@ E. ) per ml Plasma by modified Be@@ thes@@ da As@@ say .
the risk of in@@ hi@@ bit@@ oren is developing cor@@ related to the extent of exposure to exposure to the factor VIII , whereby the risk within the first 20 Ex@@ posi@@ ble is at the biggest and most of genetic and other factors .
in pre @-@ treated patients ( PT@@ Ps ) with more than 100 Ex@@ posi@@ ums and an@@ am@@ nes@@ tically well known in@@ hi@@ bit@@ ory development , after conversion from a re@@ combin@@ ant factor VIII @-@ product to another , the repeti@@ tion of ( low @-@ tri@@ gen ) in@@ hi@@ bit@@ ory is observed .
due to the rare occurr@@ ence of the h@@ amm@@ ophi@@ lia A in women lie above the application of factor VIII in the pregnancy and still no experiences yet .
in the case of the greatest number of patients , In@@ hi@@ bit@@ ors were observed against the factor VIII ( 5 patients ) , which were higher risk of inhib@@ itors , head@@ aches ( 5 patients ) , fever and Schwin@@ n ( each patient ) .
≥ 1 / 10 ) , often ( ≥ 1 / 100 to &lt; 1 / 10 ) , occasionally ( ≥ 1 / 10,000 to &lt; 1 / 100 ) , rare ( ≥ 1 / 10,000 to &lt; 1 / 10,000 ) , not known ( frequency on the basis of available data is not de@@ duc@@ ted ) .
a ) The percentage of patients was based on the sum of the patients ( 234 ) calculated after the sum of the patients ( 234 ) , the un@@ expected waste of the blood test factor VIII @-@ Spi@@ eg@@ els was post@@ oper@@ atively ( 10 - 14 post@@ oper@@ ation day ) in one patient under the continuous A@@ DV@@ OC @-@ In@@ fusion .
the blood co@@ ag@@ ulation was observed throughout the time period and both the factor of VI@@ II@@ - mirror in plasma as well as the Clear@@ ance rate was sufficient .
clinical studies with A@@ DV@@ ATE to 145 children and adults 2 with diagnos@@ ed he@@ avier than mid@@ difficult h@@ amm@@ ate ( ≥ 150 days ) and prior exposure to 26 Ex@@ clu@@ sion ( 2,4 150 days ) only one patient after 26 Ex@@ clu@@ sion ( 2,4 B.@@ E. in modified Be@@ thes@@ da approach ) .
in addition to the 53 pap@@ at@@ ric patient with a age of 6 years and diagnos@@ ed severe to moderate he@@ avi@@ ophi@@ lia A ( F@@ EST _ 2 % ) after prior exposure to the factor of VI@@ II@@ - Con@@ centric ( ≥ 50 days ) .
in the case of non @-@ treated patients with the clinical trial 5 of 25 ( 20 % ) with A@@ DV@@ OC treated patients in@@ hi@@ bit@@ ory of factor VIII .
the immune response of the patients on the traces of contam@@ in@@ ating proteins were analyzed by the investigation of anti@@ bodies against these proteins , laboratory parameters and reported effects .
however , a patient showed a statisti@@ cally significant reduction of anti @-@ CH@@ O cells in anti @-@ CH@@ O cells , however , no signs or symptoms associated to an allergi@@ c reaction or hyper@@ sensitivity .
in four patients , the occurr@@ ence of ur@@ anium , mal@@ ur@@ itus , skin care and increased number of e@@ os@@ oph@@ oph@@ ile Gran@@ u@@ lo@@ zy@@ tes was reported in several different product positions within the framework of the study .
7 As with other intra@@ ven@@ ous products , A@@ DV@@ EN@@ OS has been identified over over sensitive scal@@ ability of allergi@@ c type , including an@@ ap@@ hydr@@ ate / an@@ ap@@ hy@@ l@@ act@@ ate responses ( Frequ@@ ency is not known ) .
the activated factor VIII acts as a factor factor for the activated factor IX and reduces the formation of activated factor X from factor X .
all Ph@@ armac@@ ok@@ ine@@ tic studies with A@@ DV@@ ATE have been carried out in pre@@ treated patients with severe or moderate hem@@ ophi@@ lia A ( basic value of the factor VIII @-@ activity ≤ 2 % ) .
Ph@@ armac@@ ok@@ ine@@ tic parameters are taken from a Cross @-@ Over @-@ study with A@@ DV@@ rah in 100 previously treated patients or &gt; 10 years and are listed in the table 3 .
table 3 : Ph@@ armac@@ ok@@ ine@@ tic parameters of A@@ DV@@ OC at 100 patients with he@@ avier h@@ amm@@ ate A ( factor VIII &lt; 2 % ) PK @-@ parameters ( Phar@@ mak@@ ok@@ ine@@ tics )
not clinical data , based on the trials of safety sp@@ har@@ mac@@ ology , to acute , repeated and consistent tox@@ icity and to gen@@ oto@@ x@@ iz@@ ations , show no special risk for humans .
each individual packaging consists of a balance sheet with powder , a through@@ put bottle with 5 ml sol@@ vents ( both glass type I with chlor@@ ob@@ ut@@ yl rubber stopper ) and a device for reconstruction ( BA@@ X@@ J@@ ECT II ) .
the product is heated by electricity . 1 bathroom with shower . 1 toilet . freezer . microwave oven . dish washer . oven / mini@@ oven . wood@@ burning stove . stereo set . CD . digital satellite dish .
significant increase in the pulse frequency can be reduced by slow or time @-@ consuming the injection of injection . ( see Sec@@ ond@@ 4.4 and 5.@@ 4.8 ) .
14 proph@@ y@@ la@@ xis for long term proph@@ y@@ la@@ xis of ble@@ eding in patients with severe hem@@ ophi@@ lia A should be given between 20 and 40 I.@@ E. from factor VIII per kg body weight in distance of 2 @-@ 3 days .
due to the rare occurr@@ ence of the h@@ amm@@ ophi@@ lia A in women lie above the application of factor VIII in the pregnancy and still no experiences yet .
3 new@@ born ( at the age of 0 @-@ 1 month ) , inf@@ ants ( at the age of 1 month - 2 years ) , children ( at the age of 2 @-@ 12 years ) , adults ( at the age of 12 @-@ 16 years ) , adults ( over 16 years )
clinical studies with A@@ DV@@ ATE to 145 children and adults aged 4 with diagnos@@ ed he@@ avi@@ an he@@ avi@@ an ( ≥ 150 days ) and prior exposure to 26 Ex@@ posi@@ ums ( ≥ 150 days ) only one patient after 26 Ex@@ posi@@ tis ( 2.4 B.@@ E. in modified Be@@ thes@@ da approach ) .
18 As with other intra@@ ven@@ ous products , A@@ DV@@ EN@@ OS has been identified over over sensitive scal@@ ability of allergi@@ c type , including an@@ ap@@ hydr@@ ate / an@@ ap@@ hy@@ l@@ act@@ ate responses ( Frequ@@ ency is not known ) .
table 3 : Ph@@ armac@@ ok@@ ine@@ tic parameters of A@@ DV@@ OC at 100 patients with he@@ avier h@@ amm@@ ate A ( factor VIII &lt; 2 % ) PK @-@ parameters ( Phar@@ mak@@ ok@@ ine@@ tics )
not clinical data , based on the trials of safety sp@@ har@@ mac@@ ology , to acute , repeated and consistent tox@@ icity and to gen@@ oto@@ x@@ iz@@ ations , show no special risk for humans .
25 proph@@ y@@ la@@ xis for long term proph@@ y@@ la@@ xis of ble@@ eding in patients with severe hem@@ ophi@@ lia A should be given between 20 and 40 I.@@ E. from factor VIII per kg body weight in distance of 2 @-@ 3 days .
5 new born ( at the age of 0 @-@ 1 month ) , inf@@ ants ( at the age of 1 month - 2 years ) , children ( at the age of 2 @-@ 12 years ) , adults ( at the age of 12 @-@ 16 years ) , adults ( over 16 years )
clinical studies with A@@ DV@@ ATE to 145 children and adults 6 with diagnos@@ ed severe to moderate he@@ avi@@ ophi@@ lia A ( F@@ EST _ 2 % ) and prior exposure to 26 Ex@@ posi@@ ums ( ≥ 150 days ) only one patient after 26 Ex@@ posi@@ tis ( 2.4 B.@@ E. in modified Be@@ thes@@ da approach ) .
29 As with other intra@@ ven@@ ous products , A@@ DV@@ EN@@ OS has been identified over over sensitive scal@@ ability of allergi@@ c type , including an@@ ap@@ hydr@@ ate / an@@ ap@@ hy@@ l@@ act@@ ate responses ( Frequ@@ ency is not known ) .
not clinical data , based on the trials of safety sp@@ har@@ mac@@ ology , to acute , repeated and consistent tox@@ icity and to gen@@ oto@@ x@@ iz@@ ations , show no special risk for humans .
36 proph@@ y@@ la@@ xis for long term proph@@ y@@ la@@ xis of ble@@ eding in patients with severe pul@@ s@@ ophi@@ lia A should be given between 20 and 40 I.@@ E. from factor VIII per kg body weight in distance of 2 @-@ 3 days .
7 new@@ born ( at the age of 0 @-@ 1 month ) , inf@@ ants ( at the age of 1 month - 2 years ) , children ( at the age of 2 @-@ 12 years ) , adults ( at the age of 12 @-@ 16 years ) , adults ( over 16 years )
clinical studies with A@@ DV@@ ATE to 145 children and adults aged 8 with diagnos@@ ed he@@ avier than mid@@ difficult h@@ amm@@ ate ( ≥ 150 days ) and prior exposure to 26 Ex@@ posi@@ tis ( 2,4 150 days ) only one patient after 26 Ex@@ posi@@ tis ( 2.4 B.@@ E. in modified Be@@ thes@@ da approach ) .
40 As with other intra@@ ven@@ ous products , A@@ DV@@ EN@@ OS has been identified over over sensitive scal@@ ability of allergi@@ c type , including an@@ ap@@ hydr@@ ate / an@@ ap@@ hy@@ l@@ act@@ ate responses ( Frequ@@ ency is not known ) .
not clinical data , based on the trials of safety sp@@ har@@ mac@@ ology , to acute , repeated and consistent tox@@ icity and to gen@@ oto@@ x@@ iz@@ ations , show no special risk for humans .
47 proph@@ y@@ la@@ xis for long term proph@@ y@@ la@@ xis of ble@@ eding in patients with severe hem@@ ophi@@ lia A should be given between 20 and 40 I.@@ E. from factor VIII per kg body weight in distance of 2 @-@ 3 days .
9 New@@ born ( at the age of 0 @-@ 1 month ) , inf@@ ants ( at the age of 1 month - 2 years ) , children ( at the age of 2 @-@ 12 years ) , adults ( at the age of 12 @-@ 16 years ) , adults ( over 16 years )
clinical studies with A@@ DV@@ ATE to 145 children and adults 10 with diagnos@@ ed severe to moderate he@@ avi@@ ophi@@ lia A ( F@@ EST _ 2 % ) and prior exposure to 26 Ex@@ posi@@ ums ( ≥ 150 days ) only one patient after 26 Ex@@ posi@@ tis ( 2.4 B.@@ E. in modified Be@@ thes@@ da approach ) .
51 As with other intra@@ ven@@ ous products , A@@ DV@@ EN@@ OS has been identified over over sensitive scal@@ ability of allergi@@ c type , including an@@ ap@@ hydr@@ ate / an@@ ap@@ hy@@ l@@ act@@ ate responses ( Frequ@@ ency is not known ) .
not clinical data , based on the trials of safety sp@@ har@@ mac@@ ology , to acute , repeated and consistent tox@@ icity and to gen@@ oto@@ x@@ iz@@ ations , show no special risk for humans .
58 proph@@ y@@ la@@ xis for long term proph@@ y@@ la@@ xis of ble@@ eding in patients with severe hem@@ ophi@@ lia A should be given between 20 and 40 I.@@ E. from factor VIII per kg body weight in distance of 2 @-@ 3 days .
11 New@@ born ( at the age of 0 @-@ 1 month ) , inf@@ ants ( at the age of 1 month - 2 years ) , children ( at the age of 2 @-@ 12 years ) , adults ( at the age of 12 @-@ 16 years ) , adults ( over 16 years )
with clinical studies using A@@ DV@@ ATE to 145 children and adults 12 with diagnos@@ ed severe to moderate he@@ avi@@ ophi@@ lia A ( F@@ EST _ 2 % ) and prior exposure to 26 Ex@@ posi@@ tis ( 2,4 150 days ) , only one patient after 26 Ex@@ posi@@ tis ( 2.4 B.@@ E. in modified Be@@ thes@@ da approach ) .
62 How to other intra@@ ven@@ ous products was reported by the type of sensitive type , including an@@ ap@@ hy@@ l@@ act@@ ate / an@@ ap@@ hy@@ l@@ act@@ ate responses ( Frequ@@ ency is not known ) .
not clinical data , based on the trials of safety sp@@ har@@ mac@@ ology , to acute , repeated and consistent tox@@ icity and to gen@@ oto@@ x@@ iz@@ ations , show no special risk for humans .
Pharma@@ ko@@ vi@@ gil@@ ance system is to ensure that a pharmaceutical ko@@ vi@@ gil@@ ance system is described as described in the 1.1 of the capitalist system , as described in the 1.1 of the capitalist system , and that this system is located on the market in which the product remains on the market .
as in the CH@@ MP Directive for the risk of management of human medicine , these actuators should be submitted at the same time with the next peri@@ odic Safety Update report ( PS@@ BE ) .
• If new information is present , the influence on the valid safety regulations , the pharmaceutical ko@@ vi@@ gil@@ ance plan or measures for the risk of minim@@ izing the risk of actions may be increased by 60 days after an important event ( regarding the pharmaceu@@ ko@@ vi@@ gil@@ ance or in relation to a measure to the risk of minim@@ isation )
1 round cap with A@@ DV@@ OC 500 I.@@ E Oc@@ to@@ co@@ g al@@ fa , 1 through@@ put bottle with 5 ml of sterili@@ zed water for injection molding , 1 BA@@ X@@ J@@ ECT II medical product .
1 round cap with A@@ DV@@ OC 1000 I.@@ E Oc@@ to@@ co@@ g al@@ fa , 1 through@@ put bottle with 5 ml of sterili@@ zed water for injection molding , 1 BA@@ X@@ J@@ ECT II @-@ Medical product
special caution when using A@@ DV@@ OC is required , you should inform your doctor if you have recently been treated with factor VIII products , especially if you have developed inhib@@ itors .
these symptoms may occur early signs of an an@@ ap@@ hydr@@ ated sho@@ cks , which may also include the following symptoms : extreme vibration , loss of loss and extreme breathing protection .
in case of other medicines please inform your doctor if you have other drugs or have recently taken this medication even if it is not interested in prescription drugs .
your doctor will calculate your dose of A@@ DV@@ ICE ( in international units or I.@@ E. ) depending on your physical body and your body weight , and whether it is used for prevention or treatment of ble@@ eding .
patients , the factor @-@ VIII @-@ in@@ hi@@ bit@@ ory , if the expected factor of the factor in your plasma is not reached , or the blood pressure cannot be reached , or the blood pressure could not be achieved , this could be done in the development of factor VI@@ II@@ -
in conjunction with operations Cath@@ eter inf@@ ec@@ tions , lower number of red blood cells , sw@@ elling of gli@@ sh and joints , longer ble@@ eding according to the removal of a drainage , reduced factor @-@ VIII @-@ mirror and postoperative refra@@ ction .
rare side effects on the introduction of the drug using on the market was standardized over heavy and potential life @-@ threatening reactions ( An@@ ap@@ hydr@@ o ) and other allergi@@ c reactions ( see above ) .
inform your doctor if there are no side effects effects or if you notice side effects that are not included in this package .
Portugal Ba@@ x@@ ter Mé@@ di@@ co Far@@ mac@@ ê@@ u@@ tica L@@ da Sin@@ tra Business Park Z@@ ona Industrial , A@@ brun@@ hei@@ ra , Edi@@ f@@ í@@ cio 10 P @-@ 27@@ 10 @-@ 0@@ 89 Sin@@ tra Tel : + 351 21 925 5 00
instructions for the production of the solution • Not after the expi@@ ration date . • In BA@@ X@@ J@@ ECT II , when his ster@@ ile barrier was broken , his packaging is damaged or sign of a man@@ ip@@ ulation , as in the symbol
important note : • Not even given before you received the special training of your doctor or your hospital stay in order to check the product on Sch@@ web@@ masters or disc@@ ol@@ oration .
the solution should slowly rise up with an in@@ fusion speed that can be found in the patient , and 10 ml per minute will be administ@@ ered .
106 In case of ble@@ eding events should not fall under the specified plasma volume ( in % or I.@@ E. / ml ) .
these symptoms may occur early signs of an an@@ ap@@ hydr@@ ated sho@@ cks , which may also include the following symptoms : extreme vibration , loss of loss and extreme breathing protection .
patients , the factor @-@ VIII @-@ in@@ hi@@ bit@@ ory , if the expected factor of the factor in your plasma is not reached , or the blood pressure cannot be reached , or the blood pressure could not be achieved , this could be done in the development of factor VI@@ II@@ -
occasional side effects it@@ ching , increased swe@@ ating , heat ex@@ pe@@ eling , heat resistance , memory dys@@ function , ch@@ ills , vom@@ iting , vom@@ iting , vom@@ iting , vom@@ iting , irrit@@ ation , skin disorders , skin disorders , extreme skin
116 In case of blood pressure should the factor VIII @-@ mirror should not fall under the specified plasma volume ( in % or I.@@ E. / ml ) .
these symptoms may occur early signs of an an@@ ap@@ hydr@@ ated sho@@ cks , which may also include the following symptoms : extreme vibration , loss of loss and extreme breathing protection .
patients , the factor @-@ VIII @-@ in@@ hi@@ bit@@ ory , if the expected factor of the factor in your plasma is not reached , or the blood pressure cannot be reached , or the blood pressure could not be achieved , this could be done in the development of factor VI@@ II@@ -
126 In case of blood pressure should the factor VIII @-@ mirror should not fall under the specified plasma volume ( in % or I.@@ E. / ml ) .
these symptoms may occur early signs of an an@@ ap@@ hydr@@ ated sho@@ cks , which may also include the following symptoms : extreme vibration , loss of loss and extreme breathing protection .
patients , the factor @-@ VIII @-@ in@@ hi@@ bit@@ ory , if the expected factor of the factor in your plasma is not reached , or the blood pressure cannot be reached , or the blood pressure could not be achieved , this could be done in the development of factor VI@@ II@@ -
136 In case of blood pressure should the factor VIII @-@ mirror should not fall under the specified plasma volume ( in % or I.@@ E. / ml ) .
these symptoms may occur early signs of an an@@ ap@@ hydr@@ ated sho@@ cks , which may also include the following symptoms : extreme vibration , loss of loss and extreme breathing protection .
patients , the factor @-@ VIII @-@ in@@ hi@@ bit@@ ory , if the expected factor of the factor in your plasma is not reached , or the blood pressure cannot be reached , or the blood pressure could not be achieved , this could be done in the development of factor VI@@ II@@ -
146 In case of blood pressure should the factor VIII @-@ mirror should not fall under the specified plasma volume ( in % or I.@@ E. / ml ) .
these symptoms may occur early signs of an an@@ ap@@ hydr@@ ated sho@@ cks , which may also include the following symptoms : extreme vibration , loss of loss and extreme breathing protection .
patients , the factor @-@ VIII @-@ in@@ hi@@ bit@@ ory , if the expected factor of the factor in your plasma is not reached , or the blood pressure cannot be reached , or the blood pressure could not be achieved , this could be done in the development of factor VI@@ II@@ -
occasional side effects it@@ ching , increased swe@@ ating , heat ex@@ pe@@ eling , heat resistance , memory dys@@ function , ch@@ ills , vom@@ iting , vom@@ iting , vom@@ iting , vom@@ iting , irrit@@ ation , skin disorders , skin disorders , extreme skin
rare side effects on the introduction of the drug using on the market was standardized over heavy and potential life @-@ threatening reactions ( An@@ ap@@ hydr@@ o ) and other allergi@@ c reactions ( see above ) .
in case of blood pressure changes should not fall under the specified plasma volume ( in % or I.@@ E. / ml ) .
based on the first approval of the data , the CH@@ MP has been approved as a positive result , but in consideration that the safety profile has to be monitored for following reasons :
the CH@@ MP based on the base of security protocols of A@@ DV@@ OC , which is necessary for use of PS@@ UR@@ s all 6 months , decided to apply to a further extension procedures for 5 years .
December 2008 , Gen@@ du@@ x Molecular Diagnostics Limited ( CH@@ MP ) is officially admitted that the company expects his request to permit an authorization for an accident in the treatment of Li @-@ Frau@@ men@@ i cancer .
usually , however , the breast , the brain , the bone , or the wheat ( tissue , the other structures in the body and supports and relies ) of it .
this is a kind of virus , the gene@@ tically so changes that it can contribute to the cells of the body .
the virus has a &quot; A@@ den@@ o@@ virus &quot; which is so changes that it is no copies of themselves and thus can solve any infections due to humans .
C@@ ex@@ in would have to be heated directly into the tum@@ ours and to form the cancer cells to form normal p@@ 53 cells .
the p@@ 53 @-@ protein that is formed out of the human body of existing p@@ 53 gene is usually made to recovery damaged DNA and to kill the cells when the DNA is not restored .
li @-@ Women &apos;s cancer , in which the p@@ 53 gene is def@@ ective , the p@@ 53 @-@ protein is not correct , and the cancer cells can continue growing and share .
the company laid data from a study with a patient in the case of the li @-@ Frau@@ men@@ i cancer in the field of under@@ mining , in the bone and in the brain .
* Understand the competitive environment , the market &apos;s major players and leading brands ; * Use five @-@ year forecasts to assess how the market is predicted to develop .
based on the testing date , the CH@@ MP has a list of questions that sent to the company sent to the company .
according to the CH@@ MP , not sufficient , the injection of scal@@ e@@ in in Li @-@ Frau@@ men@@ i tum@@ ors benefits advantages for patients .
the committee also participated in the processing of the medicine by using in the body , the way to administration and security of the drug .
in addition , the company has not sufficiently proved to be manufactured in reliable way and that it is neither for the environment nor for people who come in close contact with the patient .
the CH@@ MP did not assume any of the consequences for patients who are currently working on clinical studies or &quot; Comp@@ as@@ sion@@ ate Use &quot; programs .
&quot; modified drug @-@ release &quot; means that the tablets are so summar@@ ized that one of the effective ingredients are immediately released immediately and the other slow down to some hours .
Aer@@ ina@@ ze is used to treat the symptoms of seasonal allergi@@ c Rhin@@ i@@ tis ( hypo@@ cris@@ y infections caused by an all@@ ergy against P@@ ollen ) in patients with nas@@ al abrasive sw@@ elling ( pet@@ ri@@ fu@@ gal nose ) .
for adults and adol@@ esc@@ ents from 12 years , the recommended dose of Aer@@ ina@@ ze twice a tablet that should be taken completely with a glass of water or without food .
the duration of the treatment should be as short as possible , as soon as the symptoms , especially the sw@@ elling of the nas@@ al membrane ( mu@@ zzle nose ) .
a treatment of more than 10 days is not recommended because the effects of the medicine can be carried out by cr@@ un@@ ing the nose .
most important factors were the changes of the heavy tissue of the hay fever which was reported by the patients before the treatment and during the 15 @-@ day treatment .
during the study , patients had their symptoms all 12 hours in a diary and measured with a standard sk@@ ala , like hard the symptoms in the last 12 hours .
in case of all hypo@@ cris@@ y f@@ y@@ mp@@ s apart from the con@@ sti@@ p@@ ation of the nose reported about 4@@ 6.0 % compared to a decrease of 35.@@ 9 % compared to the patients &apos; pseu@@ do@@ eph@@ ed@@ rin alone .
when only the sw@@ elling of the nas@@ al loops was considered , the patients showed a reduction of the symptoms of 37.@@ 4 % compared to 26.@@ 7 % compared with the patients who took des@@ lor@@ ate themselves alone .
the most common side effects of aer@@ ina@@ ze ( observed at 1 to 10 of 100 patients ) , Mund@@ enz@@ y@@ otic hyper@@ activity ( hel@@ pl@@ ess@@ ness ) , dent@@ ure , head@@ aches , ti@@ red@@ ness , fatigue , in@@ som@@ nia ( sleep disorders ) , som@@ nia , disorders and nerv@@ ousness .
aer@@ ina@@ ze may have to be sensitive ( allergi@@ c ) to patients who may have sensitive ( allergi@@ c ) against dis@@ lor@@ ries , pseu@@ do@@ eph@@ ed@@ rin or one of other ingredients which are not applied to treatment of allergi@@ es ) , not applied .
aer@@ os@@ ol may also be applied to patients with hyper@@ ton@@ ic ( hyper@@ ton@@ ic pressure ) , hyper@@ thy@@ ro@@ sis ( hyper@@ ton@@ ic pressure ) , hyper@@ thy@@ ro@@ sis ( hyper@@ ton@@ ic pressure ) , hyper@@ thy@@ ro@@ sis ( hyper@@ ton@@ ic pressure ) , hyper@@ thy@@ ro@@ sis ( hyper@@ ton@@ ic pressure ) , hyper@@ thy@@ ro@@ sis ( hyper@@ ton@@ ic blood pressure ) , or a risk of corrosion inhib@@ itors .
on 30 July 2007 , the European Commission shared the European Commission to provide an authorization for the transport of Aer@@ ina@@ ze in the entire European Union .
the tablets can be taken with a glass of water , however , however , in the whole , without breaking them , break or decrease .
aer@@ os@@ ol should be applied due to the lack of data for un@@ distur@@ bed and eff@@ ic@@ acy ( see Section 5.1 ) not to be applied to children under 12 years .
the duration of the application is as short as possible and should not be continued .
it is recommended to limit the use of the duration of ten days as for long term use the activity of pseu@@ do@@ eph@@ ed@@ rin with time .
after leng@@ th@@ ening of the sw@@ elling of the mu@@ ff@@ les in the upper resp@@ ir@@ atory , the treatment for need to be continued with des@@ lor@@ ries as mon@@ otherapy .
the drug may also be treated with patients who are treated with a mon@@ o@@ am@@ ino@@ xi@@ d@@ ase ( MA@@ O ) inhib@@ itors in the 2 weeks after end of such therapy .
this is due to the alph@@ am@@ im@@ al activity with combined application of pseu@@ do@@ eph@@ ed@@ rin , Per@@ g@@ oli@@ d , Per@@ g@@ oli@@ d , ra@@ yon , D@@ ih@@ y@@ dro@@ g@@ amine , phen@@ y@@ le@@ op@@ ol@@ amine , phen@@ y@@ met@@ aph@@ ine , mac@@ y@@ met@@ az@@ olin , we@@ y@@ met@@ az@@ olin , nap@@ kin , etc . ) .
the safety and effectiveness of this combination therapy were not tested for this patient &apos;s patients .
the safety and the effectiveness of Aer@@ ina@@ ze were not checked for patients with kidney or liver dys@@ function .
patients must be informed about the treatment of a hyper@@ ton@@ ic or t@@ ungsten car@@ e@@ car@@ ing or of pal@@ ms , heart rhythm or other neuro@@ logic symptoms , exercise treatments or other neuro@@ logic symptoms ( such as head@@ aches or a strengthening of head@@ aches ) must be set .
for patients with hyper@@ ton@@ al treatment of patients with hyper@@ ton@@ al defici@@ ency , patients with hyper@@ tension • patients with hyper@@ tension • patients with a M@@ yo@@ cardi@@ al inf@@ ra in the An@@ am@@ n@@ ese , Diabetes mel@@ lit@@ us , bladder , or bron@@ ch@@ os@@ pas@@ m in the An@@ am@@ n@@ ese .
aer@@ ina@@ ze is at least 48 hours prior to the execution of mat@@ ological tests , since anti@@ hist@@ amine or positive reactions to indicators for skin reactions occur .
in the context of clinical trials with deser@@ lor@@ enz@@ y@@ cin , where Er@@ y@@ thro@@ my@@ cin or K@@ eto@@ con@@ az@@ ol have been administ@@ ered , however , no clinical impact effects or changes of plasma concentration .
with the results of the psych@@ om@@ ot@@ or@@ ical tests , there were no significant differences between the dis@@ lor@@ ries and with plac@@ ebo @-@ treated patients , regardless of whether they have been taken alone or with alcohol .
for the Met@@ aboli@@ sm of Des@@ lor@@ enz@@ yme responsible enz@@ yme was not identified so that the effects of other medicines can not be excluded .
the L@@ P@@ 2@@ D@@ 6 has not been hem@@ med in @-@ vivo CY@@ P@@ 3@@ A4 , and in @-@ vitro studies , the medicine CY@@ P@@ 2@@ D@@ 6 is not an inhib@@ itor of the P @-@ gly@@ cop@@ rot@@ eins .
the sus@@ cep@@ ti@@ bility of the application of Aer@@ ina@@ ze during pregnancy is not secured , experiences from a large number of affected civilians , but no increase in the frequency of ab@@ norm@@ alities during the normal population .
there are re@@ productive studies on animals not always be transferred to people and to be applied to the vas@@ o@@ con@@ stri@@ cken properties of pseu@@ do@@ eph@@ ed@@ rin should not be applied to pregnancy .
however , patients should be aware that it can occur in very rare cases where im@@ plant@@ ation of transportation or the ability to serve machines can lead to machines .
symptoms can vary between a Z@@ NS depression , Ap@@ nea , decrease mental attention , cy@@ an@@ osis , com@@ a , cardiovascular disease ( sle@@ e@@ ess@@ ness , hal@@ lu@@ cin@@ ations , stair@@ cases ) with possible let@@ tering .
head@@ aches , anxiety , fri@@ ghtening , muscle tissue and increased muscle tension , eu@@ ph@@ ony , vom@@ iting , vom@@ iting , vom@@ iting , vom@@ iting , fem@@ dom , t@@ inn@@ itus , optic dys@@ function and hyper@@ ton@@ ic or hyp@@ ot@@ ony or hyp@@ ot@@ onie .
a zinc stimulation is especially likely to be most probably , as A@@ tro@@ pin typical symptoms ( oral tum@@ bler , p@@ up@@ ill@@ en@@ rigid and di@@ lat@@ ation , hyper@@ ther@@ m and g@@ astro@@ intestinal symptoms ) .
this close both the inhib@@ itor of pro@@ vision@@ ary cy@@ tok@@ ines such as IL @-@ 4 , IL @-@ 6 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 and IL @-@ 13 .
during a single dose study with adults showed dis@@ lor@@ at@@ adin 5 mg no impact on standard measurements including the subjective fatigue or the tasks that are connected with the flies .
in controlled clinical studies , the recommended dosage of 5 mg daily does not contain increased frequency of hits in comparison to plac@@ ebo .
the or@@ ale application of pseu@@ do@@ eph@@ ed@@ rin in the recommended dosage can be found in the recommended dosage as an increase of blood pressure , a Tach@@ y@@ car@@ e@@ or or manifest@@ ations of a Z@@ NS @-@ ar@@ ous@@ al .
we took 0.0@@ 248 patients at the age of 12 and 78 years with seasonal allergi@@ c Rhin@@ i@@ tis .
in both studies the hist@@ opath@@ ological effectiveness of Aer@@ ina@@ ze tablets , determined by the total period for the symptoms ( except nas@@ al abrasive layer ) , significantly higher than under a mon@@ otherapy with pseu@@ do@@ vi@@ gor@@ rin treatment period .
the effectiveness of Aer@@ os@@ ze tablets in terms of the sw@@ elling effect , determined by the nas@@ al grinding result , was significantly higher than under a mon@@ otherapy with dis@@ lor@@ ries using the 2 @-@ stroke treatment period .
the eff@@ ic@@ acy of Aer@@ ina@@ ze tablets appeared in regard to sex , age or eth@@ ni@@ otic plants , not significant differences .
in the context of a single dose study to Phar@@ mak@@ ok@@ ine@@ tics of Aer@@ ina@@ ze is now proven to be proven within 30 minutes after the administration in plasma .
after the per@@ gol@@ dy application from Aer@@ ina@@ ze on healthy subjects over 14 days the flow regulator of Des@@ cart@@ at@@ eurs , 3 @-@ hydro@@ xy@@ des@@ lor@@ at@@ eurs and pseu@@ do@@ eph@@ ed@@ rin to day 10 are reached .
in a phar@@ ok@@ ok@@ ine@@ tical multi@@ functional dos@@ es study that has been performed with the form@@ ulation of healthy adult patients , the four patients dis@@ lor@@ ries are poor@@ ly understood .
an components interest study shows that the exposure ( C@@ max and AU@@ C ) of pseu@@ do@@ eph@@ ed@@ rin cut is equivalent to exposure to the dosage of a aer@@ ina@@ ze tray .
based on the conventional studies on safety sp@@ har@@ mac@@ ology , tox@@ icity and re@@ productive data associated with des@@ lor@@ ulation , however , are no particular haz@@ ards for humans .
the combination is no greater tox@@ icity than their individual elements , and the observed effects were in general in relation to the constitu@@ ent pseu@@ do@@ eph@@ ony .
in re@@ productive studies , the combination of Lor@@ at@@ adin / pseu@@ do@@ eph@@ ed@@ rin results in a dosage of up to 150 mg / kg / day and an rab@@ bit in a dose of up to 120 mg / kg / day not ter@@ at@@ ogen .
March 2007 and module 1.@@ 8.1 of the author@@ isation contract , pharmaceu@@ ko@@ vi@@ gil@@ ance system is established and works before and during the product on the market .
anti @-@ hist@@ amine apply to the reduction of allergi@@ c symptoms by removing that hist@@ amine , a physical body can lead to its effect .
• Aer@@ on@@ ze tablets , which occur in connection with seasonal allergi@@ c Rhin@@ i@@ tis ( hypo@@ cris@@ p ) , like riv@@ eting , running or ju@@ ck@@ ling nose and ju@@ icy eyes at equal load of the nose .
20 Under the certain circumstances you may be especially sensitive to the mu@@ c@@ ous medication in pseu@@ do@@ eph@@ ric surgery , which is included in this medicine .
( refra@@ ct@@ omy ) , a sten@@ ography of Mag@@ en@@ or ( col@@ ony ) , a brass section of the magn@@ ets , a brass lob@@ ster clasp , bron@@ ch@@ os@@ pas@@ es in the hospital history ( resp@@ ir@@ atory surgery ) , a pro@@ state intervention or problems with the liver that have kid@@ neys or bladder .
inform your doctor if you are diagnos@@ ed under the application of Aer@@ ina@@ ze the following symptoms or diseases : • Blu@@ ff@@ och@@ pressure • heart rhythm • heart rhythm • heart pain and head@@ aches or a strengthening of the head@@ aches .
taking a doctor or pharmac@@ ies with other medicines please inform your doctor or pharmac@@ ist if you have other drugs or have recently taken this medication even if it is not authorised to prescription drugs .
transportation of transport and the use of machines with application in the recommended dosage is not to be expected that Aer@@ ina@@ ze leads to ben@@ ign or improving the attention .
if you have taken a bigger amount of Aer@@ ina@@ ze when you should be taken to your doctor or pharmac@@ ist if you have taken a bigger amount of Aer@@ ina@@ ze .
if you forget the intake of aer@@ ina@@ ze you have forgotten if you forget to take a dose in time , get the application as soon as possible and turn the next dose at the planned time .
please inform your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
heart disease , car@@ el@@ ess@@ ness with multip@@ lier physical activity , oral tum@@ ul@@ ness , sti@@ p@@ pl@@ ess@@ ness , ju@@ ices , sugar in ur@@ ine , increased blood sugar values , thir@@ st , ti@@ red@@ ness , sleep disorders , nerv@@ ousness , nerv@@ ousness , nerv@@ ousness , irrit@@ ation and depression .
heart rate or heart rhythm , prolifer@@ ation , skin disorders , skin disorders , skin disorders , stomach ble@@ eding , stomach pain , stomach pain , stomach pain , stomach pain , stomach pain , vom@@ iting , vom@@ iting , vom@@ iting , anxiety , anxiety , anxiety , anxiety , anxiety , anxiety , anxiety .
after the launch of Des@@ ig@@ at@@ ula was very rare about cases of heavy @-@ allergi@@ c reactions ( resp@@ ir@@ atory reactions ( resp@@ ir@@ atory breathing , it@@ ching , it@@ ching and sw@@ elling ) or skin care .
about cases of heart attack , heart disease , stomach p@@ ains , vom@@ iting , vom@@ iting , sm@@ lu@@ cin@@ ations , s@@ laugh@@ tering , dys@@ function , dys@@ function , dys@@ function , dys@@ function , dys@@ function of a liver cir@@ rho@@ sis and over cases of rich@@ y cir@@ rho@@ sis , is also very rare .
it is available as 5 mg tablet , 5 MG@@ - Ly@@ ophi@@ li@@ ss ( tablets , 2.@@ mg / ml @-@ mel@@ ight ) , 0.5 mg / ml @-@ sy@@ rup and as 0.5 mg / ml solution for inser@@ tion .
for children aged up to five years the dose is 1,@@ 25 mg once daily , which are in the form of 2.5 ml sy@@ rup .
for children aged six to eleven years the dose is 2,5 mg once daily , either in form of 5 ml sy@@ rup .
A@@ eri@@ us was examined in total eight studies with about 4 800 adults and adol@@ esc@@ ents with allergi@@ c Rhin@@ i@@ tis ( including four studies in seasonal Rhin@@ i@@ tis and two studies in patients who had also studied As@@ th@@ ma ) .
the eff@@ ic@@ acy was measured by changing the alter@@ ation of the symptoms ( Ju@@ ck@@ rei@@ z , number and size of the quad@@ rup@@ tible , and the capacity of the sleeping and the performance on days ) and after six @-@ week treatment .
further studies have been laid in order to reflect that the body of the Sir@@ up , the solution to take and melt the mel@@ ting of the same way as the tablets and the application of children un@@ think@@ able .
in allergi@@ c Rhin@@ i@@ tis , when the results of all studies were taken to a average decrease of the symptoms ( symptoms of symptoms ) by 25 to 32 % compared to the decrease of 12 to 26 % in comparison to decrease of 12 to 26 % in comparison to the patients who had a plac@@ ebo .
in the two studies in Ur@@ tik@@ aria was the decrease of the symptoms after six @-@ weeks treatment with A@@ eri@@ us 58 and 67 % compared with plac@@ ebo @-@ treated patients .
A@@ eri@@ us cannot be applied to patients who might be sensitive ( allergi@@ c ) against dis@@ lor@@ ries , Lor@@ at@@ ona or other ingredients .
&quot; &quot; &quot; January 2001 &quot; &quot; &quot; &quot; European Commission shared the European Commission &quot; &quot; &quot; &quot; Tax SP Europe has issued an authorization for the transport of A@@ eri@@ us in the entire European Union . &quot; &quot; &quot;
a tablet once daily , with one or without a meal , to increase the symptoms of allergi@@ c Rhin@@ i@@ tis ( including inter@@ rup@@ ture and di@@ still@@ ate all@@ erg@@ ical Rhin@@ i@@ tis ) and Ur@@ tic@@ aria ( see section 5.1 ) .
there are limited experience from clinical studies on the application of des@@ lor@@ ries , young people from 12 to 17 years ( see Sec@@ ond@@ ary 4.8 and 5.1 ) .
the treatment of inter@@ acting all@@ erg@@ ic Rhin@@ i@@ tis ( occurr@@ ence of symptoms of less than 4 days per week or less than 4 weeks ) should be done according to the result of previous treatment .
in the pers@@ ist of allergi@@ c Rhin@@ i@@ tis ( occurr@@ ence of symptoms to 4 or more days per week and more than 4 weeks ) can be recommended for the patients during the allergi@@ c time .
the relevant environmental impacts were observed in the context of clinical studies with dis@@ lor@@ ries and K@@ eto@@ con@@ az@@ ol in addition ( see section 5.1 ) .
in a clinical research study at the early intake of A@@ eri@@ us and alcohol the powerful impact of alcohol is not increased ( see section 5.1 ) .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; the patients should consider that it can lead to a very rare cases , which can lead to a imp@@ air@@ ment of transportation or the ability to serve machines . &quot; &quot; &quot;
clinical studies in different indications , including allergi@@ c Rhin@@ i@@ tis and Chr@@ onic Idi@@ opath@@ ic Ur@@ tic@@ aria , were reported in the recommended dose of 5 mg daily 3 % more side effects of patients with A@@ eri@@ us reports that patients were treated with plac@@ ebo .
the most common side effects that are more common than in plac@@ ebo , ti@@ red@@ ness ( 1.2 % ) , oral tum@@ ours ( 0.8 % ) and head@@ aches ( 0.@@ 6 % ) .
patients from 12 to 17 years has been the most common side effects of 12 to 17 years ago , the most common side effect of head@@ aches , which had been treated with des@@ lor@@ ries , and at 6.@@ 9 % of the patients who were treated with plac@@ ebo .
in a multi @-@ dose study conducted by up to 45 mg L@@ lor@@ at@@ adin ( nine clinical dose ) were observed , no clinical effects were observed .
this includes the inhib@@ itor of pro@@ vision@@ ary cy@@ tok@@ ines such as IL @-@ 4 , IL @-@ 6 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 , IL @-@ 8 and IL @-@ 13 .
in the context of a clinical trial with multi @-@ stroke , in the dis@@ lor@@ ries , in the dosage of up to 20 mg daily , no statisti@@ cally significant significant clinical cardiovascular effect was described .
in a clinical research study , in the deser@@ tification , in a dose of 45 mg daily ( the nin@@ ety of clinical dose ) , showed no extension of the Q@@ t@@ c interval .
during a single dos@@ is@@ - study with adults showed dis@@ lor@@ at@@ adin 5 mg no impact on standard measurement sizes , including the subjective fatigue or the tasks that are connected with the flies .
patients with allergi@@ c Rhin@@ i@@ tis was effective in the reduction of symptoms such as Ni@@ ese , nas@@ al secre@@ tion and it@@ ching of the nose , it@@ ching flow and cl@@ ause of the eyes and it@@ ching of the eyes as well as Ju@@ ck@@ rei@@ z at the pal@@ ate .
in addition to the established classification of seasonal and per@@ enni@@ al , allergi@@ c Rhin@@ i@@ tis can be exposed to an integral Rhin@@ i@@ tis and Per@@ is@@ tic@@ ular Rhin@@ i@@ tis .
inter@@ facing Rhin@@ i@@ tis will be defined as a occurr@@ ence of symptoms of less than 4 days per week or less than 4 weeks .
Per@@ sian Rhin@@ i@@ tis will be defined as a occurr@@ ence of symptoms to 4 or more days per week and more than 4 weeks .
as the result of the overall quality of the question@@ n@@ aires of Rhin@@ o con@@ gen@@ ital tra@@ ffi@@ tis , A@@ eri@@ us effectively decreased by seasonal fluctu@@ ations .
chronic Idi@@ opath@@ ic Ur@@ tic@@ aria was investigated for further forms of ur@@ tium , since the underlying path@@ ophysi@@ ology is un@@ aware of the underlying path@@ ology in the different forms and chronic pain .
since the hist@@ am@@ infections is expected to treat a urs@@ or factor in all ur@@ inary disorders , is expected that deser@@ ters can also be confirmed in other forms of ur@@ ine ur@@ ine in other forms of ur@@ ine symptoms ; this is confirmed by the recommendations of clinical guidelines .
in two plac@@ ebo @-@ controlled trials over 6 weeks in patients with Chr@@ onic Idi@@ opath@@ ic Ur@@ tic@@ aria was effective in the improvement of Pr@@ ur@@ itus and the decrease of size and number of squares at the end of the first d@@ os@@ is@@ tical interval .
as in other studies with anti@@ hist@@ amine , the minority of the patients who re@@ lie@@ ve the patients who are not based on anti@@ hist@@ amine , from the study .
an improvement of the ju@@ ck@@ ons to more than 50 % was treated by 55 % of the patients treated patients compared to 19 % of plac@@ ebo @-@ treated patients .
treatment with A@@ eri@@ us decreased the distur@@ b@@ ance of the sleep and the wax is caused by a 4 @-@ point rating to the evaluation of these variables .
in an Ph@@ armac@@ ok@@ ine@@ tics study , in which patients are comparable to patients with the general seasonal fluctu@@ ations of Rhin@@ i@@ tis population , 4 % of patients had a higher concentration of deser@@ lor@@ ries .
there are no restrictions for a clinical trials after once daily use of Des@@ lor@@ at@@ eurs ( 5@@ - 20 mg ) for 14 days .
for the Met@@ aboli@@ sm of Des@@ lor@@ enz@@ i &apos;s enz@@ yme was not identified , so that the impacts of other medicines cannot be excluded .
the L@@ P@@ 2@@ D@@ 6 inhib@@ itor did not show CY@@ P@@ 3@@ A4 and in @-@ vitro studies that the medicine was CY@@ P@@ 2@@ D@@ 6 and neither a sub@@ strate an in@@ hibition of the P @-@ gly@@ cop@@ rot@@ eins .
in a single dos@@ is@@ tive study with des@@ car@@ at@@ ants in a dose of 7.5 mg , meals ( f@@ etal , cal@@ ori@@ ental breakfast ) are not included in the availability of des@@ lor@@ ries .
with dis@@ lor@@ ries and Lor@@ at@@ adin especially clinical trials , the impact of Des@@ cart@@ at@@ athle@@ tics , no qualit@@ atively or quantit@@ atively affect the tox@@ icity of des@@ lor@@ ries and by Lor@@ at@@ adin .
based on conventional studies to safety sp@@ har@@ mac@@ ology , tox@@ icity , and re@@ productive data , the pre @-@ clinical data can also recognise the pre @-@ clinical data with des@@ lor@@ ries , no special d@@ angers for humans .
color@@ box film ( contains L@@ act@@ ose @-@ Mon@@ oh@@ y@@ dra@@ t , Hy@@ pro@@ m@@ ell@@ ose , titanium dioxide , Macro@@ er@@ l 400 , In@@ dig@@ oc@@ ar@@ min ( E 132 ) ) , color@@ less film ( contains Hy@@ pro@@ m@@ ell@@ ose , Macro@@ er@@ l 400 ) , Car@@ amel wax , Geb@@ ru@@ ff wax .
A@@ eri@@ us can be taken independent of the meals , reducing the symptoms of allergi@@ c Rhin@@ i@@ tis ( including inter@@ rup@@ ture and di@@ arr@@ r@@ arian Rhin@@ i@@ tis ) and Ur@@ tic@@ aria ( see section 5.1 ) .
the def@@ ective doctor should be aware that most cases of Rhin@@ i@@ tis can be caused by children under 2 years ( see Section 4.4 ) and that no data is detected , which support a treatment of inf@@ ec@@ ous Rhin@@ i@@ tis with A@@ eri@@ us .
in addition to the out@@ lining of the resp@@ ir@@ atory infections or anatom@@ ical an@@ om@@ ers , diagnosis , treatment and appropriate laboratory tests have to play a role .
for about 6 % of adults and children between 2 and 11 years ago , des@@ lor@@ ries wear and get a higher sub@@ st@@ amping loads ( see Section 5.2 ) .
the requirements of A@@ eri@@ us Sir@@ up in children between 2 and 11 years are restricted to children between 2 and 11 years , are identical with the children of children .
this medicine contains Sac@@ char@@ ose and Sor@@ bit@@ ol ; therefore , patients should not take care of any fru@@ ct@@ ose int@@ oler@@ ance , glu@@ cose @-@ Gal@@ act@@ ose absorption or a Sac@@ ri@@ ase I@@ som@@ alt@@ or in@@ suffici@@ ency of this medicine .
clinical met@@ abolic effects were observed in the context of clinical studies with A@@ eri@@ us tablets as part of which Er@@ y@@ thro@@ my@@ cin or K@@ eto@@ con@@ az@@ ol ( see section 5.1 ) .
in a clinical research study at the early intake of A@@ eri@@ us tablets and alcohol the powerful impact of alcohol is not reinforced ( see section 5.1 ) .
the total amount of side @-@ effects of children between 2 and 11 years were similar to A@@ eri@@ us Sy@@ rup Group , similar to plac@@ ebo @-@ group .
clinical studies with adults and adol@@ esc@@ ents in different indications , including allergi@@ c Rhin@@ i@@ tis and Chr@@ onic Idi@@ opath@@ ic Ur@@ tic@@ aria , were reported in the recommended dose of 3 % more side effects of patients with A@@ eri@@ us reports that patients were treated with plac@@ ebo .
in a multi @-@ dose study on adults and young people who have been administ@@ ered up to 45 mg L@@ lor@@ at@@ adin ( nine clinical dose ) were observed , no clinical effects were observed .
children aged between 1 and 11 years that came to a anti@@ hist@@ amine therapy in question , a daily des@@ car@@ at@@ op@@ in@@ dose of 1,@@ 25 mg ( at the age between 1 and 5 years ) or 2.5 mg ( age between 6 and 11 years ) .
since the course of allergi@@ c Rhin@@ i@@ tis / Chr@@ onic Idi@@ opath@@ ic Ur@@ tik@@ aria and the profile of deser@@ lor@@ ries , adults and children can be extra@@ cted in adults and children to extra care of the children population in adults .
in the context of a clinical study with multi @-@ professional study on adults and adol@@ esc@@ ents , in the deser@@ tification , was applied after 14 days after 14 days , no statistical significant significant clinical cardiovascular effect was described .
in a clinical research study on adults and adol@@ esc@@ ents , in the deser@@ tification , in a dose of 45 mg daily ( the nin@@ ety of clinical dose ) , showed no extension of the Q@@ t@@ c Inter@@ v@@ ae .
in controlled clinical studies , the recommended dosage of 5 mg daily for adults and adol@@ esc@@ ents no increased frequency of hits of hits . compared to plac@@ ebo .
during a single daily dose of 7.5 mg led A@@ eri@@ us tablets of adults and adol@@ esc@@ ents in clinical studies were no imp@@ air@@ ment of psych@@ om@@ ot@@ echnology .
in clinical pharmac@@ ological studies of adults , it came to increase alcohol abuse neither to a strengthening of alcohol @-@ induced power failure .
in adult and adol@@ escent patients with allergi@@ c Rhin@@ i@@ tis , A@@ eri@@ us tablets have been effective in the reduction of symptoms such as Ni@@ ese , nas@@ al secre@@ tion and it@@ ching of the nose , it@@ ching flow and cl@@ ause of the eyes as well as Ju@@ ck@@ rei@@ z at the pal@@ ate .
as the result of the overall quality of the question@@ n@@ aires of Rhin@@ o con@@ gen@@ ital tra@@ ffi@@ tis , A@@ eri@@ us tablets effectively vary by seasonal allergi@@ c pills effectively by seasonal allergi@@ c Rhin@@ i@@ tis .
in two plac@@ ebo @-@ controlled trials over 6 weeks in patients with Chr@@ onic Idi@@ opath@@ ic Ur@@ tic@@ aria was effective in the improvement of Pr@@ ur@@ itus and the decrease of size and number of squares at the end of the first d@@ os@@ is@@ tical interval .
the spread of this limited edition is comparable to adults ( 6 % ) and children between 2 and 11 years ( 6 % ) and children between 2 and 11 years ( 6 % adults , 16 % children ) as in Kau@@ k@@ asi@@ ern ( 2 % adults , 3 % children ) .
similar pharmac@@ ological parameters were observed in a pharmac@@ ological basis for children between 2 and 11 years with allergi@@ c reactions to children between 2 and 11 years .
the load ( AU@@ C ) is approximately 6@@ times higher and the C@@ max approximately 3 to 6 times higher and the C@@ max approximately 3 to 4@@ times higher than 120 hours .
there are no restrictions for a clinical evidence based on des@@ lor@@ enz@@ i ( 5@@ - 20 mg ) for adults and adol@@ esc@@ ents .
12 In various single dose studies showed that AU@@ C and C@@ max values of Des@@ lor@@ at@@ inate patients were comparable to the recommended dos@@ es , of adults who were dis@@ lor@@ at@@ ened sy@@ rup in a dose of 5 mg .
for the Met@@ aboli@@ sm of Des@@ lor@@ enz@@ i &apos;s enz@@ yme was not identified , so that the effects of other medicines can not be excluded .
A@@ eri@@ us Sir@@ up is offered in type III bra@@ in@@ las@@ ers with cri@@ mp poly@@ prop@@ ylen , with 30 , 50 , 60 , 120 , 120 , 150 , 225 and 300 ml .
equipped with a rigid , transparent pol@@ ysty@@ rene measuring spo@@ ons , cali@@ br@@ ated with 2.5 ml and 5 ml or with a application with sc@@ allo@@ ys of 2.5 ml and 5 ml ( only for 150 ml bottle ) .
a dose of A@@ eri@@ us Ly@@ bia must take a daily dose in the mouth to remove the symptoms of allergi@@ c Rhin@@ i@@ tis ( including inter@@ rup@@ ture and di@@ arr@@ r@@ arian Rhin@@ i@@ tis ) and Ur@@ tic@@ aria ( see section 5.1 ) .
immediately prior to the application , the bli@@ ster must be carefully open and the dose of the Ly@@ dia is taken to remove it without damage .
clinical met@@ abolic effects were not detected in clinical studies with A@@ eri@@ us tablets as part of the clinical studies using A@@ eri@@ us tablets or K@@ eto@@ con@@ az@@ ol ( see section 5.1 ) .
clinical studies in different indications , including allergi@@ c Rhin@@ i@@ tis and Chr@@ onic Idi@@ opath@@ ic Ur@@ tic@@ aria , were reported in the recommended dose of 5 mg daily 3 % more side effects in patients with A@@ eri@@ us tablets were reported in patients with plac@@ ebo .
in a multi @-@ dose study , which were applied to 45 mg dis@@ lor@@ at@@ adin ( nine clinical dose ) were applied , no clinical effects were observed .
in two single dose studies , A@@ eri@@ us Ly@@ ophi@@ li@@ ss would be well toler@@ ated ; this was documented by clinical laboratory results , medical exam@@ inations , vit@@ ality and EC@@ G interaction data .
in the context of a clinical trial with multi @-@ stroke , in the dis@@ lor@@ ries , in the dosage of up to 20 mg daily , no statistical significant significant clinical cardiovascular effect was described .
in a clinical research study , in the deser@@ tification , in a dose of 45 mg daily ( the nin@@ ety of clinical dose ) , showed no extension of the Q@@ t@@ c interval .
in controlled clinical studies , the recommended dosage of 5 mg daily does not contain increased frequency of hits in comparison to plac@@ ebo .
during a 17 individual dose study with adults showed dis@@ lor@@ ries , 5 mg no influence on standard measurements including the subjective fatigue or the tasks that are connected with the flies .
patients with allergi@@ c Rhin@@ i@@ tis were effective in the reduction of symptoms such as Ni@@ ese , nas@@ al secre@@ tion and it@@ ching of the nose , it@@ ching flow and cl@@ ause of the eyes and it@@ ching of the eyes as well as Ju@@ ck@@ rei@@ z at the pal@@ ate .
as the result of the overall quality of the question@@ n@@ aires of Rhin@@ o con@@ gen@@ ital tra@@ ffi@@ tis , A@@ eri@@ us effectively decreased by seasonal fluctu@@ ations .
18 In an Ph@@ armac@@ ok@@ ine@@ tics study , in which patients are comparable to patients with the general seasonal fluctu@@ ations of Rhin@@ i@@ tis population , 4 % of patients had a higher concentration of deser@@ lor@@ ries .
food has no significant influence on AU@@ C and C@@ max by A@@ eri@@ us Ly@@ ophi@@ li@@ ss , while food T@@ max of Des@@ can@@ at@@ ants from 2.5 to 4 hours and T@@ max of 3 @-@ OH @-@ deser@@ lor@@ ries from 4 to 6 hours .
gel@@ atine Mann@@ it@@ ol A@@ symmet@@ am ( E 9@@ 51 ) Pol@@ ac@@ ri@@ lin @-@ Kali@@ um Op@@ at@@ int Red ( E 9@@ 51 ) and Hy@@ pro@@ m@@ ell@@ ose ( E 464 ) and Hy@@ pro@@ m@@ ell@@ ose ( E 464 ) ) aroma T@@ utti @-@ Fr@@ utti water @-@ free Cit@@ ron@@ ens@@ ic acid
a A@@ eri@@ us 2.5 mg mel@@ ting once daily in the mouth to put the symptoms of allergi@@ c Rhin@@ i@@ tis ( including inter@@ rup@@ ture and di@@ arr@@ r@@ arian Rhin@@ i@@ tis ) and Ur@@ tic@@ aria ( see section 5.1 ) .
two A@@ eri@@ us 2.5 mg mel@@ ting once daily in the mouth , put the symptoms of allergi@@ c Rhin@@ i@@ tis ( including inter@@ rup@@ ture and di@@ arr@@ r@@ arian Rhin@@ i@@ tis ) and Ur@@ tic@@ aria ( see section 5.1 ) .
there are limited experience from clinical studies on the application of des@@ lor@@ ries , young people from 12 to 17 years ( see Sec@@ ond@@ ary 4.8 and 5.1 ) .
immediately prior to the application , the bli@@ ster must be carefully open and the dose of mel@@ ting furnace is removed without having to be damaged .
effectiveness and incorrect degra@@ dation of A@@ eri@@ us 2.5 mg enam@@ elled on the treatment of children under 6 years of age have not been proved .
the total limit of side effects between the deser@@ lor@@ at@@ ad@@ ine Sir@@ up@@ - and the plac@@ eb@@ og@@ group was equal and wich was not significantly improved by an adult patient .
during the recommended dose , A@@ eri@@ us melt enam@@ elled as bio@@ fuel are equivalent to the A@@ eri@@ us 5 mg conventional tablet form@@ ulation and the A@@ eri@@ us 5 mg Ly@@ bia .
in the context of a clinical trial with multi @-@ stroke , in the dis@@ lor@@ ries , in the dosage of up to 20 mg daily , there was no statisti@@ cally significant or clinical trial
during a single dose study with adults showed dis@@ lor@@ at@@ adin 5 mg no impact on standard measurements including the subjective fatigue or the tasks that are connected with the flies .
the spread of this poor@@ ly quantitative phenomenon was comparable to adult ( 6 % ) and pap@@ al patients between 2 and 11 years ( 6 % ) , and under the black ( adults 18 % , children 16 % ) , the safety profile of this patient was not specified by the general population .
the wording strengthens the credibility of your review . we kindly ask you to take about ten minutes to take part in this Online Survey . online Survey
A@@ eri@@ us 2.5 mg tablets were not studied in Pap@@ di@@ at@@ ric patients in connection with the D@@ os@@ is@@ in@@ ven@@ tive studies in children but pharmac@@ ological data for A@@ eri@@ us mel@@ ting machine , using the use of 2.5 mg dosage in children from 6 to 11 years .
food has no significant influence on AU@@ C and C@@ max by A@@ eri@@ us A@@ eri@@ us Ly@@ ophi@@ li@@ ss from 2,5 to 4 hours and T@@ max of 3 @-@ WIT@@ HO@@ W , 3 hours and 6 hours .
the total analysis of the pre @-@ clinical and clinical clinical outcome tests for mel@@ ting tabl@@ ette revealed that form@@ ulation is an unlikely risk for local Ir@@ rit@@ ations in clinical application .
micro@@ cryst@@ ine Cell@@ ul@@ ose Cell@@ ul@@ ose cavity thickness of Car@@ in@@ y@@ meth@@ yl meth@@ yl meth@@ yl meth@@ yl meth@@ yl meth@@ yl meth@@ yl meth@@ yl meth@@ yl meth@@ yl meth@@ yl meth@@ yl phosph@@ ate ( E@@ 9@@ 51 ) aroma T@@ utti Fr@@ utti ( E@@ 9@@ 51 ) aroma T@@ utti Fr@@ utti
the cold form@@ ulated film consists of poly@@ vin@@ yl@@ chl@@ oride ( PVC ) , lam@@ inated on a aluminium foil , liable for a poly@@ vin@@ yl@@ chl@@ oride ( PVC ) film .
a A@@ eri@@ us 5 mg mel@@ ting once daily in the mouth to put the symptoms of allergi@@ c Rhin@@ i@@ tis ( including inter@@ rup@@ ture and di@@ arr@@ r@@ arian Rhin@@ i@@ tis ) and Ur@@ tic@@ aria ( see section 5.1 ) .
at the recommended dose , A@@ eri@@ us 5 mg fast tablets of the A@@ eri@@ us 5 mg conventional tablet form@@ ulation and the A@@ eri@@ us 5 mg Ly@@ bia .
in the context of a clinical trial with multi @-@ stroke , in the dis@@ lor@@ ries , in the dosage of up to 20 mg daily , no statistical significant significant clinical cardiovascular effect was described .
during a 30 single dose study with adults showed dis@@ lor@@ at@@ adin 5 mg no impact on standard measurements including the subjective fatigue or the tasks that are connected with the flies .
patients with allergi@@ c Rhin@@ i@@ tis were effective in the reduction of symptoms such as Ni@@ ese , nas@@ al secre@@ tion and it@@ ching of the nose , it@@ ching flow and cl@@ ause of the eyes and it@@ ching of the eyes as well as Ju@@ ck@@ rei@@ z at the pal@@ ate .
the wording strengthens the credibility of your review . we kindly ask you to take about ten minutes to take part in this Online Survey . online Survey
the total analysis of the pre @-@ clinical and clinical clinical outcome tests for mel@@ ting tabl@@ ette revealed that form@@ ulation is an unlikely risk for local Ir@@ rit@@ ations in clinical application .
it is recommended for children between 2 and 11 years , which are restricted to children between 2 and 11 years , are identical with the children of children .
this medicine contains Sor@@ bit@@ ol ; therefore , patients should not take prevent@@ ative problems of a Fru@@ ct@@ os@@ e- int@@ oler@@ ance , glu@@ cose @-@ Gal@@ act@@ ose absorption or a Sac@@ ri@@ ase I@@ som@@ alt@@ ase inhib@@ itors .
the total amount of side @-@ effects of children between 2 and 11 years was similar to the deser@@ tification group , similar to plac@@ ebo @-@ group .
for small children between 6 and 23 months were the most frequent side effects that occurs more often than in plac@@ ebo . di@@ arr@@ ho@@ e ( 3.4 % ) , fever ( 2,3 % ) and sle@@ e@@ pl@@ ess@@ ness ( 2,3 % ) .
in an additional study , no adverse effects were observed at a single dose of 2.5 mg charged , no side effects were observed in age between 6 and 11 years .
the recommended dos@@ es were comparable with the recommended dos@@ es of Des@@ cart@@ at@@ eurs ( see Section 5.2 ) in the children &apos;s and adult population .
in controlled clinical studies , the recommended dosage of 5 mg daily for adults and adol@@ esc@@ ents no increased frequency of hits of hits . compared to plac@@ ebo .
in addition to the established classification of seasonal and per@@ enni@@ al , allergi@@ c Rhin@@ i@@ tis can be used in an interactive Rhin@@ i@@ tis .
as the result of the overall quality of the question@@ n@@ aires of Rhin@@ o con@@ gen@@ ital tra@@ ffi@@ tis , A@@ eri@@ us tablets effectively decreased by seasonal allergi@@ c reactions .
the spread of this limited edition is comparable to adults ( 6 % ) and children between 2 and 11 years ( 6 % ) and children between 2 and 11 years ( 6 % adults , 16 % children ) as in Kau@@ k@@ asi@@ ern ( 2 % adults , 3 % children ) .
as A@@ eri@@ us solution is required to take the same concentration of the lor@@ ries , no bio@@ fuel study is required and it is expected that they corresponds to the Sir@@ up and the tablets .
in various single dose studies showed that AU@@ C and C@@ max values of Des@@ lor@@ at@@ inate patients were comparable to the recommended dos@@ es , of adults who were dis@@ lor@@ at@@ ened sy@@ rup in a dose of 5 mg .
Sor@@ bit@@ ol , propeller holder E 9@@ 55 , Hy@@ pro@@ m@@ ell@@ ose E 9@@ 55 , Hy@@ pro@@ m@@ ell@@ ose E 9@@ 55 , natural and artificial fla@@ vors ( Bub@@ ble @-@ G@@ um ) , water @-@ free Cit@@ ron@@ ens@@ ic acid , Nat@@ ri@@ um@@ ed@@ ate ( Ph.@@ Eur@@ . ) , ger@@ ated water .
A@@ eri@@ us solution can be used with 30 , 50 , 60 , 120 , 150 , 225 , 225 , 225 , 225 , 225 , 225 , and 300 ml in type III Bra@@ in@@ las@@ hes with a cri@@ tically sealed connector .
all pack@@ aged sizes except the 150 ml package size are offered with a measuring spo@@ on with mark@@ ings for dos@@ ages of 2.5 ml and 5 ml .
the 150 ml package size is a measuring spo@@ on or a application with sc@@ anners for feed with sc@@ ations of 2.5 ml and 5 ml .
subsequently , author@@ isation of author@@ isation shall be sent to the regular reports on the in@@ concei@@ vable view of a drug by all two years , except there will be something different from the CH@@ MP .
1 Film Sticker 2 film screening 5 film@@ strip 30 film@@ strip 30 film@@ strip 30 film coffee table 100 film coffee table
1 Film Sticker 2 film screening 5 film@@ strip 30 film@@ strip 30 film@@ strip 30 film coffee table 100 film coffee table
sy@@ rup 30 ml with 1 test spo@@ ons 100 ml with 1 measurement l@@ one 100 ml with 1 measuring spo@@ ons 150 ml with 1 test @-@ spo@@ ons 150 ml with 1 test spo@@ ons 100 ml with 1 test spo@@ ons 100 ml with 1 test spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml
30 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 120 ml with 1 measuring spo@@ ons 150 ml with 1 test spo@@ ons 150 ml with 1 test spo@@ ons 100 ml with 1 test spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml
oral Ly@@ s@@ ophi@@ li@@ bi@@ ost@@ a , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ bia , Ly@@ s@@ ophi@@ li@@ us
5 mel@@ ting tray 10 mel@@ ting tray 60 mel@@ ting tray 60 mel@@ ting tray 60 mel@@ ting tray 60 mel@@ ting furnace
for one @-@ spo@@ ons 100 ml with 1 measurement l@@ one 100 ml with 1 measurement l@@ one 100 ml with 1 test spo@@ ons 150 ml with 1 test @-@ spo@@ ons 150 ml with 1 test @-@ spo@@ ons 100 ml with 1 test spo@@ ons 100 ml with 1 test spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1 measuring spo@@ ons 100 ml with 1
pregnancy and still questions during pregnancy and eating time before taking care of your doctor or pharmac@@ ist to advice .
transportation of transport and the use of machines in the recommended dosage is not to be expected that A@@ eri@@ us leads to ben@@ chmark or the attention .
if you have told of your doctor that you have a int@@ oler@@ ance against certain sugar , ask your doctor before you take this medicine .
in terms of treatment , your doctor will notice the type of all@@ erg@@ ical Rhin@@ i@@ tis will suffer from which you suffer and will notice how long you should take A@@ eri@@ us .
if your all@@ erg@@ ische Rhin@@ i@@ tis inter@@ fere ( the symptoms rare than 4 days per week or less than 4 weeks ) , your doctor will recommend you a treatment for treatment , depending on your previous symptoms .
if your allergi@@ c Rhin@@ i@@ tis pers@@ ist ( the symptoms to 4 or more days per week and more than 4 weeks ) , your doctor may recommend you a longer lasting treatment .
if you forget the intake of A@@ eri@@ us if you forget to take your dose in time , take it as soon as possible , and follow the normal treatment plan .
71 After market introduction of A@@ eri@@ us was very rare about cases of heavy allergi@@ c reactions ( difficulty breathing , whe@@ eled , it@@ ching , red@@ dish and sw@@ ell@@ ings ) and skin r@@ ash .
about cases of heart attack , heart disease , abdominal pain , vom@@ iting , sm@@ el@@ iness , sm@@ el@@ ess@@ ness , s@@ ess@@ ness , s@@ ess@@ ness , s@@ ess@@ ness , s@@ ess@@ ness , s@@ ess@@ ness with multip@@ ly physical activity , liver illnesses and unusual cir@@ rho@@ sis .
tablets consists of far@@ a film ( contains L@@ act@@ os@@ - Mon@@ oh@@ y@@ dra@@ t , Hy@@ pro@@ m@@ ell@@ ose , titanium dioxide , Macro@@ er@@ l 400 , In@@ dig@@ oc@@ ar@@ min ( E 132 ) ) , color@@ less film ( includes Hy@@ pro@@ m@@ ell@@ ose , Macro@@ er@@ l 400 ) , Car@@ amel wax , fried wax .
A@@ eri@@ us 5 mg bonus tablets are available individually in Bli@@ ster@@ pack@@ ungen with 1 , 2 , 3 , 5 , 7 , 20 , 20 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 or 100 tablet .
A@@ eri@@ us Sir@@ up is displayed for children aged between 1 and 11 years , young people ( 12 years and older ) and adults , elderly people .
important information about certain other ingredients of A@@ eri@@ us you should not take A@@ eri@@ us Sy@@ rup if you are allergi@@ c to the colour of E 110 .
if your doctor says that you have an int@@ oler@@ ance to some sugar types , please contact your doctor before you take this medicine .
when the sy@@ rup can have a product @-@ proof injection for use with sc@@ allo@@ ys , you can use this alternatively to use the appropriate amount of Sir@@ up .
in terms of treatment , your doctor will notice the type of all@@ erg@@ ical Rhin@@ i@@ tis will suffer from which you suffer and will take you how long you should take A@@ eri@@ us Sy@@ rup .
however , with children under 2 years of age , fever and sle@@ e@@ pl@@ ess@@ ness are frequent side effects , during stress , oral tum@@ ours and head@@ aches are often considered to plac@@ ebo .
after market introduction of A@@ eri@@ us was very rare in cases of severe allergi@@ c reactions ( difficulty breathing , whe@@ eled , it@@ ching , red@@ dish and sw@@ ell@@ ings ) and skin r@@ ash .
77 A@@ eri@@ us Sir@@ up is available in bottles with a minimum of 20 , 50 , 60 , 120 , 120 , 150 , 225 and 300 ml .
A@@ eri@@ us Ly@@ bia also improves the symptoms of allergi@@ c Rhin@@ i@@ tis ( caused by a allergi@@ c reaction of the nas@@ al movement , for example lo@@ af or household det@@ erg@@ ent @-@ allergi@@ es ) .
in case of using A@@ eri@@ us Ly@@ ophi@@ li@@ us and take care of food and drinks A@@ eri@@ us Ly@@ ophi@@ li@@ ere , do not need to be taken with water or any other liquid .
in terms of treatment , your doctor will notice the type of all@@ erg@@ ical Rhin@@ i@@ tis will suffer from which you suffer and will notice how long you should take A@@ eri@@ us Ly@@ bia .
81 If you forget the intake of A@@ eri@@ us Ly@@ ophi@@ li@@ ere , if you forget to take your dose in time , take it as soon as possible , and follow the normal treatment plan .
after market introduction of A@@ eri@@ us was very rare in cases of severe allergi@@ c reactions ( difficulty breathing , whe@@ eled , it@@ ching , red@@ dish and sw@@ ell@@ ings ) and skin r@@ ash .
a total of 1 , 2 , 3 , 5 , 7 , 20 , 20 , 20 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 , 50 .
A@@ eri@@ us melt filtration improves the symptoms of allergi@@ c Rhin@@ i@@ tis ( caused by a allergi@@ c reaction of the nas@@ al movement , for example lo@@ af or household det@@ erg@@ ents ) .
taking A@@ eri@@ us melt chocolate with food and drinks A@@ eri@@ us melt enam@@ el cannot be taken with water or any other fluid .
in terms of treatment , your doctor will notice the type of all@@ erg@@ ical Rhin@@ i@@ tis will suffer from which you suffer and will notice how long you take A@@ eri@@ us melt .
86 If you forget the intake of A@@ eri@@ us mel@@ ting tabl@@ ette , if you forget to take your dose in time , take it as soon as possible , and follow the normal treatment plan .
A@@ eri@@ us mel@@ ting furnace is available individually in Bli@@ ster@@ pack@@ ets with 5 , 6 , 10 , 12 , 20 , 20 , 50 , 50 , 50 , 60 , 60 and 100 cans of the melt chips .
taking A@@ eri@@ us melt chocolate with food and drinks A@@ eri@@ us melt enam@@ el cannot be taken with water or any other fluid .
if you forget the intake of A@@ eri@@ us mel@@ ting tabl@@ ette , if you forget to take your dose in time , take it as soon as possible , and follow the normal treatment plan .
after market introduction of A@@ eri@@ us was very rare in cases of severe allergi@@ c reactions ( difficulty breathing , whe@@ eled , it@@ ching , red@@ dish and sw@@ ell@@ ings ) and skin r@@ ash .
A@@ eri@@ us solution is shown for children aged between 1 and 11 years , young people ( 12 years and older ) and adults , elderly people included .
if the solution to take a application with sc@@ allo@@ ys for inser@@ tion with sc@@ allo@@ ys , you can use this alternatively to take the appropriate amount of solution to remove the appropriate amount of solution .
in terms of treatment , your doctor will notice the type of all@@ erg@@ ical Rhin@@ i@@ tis will suffer from you and will notice how long you will take a solution to take it .
however , with children under 2 years of age , fever and sle@@ e@@ pl@@ ess@@ ness are frequent side @-@ effects , oral tum@@ ours and head@@ aches are often considered to plac@@ ebo .
97 A@@ eri@@ us solution for entrance is available in bottles with a minimum of 20 , 50 , 60 , 120 , 120 , 150 , 225 and 300 ml .
the 150 ml package size is a measuring spo@@ on or a application with sc@@ opes of 2,5 ml@@ - and 5 ml @-@ dos@@ es .
in June 2008 , Nov@@ arti@@ s V@@ acc@@ ines and Diagnostics S.@@ r.@@ l. the Committee for Human@@ izing Plant ( CH@@ MP ) officially announced that the company will bring its request to approval for the in@@ traffic of the avi@@ cular H@@ 5@@ N@@ 1 Inf@@ lu@@ enza in adults and older people .
A@@ fl@@ un@@ ov should be used for adults and elderly persons for protection against flu , which is caused by the trunk ( type ) H@@ 5@@ N@@ 1 of the Inf@@ lu@@ enza @-@ A virus .
this is a special type of vacc@@ ine that could result in a trunk of influ@@ enza virus which could cause a future pan@@ dem@@ ie .
a Gri@@ pp@@ ep@@ an@@ de@@ mic breaks out if a new trunk of Gri@@ pp@@ s@@ virus emerged , which can easily spread from man to humans because people still have no immun@@ ity ( no protection ) .
following administration of the vacc@@ ine , the immune system reco@@ gnis@@ es the immune system in the vacc@@ ination of the influ@@ enza virus and the body of anti@@ body .
this ensures the immune system later in a contact with a influ@@ enza virus of this kind of anti@@ body .
depending on the membrane of the virus with the &quot; surface anti@@ gens &quot; ( proteins on the membrane surface that recogni@@ zes the human body as body det@@ oxi@@ fication ) , combined and used as a component of the vacc@@ ine .
a inspection of some of the study centers showed that the study was not performed according to the &quot; good clinical practice &quot; ( G@@ CP ) .
the scope of the clinical data base for the evaluation of the safety of the vacc@@ ine is not made to fulfil the requirements of the management lines in EME@@ A .
should you participate in a clinical testing and further information on your treatment , please contact your treatment doctor .
if you want more information regarding the recommendations of the CH@@ MP , please read the scientific discussion ( also part of the EP@@ AR ) .
it is applied in combination with other anti@@ viral medicines for treatment of adults and children over four years that may be infected with the human immune disease from the type 1 ( HIV @-@ 1 ) which causes the immune immune system .
for patients who can not swal@@ low the capsules , can not be taken as a solution to a solution , but these can &apos;t be taken together with ritu@@ als because the safety of these combination is not investigated .
the doctor should only be prescribed when the doctor has checked out which anti@@ viral medicines in patient has previously been taken before and the probability that the virus is to speak about the medicine .
the recommended dose for patients over twelve years is 600 mg twice a day which together with twice a daily 100 mg of ritu@@ als and with other anti@@ viral medicines .
children between four and twelve years and in patients with a body weight of less than 50 kg , the recommended dose of as@@ cent after body weight .
in combination with other anti@@ viral medicines , the HIV @-@ quantity in blood and keeps them at a low level .
aids do not heal itself , however , the damage of the immune system and to serve as well as the development of AIDS infections and diseases .
the gener@@ osity was treated in combination with other anti@@ viral medicines , but without ritu@@ als , in two primary studies with 7@@ 36 HIV @-@ infected adults who had been treated with prot@@ e@@ as@@ par@@ agus .
this with low do@@ si@@ cal ritu@@ als had been taken in 206 adults who had been taken in the former prot@@ e@@ as@@ sion@@ ers with other prot@@ e@@ as@@ tics .
main indicators for the effectiveness was the proportion of patients with non @-@ proven concent@@ rations of HIV in blood ( Vir@@ us@@ last ) or the change of the virus .
in the studies of patients that previously had no prot@@ e@@ as@@ infections had been taken under 400 copies / ml as under plac@@ ebo , but A@@ gener@@ ase was less effective than In@@ din@@ avi@@ r .
children have been treated also by the children who were treated with prot@@ e@@ as@@ ers , but only few of them were treated with prot@@ e@@ as@@ ers .
in the study with adults who were treated with Prot@@ e@@ as@@ r reinforced pharmaceu@@ ticals have been treated to the virus attack after 16 @-@ weekly treatment as effective as other prot@@ e@@ as@@ yc@@ ots :
in the patients with HIV , which was resistant against four other prot@@ e@@ as@@ m , it was among the gener@@ ase together with Rit@@ on@@ avi@@ r for four weeks after four weeks after the patients who took their previous prot@@ e@@ as@@ sion@@ ist :
the most common side effects of A@@ gener@@ ase ( observed in more than 1 of 10 patients ) are head@@ aches , di@@ arr@@ ho@@ ea ( har@@ dening ) , di@@ arr@@ ho@@ ea , vom@@ iting , skin r@@ ash and F@@ ati@@ gue ( ti@@ red@@ ness ) .
2 / 3 axis may not be applied to patients who may possibly be sensitive ( allergi@@ c ) against am@@ ster@@ avi@@ r or any other ingredients .
A@@ gener@@ ase may also be applied to patients who are treated with herbal preparations ( a herbal preparations for treatment of depression ) or medicine which are just like sul@@ ph@@ ase and in high concent@@ rations of the blood of health harmful .
like other drugs against HIV , the risk of a Li@@ pod@@ yst@@ rop@@ hi@@ e ( changes in the distribution of body fat ) , a ost@@ e@@ op@@ sis ( de@@ par@@ sed from bone tissue ) or a immune activation ( symptoms of infection that causes disease symptoms ) .
the Committee for Human@@ izing Human Behavi@@ or ( CH@@ MP ) became the conclusion that the benefits of A@@ gener@@ ase inhib@@ itors with other anti@@ oph@@ thal@@ al drug treatment in combination with prot@@ e@@ as@@ ms treated HIV @-@ 1 infected adults and children over four years towards risks .
patients should be taken along with the pharmac@@ ological parameters of ritu@@ als in combination with the pharmac@@ ological parameters in combination with ritu@@ als in combination with Rit@@ on@@ avi@@ r patients who have no prot@@ e@@ as@@ infections .
&quot; &quot; &quot; A@@ gener@@ ase was originally intended under &quot; &quot; &quot; &quot; unusual circumstances &quot; &quot; &quot; , as at the time of approval for scientific reasons only limited information . &quot; &quot; &quot;
in October 2000 , the European Commission issued the G@@ lax@@ o Group &apos;s approved approval for the transport of as@@ gener@@ ase in the entire European Union .
in combination with other anti@@ oph@@ thal@@ al drug , treatment of HIV @-@ 1 infected , Prot@@ e@@ as@@ ei@@ mer ( PI ) -@@ vor@@ treated adults and children from 4 years ago .
patients should usually be administ@@ ered in patients with male patients at pharmac@@ ology of ritu@@ als ( see Figure 4.2 and 4.5 ) .
the use of am@@ ster@@ avi@@ r should be performed with respect of the individual viral resistance of the patient and the pre @-@ treatment of the patient ( see Section 5.1 ) .
the bi@@ polar capacity of Am@@ wel@@ avi@@ r as a solution to insert more than 14 % lower than from Am@@ end@@ avi@@ r as a capsule , therefore A@@ gener@@ ase capsules and solution can not replac@@ eable per milli@@ gram per milli@@ gram ( see Section 5.2 ) .
the recommended dose for A@@ gener@@ ase capsules amounts 600 mg Am@@ end@@ avi@@ r twice daily together with 100 mg of rite twice a day in combination with other anti@@ oph@@ thal@@ al drug .
2 If a gener@@ ase capsules without the increased additives of rite ( booster pump ) , higher dos@@ es can be applied to as@@ gener@@ ase ( 1200 mg twice a day ) .
the recommended dose for A@@ gener@@ ase capsules amounts 20 mg Am@@ wel@@ i@@ r / kg body weight twice daily in combination with other anti@@ oph@@ thal@@ al drug , which should not be exceeded , ( see Section 5.1 ) .
Ph@@ armac@@ ok@@ ine@@ tics , eff@@ ic@@ acy and safety of as@@ ef@@ ase in combination with low dos@@ es of ritu@@ als or other prot@@ e@@ as@@ tics were not investigated .
this is not recommended for use in children under 4 years , due to the lack of data for un@@ desirable and eff@@ ic@@ acy ( see Section 5.2 ) .
based on the phar@@ yn@@ ok@@ ine@@ tic data , the dose should be reduced to adults in adult patients with HER2 @-@ severe liver dys@@ function treatment at 300 mg twice a day and patients with severe liver dys@@ function disorders in 300 mg twice a day .
the simultaneous application is intended for patients with light or reduced liver dys@@ function with caution with severe liver dys@@ function ( see Section 4.3 ) .
not at the same time with medication , which have a low therapeutic width and also sub@@ strates the cy@@ to@@ chrome P@@ 450 @-@ I@@ so@@ enz@@ y@@ ms 3@@ A4 ( CY@@ P@@ 3@@ A4 ) .
herbal remedi@@ es , the Johann@@ is@@ k@@ raut ( hyper@@ ic@@ um perfor@@ atum ) , may not be applied on the risk of reduced plasma concent@@ rations , and a decreased therapeutic effect of am@@ ster@@ avi@@ r during the intake of am@@ ster@@ avi@@ r ( see Section 4.5 ) .
patients should be advised that A@@ gener@@ ase or any other anti@@ oph@@ thal@@ al therapy does not lead to healing the HIV infection and that they continue to develop opportun@@ istic infections or other complications of HIV infections .
the present anti@@ retro@@ vir@@ al therapy including the treatment with as@@ gener@@ ase does not prevent the risk of transmission of HIV on other through sexual contact or contamination with blood .
for usually the gener@@ ase patients should be applied with low dos@@ es of rite and in combination with other anti@@ oph@@ thal@@ al drug ( see Section 4.2 ) .
patients who are treated with chronic hep@@ atitis B or C and treated with an anti@@ oph@@ thal@@ al combination therapy , a higher risk of serious liver impacts caused by potential balance .
for the case of an equal anti@@ viral treatment of hep@@ atitis B or C , please read the number of information in this medicine .
patients with pre @-@ active cir@@ rho@@ sis , including chronic chronic hep@@ atitis show a higher frequency of liver dys@@ function , under an anti@@ angi@@ ity combination therapy and should be monitored according to clinical practice .
the simultaneous application of A@@ gener@@ ase and Rit@@ on@@ avi@@ r with Flu@@ tic@@ ancer or other gluten @-@ co@@ co@@ ster@@ oids , which are not recommended , unless the possible use of a treatment system@@ ic cor@@ on@@ isation function , including Mor@@ bus C@@ us@@ kara and collec@@ ti@@ bility of the cor@@ relation function . ( see section 4.5 ) .
since the interfer@@ on of the H@@ MG @-@ Co@@ A @-@ reduc@@ t@@ ase inhib@@ itor and Sim@@ v@@ ast@@ atin strong from CY@@ P@@ 3@@ A4 , is not recommended for the increased risk of my@@ opath@@ ies including R@@ hab@@ dom@@ y@@ oly@@ sis .
4 For some medicines , the serious or life @-@ threatening side effects can cause cancer , phen@@ y@@ to@@ in , phen@@ y@@ to@@ in , tri@@ cycli@@ c , phen@@ y@@ to@@ in , tri@@ cycli@@ c anti@@ de@@ press@@ ants and war@@ far@@ in ( under surveillance of the International norm@@ ous R@@ atio ) , methods for determining the drug concent@@ rations .
patients who can take this medicine at the same time , the gener@@ ase can be less effective because of a lower plasma spheres of am@@ ster@@ avi@@ r less effective ( see Section 4.5 ) .
due to the possibility to adjust the effects of hormon@@ es contra@@ ctor , the effectiveness of hormon@@ es contra@@ cep@@ tiva can be changed , however , the information is not sufficient to estimate the type of interactions .
if meth@@ ad@@ on is given at the same time with Am@@ end@@ avi@@ r , the patients should therefore be monitored to O@@ pi@@ at@@ ul@@ asi , especially if it will also be given low dos@@ es of ritu@@ als .
due to the possible risk of a tox@@ icity due to the high prop@@ yl@@ li@@ l@@ act@@ ate solution , this medication is applied to children under a age of four years and should be applied with caution in specific other patient groups .
A@@ gener@@ ase should be set in duration 5 if a skin effect of system@@ ic or allergi@@ c symptoms are involved in or the mu@@ c@@ ous symptoms ( see Section 4.8 ) .
patients who received a anti@@ oph@@ onic therapy including prot@@ e@@ as@@ ei@@ tis , hyper@@ gl@@ yc@@ emia , or an ex@@ az@@ ur@@ ation of an existing diabetes mel@@ lit@@ us reports .
many of the patients had other diseases caused by the treatment of a diabetes mel@@ lit@@ us or hyper@@ gl@@ yc@@ emia .
B. higher age , and with drug @-@ dependent factors , such as a longer lasting anti@@ oph@@ thal@@ al treatment and associated with cardiovascular disorders .
patients with h@@ amm@@ op@@ hil@@ es patients ( type A and B ) , which were treated with prot@@ e@@ as@@ ers , are reports on a increase of ble@@ eding , including spont@@ aneous trau@@ mas and hem@@ ati@@ sm .
in HIV patients with severe immun@@ ity , at the time of the introduction of an anti@@ retro@@ vir@@ al combination therapy ( ART ) an inflam@@ matory response to asy@@ mp@@ tom@@ atic or red@@ du@@ ale opportun@@ istic infections which leads to severe clinical indications or imp@@ air@@ ment of symptoms .
although a multi@@ fac@@ t@@ orial abl@@ eness is accepted ( including application of cor@@ on@@ ero@@ ids , alcohol , heavy immune disorders , higher body mass index ) , cases of ost@@ e@@ ek@@ rose , particularly in patients with advanced HIV disease and / or long term use of an anti@@ oph@@ thal@@ al combination therapy ( ART ) .
CY@@ P@@ 3@@ A4 sub@@ strates with low therapeutic width of the gener@@ ase can not be measured at the same time with medication , which have a low therapeutic width and also sub@@ strates the cy@@ to@@ chrome P@@ 450 @-@ I@@ so@@ enz@@ y@@ ms 3@@ A4 ( CY@@ P@@ 3@@ A4 ) .
CY@@ P@@ 2@@ D@@ 6 sub@@ strates with low therapeutic width A@@ gener@@ ase with sem@@ on@@ avi@@ r can not be remedi@@ ed with medication , whose active ingredients are mainly financed by CY@@ P@@ 2@@ D@@ 6 , and for increased plasma levels with severe and / or life @-@ threatening side effects .
it was shown that ri@@ f@@ amp@@ ic@@ in a 82 % reduction in the AU@@ C of Am@@ wel@@ avi@@ r causes that lead to a vi@@ ro@@ log@@ ic failure and can lead to a resistance development .
in the attempt to increase the lowest plasma levels by another prototype of other proteins inhib@@ itors in combination with ritu@@ als were observed very frequently un@@ desired effects on the liver .
St. JO@@ HN &apos;S WOR@@ T ( hyper@@ ic@@ um perfor@@ atum ) can be reduced by the simultaneous application of herbal remedi@@ es with the simultaneous use of herbal remedi@@ es ( hyper@@ ic@@ um perfor@@ atum ) .
when a patient has already been bapti@@ sed at Johann@@ is@@ k@@ raut , the Am@@ stra@@ avi@@ an level and when possible to check the Vir@@ us@@ last level and to the Johann@@ is@@ k@@ raut .
a dys@@ function adaptation for one of the medicine is not required if Nel@@ fin@@ avi@@ r is administ@@ ered together with Am@@ end@@ avi@@ r ( see also E@@ f@@ avi@@ ren@@ z below ) .
508 % increased , for C@@ max by 30 % , if Rit@@ on@@ avi@@ r ( 100 mg twice a day ) in combination with Am@@ end@@ avi@@ r capsules ( 600 mg twice a day ) .
clinical studies were used twice daily and ritu@@ als twice daily and ritu@@ als twice a daily and ritu@@ als of this treatment .
52 % lower if Am@@ end@@ avi@@ r ( 750 mg twice a day ) in combination with Kal@@ et@@ ra ( 400 mg Lop@@ in@@ avi@@ r + 100 mg sul@@ ph@@ avi@@ r twice a day ) .
the C@@ min @-@ values of Am@@ wel@@ ba@@ r ( 600 mg twice daily ) with Kal@@ et@@ ra ( 600 mg twice daily ) , are approximately 40 to 50 % lower than when Am@@ mag@@ avi@@ r ( 600 mg twice a day ) .
a dosing recommendation for the consistent administration of am@@ mon@@ avi@@ r and Kal@@ et@@ ra is not known , but it is not known as the effectiveness and in@@ concei@@ vable of this combination is not known .
it was performed in combination with Di@@ dan@@ os@@ in combination with Di@@ dan@@ os@@ in combination with Di@@ dan@@ os@@ in , however , due to the an@@ ta@@ zi@@ al component of Di@@ dan@@ os@@ in and as@@ gener@@ ase at least one hour ( see An@@ ta@@ zi@@ da below ) .
therefore it is necessary for the gift of E@@ f@@ avi@@ ren@@ z in combination with Am@@ end@@ avi@@ r ( 600 mg twice daily ) and ritu@@ als ( 100 mg twice a day ) .
the treatment with E@@ f@@ avi@@ ren@@ z can not be recommended as the exposure of both prot@@ e@@ as@@ yc@@ ots .
the effect of Ne@@ vi@@ ra@@ pin indicates that Ne@@ vi@@ ra@@ pin indicates that Ne@@ vi@@ ra@@ pin indicates that Ne@@ vi@@ ra@@ pin reaches the ser@@ en@@ concentration of Am@@ mag@@ avi@@ r .
in case this medication may be used at the same time as Del@@ avi@@ r@@ din because of the reduced and possibly sub@@ stitut@@ ing plasma levels are less effective .
if this medication may be applied , caution is required ; a thorough clinical and vi@@ ro@@ logical monitoring is to be made , as a exact predi@@ ction of the combination of Am@@ wel@@ ba@@ r and Rit@@ on@@ avi@@ r to Del@@ avi@@ r@@ din is difficult .
the simultaneous gift of Am@@ wel@@ ba@@ r and Ri@@ fab@@ u@@ tin led to a rise of plasma concentration ( AU@@ C ) by Ri@@ van@@ u@@ tin to 193 % and thus contributes to a rise of ri@@ ghtly connected side @-@ side effects .
if it is necessary for clinical reasons , Ri@@ van@@ u@@ tin is given to a reduction of the dosage of Ri@@ van@@ u@@ tin on at least half of the recommended dose , although no clinical data is guaranteed .
Ph@@ armac@@ ok@@ ine@@ tical studies were not carried out in combination with er@@ y@@ thro@@ my@@ cin , but could be increased the plasma levels of both medicines in the case of simultaneous audit .
the simultaneous application of twice daily 700 m@@ k@@ eto@@ con@@ az@@ ol and 100 mg K@@ eto@@ con@@ az@@ ol on a daily basis , the C@@ max of K@@ eto@@ con@@ az@@ ol in plasma around 25 % and the AU@@ C ( 0 @-@ time ) compared to the value that was observed after 200 mg K@@ eto@@ con@@ az@@ ol a day without even simultaneous application of fossi@@ ls .
other medicines that are listed below are listed below are sub@@ strates , inhib@@ itors or in@@ fra@@ ctors of CY@@ P@@ 3@@ A4 if they are applied to inter@@ gener@@ ational effects .
patients should therefore be applied on toxic reactions that are connected to these medicines when they are applied in combination with map@@ pers .
based on the data of other prot@@ e@@ as@@ l , it is advis@@ able that An@@ ta@@ zi@@ da is not taken to the same time such as the gener@@ osity , as it can occur to res@@ or@@ tion disorders .
the simultaneous application of Anti@@ conv@@ uls@@ si@@ va , known as enz@@ y@@ to@@ sis ( phen@@ y@@ to@@ in , phen@@ y@@ to@@ in , carb@@ amaz@@ ep@@ in ) , with Am@@ wel@@ avi@@ r can lead to a humili@@ ation of the plasma spheres .
the ser@@ um concent@@ rations of calcium cri@@ bs such as am@@ lo@@ di@@ pin , bi@@ odiversity pin , Fel@@ odi@@ pine , Ni@@ odi@@ pine , N@@ ins@@ di@@ pin , N@@ ins@@ di@@ pin and Ver@@ ap@@ am@@ il can be increased from 10 through Am@@ wel@@ peter , so that the activity and tox@@ icity of this drug may be increased .
the simultaneous translation with the gener@@ ase can increase substantially and increase with P@@ DE@@ 5 inhib@@ itors in combination @-@ side effects including hyp@@ ot@@ en@@ sion , tend@@ ons and pri@@ ap@@ ism ( see Section 4.4 ) .
in a clinical trial , in the Rit@@ on@@ avi@@ r 100 mg capsules twice a day together with 50 µ@@ g flu@@ tic@@ cio pro@@ pion@@ ate plasma membrane ( 4 times daily ) , the flu@@ tic@@ ulated cor@@ ti@@ sol was significantly more than 86 % ( 90 % ) .
as a result , the simultaneous increase of A@@ gener@@ ase with Rit@@ on@@ avi@@ r is not recommended , unless the possible use of a treatment system@@ ic cor@@ relation is applied to the risk of system@@ ic cor@@ relation ( see Section 4.4 ) .
with H@@ MG @-@ Co@@ A @-@ Redu@@ kt@@ ase inhib@@ itors such as Lov@@ ast@@ atin and Sim@@ v@@ ast@@ atin , whose break@@ age is strong of CY@@ P@@ 3@@ A4 , are pronounced slow@@ ing of plasma levels during simultaneous audit from A@@ gener@@ ase .
the use of this H@@ MG @-@ Co@@ A @-@ reduc@@ t@@ ase inhib@@ itors can lead to my@@ opath@@ ie including R@@ hab@@ dom@@ y@@ oly@@ sis , the combined application of this medicine is not recommended .
there is a common monitoring of the therapeutic concent@@ rations to stabili@@ sation of the mirror , since plasma concent@@ rations of CY@@ CLO@@ SPOR@@ IN , Rap@@ am@@ yc@@ in and Tac@@ ro@@ li@@ m even can be increased ( see Section 4.4 ) .
therefore , A@@ gener@@ ase must not be applied together with oral bi@@ da@@ z@@ ol@@ am ( see Section 4.3 ) while during the application of as@@ gener@@ ase with par@@ abolic ap@@ da@@ z@@ ol@@ am .
data for the simultaneous application of par@@ enter@@ ed Mi@@ da@@ z@@ ol@@ am with other prot@@ e@@ as@@ hi@@ bit@@ ory can be found on a possible rise of plasma levels by Mi@@ da@@ z@@ ol@@ am around the 3- to 4 @-@ pin .
if meth@@ ad@@ on is administ@@ ered together with Am@@ end@@ avi@@ r , the patients should therefore be monitored to O@@ pi@@ at@@ ul@@ asi , especially if it can be administ@@ ered even lower dos@@ es of ritu@@ als .
there are currently no recommendation to be given as the am@@ ster@@ avi@@ r@@ - dose is at the same time with meth@@ ad@@ on at the same time with meth@@ ad@@ on at the same time .
in the same gift of war@@ far@@ in or other oral anti@@ o@@ ag@@ ul@@ ants together with the gener@@ ase , a increased control of the In@@ r ( International norm@@ ous R@@ atio ) is recommended for the possibility of a reduction or strengthening of anti@@ co@@ axial effects ( see Section 4.4 ) .
the effect of an additional appointments of ritu@@ als to hormon@@ al contra@@ cep@@ tiva is not provided , hence an alternative methods are recommended .
the therapeutic effects of therapeutic effects and side @-@ effects of tri@@ cycli@@ c anti@@ de@@ press@@ ants ( for example Des@@ i@@ pra@@ min and Nor@@ tr@@ yp@@ ti@@ lin ) is recommended for equal gift of A@@ gener@@ ase ( see Section 4.4 ) .
this medication may only be applied during pregnancy during pregnancy .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; in the milk of l@@ act@@ ose rats , Am@@ iga was not known whether Am@@ end@@ avi@@ r is not known whether Am@@ iga &apos;s milk is over@@ taking into the wom@@ b milk . &quot; &quot; &quot;
a reproduction study at the imp@@ etus of imp@@ air@@ ment in U@@ ter@@ us up until the end of the stand@@ still in the U@@ ter@@ us up until the end of the stand@@ still period was decreased during the down@@ time .
the further development of the realis@@ ation including fer@@ mentation and reproduction capacity was not affected by the administration of am@@ ne@@ avi@@ r to the parent &apos;s wom@@ b .
the in@@ concei@@ vable of A@@ gener@@ ase was examined in adults and children aged 4 years in controlled clinical studies in combination with different other anti@@ oph@@ thal@@ al drug trials .
most of the treatment with the generic treatment were light up to moder@@ ately pronounced , early on and led to the treatment of treatment .
in many of these events it is not possible if they are in connection with the intake of as@@ gener@@ ase or another at the same time to treat HIV treatment .
most of the mentioned adverse events are taken from two clinical studies ( PRO@@ AB@@ 300@@ 1 , PRO@@ AB@@ 300@@ 6 , PRO@@ AB@@ 300@@ 6 ) , where proteins were not treated with prot@@ e@@ as@@ ers twice a daily .
events ( grade 2 to 4 ) that were distributed as in connection with the study of study medicine , and with more than 1 % of the patients were observed , as well as with the treatment problems ( degrees 3 to 4 ) .
the anti@@ retro@@ vir@@ al combination therapy was associated with a re@@ distribution of the body fat ( Li@@ pod@@ yst@@ rop@@ hi@@ e ) in HIV patients , including a loss of peri@@ o@@ dys@@ function , increased intra@@ ocular and vis@@ cer@@ al fat tissue , hyper@@ tro@@ phy of the bre@@ asts and dor@@ so@@ vi@@ cal grease .
under 113 anti@@ bacterial non @-@ treated persons , which were treated with am@@ big@@ u@@ din / zi@@ z@@ vu@@ din to a medium duration of 36 weeks , only one case ( Sti@@ pul@@ ls ) was observed ( &lt; 1 % ) .
in the study PRO@@ AB 300@@ 6 at 245 NR@@ TI@@ - pre @-@ treated patients under Am@@ end@@ avi@@ r 7 cases ( 3 % ) compared to 27 cases ( 11 % ) compared to 27 cases ( 11 % ) in combination with different NR@@ TI@@ s over a medium duration of 56 weeks ( p &lt; 0,@@ 001 ) .
skin defects were usually slightly up to moder@@ ately pronounced , er@@ y@@ sack and ma@@ ku@@ b pap@@ rika , with or without ju@@ ck@@ ching , and usually during the second treatment week , and w@@ alled after two weeks without having had to be broken during the second treatment week , and had to be broken during the second treatment week .
Oste@@ on@@ ek@@ rose , particularly in patients with commonly known risk factors , advanced HIV disease or long term use of anti@@ angi@@ oid therapy ( ART ) reports .
with HIV attack patients with severe immun@@ ity , at the time of the introduction of an anti@@ retro@@ vir@@ al combination therapy ( ART ) an inflam@@ matory response to asy@@ mp@@ tom@@ atic or red@@ du@@ ale opportun@@ istic infections ( see Section 4.4 ) .
with PI pre @-@ treated patients , the 600 mg A@@ gener@@ ase twice daily together with low do@@ si@@ zing ritu@@ als ( grade 3 to 4 ) and laboratory changes ( degrees 3 to 4 ) and laboratory changes ( degrees 3 to 4 ) and laboratory changes ( grade 3 and 4 ) , which were associated with low do@@ si@@ zing ritu@@ als .
in case of over@@ dosing , the patient is to observe the signs of an in@@ tox@@ ic@@ ation ( see Section 4.8 ) if necessary , if necessary , supp@@ or@@ tive actions are necessary .
Am@@ mon@@ avi@@ r bin@@ det at the active centre of the HIV @-@ 1 prot@@ ector , avo@@ ids the procedure of viral g@@ ag@@ erial and g@@ ag @-@ pol@@ - Poly@@ phen@@ ant levels with a result of a formation of un@@ distur@@ bing , un@@ inf@@ ec@@ tious virus particles .
the anti@@ viral activity of Am@@ ne@@ avi@@ r in vitro against HIV @-@ 1 II@@ IB was examined both on acute and chronic ly@@ mp@@ ho@@ blas@@ tic cells ( MT @-@ 4 , CE@@ M @-@ C@@ CR@@ F , H@@ 9 ) as well as peripheral blood ly@@ mp@@ ho@@ cy@@ tes .
the 50 % inhib@@ itor concent@@ rates ( IC@@ 50 ) of Am@@ end@@ avi@@ r is located in the area of 0,@@ 012 to 0.@@ 08 µ@@ M at acute infected cells and amounts 0.@@ 41 µ@@ M with chronic cells .
the connection between the activity of Am@@ ne@@ avi@@ r against HIV @-@ 1 in vitro and the inhib@@ itor of the HIV @-@ 1 rep@@ lication with humans is not defined .
in the treatment of anti@@ bacterial non @-@ treated patients with the currently permitted Fos@@ amp@@ en@@ avi@@ r / Rit@@ on@@ avi@@ r @-@ Do@@ si@@ ations were observed with proteins associated with proteins inf@@ lic@@ ations .
in six@@ teen of 434 anti@@ angi@@ ography no pre @-@ treated patients , 700@@ mg F@@ amp@@ en@@ avi@@ r with 100mg ritu@@ als twice a day in the study ES@@ S@@ 100@@ 732 , a vi@@ ro@@ logical failure will be examined up to week 48 , whereby 14 isol@@ ate occur@@ ren@@ ces could be investigated .
a gen@@ otyp@@ ical analysis of the Isol@@ ate of 13 of 14 children under which a vi@@ ro@@ log@@ ic failure in the 59 were not treated treated with prot@@ e@@ as@@ sion@@ ers , which were similar to adults were similar to adults .
L@@ 10@@ F / I / V , V@@ 11@@ I , I@@ 13@@ I , V@@ 32@@ I , I@@ 46@@ I , I@@ 46@@ I , I@@ 54@@ V , I@@ 54@@ V , I@@ 6@@ 2V , I@@ 6@@ 2V , I@@ 6@@ 2V , V@@ 8@@ 2A / I , I@@ 8@@ 2V , I@@ 8@@ M , I@@ 8@@ M , L@@ 90@@ M , L@@ 90@@ M , L@@ 90@@ M , L@@ 90@@ M , L@@ 90@@ M , L@@ 90@@ M , L@@ 90@@ M , L@@ 90@@ M , L@@ 90@@ M / M .
in the study AP@@ V@@ 300@@ 03 and their extension AP@@ V@@ 300@@ 05 ( 700 mg F@@ amp@@ ren@@ avi@@ r / 100 mg sul@@ ph@@ avi@@ r twice daily : n = 107 ) were treated with prot@@ e@@ as@@ sion@@ ic failure over 96 weeks , the following prot@@ e@@ as@@ hin@@ dran@@ ces to :
based on gen@@ otyp@@ ical interpre@@ ter analyses , analyses of the activity of Am@@ ne@@ avi@@ r / Rit@@ on@@ avi@@ r / Rit@@ on@@ avi@@ r / Rit@@ on@@ avi@@ r for patients with Prot@@ e@@ as@@ inhib@@ r patients with Prot@@ e@@ as@@ inhib@@ r patients .
the current ( July 2006 ) AN@@ RS @-@ AC @-@ 11 algorithm for Fos@@ amp@@ het@@ r / rite / S / S / S / S / F , I@@ 8@@ 2V , V@@ 8@@ 2A / C / F , I@@ 8@@ 2V , V@@ 8@@ 2A / C / F , I@@ 8@@ 2V , V@@ 8@@ 2A / C / F , I@@ 8@@ 2V , V@@ 8@@ 2A / C / F , I@@ 8@@ 2V , V@@ 8@@ 2A / C / F , I@@ 8@@ 2V and L@@ 90@@ M .
the conclusions regarding the relevance of specific mut@@ ations or mut@@ ation patterns can be subject to changes through additional data , and it is recommended to attract the current interpretation systems for analysis of the outcomes of testing purposes .
based on ph@@ otyp@@ ing analysis based analyses based on an evaluation of the activity of Am@@ ne@@ avi@@ r / Rit@@ on@@ avi@@ r / Rit@@ on@@ avi@@ r / Rit@@ on@@ avi@@ r / Rit@@ on@@ avi@@ r for patients with Prot@@ e@@ as@@ inhib@@ r / Rit@@ on@@ avi@@ r patients with Prot@@ e@@ as@@ inhib@@ r patients .
the diagnostic tests cell tests are designed to be applied to the interpretation of further tests at the same time .
each of these four with a dimin@@ ished sensitivity against am@@ ster@@ avi@@ r associated with genetic design creates a certain cross @-@ resistant agent against ritu@@ als , Nel@@ fin@@ avi@@ r and Sa@@ quin@@ avi@@ r .
there are currently data for cross@@ fire between am@@ mon@@ avi@@ r and other prot@@ e@@ as@@ ers for all 4 fossi@@ ls , either alone or in combination with other mut@@ ations .
on the basis of twenty @-@ twenty anti @-@ treated patients ( one of 25 Isol@@ ates ) , Dar@@ fur avi@@ r / Rit@@ on@@ avi@@ r ( three of 25 Isol@@ ates ) , In@@ din@@ avi@@ r / Rit@@ on@@ avi@@ r ( three of 24 isol@@ ates ) and Ti@@ ag@@ avi@@ r ( three of 24 isol@@ ates ) and Ti@@ ag@@ avi@@ r ( four of 24 isol@@ ates ) .
on the other hand , Am@@ stra@@ avi@@ r maintains its activity against some other prot@@ e@@ as@@ inhib@@ iting isolation from the number and type of resistance mut@@ ations in the isol@@ ates .
early fatigue is recommended to keep the expectations of a large number of mut@@ ations in limitations that can act on the subsequent treatment .
the loading of the eff@@ ic@@ ase in combination with Rit@@ on@@ avi@@ r 100 mg twice a day based on the study PRO@@ 300@@ 17 , a random@@ ised open study conducted by PI ( twice daily ) and Nu@@ cle@@ osi@@ dan@@ alog@@ a ( N@@ RT@@ I ) or a standard therapy ( standard of care , So@@ c ) with a PI , mainly with low @-@ cast rite .
one hundred and sixty @-@ one ( n = 163 ) patients with pre @-@ weigh@@ ted virus sensitivity and at least one N@@ RT@@ I were included in the sub @-@ study A of PRO@@ 300@@ 17 .
the primary analysis provided the non @-@ sub@@ strate of AP@@ V / Rit@@ on@@ avi@@ r compared to the So@@ c @-@ PI group in terms of high output value ( A@@ AU@@ C@@ MB ) in plasma to 16 weeks , with an non @-@ sub@@ gen@@ esis of 0.@@ 4 log@@ 10 copies / ml .
the loading of effectiveness of in@@ sured patients is based on two un@@ controlled trials with a total of 288 HIV @-@ infected children aged 2 to 18 years , of which 152 were treated with PI .
in the studies of a gener@@ ase solution to remove and capsules in dosing of 15 mg / kg three times daily , 20 mg / kg twice daily and 2@@ 2.5 mg / kg twice a day , whereby the majority of patients 20 mg / kg twice a day .
there was no low do@@ si@@ zing ritu@@ als at the same time ; the majority of with PI pre @-@ treated patients had at least one ( 78 % ) or two ( 42 % ) .
after 48 weeks , about 25 % of the study included a plasma @-@ HIV @-@ 1 @-@ RNA concentration &lt; 10,000 copies / ml and 9 % &lt; 400 copies / ml to a medi@@ an increase of 26 cells / mm ³ ( n = 74 ) compared to the output value .
19 Basi@@ c@@ tures on these data should be taken into consideration with the treatment of treatment of patients who be expected to be taken into consideration .
after or@@ aler we use the medium duration ( t@@ max ) up to the maximum servo concentration of Am@@ iga , approximately 1 to 2 hours for the capsule and approximately 0.5 to 1 hour for the solution .
508 % increased , for C@@ max by 30 % , if Rit@@ on@@ avi@@ r ( 100 mg twice a day ) together with Am@@ end@@ avi@@ r ( 600 mg twice a day ) .
the administration of am@@ ne@@ avi@@ r with a meal leads to a 25 % of the AU@@ C , but has no effect on the concentration of Am@@ end@@ avi@@ r 12 hours after dos@@ es ( C@@ 12 ) .
therefore , the minimum concentration in the Ste@@ ady State State ( C@@ min , ss ) of the food intake , exclu@@ des the extent to the extent and rate the rate of res@@ or@@ ption .
the apparent con@@ sign@@ ment volume is approximately 430 l ( 6 l / kg with a body weight of 70 kg ) and can be reached on a large distribution volume as well as a non @-@ explosive solvent from the blood circulation .
this change leads to a decrease in the determination of the active ingredient in plasma , with the amount of un@@ matched am@@ an@@ avi@@ r which remains the active part , probably remains unchanged .
during the absolute concentration of non@@ linear am@@ mon@@ stro@@ kes , the pro@@ cent@@ u@@ ary proportion of free active components in the Ste@@ ady concentration in the Ste@@ ady concentration in the Ste@@ ady concentration on the area of C@@ max , ss up to C@@ min .
therefore you need medicines , the CY@@ P@@ 3@@ A4 , or in@@ ject or sub@@ strate of CY@@ P@@ 3@@ A4 , with caution when they are given to the gener@@ ase ( see Sec@@ tion@@ 4.3 , 4.4 and 4.5 ) .
the gift of A@@ gener@@ ase capsules , either 20 mg / kg twice or 15 mg / kg three times a day , leads to a similar daily am@@ ic@@ r exposure like adults with a dose of 1200 mg twice a day .
Am@@ wel@@ avi@@ r is able from the solution of 14 % less bi@@ polar additives as of the capsules ; therefore A@@ gener@@ ase solution and as@@ gener@@ ase capsules are not inter@@ changeable at a milli@@ bar basis .
the ren@@ al clearing of ritu@@ als is neg@@ li@@ gible , therefore , the effect of a kidney dys@@ function calls on the Eli@@ min@@ ation of Am@@ wel@@ ba@@ r and Rit@@ on@@ avi@@ r .
these treatment techniques lead to am@@ ster@@ avi@@ r plasma levels comparable to those who are treated with healthy subjects after a dose of 1200 mg Am@@ iga , twice a day without even simultaneous administration of ritu@@ als .
in long @-@ term studies with Am@@ wel@@ i@@ r on the mice and rats were treated with male animals ben@@ ig@@ ne hep@@ at@@ ogen@@ ic as@@ den@@ ome at Do@@ si@@ fication , which twice a day of gift of 1200 mg Am@@ wel@@ i@@ r , relaxing .
the fundamental mechanism for the emergence of hep@@ at@@ aly@@ sis and car@@ cin@@ oma were not yet unknown , and the relevance of these observ@@ ations have been un@@ clear .
the aim is to gather information on the quality and variety of what IAB offers , on comprehen@@ sibility , motivation for use , and new user requirements , with a view to improving IAB &apos;s web presence even further .
in a standard battery of In @-@ vi@@ vo@@ - and in @-@ vitro diagnostic tests , the bacter@@ ium test tests ( Am@@ es @-@ Test ) , Maus @-@ ly@@ mp@@ ho@@ cy@@ tes @-@ test , micro@@ core test at rats and chrom@@ os@@ ome .
these liver disease can be monitored in clinical everyday life through measurement of AST , AL@@ T and the activity of the alkal@@ ine phosph@@ ate gases and proved .
so far in clinical trials , no significant liver toxic tox@@ icity in patients observed , neither during the administration of A@@ fr@@ ase after the end of treatment .
studies on the tox@@ icity of young men who were treated by a age of 4 days were treated both in the control as well as with Am@@ end@@ avi@@ r treated animals .
under a system@@ ic Plas@@ ma@@ stery , the significantly below ( rab@@ bit ) or not significantly higher ( rats ) than the expected exposure under therapeutic dosage in humans , however , a number of minimal changes including thy@@ mus@@ el@@ ong@@ ation and low sk@@ el@@ etal changes which indicate that delayed development .
24 If the gener@@ ase capsules contain liquid capsules without the increased additives of rite ( booster pump ) , higher dos@@ es can be applied to as@@ gener@@ ase ( 1200 mg twice a day ) .
the recommended dose for A@@ gener@@ ase capsules amounts 20 mg Am@@ wel@@ i@@ r / kg body weight twice daily in combination with other anti@@ oph@@ thal@@ al drug , which should not be exceeded , ( see Section 5.1 ) .
the simultaneous application is intended for patients with low or lighter liver dys@@ function with caution with severe liver cells ( see Section 4.3 ) .
26 For some medicines , the serious or life @-@ threatening side effects can cause cancer , phen@@ y@@ to@@ in , phen@@ y@@ to@@ in , tri@@ cycli@@ c , phen@@ y@@ to@@ in , tri@@ cycli@@ c anti@@ de@@ press@@ ants and war@@ far@@ in ( under surveillance of the International norm@@ ous R@@ atio ) , methods for determining the drug concent@@ rations .
A@@ gener@@ ase should be set in duration 27 when a skin effect of system@@ ic or allergi@@ c symptoms are involved in or the mu@@ c@@ ous symptoms ( see Section 4.8 ) .
an increased risk for a Li@@ pod@@ yst@@ rop@@ hi@@ e , with individual factors such as higher age , and with drug @-@ dependent factors , such as a longer lasting anti@@ oph@@ thal@@ al treatment and associated with cardiovascular disorders .
it was shown that ri@@ f@@ amp@@ ic@@ in a 82 % reduction in the AU@@ C of Am@@ wel@@ avi@@ r causes that lead to a vi@@ ro@@ log@@ ic failure and can lead to a resistance development .
508 % increased , for C@@ max by 30 % , if Rit@@ on@@ avi@@ r ( 100 mg twice a day ) in combination with Am@@ end@@ avi@@ r capsules ( 600 mg twice a day ) .
the C@@ min @-@ values of Am@@ wel@@ ba@@ r ( 600 mg twice daily ) with Kal@@ et@@ ra ( 600 mg twice daily ) , are approximately 40 to 50 % lower than when Am@@ mag@@ avi@@ r ( 600 mg twice a day ) .
a dosing recommendation for the consistent administration of am@@ mon@@ avi@@ r and Kal@@ et@@ ra is not known , but it is not known as the effectiveness and in@@ concei@@ vable of this combination is not known .
the treatment with E@@ f@@ avi@@ ren@@ z can not be recommended as the exposure of both prot@@ e@@ as@@ yc@@ ots .
if this medication may be applied , caution is required ; a thorough clinical and vi@@ ro@@ logical monitoring is to be made , as a exact predi@@ ction of the combination of Am@@ wel@@ ba@@ r and Rit@@ on@@ avi@@ r to Del@@ avi@@ r@@ din is difficult .
if it is necessary for clinical reasons , Ri@@ van@@ u@@ tin is given to a reduction of the dosage of Ri@@ van@@ u@@ tin on at least half of the recommended dose 31 , although no clinical data is guaranteed .
the ser@@ um concent@@ rations of calcium cri@@ bs such as am@@ lo@@ di@@ pin , bi@@ odiversity pin , Fel@@ odi@@ pine , Ni@@ odi@@ pine , N@@ ins@@ di@@ pin , N@@ ins@@ di@@ pin and Ver@@ ap@@ am@@ il may increase the activity and tox@@ icity of this medication .
in a clinical trial , in the Rit@@ on@@ avi@@ r 100 mg capsules twice a day together with 50 µ@@ g flu@@ tic@@ cio pro@@ pion@@ ate plasma membrane ( 4 times daily ) , the flu@@ tic@@ ulated cor@@ ti@@ sol was significantly more than 86 % ( 90 % ) .
in the same gift of war@@ far@@ in or other oral anti@@ o@@ ag@@ ul@@ ants together with the gener@@ ase , a increased control of the In@@ r ( International norm@@ ous R@@ atio ) is recommended for the possibility of a reduction or strengthening of anti@@ co@@ axial effects ( see Section 4.4 ) .
the simultaneous administration of OR@@ TH@@ O @-@ Nov@@ um 1 / 35 ( 0.@@ 0@@ 35 mg Eth@@ in@@ y@@ le@@ stra@@ di@@ ol plus 1.0 mg Nor@@ eth@@ in@@ dr@@ on ) led to a decrease of AU@@ C and C@@ min of Am@@ end@@ avi@@ r to 22 % .
this medication may only be applied when pregnancy may only be applied to the possible risks for the mother in comparison to the potential risks for F@@ öt@@ us .
a reproduction study at the imp@@ etus of imp@@ air@@ ment in U@@ ter@@ us up until the end of the stand@@ still in the U@@ ter@@ us up until the end of the stand@@ still period was decreased during the down@@ time .
the in@@ concei@@ vable of A@@ gener@@ ase was examined in adults and children aged 4 years in controlled clinical studies in combination with different other anti@@ oph@@ thal@@ al drug trials .
in case of over@@ dosing , the patient is to observe the signs of an in@@ tox@@ ic@@ ation ( see Section 4.8 ) if necessary , if necessary , supp@@ or@@ tive actions are necessary .
the anti@@ viral activity of Am@@ ne@@ avi@@ r in vitro against HIV @-@ 1 II@@ IB was examined both on acute and chronic ly@@ mp@@ ho@@ blas@@ tic cells ( MT @-@ 4 , CE@@ M @-@ C@@ CR@@ F , H@@ 9 ) as well as peripheral blood ly@@ mp@@ ho@@ cy@@ tes .
the 50 % Hem@@ isph@@ ere ( IC@@ 50 ) is located in the area of 0,@@ 012 to 0.@@ 08 µ@@ M with chronic cells ( 1 µ@@ M = 0.50 µ@@ g / ml ) .
on the other hand , Am@@ stra@@ avi@@ r maintains its activity against some other prot@@ e@@ as@@ inhib@@ iting isolation from the number and type of resistance mut@@ ations in the isol@@ ates .
based on these data we should be considered during therapy optimization at PI and treated children under expected use of &quot; un@@ diagnos@@ ed &quot; as@@ simil@@ ation .
during the absolute concentration of non@@ linear am@@ mon@@ stro@@ kes , the pro@@ cent@@ u@@ ary proportion of free active components in the Ste@@ ady concentration in the Ste@@ ady concentration in the Ste@@ ady concentration on the area of C@@ max , ss up to C@@ min , ss ..
therefore you need medicines , the CY@@ P@@ 3@@ A4 , or in@@ ject or sub@@ strate of CY@@ P@@ 3@@ A4 , with caution when they are given to the gener@@ ase ( see Sec@@ tion@@ 4.3 , 4.4 and 4.5 ) .
the ren@@ al clearing of ritu@@ als is neg@@ li@@ gible ; therefore , the effect of a kidney dys@@ function distur@@ b@@ ance on the Eli@@ min@@ ation of Am@@ wel@@ ba@@ r and Rit@@ on@@ avi@@ r low .
in long @-@ term studies with Am@@ wel@@ i@@ r on the mice and rats were treated with male animals ben@@ ig@@ ne hep@@ at@@ ogen@@ ic as@@ den@@ ome at Do@@ si@@ fication , which has twice daily gift of 1200 mg Am@@ mag@@ avi@@ r .
the underlying mechanism for the emergence of hep@@ ato@@ zel@@ al A@@ den@@ ome and car@@ cin@@ oma was not yet unknown , and the relevance of those observed effects are un@@ clear .
the aim is to gather information on the quality and variety of what IAB offers , on comprehen@@ sibility , motivation for use , and new user requirements , with a view to improving IAB &apos;s web presence even further .
in a standard battery of In @-@ vi@@ vo@@ - and in @-@ vitro diagnostic tests , the bacter@@ ium test tests ( Am@@ es @-@ Test ) , Maus @-@ ly@@ mp@@ ho@@ cy@@ tes @-@ test , micro@@ core test at rats and chrom@@ os@@ ome .
studies on the tox@@ icity of young men who were treated by a age of 4 days were treated both in the control as well as with Am@@ end@@ avi@@ r treated animals .
these results indicate that they are not fully equipped with the met@@ abolic path@@ ways , so that Am@@ end@@ avi@@ r or other critical components of the form@@ ulation ( z ) .
this solution can be used in combination with other anti@@ angi@@ oid medicine for treatment of HIV @-@ 1 infected , Prot@@ e@@ as@@ ei@@ tis ( PI ) -@@ vor@@ treated adults and children from 4 years ago .
the benefits of Rit@@ on@@ avi@@ r , &quot; as@@ oo@@ ster@@ ter &quot; as@@ gener@@ ase solution is neither associated with PI pre@@ treated patients even with PI pre @-@ treated patients .
the bi@@ polar capacity of Am@@ wel@@ avi@@ r as a solution to insert more than 14 % lower than from Am@@ end@@ avi@@ r as a capsule , therefore A@@ gener@@ ase capsules and solution can not replac@@ eable per milli@@ gram per milli@@ gram ( see Section 5.2 ) .
patients should be as soon as they are able to swal@@ low the capsules , using the intake of the solution to stop ( see Section 4.4 ) .
the recommended dose for as@@ gener@@ ase solution is 17 mg ( 1,1 ml ) Am@@ wel@@ avi@@ r / kg body weight three times daily in combination with other anti@@ oph@@ thal@@ al drug , which should not be exceeded ( see Section 5.1 ) .
in addition , there is no D@@ os@@ is@@ recommendation for simultaneous application of as@@ gener@@ ase solution to remove and low do@@ si@@ zing ritu@@ als , this combination with these patient groups can be avoided .
although a dys@@ function adaptation for am@@ ster@@ avi@@ r is not required for patients with kidney gri@@ ds ( see Section 4.3 ) .
due to the potential risk of a toxic reaction as a result of the high propeller @-@ col@@ oni@@ das , A@@ gener@@ ase solution can be used for small children and children under 4 years , pregnant women , with limited risk function or liver failure .
the consistent administration can lead to a mul@@ tiv@@ ating inhib@@ itor of this medicine and may potentially serious side effects such as heart rhythm disorders ( z . ) .
patients should be advised that A@@ gener@@ ase or any other anti@@ oph@@ thal@@ al therapy does not lead to healing the HIV infection and that they continue to develop opportun@@ istic infections or other complications of HIV infections .
the current anti@@ retro@@ vir@@ al therapy including the treatment with as@@ gener@@ ase does not prevent the risk of transmission of HIV on other through sexual contact or contamination with blood .
for some medicine , the serious or life @-@ threatening side effects can cause cancer , phen@@ y@@ to@@ in , phen@@ y@@ to@@ in , tri@@ cycli@@ c , phen@@ y@@ to@@ in , tri@@ cycli@@ c anti@@ de@@ press@@ ants and war@@ far@@ in ( under surveillance of the International norm@@ ous R@@ atio ) , methods for determining the drug concent@@ rations .
A@@ gener@@ ase should be set in duration if a skin effect of system@@ ic or allergi@@ c symptoms are involved or the mu@@ c@@ ous symptoms ( see Section 4.8 ) .
an increased risk for a Li@@ pod@@ yst@@ rop@@ hi@@ e , with individual factors such as higher age , and with drug - 49 dependent factors , such as a longer lasting anti@@ oph@@ thal@@ al treatment and associated with cardiovascular disorders .
patients with h@@ amm@@ op@@ hil@@ es patients ( type A and B ) , which were treated with prot@@ e@@ as@@ ers , are reports on a increase of ble@@ eding , including spont@@ aneous trau@@ mas and hem@@ ati@@ sm .
it was shown that ri@@ f@@ amp@@ ic@@ in a 82 % reduction in the AU@@ C of Am@@ wel@@ avi@@ r causes that lead to a vi@@ ro@@ log@@ ic failure and can lead to a resistance development .
508 % increased , for C@@ max by 30 % , if Rit@@ on@@ avi@@ r ( 100 mg twice a day ) in combination with Am@@ end@@ avi@@ r capsules ( 600 mg twice a day ) .
the simultaneous translation with the gener@@ ase can increase substantially and increase with P@@ DE@@ 5 inhib@@ itors in combination of side effects including hyp@@ ot@@ en@@ sion , tend@@ ons and pri@@ ap@@ ism ( see Section 4.4 ) .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
the potential risk for humans is not known . as@@ gener@@ ase solution can be used to take part due to possible toxic reactions of fo@@ etus to the gly@@ col ind@@ ly@@ col should not be applied during pregnancy ( see Section 4.3 ) .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; in the milk of l@@ act@@ ose rats , Am@@ iga was not known whether Am@@ end@@ avi@@ r is not known whether Am@@ iga &apos;s milk is over@@ taking into the wom@@ b milk . &quot; &quot; &quot;
a reproduction study at the imp@@ etus of imp@@ air@@ ment in U@@ ter@@ us up until the end of the stand@@ still in the U@@ ter@@ us up until the end of the stand@@ still period was decreased during the down@@ time .
the in@@ concei@@ vable of A@@ gener@@ ase was examined in adults and children aged 4 years in controlled clinical studies in combination with different other anti@@ oph@@ thal@@ al drug trials .
in many of these events it is not possible if they are in connection with the intake of as@@ gener@@ ase or another at the same time to treat HIV treatment .
in the treatment of anti@@ bacterial non @-@ treated patients with the currently permitted Fos@@ amp@@ en@@ avi@@ r / Rit@@ on@@ avi@@ r @-@ Do@@ si@@ ations were observed with proteins associated with proteins inf@@ lic@@ ations .
early detection of a de@@ ag@@ ment 60 therapy is recommended to keep the expectations of a large number of mut@@ ations in limitations that can act on the subsequent treatment .
62 Basi@@ c@@ tures on this data should be taken into consideration with the treatment of patients who were expected to be taken into consideration .
the apparent distribution volume is approximately 430 l ( 6 l / kg with a body weight of 70 kg ) and leaves on a large number of Vet@@ r@@ avi@@ r of the blood circulation into the tis@@ sues .
the underlying mechanism for the emergence of hep@@ at@@ aly@@ tic retin@@ os@@ ome and car@@ cin@@ oma was not yet unknown , and the relevance of those observed effects are un@@ clear .
under a system@@ ic Plas@@ ma@@ stery , the significantly below ( rab@@ bit ) or not significantly higher ( rats ) than the expected exposure under therapeutic dosage in humans , however , a number of minimal changes including thy@@ mus@@ el@@ ong@@ ation and low sk@@ el@@ etal changes which indicate that delayed development .
if you have any further questions , please contact your doctor or pharmac@@ ist . your doctor was prescribed by your doctor or pharmac@@ ist .
it can harm other people even if they have the same complaints such as you . − If one of the remaining side effects you are affected or do side effects that are not specified in this use information , please refer to your doctor or pharmac@@ ist .
your doctor will usually show you usually reported , A@@ gener@@ ase capsules along with low dos@@ es ritu@@ als to increase the effect of as@@ pl@@ ase .
the use of A@@ gener@@ ase will be based on your doctor before purchasing the individual viral infections , and your treatment of treatment .
inform your doctor if you suffer from one of the above diseases or any one of the above mentioned medicine .
if your doctor is recommended that you take A@@ gener@@ ase capsules together with low dos@@ es of ritu@@ als ( Boo@@ st@@ ine ) to ensure the use of the treatment information about ritu@@ als .
there are no sufficient information to improve the application of as@@ ase capsules in patients at age of 4 to 12 years or in general in patients with 50 kg body weight .
therefore it is important that you can read the section &quot; In case of your gener@@ ase with other medicines , &quot; before you start with the intake of the gener@@ ase .
possibly you require additional factor VIII to control the blood circulation . − In case of patients who obtain an anti@@ retro@@ vir@@ al combination therapy , a distribution of loss or loss of body fat can occur .
if you take certain medicine which may lead to serious side effects such as Carb@@ ine , phen@@ y@@ to@@ in , Li@@ doc@@ ain , CY@@ CLO@@ SPOR@@ IN , Tac@@ ro@@ li@@ m , pre@@ cy@@ clic@@ al , tri@@ cycli@@ c @-@ anti@@ de@@ press@@ ant and war@@ far@@ in , which can take additional blood tests to minimize potential problems .
it is recommended that HIV positive women should do their children under any circumstances to avoid a transmission of HIV .
equi@@ p@@ ments and the use of machines there were no studies on the influence of as@@ simil@@ ation on driving or the ability to serve machines .
please take this medicine after returning to your doctor if you know that you suffer from an int@@ oler@@ ance to certain zu@@ res .
Di@@ dan@@ os@@ in ) , it is advis@@ able to take this more than one hour before or after the gener@@ ase , otherwise the effects of A@@ gener@@ ase should be decreased .
dosage of as@@ gener@@ ase capsules amounts to 600 mg twice a day together with other anti@@ oph@@ thal@@ al drug .
if your doctor decides that intake of rite for you are not suitable , you will take higher dos@@ es ( 1200 mg Am@@ wel@@ ba@@ r twice daily ) .
85 Dam@@ it A@@ gener@@ ase a great benefit , it is very important that you have prescribed your doctor if your doctor has prescribed your doctor .
if you have taken a bigger amount of as@@ ase when you have taken longer than the prescribed dose of as@@ ase , you should contact your doctor or pharmac@@ ist .
if you forget the intake of A@@ gener@@ ase If you forget the intake of the gener@@ ase , take it as soon as you think , and contact you as far as far .
in the treatment of a HIV infection it is not always possible to say whether such adverse effects through the gener@@ ase , caused by other medicines , which may be taken at the same time , or through the HIV disease itself .
head@@ aches , ti@@ red@@ ness , disease , vom@@ iting , vom@@ iting , bl@@ ess@@ ments ( Romans , bli@@ ss or it@@ ching ) - occasionally may be the skin of serious nature and you to break the remedy of this medication .
mood , depression , sleep disorders , appetite and appetite in the lips , and in the mouth , un@@ controlled movements of pain , un@@ well @-@ aci@@ dity , soft chairs , rise of a enz@@ yme called am@@ y@@ las@@ e .
increased blood values for sugar or cholesterol ( a specific BLU@@ ES and cholesterol ) of a substance called Bi@@ li@@ ru@@ ba sw@@ elling of the body , the lips and the tongue ( An@@ gi@@ o@@ ily ) .
this can be fat loss in legs , arms and in the face , a fat scarf on the belly and in other inner organs , breast magni@@ fication and fat loss in the neck ( &quot; strings &quot; ) .
please inform your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
therefore it is important that you can read the section &quot; In case of your gener@@ ase with other medicines , &quot; before you start with the intake of the gener@@ ase .
in some patients who obtain a anti@@ retro@@ vir@@ al combination can be used as ost@@ e@@ op@@ sis ( de@@ die of bone tissue from bone tissue from bone tissue ( in@@ adequate blood supply of bone ) in bone illnesses .
Di@@ dan@@ os@@ in ) , it is advis@@ able to take this more than one hour before or after the gener@@ ase , otherwise the effects of A@@ gener@@ ase should be decreased .
94 Dam@@ it A@@ gener@@ ase a great benefit , it is very important that you have prescribed your doctor if your doctor has prescribed your doctor .
if you forget the intake of A@@ gener@@ ase If you forget the intake of the gener@@ ase , take it as soon as you think , and put it as far as before .
head@@ aches , ti@@ red@@ ness , disease , vom@@ iting , vom@@ iting , bl@@ ess@@ ments ( Romans , bli@@ ss or it@@ ching ) - occasionally may be the skin of serious nature and you to break the remedy of this medication .
please inform your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
dosage of as@@ gener@@ ase capsules amounts to 600 mg twice a day together with other anti@@ oph@@ thal@@ al drug .
in order to get a great benefit , it is very important that you have prescribed your doctor to take your doctor if you have prescribed your doctor .
if you have taken a larger quantities of A@@ gener@@ ase when you have taken longer than the prescribed dose of as@@ ase , you should contact your doctor or pharmac@@ ist .
the benefits of Rit@@ on@@ avi@@ r &quot; as@@ oo@@ ster@@ ter &quot; as@@ simil@@ ation solution is neither to be affected by prot@@ e@@ as@@ ticity in patients with prot@@ e@@ as@@ ms treated patients .
for the use of ir@@ ony of ritu@@ als ( usually applied to strengthening the effects of le@@ ase capsules ) together with a gener@@ ase solution to the use of a gener@@ ase solution .
Rit@@ on@@ avi@@ r solution to take @-@ up , or in addition of Prop@@ ylene gly@@ col during the intake of the gener@@ ase solution ( see also the gener@@ ase must not be taken ) .
your doctor may possibly be aware of side effects that are associated with pro@@ u@@ pro@@ ly@@ mp@@ al content of the gener@@ ase solution to remove in connection , in particular if you have an kidney or liver disease .
111 If you take certain drugs that can lead to serious side effects such as Carb@@ ine , phen@@ y@@ to@@ in , Li@@ doc@@ ain , CY@@ CLO@@ SPOR@@ IN , Tac@@ ro@@ li@@ m , pre@@ cy@@ clic@@ al , tri@@ cycli@@ c @-@ anti@@ de@@ press@@ ant and war@@ far@@ in , at the same time such as the gener@@ ase , your doctor may perform additional blood tests to minimize potential problems .
Rit@@ on@@ avi@@ r solution to remove or additional Prop@@ ylene gly@@ col should not take ( see A@@ gener@@ ase should not be taken ) .
important information about certain other ingredients of as@@ gener@@ ase solution to remove the solution to a pro@@ pul@@ l@@ ly@@ col which can lead to side effects in high dos@@ es .
pro@@ pul@@ s@@ ly@@ col can cause a number of side effects including cra@@ mp@@ tor@@ es , cardi@@ ac disease , cardi@@ ac and reduction of red blood body .
if you forget the intake of A@@ gener@@ ase If you forget the intake of the gener@@ ase , take it as soon as you think , and contact you as far as far .
head@@ aches , ti@@ red@@ ness , disease , vom@@ iting , vom@@ iting , bl@@ ess@@ ments ( Romans , bli@@ ss or it@@ ching ) - occasionally may be the skin of serious nature and you to break the remedy of this medication .
this can be fat loss in legs , arms and in the face , a fat scarf on the belly and in other inner organs , breast magni@@ fication and fat loss in the neck ( &quot; strings &quot; ) .
other components are pro@@ propylene gly@@ col , Macro@@ er@@ l 400 ( poly@@ ethylene gly@@ col 400 ) , To@@ co@@ fer@@ sol@@ an ( TP@@ GS ) , To@@ es@@ ul@@ f@@ am @-@ Kali@@ um , Phen@@ omen@@ tho@@ l , Cit@@ ron@@ tho@@ l , Cit@@ ron@@ ens@@ or , Cit@@ ron@@ re@@ cit@@ rate , Nat@@ ri@@ um@@ cit@@ rate @-@ D@@ ih@@ y@@ dra@@ t , ger@@ ated water .
the treatment of the treatment with al@@ dar@@ a depend on the treatment of the treatment with al@@ dar@@ a to a maximum of 16 weeks in the gen@@ ital area of Al@@ dar@@ a to a maximum of 16 weeks in the gen@@ ital area .
the skin depends on the skin of the skin , so that it is enough for a long time ( about eight hours ) before they are washed before they washed .
in all studies Al@@ dar@@ a was compared with a plac@@ ebo ( the same cream , but without active ingredients ) . • Al@@ dar@@ a was tested in four primary studies on 9@@ 23 patients with war@@ ts in the gen@@ ital area each 16 weeks .
the basic agent for the effectiveness was the number of patients with full discharge of the treated rats . • Al@@ dar@@ a was treated to 7@@ 24 patients with small bas@@ al cell car@@ cin@@ oma in two studies where patients were treated for six weeks , and Al@@ dar@@ a or the plac@@ ebo either day or five times a week .
the basic agent for the effectiveness was the number of patients with full discharge of the tum@@ ours after twelve weeks . • Al@@ dar@@ a was tested in two studies on a total of 505 patients with ac@@ tin@@ ic ker@@ at@@ ars .
in all studies , Al@@ dar@@ a is more effective than the plac@@ ebo . • For the treatment of war@@ nings in gen@@ ital treatment in all four main instruments 15 % up to 52 % in the plac@@ ebo @-@ treated patients , but only 3 % to 18 % in the plac@@ ebo @-@ treated patients in comparison with Al@@ dar@@ a treated patients compared to 0 % to 3 % in plac@@ ebo group .
the most common side effects of Al@@ dar@@ a ( observed in more than 1 of 10 patients ) are reactions to the use of cream ( pain or it@@ ching ) .
on the other hand , hyper@@ ker@@ at@@ ot@@ opic , non @-@ hyper@@ tro@@ phy , not hyper@@ tro@@ phic ker@@ at@@ pants ( AK@@ s ) in the face or on the scal@@ p at immun@@ otherapy adults , if the size or the number of ti@@ ghts the effectiveness and / or acceptance of a cr@@ y@@ otherapy .
Monday , Wednesday and Friday , Saturday or Tuesday , Thursday and Saturday ) before the Z@@ ub@@ ette were up to 10 hours at the skin .
treatment with I@@ mi@@ qu@@ im@@ od @-@ cream is so long as long as all visible ca@@ vern@@ s in gen@@ ital or Peri@@ pher@@ als are disappeared or up to 16 weeks per treatment period .
the inter@@ ruption of the procedure described in the procedure of the procedure should occur if intensive local inflam@@ matory reactions occur ( see Section 4.4 ) or when treatment is observed .
if at the setting up examination of 4 to 8 weeks after the second treatment period the treated lung function should only be invisible , another therapy should be started ( see Section 4.4 ) .
if a dose was released , the patient was noticed , as soon as he / she noticed it and then continue with the usual therapy plan .
I@@ mi@@ qu@@ im@@ od @-@ cream is composed in a thin layer and cleaned , with wr@@ inkl@@ ing in@@ infected skin area , until the cream is completely exhau@@ sted .
it should take place in these patients , using I@@ mi@@ qu@@ im@@ od and with a potential dis@@ rup@@ tive risk of their auto@@ immune diseases .
it should take place in this case if the benefits of a treatment with I@@ mi@@ qu@@ im@@ od and with a possible organ transplan@@ tation or GRA@@ FT @-@ versus @-@ Host@@ - response .
in other studies , in which no daily pre@@ h@@ auth@@ y@@ giene was performed , two cases were observed , two cases were observed with a circum@@ c@@ ision .
in a application of I@@ mi@@ qu@@ im@@ od @-@ cream into higher than the recommended dos@@ es , there is a higher risk of heavy @-@ skin irrit@@ ations ( see Section 4.2 ) .
in cases where such reactions occur at the output of the ur@@ ine , some women had difficulties in water , which needed a not@@ ari@@ zation and a treatment of the affected area required .
the application of I@@ mi@@ qu@@ im@@ od @-@ cream is directly responsible for the treatment of external blin@@ dness in the Gen@@ ital and Peri@@ pher@@ om@@ ile area as previously no clinical experiences yet .
limited data can be found on a higher rate of F@@ eig@@ ma reduction in patients with HIV positive patients , I@@ mi@@ qu@@ im@@ od @-@ cream , however , in respect to elim@@ ination of the compound , however , a lower effectiveness .
the treatment of the bas@@ al cell car@@ cin@@ oma with I@@ mi@@ qu@@ im@@ od within 1 cm around the eye , the nose , the lips or the hair loss was not investigated .
local power reactions are often , but the intensity of these reactions occur in general during therapy or reactions occur after completion of the treatment with I@@ mi@@ qu@@ im@@ od @-@ cream .
if it is necessary due to the complaints of the patient or due to the dis@@ appointment of the local control activities , a treatment period of several days can be made .
the clinical outcome of the therapy can be evaluated after re@@ generation of the treated skin about 12 weeks after the treatment .
there is no data about the long @-@ term therapeutic rates of more than 36 months after the treatment at super@@ fic@@ al bas@@ al cell car@@ cin@@ ogen@@ ic treatments .
patients with re@@ zi@@ ating and pre @-@ treated B@@ CC@@ s are no clinical experiences yet , therefore the application is not recommended for pre @-@ treated tumor .
data from an open clinical trial indicate that in large tum@@ ours ( &gt; 7.@@ 25 c@@ m2 ) is a decrease of the response to the I@@ mi@@ qu@@ im@@ od therapy .
I@@ mi@@ qu@@ im@@ od was not studied in the treatment of acute trau@@ ma , in the inside of the nose or ears , or on the Li@@ ppen@@ field .
there are only very limited data via the application of I@@ mi@@ qu@@ im@@ od for treatment of ac@@ tin@@ ic ker@@ at@@ ars in anatom@@ ical positions outside of the facial and scal@@ p .
the available data about the ak@@ tin@@ ische cher@@ ries on the lower and hands the effectiveness of this use is not recommended , such as such application is not recommended .
these reactions occur often , but these reactions occur usually in the course of treatment to intensity or go after the therapy with I@@ mi@@ qu@@ im@@ od @-@ cream .
if the local van@@ guard of the patient could cause large dis@@ comfort or very strong , the treatment can be exposed to a few days .
&quot; &quot; &quot; results appear ordered &quot; &quot; &quot; &quot; by relevance &quot; &quot; &quot; &quot; or &quot; &quot; &quot; &quot; by date &quot; &quot; &quot; &quot; ( publication date ) , &quot; &quot; &quot;
due to immun@@ os@@ stimul@@ ating properties , I@@ mi@@ qu@@ im@@ od ™ should be applied to patients who receive immun@@ os@@ upp@@ res@@ sive treatment ( see 4.4 ) .
apart from animal studies , no direct or indirect effects on the pregnancy , the embr@@ y@@ onic / f@@ öt@@ als development , the un@@ cover or the post@@ nat@@ al development ( see 5.3 ) .
although neither according to the mal@@ function of quanti@@ fied ser@@ rate ( &gt; 5@@ ng / ml ) , no recommendation can be used during the stand@@ still .
the most frequently updated and possibly possibly by the application of I@@ mi@@ qu@@ im@@ od @-@ cream in relation to the studies of I@@ mi@@ qu@@ im@@ od @-@ cream ( 33.@@ 7 % of the I@@ mi@@ qu@@ im@@ od patients ) .
to the most commonly reported and likely , or possibly by the application of I@@ mi@@ qu@@ im@@ od @-@ cream in relation to the side effects are reduced by a frequency of 28,@@ 1 % .
the 185 with I@@ mi@@ qu@@ im@@ od @-@ cream treated Bas@@ ali@@ om patients from a plac@@ ebo @-@ controlled clinical trial of the phase III of the effects are displayed .
the most common , likely or possibly with the application of I@@ mi@@ qu@@ im@@ od @-@ cream in the following studies were a reaction to this studies at the application location ( 22 % of the I@@ mi@@ qu@@ im@@ od patients ) .
side effects that were indicated by 252 in the plac@@ atic controlled clinical studies of Phase III with I@@ mi@@ qu@@ im@@ od @-@ cream and treated patients with ac@@ tin@@ ic ker@@ at@@ osis are listed below .
these according to test schedule the clinical signs shows that it is commonly used in these plac@@ ebo @-@ controlled clinical studies with three times weekly treatment with I@@ mi@@ qu@@ im@@ od @-@ cream , including exhaus@@ tion / ab@@ stain@@ s ( 61 % ) , recy@@ cl@@ ation / drain / drain ( 14 % ) ( see Section 4.4 ) .
these according to test schedule , the assessment of the clinical signs shows that in these studies with five times weekly treatment with I@@ mi@@ qu@@ im@@ od @-@ cream is very frequently too difficult to severe wor@@ sen@@ sions ( 31 % ) , heavy cum@@ bers ( 13 % ) , and increased loss ( 19 % ) .
for clinical studies at the application of I@@ mi@@ qu@@ im@@ od for the treatment of acute trau@@ mat@@ osis , Alo@@ is zie a frequency of 0.@@ 4 % ( 5 / 12@@ 14 ) to the treatment centre or in the surrounding area .
the acci@@ dental intake of 200 mg I@@ mi@@ qu@@ im@@ od , which corresponds to the contents of approximately 16 lo@@ aves could lead to exercise , vom@@ iting , head@@ aches , my@@ al@@ ms and fever .
the clin@@ ically significant side effect that resulted in several or@@ als of &gt; 200 mg up , consisted in hyp@@ ot@@ ony , which norm@@ alized to or@@ ally or intra@@ ven@@ ous fluid reduc@@ tions .
in a pharmac@@ ological study according to top@@ ical application of I@@ mi@@ qu@@ im@@ od @-@ system@@ ic concent@@ rations of the Alpine ha@@ eg@@ ons and other cy@@ tok@@ ines .
in 3 monitoring phase II , the eff@@ ic@@ acy data could be shown that the effectiveness in relation to a complete evaluation of the F@@ eig@@ ma treatment over 16 weeks of plac@@ ebo @-@ treatment is quite superior to a plac@@ ebo @-@ treatment .
in 60 % of the total population of patients with I@@ mi@@ qu@@ im@@ od patient treat@@ ment@@ ed patients in patients with plac@@ ebo . this was in 20 % of the 105 with plac@@ ebo . patients ( 95 % CI :
a complete divi@@ ding could be reached with 23 % of 157 by I@@ mi@@ qu@@ im@@ od treated male patients with plac@@ ebo @-@ treated male patients ( 95 % CI :
I@@ mi@@ qu@@ im@@ od &apos;s effectiveness of I@@ mi@@ qu@@ im@@ od for five weeks has been examined in two double @-@ blind , plac@@ ebo @-@ controlled clinical studies .
the cross @-@ tum@@ ors were the hist@@ ologically active super@@ fi@@ ci@@ elle bas@@ al cell car@@ cin@@ oma with a minimum size of 0.5 c@@ m2 and a maximum diameter of 2 cm .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
the eff@@ ic@@ acy of I@@ mi@@ qu@@ im@@ od &apos;s effectiveness in one or two treatment period of 4 weeks , interrupted by a four @-@ blind , treated free time period , was examined in two double @-@ blind , plac@@ ebo @-@ controlled clinical studies .
the patients had clin@@ ically typical , visible , discre@@ te , not hyper@@ ker@@ at@@ ot@@ ische , not HY@@ PER@@ TRO@@ PH@@ E AK@@ - L@@ ä@@ o@@ ists within a related 25 c@@ m2 large treatments than on the un@@ ha@@ iry of scal@@ p or in the face .
the inclusion data made of two combined observ@@ ational studies indicate that patients with clinical ab@@ duction of 27 % ( 35 / 128 patients ) .
the approved indications , actor , actor and super@@ sti@@ cal bas@@ al cell car@@ cin@@ oma are usually not on and were therefore not investigated .
this paper investigates the impact of non @-@ take @-@ up for two hypothe@@ tical scenarios , namely increasing and decreasing the base amount of social assistance in Germany by € 100 per month . IAB @-@ Discussion Paper 20 / 2015
the effectiveness of I@@ mi@@ qu@@ im@@ od could not be shown in these studies ( 3x / week for a period of ≤ 16 weeks ) .
a minim@@ alist recording of the 5 % of I@@ mi@@ qu@@ im@@ od @-@ cream by the skin of 58 patients with ac@@ tin@@ ic ker@@ at@@ ose was observed in three times weekly basis during 16 weeks .
the highest pharmaceutical concent@@ rations in the ser@@ um at the end of the week 16 were observed between 9 and 12 hours and bet@@ tered 0.1 , 0.2 and 1.6 ng / ml for application in the face ( 12.5 mg , 1 bag ) , on the hand / arms ( 75 mg , 6 bags ) .
the calculated semi @-@ value date was approximately 10@@ times higher than the 2@@ hours of half @-@ value due to the sub@@ cut@@ aneous application in a previous study ; that indicates a longer retention of the drug using the skin .
data for system@@ ic exposure showed that the Res@@ or@@ ption of I@@ mi@@ qu@@ im@@ od after top@@ ical application on MC @-@ disease was low and comparable to the age of 6 - 12 years and comparable was comparable with healthy adults and adults with ac@@ tin@@ ic bas@@ al cell car@@ cin@@ oma .
in a four month study used to produce tox@@ icity in rats developed by 0.5 and 2.5 mg / kg kg also significantly boost weight of body weight and increased Mil@@ z weight ; it also showed four months long @-@ term study for the application using mouse no similar effects .
a two @-@ year study for car@@ cin@@ ogen@@ icity in mice with mice received at three days per week , no tum@@ ours on the use interface .
the appropriate mechanism is not known , but as I@@ mi@@ qu@@ im@@ od only has a low system absorption from human skin and not mut@@ ations , is a risk for people due to system@@ ic exposure as a very low .
the tum@@ ours began in the group of mice , which was treated with the effective @-@ free cream , formerly and in larger number than in the control group with lower U@@ VR .
it can harm other people even if these are the same symptoms as you .
● F@@ eig@@ ware ( Con@@ d@@ yl@@ om@@ ata ac@@ umin@@ ata ) , which formed on the skin in the body of gen@@ it@@ als ( sexual organs ) and An@@ us ( after ) are formed , slow growing , slow growing form of skin cancer with very low lik@@ eli@@ hood of the spread on other parts of the body .
treatment : untreated clarity : opaque 1 piece 25x@@ 18 mm EUR@@ 14.@@ 40 &lt; &lt; BACK TO CATEGORY tour@@ maline ( ver@@ del@@ ite ) Add to Cart
actors are rough areas of skin that occur with people who are exposed to people who were exposed throughout their previous life .
Al@@ dar@@ a should only be applied at shallow depression in the face and on the scal@@ p in patients with a healthy immune system where your doctor has decided that Al@@ dar@@ a is the best suitable treatment .
Al@@ dar@@ a cream supports your physical immune system in the production of natural substances that help your body , the super@@ ficial bas@@ al cell car@@ cin@@ oma , the ak@@ tin@@ ic ker@@ at@@ osis , or for infection with the infection of the virus .
if you have been used once Al@@ dar@@ a cream or other similar products , please inform your doctor if you have problems with your immune system . if you have problems with your immune system , please ask your doctor if you have problems with your immune system . if you have problems with your immune system , please ask your doctor if you have problems with your immune system .
with acci@@ dental contact the cream is not in@@ sol@@ uble with water . you do not leave the cream after the cure of al@@ dar@@ a cream . if reactions occur after the treatment of al@@ dar@@ a cream do not apply to the treat@@ ment@@ .@@ o if you are able to prepare the strong in@@ convenience , wash the cream with a mild soap and water .
as soon as the reactions occur , you can continue the treatment . o Inform@@ ations your doctor if they don &apos;t have a normal blood image
these daily cleaning under the fores@@ kin is not carried out with increased occurr@@ ence of dis@@ rup@@ tions of sw@@ elling , fertilizer , skin or difficulty breathing during the fores@@ kin .
turn al@@ dar@@ a creme to U@@ re@@ th@@ ra ( ur@@ ine ) , in the vagina ( she@@ en ) , the Zer@@ vi@@ x ( Geb@@ y@@ mut@@ ter@@ h@@ als ) or within the An@@ us ( after ) .
taking other medicines serious problems with your immune system you should use this medication for no more than one treatment cycle .
if you have sexual inter@@ course in the gen@@ ital area inter@@ course , the treatment with Al@@ dar@@ a cream after sexual inter@@ course ( not before ) .
please inform your doctor or pharmac@@ ist if you apply other drugs or recently or recently applied to prescription drugs .
sti@@ llen an inf@@ ant while the treatment with al@@ dar@@ a cream is not known whether I@@ mi@@ qu@@ im@@ od occurs in the mother &apos;s milk .
frequency and duration of treatment are different in barrels , bas@@ al cell car@@ cin@@ oma and ak@@ tin@@ ic ker@@ at@@ ose ( see specific instructions for any application area ) .
apply a thin layer Al@@ dar@@ a cream on the clean , dry skin element with the wr@@ inkl@@ ing and put the cream carefully on the skin , until the cream is completely exhau@@ sted .
men with filling out under the fores@@ kin need the fores@@ kin any day and wash the skin area below ( see Section 2 ) What must you be aware of Al@@ dar@@ a cream ( see section 2 ) .
please talk to your doctor or pharmac@@ ist if you have the impression that the effect of algae is too strong or weak .
for 6 weeks for 5 days a week after a sufficient amount of Al@@ dar@@ a cream to cover the affected area and 1 cm around this area .
very frequent side @-@ effects ( in less than 1 of 10 patients ) Frequ@@ ently side effects ( less than 1 of 10 patients ) are expected to expect significant side effects ( less than 1 of 10 patients )
inform your doctor / your doctor or pharmac@@ ist / your pharmac@@ ist immediately if you do not feel at the application of Al@@ dar@@ a cream .
if your skin is too strong on the treatment with Al@@ dar@@ a cream , you should not use the cream using water and mild soap and wash your doctor or pharmac@@ ist .
a lower number of blood bo@@ ils may cause you to make an@@ tig@@ rid of infections ; it can cause you to get rid of a bl@@ ender , or they can call de@@ bug@@ ging .
inform your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
in addition , Ju@@ ck@@ rei@@ z ( 32 % of the patient ) , burning ( 26 % of the patient ) or pain in the areas where you have applied al@@ dar@@ a cream ( 8 % of patients ) .
usually it is easier to draw attention within about 2 weeks after treatment of the treatment .
occasionally , some patients have changes on application site ( wound healing , inflammation , sw@@ elling , skin destro@@ ying , bli@@ stering , dry mouth , dry mouth , gri@@ t similar symptoms and ti@@ red@@ ness .
occasionally some patients suffer from application on application site ( bru@@ te , inflammation , sw@@ elling , sw@@ elling , sw@@ elling , sw@@ elling , sw@@ elling , sw@@ elling , sw@@ elling , sw@@ elling , sw@@ elling , facial cum@@ ulus , pain , g@@ astro@@ us , pain , weakness , weakness , weakness or ch@@ ills .
Al@@ dur@@ az@@ ol is applied for the enz@@ yme treatment in patients with secured diagnostic of a Mu@@ kop@@ ol@@ ys@@ ac@@ chari@@ dosis I ( M@@ PS I ; α -@@ L @-@ I@@ dur@@ oni@@ d@@ ase defici@@ ency ) to treat the non @-@ neuro@@ logical manifest@@ ations ( the symptoms associated with brain or nerve cells ) .
this means that certain substances ( gly@@ cos@@ amin@@ og@@ ly@@ cans , G@@ ags ) are not re@@ built and thus gets in most of the organs in the body .
the following non @-@ neuro@@ logical symptoms of M@@ PS I may occur : increased liver , rigid joints , the movements , reduce lung volume , heart and oph@@ thalm@@ ology .
the treatment with Al@@ dur@@ az@@ ol should be monitored by a doctor that has the experience in the treatment of patients with m@@ PS I or other met@@ abolic disorders .
the administration of Al@@ bi@@ az@@ ym should take place in a hospital or clinic with re@@ vit@@ ating equipment and patients need to prevent appropriate medicine to prevent an allergi@@ c reaction .
( 44 @-@ 20 ) 74 18 86 00 Fax ( 44 @-@ 20 ) 74 18 86 68 E @-@ mail : mail @ em@@ e@@ a.@@ o. htt@@ p : / / www.@@ em@@ e@@ a.@@ europ@@ a.@@ eu
in the study was measured mainly in the study was measured by the security of the drug , but it was also measured by the effectiveness of the drug concent@@ rations in relation to the reduction of the G@@ AG concent@@ rations in the ur@@ ine and in relation to the size of the liver .
for children under five years of age , Al@@ dur@@ az@@ iland the G@@ AG concent@@ rations of the ur@@ ine around 60 % , and half of the treated children reported in the end of the study a normal liver .
the most common side effects of algae in patients at age of over five years ( observed in more than 1 of 10 patients ) , head@@ aches , abdominal pain , skin r@@ ash , skin r@@ ushes , pain and reactions in the gli@@ sh ( in hands and feet ) , heat treatment , fever and reactions to in@@ fusion interface .
very frequent side @-@ effects in patients with five years increased blood pressure , reduced oxygen satur@@ ation ( acceler@@ ated heart rate ) , t@@ ungsten car@@ ts ( acceler@@ ated heart rate ) , fever and ch@@ ills .
Al@@ dur@@ az@@ ym consists of patients who might react very sensitive ( allergi@@ c ) to Lar@@ oni@@ om@@ ase or one of the other components ( an@@ ap@@ hy@@ l@@ act@@ ant reaction ) .
the European Medic@@ ines Agency ( EME@@ A ) will be well @-@ known every year all the new information that may be known , and that summary should be at best possible .
the manufacturer of Al@@ dur@@ az@@ ym will receive patients who observe the algae of algae in order to observe the in@@ fusion and development of anti@@ bodies .
in June 2003 , the European Commission opened the European Commission of Gen@@ zy@@ me Europe B.@@ V. an authorization for the transport of Al@@ bi@@ az@@ iland throughout the European Union .
Lar@@ oni@@ d@@ ase is a re@@ combin@@ ant form of human@@ ities -@@ L @-@ I@@ bra@@ oni@@ d@@ ase and is produced using re@@ combin@@ ant DNA technology with using re@@ combin@@ ant DNA technology .
Al@@ dur@@ az@@ ym is the long @-@ term inf@@ rin@@ gement of patients with secured diagnostic of a Mu@@ kop@@ ol@@ ys@@ ac@@ chari@@ dosis I ( M@@ PS I , α -@@ L @-@ I@@ dur@@ oni@@ d@@ ase defici@@ ency ) in order to treat the non @-@ neuro@@ logical manifest@@ ations of the disease ( see section 5.1 ) .
the treatment with Al@@ dur@@ az@@ ol should take place by a doctor that has experience in the treatment of patients with M@@ PS I or other met@@ abolic disease .
the initial in@@ fusion rate of 2 E / kg / h when the patient contributes to a maximum dose of 43 E / kg / h .
the safety and effectiveness of Al@@ dur@@ az@@ ol at adults over 65 years has not been obtained , and for this patient cannot be recommended .
the safety and eff@@ ic@@ acy of algae cells in patients with kidney or liver failure has not been obtained , and for this patient cannot be recommended .
with Al@@ dur@@ az@@ ym treated patients , patients can develop in@@ fusion @-@ related reactions that are defined as each in relation to the fusion of in@@ fusion or until the end of the In@@ fusion Tour ( see Section 4.8 ) .
for this reason , these patients should continue to be monitored , and the in@@ fusion of Al@@ bi@@ az@@ ome should take place in a reasonable clinical environment in the re@@ vit@@ alisation of medical emergency cases .
due to the clinical phase 3 study is expected that nearly all patients Ig@@ G @-@ anti@@ bodies are formed against lar@@ oni@@ fer@@ ase , usually within 3 months from the treatment beginning .
patients , anti@@ bodies or symptoms of in@@ fu@@ sion@@ ist reaction , must be treated with caution ( see Sec@@ ure@@ 4.3 and 5.7 ) .
because little experience concerning the recovery of the treatment after a longer inter@@ ruption , must be careful because of the increased risk reduction after an inter@@ ruption of the treatment .
60 minutes before the start of in@@ fusion with medication ( anti @-@ hist@@ amine and / or anti@@ py@@ re@@ tika ) to minim@@ ise the potential occurr@@ ence of in@@ fusion reactions .
in case of a light or medium hard @-@ resistant reaction , the treatment with anti @-@ hist@@ amine and par@@ acet@@ am@@ ol / I@@ bu@@ pro@@ fen , and / or a reduction of in@@ fusion rate , in half of the in@@ fusion rate , in which the reaction has occurred .
in case of individual , severe in@@ fusion reaction must be brought to in@@ fusion , the in@@ fusion may be brought to decrease , treatment with anti @-@ hist@@ amine and par@@ acet@@ am@@ ol / I@@ bu@@ pro@@ fen .
the in@@ fusion can be recorded with a reduction of in@@ fusion rate to 1 / 2 - 1 / 4 of in@@ fusion rate , which is recorded in response to the reaction .
3 are used ( anti@@ hist@@ amine and par@@ acet@@ am@@ ol / I@@ bu@@ pro@@ ps and / or cor@@ ti@@ co@@ ster@@ oids ) , as well as reduction of in@@ fusion rate to 1 / 2 - 1 / 4 of in@@ fusion rate , in which the preceding reaction is detected .
Al@@ dur@@ az@@ ym should not be applied at the same time with chlor@@ o@@ qu@@ in or Proc@@ ain , because a potential risk of interaction with intra@@ cellular connection of Lar@@ oni@@ d@@ ase .
the experimental studies cannot be found on direct or indirect effects on the pregnancy , the embr@@ y@@ onic / o@@ ale development , birth and post@@ nat@@ al development ( see Section 5.3 ) .
as a result , no data at Neu@@ born , which were exp@@ on@@ ated towards Lar@@ oni@@ d@@ ase over the mother &apos;s milk is recommended , while the treatment with Al@@ dur@@ az@@ ome is not sti@@ g@@ ated during the treatment with Al@@ dur@@ az@@ ome .
adverse events in clinical trials were discussed as in@@ fu@@ sion@@ ary reactions caused by 53 % of patients in the phase @-@ 3 study ( treatment period up to 4 years ) and at 35 % of patients in the study with participants under 5 years ( treatment period up to 1 year ) .
un@@ desired drug interactions in connection with Al@@ dur@@ az@@ ym that were observed during the phase II study and their extension with a total of 45 patients ( ≥ 1 / 10 ) ; frequently ( ≥ 1 / 100 to &lt; 1 / 10 ) .
in some patients with severe M@@ PS @-@ I @-@ conditional participation of the upper resp@@ ir@@ atory tra@@ ct and lungs in the history , beyond , heavy reactions , including Bron@@ ch@@ os@@ pas@@ m , resp@@ ir@@ rel and facial expressions ( see Section 4.4 ) .
children un@@ desired drug interactions in connection with Al@@ dur@@ az@@ ol , which were reported in the age of 5 patients with a total of 20 patients in the age of 5 years , were reported in the age of 5 months , were reported in the table .
100 E / kg in@@ ven@@ ous once weekly ( recommended dose ) , 200 E / kg intra@@ ven@@ ous once weekly , 200 E / kg intra@@ ven@@ ous all 2 weeks or 300 E / kg intra@@ ven@@ ous all 2 weeks .
in most cases , patients came within 3 months after the treatment for a ser@@ o@@ con@@ version , while the patients died under 5 years after the age of 5 days ( average after 26 days after 45 days at age of 5 years and older ) .
according to the end of the phase 3 study ( or up to a premature expi@@ ration of the study ) , 13 / 45 patients are not detected by Radio@@ kan@@ op@@ hr@@ enia ( RI@@ P ) as@@ certain@@ ment anti@@ bodies , including 3 patients , where it was never too busy .
patients with inf@@ erior to lower anti@@ bodies - a robust reduction in the G@@ AG Spi@@ eg@@ els in Har@@ n , during patients with high anti@@ bodies a variable reduction of G@@ AG in Har@@ n .
four patients ( three in the phase @-@ 3 study and one in the phase @-@ 2 study ) showed a margin@@ ale to low neutral in@@ hi@@ bit@@ ory effects on enz@@ ym@@ atic lar@@ oni@@ ze activity in vitro , which could not affect the clinical effectiveness and / or reducing G@@ AG in Har@@ n .
the presence of anti@@ bodies appeared not in connection with the intra@@ ocular un@@ desirable drug reactions , even if the occurr@@ ence of un@@ desired drug reactions occur usually with the formation of Ig@@ G anti@@ bodies .
the reason for the enz@@ yme treatment lies in one for the hydro@@ ly@@ sis of the accumulation of the sub@@ strate and the prevention of a further accumulation of enz@@ yme .
after intra@@ ven@@ ous in@@ fusion , Lar@@ oni@@ d@@ ase is quickly removed from the circulation and of cells in Ly@@ s@@ os@@ omas , most likely the most likely about Mann@@ ose @-@ 6 phosph@@ ate recep@@ tors .
the security and eff@@ ic@@ acy of algae were formed in a random@@ ised , dou@@ blin@@ ding , plac@@ ebo @-@ controlled phase @-@ 3 study at 45 patients in the age of 6 to 43 years .
although patients were rec@@ alled by the study , the majority of patients from the middle phenomenon , and only one patient was treated with severe phenomena .
patients were recru@@ ited when they had an integral exp@@ ir@@ atory volume ( Fe@@ V ) of less than 80 % of the expected value , and they had to be able to stand for 6 minutes .
the primary end@@ points for the eff@@ ic@@ acy were the pro@@ vision@@ ed change of expected Fe@@ V and the absolute speed of the 6 @-@ min@@ ut@@ ors .
all patients were subsequently tested for an open label @-@ extension study , where she received additional 3.5 years ( 182 weeks ) each week 100 e / kg Al@@ dur@@ az@@ ym .
after 26 weeks therapy was treated with Al@@ dur@@ az@@ ym treated patients with the placement of lung function and the ability to be depicted in the following table .
in the open @-@ extension study , an improvement and / or maintaining this effects of up to 208 weeks in the Al@@ dur@@ az@@ ym / Al@@ dur@@ az@@ ym group and 182 weeks in the plac@@ ebo / Al@@ dur@@ az@@ ym group , as follows from the following table .
the acceptance of the expected exp@@ on@@ ary Fe@@ V is not significantly significant and the absolute lung volum@@ ina increased significantly to the body size @-@ growing children .
from the 26 patients with a hep@@ atom@@ eg@@ aly prior to treatment : 22 ( 85 % ) until the end of the study a normal liver size .
within the first 4 weeks , a clear waste of G@@ AG @-@ mirror in Har@@ n ( µ@@ g / mg Kre@@ at@@ in@@ ine ) was established until the study period remained constant .
in addition to the hetero@@ geneous cases of disease between the patients , the clinical significant changes were taken into consideration by using a combined final result ( compared to 14 patients ( 58 % ) , no change in 10 patients ( 22 % ) , no change in 10 patients ( 20 % ) and a decrease of 9 patients ( 20 % ) .
it was conducted in an open phase 2 study conducted in which mainly the safety and Phar@@ mak@@ ok@@ ine@@ tics of Al@@ dur@@ az@@ ol at 20 patients were examined at the time of their intake in 5 years ( 16 patients with severe con@@ flu@@ ence form and 4 with the mean follow @-@ form ) .
four patients had increased the dosage due to increased G@@ AG@@ - mirror in Har@@ n in week 22 in the last 26 weeks to 200 E / kg .
with several patients , a size growth ( n = 7 ) and a weight gain ( n = 3 ) and all 4 patients with the mean follow @-@ form ( &lt; 2.5 years ) and all 4 patients with severe con@@ form@@ ulation form , whereas in patients with severe con@@ form@@ ulation form , only limited or no progress in cognitive development .
in a phase 4 study tests were conducted using pharmac@@ o@@ co@@ dynamic effects of different Al@@ dur@@ az@@ ol gly@@ cer@@ ol chemicals to the G@@ AG mirror in Har@@ n , the liver volume and 6 @-@ minute @-@ test results .
100 E / kg in@@ ven@@ ous once weekly ( recommended dose ) , 200 E / kg intra@@ ven@@ ous once weekly , 200 E / kg intra@@ ven@@ ous all 2 weeks or 300 E / kg intra@@ ven@@ ous all 2 weeks .
the dosing ema with 200 E / kg in@@ ven@@ ous all 2 weeks can have difficulties in patients , the difficulties with a weekly in@@ fu@@ sions , however is not proved that the long @-@ term clinical effectiveness of these two dos@@ es form is equal .
the European Medic@@ ines Agency ( EME@@ A ) will make any new information that are available annually , and if necessary , the summary of the condition will be updated .
Ph@@ armac@@ ok@@ ine@@ tic profile in patients aged 5 years ago , similar to older and less strongly affected patients .
based on conventional studies on safety sp@@ har@@ mac@@ ology , tox@@ icity in mal@@ ign@@ ant treat , tox@@ icity and reproduction of re@@ productive data , the pre@@ clinical data are no particular haz@@ ards for humans .
there are no mat@@ urity of studies , this medication may not be mixed with other medicines , except under 6.@@ 6 .
if the use of use is not used immediately , this is not longer than 24 hours at 2 ° C - 8@@ º C if the use under controlled and vali@@ dated patients .
5 ml concentrate on the manufacture of a solution in continuous bottle ( type I @-@ glass ) with plug ( silicone chlor@@ but@@ yl rubber ) and sealing ( aluminium ) with tear @-@ off cap ( polypropylene ) .
10 preparation of the algae plant in@@ fusion ( by as@@ ep@@ tic technology ) • J@@ e after body weight of the individual patients first to determine the number of dil@@ uted penetration .
the owner of the approval of approval for the transport system has to complete the following study program which form the basis for the benefit of the annual review results for the benefit of the benefit .
this register is recommended for long @-@ term safety and eff@@ ic@@ acy information to patients who were treated with Al@@ dur@@ az@@ aki , as well as data for the natural propor@@ tion@@ ence of the disease in patients without these treatment .
for patients who suffer from M@@ PS I suffer an enz@@ yme called α -@@ L @-@ I@@ bra@@ oni@@ om@@ ase , the certain substances in the body ( gly@@ cos@@ amin@@ og@@ ly@@ cans ) , either in a smaller amount of or this enz@@ yme is missing .
if you are allergi@@ c ( over@@ sensitive ) compared to the parts of Al@@ dur@@ az@@ ome , or if you have a severe allergi@@ c reaction to Lar@@ oni@@ d@@ ase .
an in@@ fusion @-@ conditioned reaction is any side effect that occurs during in@@ fusion or until the end of the In@@ fusion Tour ( see Section 4 of What effects are possible ) .
in application of Al@@ dur@@ az@@ iland with other medicines please inform your doctor if you are pregnant , the Chlor@@ o@@ qu@@ in or Proc@@ ain , because an impossible risk of a decrease effect of algae disease exists .
please inform your doctor or pharmac@@ ist if you have other drugs or have recently taken some prescription , including non @-@ prescription drugs .
the application for handling and application The concentration of the production solution must be dil@@ uted and is intended for intra@@ ven@@ ous application ( see Information for doctors and medical specialists ) .
the initial in@@ fusion rate of 2 E / kg / h when the patient contributes to a maximum dose of 43 E / kg / h .
in some patients with severe M@@ PS @-@ I@@ - un@@ conditional participation of the upper resp@@ ir@@ atory infections and lungs in the history , but heavy reactions , including Bron@@ ch@@ os@@ pas@@ m , resp@@ ir@@ rel and facial expressions .
very often ( occurr@@ ence of more than 1 of 10 patients ) : • head@@ aches , pain , pain , pain , pain , pain , pain , pain , pain in arms and legs • Fl@@ ame • Some oxygen in the blood • reaction to the in@@ fu@@ sion@@ ary station
the European Medic@@ ines Agency ( EME@@ A ) will require any new information that are available annually , and if necessary , the Pack@@ ager will be updated .
if the use of use is not used immediately , this is not longer than 24 hours at 2 ° C - 8@@ º C if the use under controlled and vali@@ dated patients .
preparation of the algae plant in@@ fusion ( by as@@ ep@@ tic technology ) • J@@ e after body weight of the individual patients first to determine the number of dil@@ uted penetration .
A@@ lim@@ ta is applied together with C@@ is@@ pl@@ atin ( a other drug against cancer ) when the cancer is not removed , if the cancer is not removed to other parts of the body .
A@@ lim@@ ta is used in patients who have not treated just yet treated with C@@ is@@ pl@@ atin and patients who have previously applied to other chem@@ otherapy than allergi@@ c therapy .
in order to reduce side effects , the patients should take a cor@@ ti@@ co@@ ster@@ oid as well as foli@@ c acid ( vitamin B@@ 12 ) and injection of vitamin B@@ 12 .
if A@@ lim@@ ta is administ@@ ered together with C@@ is@@ pl@@ atin , in addition , or after the gift of C@@ is@@ pl@@ atin , a &quot; anti@@ em@@ e@@ ology &quot; ( medicine against vom@@ iting ) and liquids ( to prevent a reduction of liquid defici@@ ency ) .
patients , whose blood is changed or where certain other side effects should occur , the treatment should decreased , or the dose should be reduced .
the active form of P@@ ico re@@ cooled down s@@ lower and prevents the formation of DNA and RNA , that cells share cells .
converting P@@ emet@@ re@@ ins into cancer cells easier to be easier than in healthy cells that leads to higher concent@@ rations of the active shape of the medicine by and a longer duration of cancer cells .
A@@ lim@@ ta has been studied at the main study of 456 patients who had received no chem@@ otherapy against their disease .
in the treatment of non @-@ vol@@ atile lung cancer , the effects of A@@ lim@@ ta in a study at 5@@ 71 patients were treated with local advanced or metast@@ atic disease which previously had been treated with a chem@@ otherapy , with the effects of doc@@ et@@ ax@@ el ( one other drugs against cancer ) .
A@@ lim@@ ta was also compared with Gem@@ cit@@ ab@@ in ( another medicine against cancer ) , and both in combination with C@@ is@@ pl@@ atin in a study at 1 7@@ 25 patients who had not received any chem@@ otherapy for lung cancer .
patients who treated with A@@ lim@@ ta and C@@ is@@ pl@@ atin were treated at average 12.@@ 1 month , compared with 9.@@ 3 months compared to the first administration of C@@ is@@ pl@@ atin .
patients who had previously received a chem@@ otherapy was compared with A@@ lim@@ ta 8.2 months compared with 7.@@ 9 months in doc@@ et@@ ax@@ el .
however , in both studies , patients in which the cancer are not the record of the cor@@ relation of epithel@@ ial cells in the administration of A@@ lim@@ ta &apos;s long life times .
in September 2004 the European Commission shared the European Commission on El@@ i Lil@@ ly Wein@@ land B.@@ V. an authorization for the transport of A@@ lim@@ ta in the entire European Union .
each particle size has to be detected with 4,@@ 2 ml 0.@@ 9 % of l@@ oride injection solution ( 9 mg / ml ) , which yields a solution from 25 mg / ml .
the corresponding volume of the necessary dosage is taken out and with 0.@@ 9 % of Nat@@ ri@@ um chl@@ oride @-@ injection solution ( 9 mg / ml ) to 100 ml further ( see Section 6.6 ) .
ALI@@ M@@ TA is shown in combination with C@@ is@@ pl@@ atin in combination with C@@ is@@ pl@@ atin in combination with metast@@ atic or metast@@ atic car@@ cin@@ oma ( see section 5.1 ) .
ALI@@ M@@ TA in mon@@ otherapy is displayed in two @-@ line treatment therapy of patients with lo@@ - K@@ al advanced or metast@@ atic car@@ cin@@ oma ( see section 5.1 ) .
the recommended dose of ALI@@ M@@ TA 500 mg / m ² of body surface ( K@@ of ) is administ@@ ered as in@@ ven@@ ous in@@ fusion about a period of 10 minutes on the first day of any 21 day treatments .
the recommended dose of C@@ is@@ pl@@ atin is 75 mg / m ² K@@ of as in@@ fusion about a period of 2 hours about 30 minutes after finishing the P@@ emet@@ re@@ x@@ ed@@ - in@@ fusion on the first day of any 21 day treatments .
the recommended dose of ALI@@ M@@ TA 500 mg / m ² K@@ of administ@@ ered as in@@ ven@@ ous in@@ fusion about a period of 10 minutes on the first day of every 21 day treatment cycle cycle .
due to the reduction of frequency and sever@@ ity of skin fragments must be given the day before and at the day of the P@@ emet@@ re@@ - gift as well as the day after treatment a cord ost@@ ero@@ id .
during the seven days before the first dose of P@@ emet@@ re@@ des must be taken at least 5 cans of foli@@ c acid and the intake must be continued to be continued throughout the past P@@ emet@@ re@@ x@@ ed@@ - dose .
patients must also have a intra@@ mus@@ cular injection moulding of vitamin B@@ 12 ( 1000 micro@@ dosing ) in the week before the first p@@ ushes re@@ ins as well as after each third breeding cycle cycle .
in patients having obtained a complete blood test should be created prior to any gift of a complete blood image , including a differentiation of the leu@@ ko@@ zy@@ tes and a Th@@ rom@@ bo@@ cy@@ ten@@ sile .
the alkal@@ ine phosph@@ ate ase ( AP ) , A@@ symmet@@ ate trans@@ amin@@ ase ( AST or S@@ GO@@ T ) and Al@@ an@@ in @-@ Trans@@ actions ( AL@@ T or SG@@ PT ) , ≤ 3 @-@ fold the upper limit value .
at the beginning of a new treatment cycle , a d@@ os@@ is@@ cation is to take place under the for@@ tification of the blood vessel or the maximum non @-@ cro@@ mat@@ ological toxic tox@@ icity of the predi@@ ct@@ ory therapy .
after the recovery , patients must be treated accordingly to the tables 1 , 2 and 3 used for ALI@@ M@@ TA as mon@@ otherapy or in combination with C@@ is@@ pl@@ atin .
these criteria correspond to the definition of the National Cancer Institute common Tox@@ ic Drugs ( C@@ TC v@@ 2.0 ; N@@ CI 1998 ) ≥ C@@ TC grade 2 ble@@ eding .
the therapy with ALI@@ M@@ TA , the patient must identify the treatment with ALI@@ M@@ TA , until the patient has the value before the treatment .
the treatment with ALI@@ M@@ TA has to be cali@@ br@@ ated if patients after 2 dys@@ os@@ clerosis chemical tox@@ icity or non @-@ toxic tox@@ icity of 3 or 4 layers or so@@ - fort in the occurr@@ ence of degrees 3 or 4 ne@@ oto@@ x@@ iz@@ ations .
clinical studies have no reference to patients in the age of 65 Jah@@ n or in comparison to patients aged 65 years .
ALI@@ M@@ TA is not recommended for use in children under 18 years due to not sufficient data for in@@ concei@@ vable and eff@@ ic@@ acy .
clinical studies were also necessary in clinical studies with a cre@@ at@@ in@@ in @-@ Clear@@ ance of ≥ 45 ml / min .
the data situation in patients with a cre@@ at@@ in@@ in @-@ Clear@@ ance of under 45 ml / min was not sufficient ; therefore the application is not recommended ( see Section 4.4 ) .
patients with a liver function restri@@ ction of &gt; the top of the top Bi@@ li@@ ru@@ bin@@ ian border assets and / or trans@@ am@@ per@@ sever@@ ance from the upper limit of the upper border ( at the disposal of liver metast@@ ases ) or &gt; 5,0 @-@ fold of the upper border ( at the pre @-@ hand of liver metast@@ ases ) is not specifically analysed in the studies .
patients must be administ@@ ered with regard to the Kno@@ - chen@@ mark@@ ings and P@@ emet@@ re@@ ins may not be given to patients before their absolute neut@@ ro@@ phil@@ atel@@ ic count had a value of ≥ 1500 cells / mm ³ and the Th@@ rom@@ bo@@ - cycles back again a value of ≥ 100,000 cells / mm ³ n .
a D@@ os@@ is@@ reduction for further cycles is based on the size of the absolute neut@@ ro@@ achment number , Th@@ rom@@ bo@@ cy@@ ten@@ ants and maximum non @-@ toxic tox@@ icity , as they observed in the preceding treatment cycles . ( see section 4.2 ) .
a lower tox@@ icity and reduction of the degree 3 / 4 layers of tox@@ icity such as Neut@@ rop@@ en@@ ie , f@@ eb@@ rile neutr@@ rop@@ y and infection with degrees 3 / 4 neutr@@ rop@@ y was observed , when a pre @-@ treatment with foli@@ c acid and vitamin B@@ 12 .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; so , all patients must go to patients , foli@@ c acid and vitamin B@@ 12 , as a proph@@ yl@@ actic measure for reduction of the treatment of tox@@ icity ( see Section 4.2 ) .
patients with light to medium size in@@ suffici@@ ency ( Kre@@ at@@ in@@ in @-@ Clear@@ ance 45 to 79 ml / min ) , as I@@ bu@@ pro@@ fen and Ac@@ et@@ yl@@ s@@ ali@@ - cy@@ te acid ( &gt; 1,3 g daily ) for minimum 2 days prior to therapy with P@@ emet@@ re@@ es ( see Section 4.5 ) .
all patients , for which a therapy with P@@ emet@@ re@@ ins is necessary , the intake of N@@ SA@@ I@@ Ds need a long half @-@ value for minimum 5 days prior to treatment , at the day of therapy and at least 2 days after therapy with p@@ ushes ( see Section 4.5 ) .
many patients , where these events were up , the corresponding risk factors for the occurr@@ ence of ren@@ al events , including Deh@@ ment of hyper@@ tension , or diabetes .
therefore , patients with clin@@ ically significant reduction - treatment of glau@@ coma in trans@@ boundary conditions a drainage of the ergonom@@ ics from the pie@@ zo treatment .
5 severe cardiovascular events including M@@ yo@@ cardi@@ al inf@@ eri@@ als , and zer@@ eb@@ rov@@ ascular events were reported in clinical studies with pesti@@ cides . however , if this active ingredient is usually used in combination with another cy@@ tot@@ ox@@ ic drug .
for this reason , the simultaneous use of the liver cells ( excluding the yellow fever ) , these vacc@@ ination is not recommended ( see Section 4.3 and 4.5 ) .
since the possibility of an ir@@ rever@@ sible decrease in the reproduction of reproduction is caused by P@@ emet@@ re@@ ins , men should be informed of the treatment - are advised to obtain advice regarding the sper@@ ma@@ con@@ dens@@ ation .
patients with regular kidney function ( Kre@@ at@@ in@@ in @-@ Clear@@ ance ≥ 80 ml / min ) , high dos@@ es non ster@@ o@@ id@@ al anti@@ ph@@ onic acid ( ≥ 2.@@ g daily ) and acet@@ yl@@ sal@@ ic@@ y@@ lic acid in high dos@@ es ( ≥ 2.@@ g daily ) .
therefore caution is required if patients with regular kidney function ( Kre@@ at@@ in@@ in @-@ Clear@@ ance ≥ 80 ml / min ) high dos@@ es of N@@ SA@@ I@@ Ds or Ac@@ ousti@@ t@@ yl@@ sal@@ ic@@ y@@ lic acid in high dos@@ es .
I@@ bu@@ pro@@ fen ) or Ac@@ et@@ yl@@ sal@@ ic@@ y@@ lic acid in high dos@@ es for minimum 2 days prior to therapy , therapy and treatment - two days after therapy with P@@ emet@@ re@@ des are avoided ( see Section 4.4 ) .
since there is no data regarding the interaction potential as a N@@ SA@@ I@@ Ds with long semi @-@ value times such as Pi@@ ro@@ - x@@ ic@@ am or Ro@@ dent oxi@@ b , the simultaneous application has to be avoided at least 5 days prior to treatment .
the large in@@ tra @-@ individual vari@@ ability of the sound status during the disease and the possibility of interactions between or@@ ally anti@@ o@@ ag@@ ul@@ ants and ant@@ ine@@ tic chem@@ otherapy , if the decision was made to treat patients with oral anti@@ o@@ ag@@ ul@@ ants .
there are no data for the usage of P@@ ico rec@@ u@@ des during pregnancy , but as at an@@ de@@ - squ@@ ared sti@@ ckers are expected to be expected during pregnancy .
if the cancellation must be applied during pregnancy , unless necessarily required and after careful examination of the service for the mother and the risk for F@@ öt@@ us ( see Section 4.4 ) .
since the possibility of an ir@@ rever@@ sible damage of the reproduction of reproduction by P@@ emet@@ re@@ ins , men should be advised from the treatment of the treatment of the treatment of the sper@@ ma@@ ids .
it is not known whether P@@ ellets re@@ leg@@ ged into the mother &apos;s milk and un@@ desired effect during di@@ still@@ ed species can not be excluded .
the following table shows the frequency and volume of un@@ desirable effects that were reported in &gt; 5 % of 168 patients with Mes@@ o@@ pl@@ atin and P@@ emet@@ re@@ es , and 163 patients with Mes@@ o@@ i@@ oma , the random@@ ized C@@ is@@ pl@@ atin as a mono therapy .
- ≥ 1 / 10 , common ( ≥ 1 / 100 and &lt; 1 / 10 ) , occasionally ( ≥ 1 / 10,000 and &lt; 1 / 100 ) , rare ( ≥ 1 / 10,000 and &lt; 1 / 1000 ) , rare ( ≥ 1 / 10,000 and &lt; 1 / 1000 ) , rare ( ≥ 1 / 10,000 and &lt; 1 / 1000 ) .
* Understand the National Cancer Institute C@@ TC version 2 for any Tox@@ icity of the event &quot; Cre@@ at@@ in@@ in @-@ Clear@@ ance &quot; * * * derived from the term &quot; N@@ ate / gen@@ ital tra@@ ct other . * * * derived from National Cancer Institute C@@ TC ( v@@ 2.0 ; N@@ CI 1998 ) must be considered fla@@ vor and hair loss only as part 1 or 2 reported .
for this table , a threshold of 5 % has been defined in terms of the recording of all events in which the reporting doctor has a connection with P@@ emet@@ re@@ ins and C@@ is@@ pl@@ atin for this table .
clinical @-@ relevant C@@ TC tox@@ icity , which were reported at &lt; 1 % ( occasionally ) patients reported , random@@ ised C@@ is@@ pl@@ atin and P@@ emet@@ re@@ ins were reported , the ar@@ rhyth@@ mic ar@@ rhyth@@ mic and motor re@@ rop@@ athy .
the following table shows the frequency and volume of un@@ desirable effects that were published at &gt; 5 % of 265 patients , random@@ ised rhe@@ ological and vitamin B@@ 12 patients and 276 patients , the random@@ ized doc@@ et@@ ax@@ el as mon@@ otherapy .
* reference to National Cancer Institute C@@ TC version 2 for each toxic formation . * * related to National Cancer Institute C@@ TC ( v@@ 2.0 ; N@@ CI 1998 ) should be hair loss only as grade 1 or 2 reported .
for this table , the threshold of 5 % has been defined in terms of the recording of all events in which the reporting doctor has a connection with dis@@ advantages .
clinical @-@ relevant C@@ TC tox@@ icity , which was reported at &lt; 1 % ( occasionally ) patients were reported , random@@ ised P@@ emet@@ re@@ ins were compiled in su@@ pra@@ vent@@ ri@@ cular ar@@ rhyth@@ ms .
posted in English , English , French , Russian , Russian , Russian , English , French , Russian , Russian , Russian , English , French , Russian , Russian , Russian , English , French , Russian , Russian , Russian , English , French , Russian , Russian , Russian , English , French , Russian , Russian , French , Russian , Russian , Russian , English , French , Russian , Russian , French , Russian , Russian , English , French , Russian , Russian , French , Russian , Russian , French , Russian , Russian , Russian , English , French , Russian , Russian , French , Russian , Russian , French , Russian , Russian , Russian , English , French , Russian , Russian , French , Russian , Russian , French , Russian , Russian , French , Russian , Russian , French , Russian , Russian , French , Russian , Russian , French , Russian , Spanish , Russian , Portuguese , Spanish , Russian .
these sub @-@ types are likely to lead to differences in patient population as the P@@ ha@@ - se 2 studies both chem@@ on@@ ai@@ ve and significantly treated breast cancer patients with existing liver metast@@ ases and / or ab@@ out@@ lines of the liver failure tests .
at &gt; 5 % of 8@@ 39 Pati@@ ents with N@@ SC@@ LC report , random@@ ized C@@ is@@ pl@@ atin and P@@ emet@@ re@@ ins were published in &gt; 5 % of 8@@ 39 patients with N@@ SC@@ LC , random@@ ized C@@ is@@ pl@@ atin and mix@@ cit@@ ab@@ in .
&quot; &quot; &quot; 11 * P values &lt; 0,@@ 05 compared to P@@ ico re@@ formed / C@@ is@@ pl@@ atin and mix@@ cit@@ ab@@ ine / C@@ is@@ pl@@ atin , under use of the &quot; &quot; &quot; &quot; Fisher Ex@@ act &quot; &quot; &quot; . * * * based on National Cancer Institute C@@ TC ( v@@ 2.0 ; N@@ CI 1998 ) to the National Cancer Institute C@@ TC ( v@@ 2.0 ; N@@ CI 1998 ) must be considered fla@@ vor and hair loss only as part 1 or 2 reported .
for this table , for the recording of all events in which the reporting doctor has a connection with pesti@@ cides and C@@ is@@ pl@@ atin for possible , an threshold of 5 % .
retinal @-@ relevant tox@@ icity , which reported similar to ≥ 1 % and ≤ 5 % ( frequently ) of the patients reported , random@@ ised C@@ is@@ pl@@ atin and P@@ emet@@ re@@ ins were reported :
retinal @-@ relevant tox@@ icity , which were reported at &lt; 1 % ( occasionally ) the patients reported that ran@@ ge@@ - dom@@ ini@@ zed C@@ is@@ pl@@ atin and P@@ emet@@ re@@ ins were included :
serious kar@@ di@@ ov@@ aries and zer@@ eb@@ rov@@ ascular events , including M@@ yo@@ cardi@@ al inf@@ eri@@ als , An@@ gina p@@ ect@@ or@@ is , zer@@ eb@@ rov@@ ascular disease and tran@@ sit@@ ory attacks were usually given in combination with another cy@@ tot@@ ox@@ ic drug .
clinical studies were reported in patients with trau@@ matic injuries caused by C@@ oli@@ - tis ( including THC in@@ ale and re@@ kt@@ ale blood@@ lines , sometimes fatal anxiety disorders , sometimes fatal inflammation and ty@@ ph@@ li@@ tis ) .
clinical studies were reported in patients with p@@ airing complaints stem@@ ming from sometimes ev@@ enly distributed inter@@ rup@@ ti@@ zation oph@@ oni@@ tis with resp@@ ir@@ atory in@@ suffici@@ ency at resp@@ ir@@ atory in@@ suffici@@ ency .
it was reported about cases of acute n@@ anc@@ ill@@ ages at P@@ emet@@ re@@ gli@@ de mon@@ otherapy or in combination with other chem@@ otherap@@ ists ( see Section 4.4 ) .
cases of radiation pneum@@ oni@@ tis in patients reported earlier , during or after their p@@ ushes therapy ( see Section 4.4 ) .
ALI@@ M@@ TA ( P@@ emet@@ re@@ ins ) is an ant@@ ine@@ tic anti @-@ inflam@@ matory anti@@ fol@@ ate that is necessary to cure their effect by ref@@ usal , which is necessary for cell rep@@ lication .
in vitro studies showed that P@@ emet@@ re@@ ins acts as anti@@ fol@@ lic@@ as than anti@@ fol@@ lic@@ ant ( TS ) , D@@ ih@@ y@@ dro@@ cop@@ h@@ ase ( TS ) , D@@ ih@@ y@@ dro@@ ple@@ ases ( GAR@@ FT ) , the fol@@ lic@@ ted key @-@ dependent keys of the nov@@ o Bios@@ yn@@ thesis of Thy@@ mid@@ ine and Pur@@ inn@@ u@@ cle@@ osi@@ tions .
EMP@@ H@@ AC@@ IS , a multi@@ centr@@ ist , random@@ ized , easy @-@ blin@@ ding phase 3 study from ALI@@ M@@ TA and C@@ is@@ pl@@ atin treat patients with ALI@@ M@@ TA and C@@ is@@ pl@@ atin treat patients with ALI@@ M@@ TA and C@@ is@@ pl@@ atin treat patients with ALI@@ M@@ TA and C@@ is@@ pl@@ atin treat .
primary analysis of this study was made in the population of all patients who received the test results ( random@@ ised and treated ) .
a statistical significant improvement of clinical immun@@ ity relevant symptoms ( pain and Dy@@ sp@@ no@@ e ) in connection with the mal@@ evol@@ ent Ple@@ ur@@ am@@ es@@ angi@@ i@@ oma was shown in the application of the Lun@@ - gen@@ ital cancer cells in the ALI@@ M@@ TA / C@@ is@@ pl@@ atin arm ( 212 patients ) .
the differences between the two treatment units are systematically measured by improving the lung function parameters in the ALI@@ M@@ TA / C@@ is@@ pl@@ atin arm and a decrease of lung function in the course of the control arm .
a multi @-@ centric , random@@ ized , open phase III study with ALI@@ M@@ TA treated in patients with local advanced or metast@@ atic N@@ SC@@ LC compared with ALI@@ M@@ TA treated patients ( Int@@ ent to treat acute patients ( IT@@ T n = 288 ) .
analysis of the influence of the hist@@ ology on the effect effect of ALI@@ M@@ TA for patients with N@@ SC@@ LC involving a predomin@@ antly non @-@ epithel@@ ial hist@@ ological type ( n = 172 , 6,@@ 2 versus 7,@@ 4 months ) , adapted HR = 1,@@ 56 ; 95 % CI = 1,@@ 08 @-@ 2,@@ 26 , p = 0,@@ 08 @-@ 2,@@ 26 , p = 0,@@ 08 .
limited data of a separate random@@ ised controlled phase 3 study show that eff@@ ic@@ acy data ( survival and progressive survival ) for P@@ emet@@ re@@ ins between patients with ( n = 41 ) and without ( n = 540 ) pre @-@ treatment by doc@@ et@@ ax@@ el is similar .
the eff@@ ability analyses of the P@@ Q population are consistent with the analysis of the IT@@ T population and support the non @-@ sub@@ stitution of the ALI@@ M@@ TA C@@ is@@ pl@@ atin combination compared to the mix@@ tures in C@@ is@@ pl@@ atin .
average P@@ FS was 4,@@ 8 months for the combination ALI@@ M@@ TA C@@ is@@ pl@@ atin as well compared to 5,@@ 1 months ( 95 % CI = 27.@@ 3 % CI = 27.@@ 3 % CI = 27.@@ 3 % ( 95 % CI = 25,@@ 4 - 31,@@ 4 ) for the combination ALI@@ M@@ TA C@@ is@@ pl@@ atin = 25,@@ 4 % ( 95 % CI = 25,@@ 4 - 31,@@ 4 ) for the combination of cit@@ rus in C@@ is@@ pl@@ atin .
the analysis of the influence of the N@@ SC@@ LC hist@@ ology is presented to the survival of clinical sub @-@ relevant sub @-@ phenomena according to the hist@@ ology , see the table below .
CI = Con@@ fi@@ den@@ z@@ interval ; IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T = IT@@ T ) .
the analysis particularly foc@@ usses on the hetero@@ geneity of regional dynamics and the spati@@ ally structured inter@@ dependency between locations . IAB @-@ Bibliothek 354 Archive Info@@ bereich . online Survey of the IAB web presence
also the patients compl@@ ying with er@@ y@@ thro@@ po@@ tin / D@@ arb@@ op@@ o@@ e@@ tin ( 10,@@ 4 % versus 4,@@ 1 % , p &lt; 0,@@ 001 ) , G @-@ CS@@ F / GM @-@ CS@@ F ( 3.6 % versus 7,@@ 0 % , p = 0,@@ 0@@ 21 ) .
the Ph@@ armac@@ ok@@ ine@@ tic properties of rhe@@ a was investigated after injection as mon@@ otherap@@ ists in 4@@ 26 cancer patients with various solid tum@@ ours in D@@ osen from 0.2 to 8@@ 38 mg / m ² in in@@ fu@@ si@@ - ons via a period of 10 minutes .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; dirt &quot; &quot; &quot; &quot; is mainly unchanged in the ur@@ ine rose and 70 % up to 90 % of the possible dose within 24 hours after the application is reached within 24 hours . &quot; &quot; &quot;
has a total surface of 9@@ 1.8 ml / min and the semi @-@ value @-@ time in plasma is 3.5 hours with regular kidney ( Kre@@ at@@ in@@ in @-@ Clear@@ ance 90 ml / min ) .
in a study with Be@@ agle @-@ dogs that had received intra@@ ven@@ ous bol@@ us injection were observed , tes@@ tic@@ ular changes were observed ( Deg@@ en@@ nia ration / nec@@ ro@@ sis of sem@@ ini@@ fer@@ ous epithel@@ ial ) .
unless otherwise expressly agreed , the storage times and conditions after preparation of the user &apos;s responsibility and should not exceed 24 hours at 2 to 8 ° C , unless they take care / th@@ inner has taken under controlled and vali@@ dated conditions .
solve the contents of the 100 mg x 0.@@ 9 % of l@@ oride concent@@ rations ( 9 mg / ml ) without preser@@ v@@ atives , resulting a solution with a concentration of about 25 mg / ml P@@ emet@@ re@@ ins .
the resulting solution is clear and the col@@ oring is sufficient for colour@@ less to yellow or yellow , without breaking the product quality .
each continuous bottle must be treated with 20 ml 0.0@@ 9 % of l@@ oride injection solution ( 9 mg / ml ) , which yields a solution from 25 mg / ml .
23 &quot; &quot; &quot; &quot; &quot; &quot; 23 &quot; &quot; &quot; &quot; the anti @-@ drug discovery , including M@@ yo@@ cardi@@ al inf@@ ra , and zer@@ eb@@ rov@@ ascular events were considered in combination with other cy@@ tot@@ ox@@ ical ingredients . &quot; &quot; &quot;
* Understand the National Cancer Institute C@@ TC version 2 for any Tox@@ icity of the event &quot; Cre@@ at@@ in@@ in @-@ Clear@@ ance &quot; * * * derived from the term &quot; N@@ ate / gen@@ ital tra@@ ct other . * * * derived from National Cancer Institute C@@ TC ( v@@ 2.0 ; N@@ CI 1998 ) shall be used for fla@@ vor and hair loss .
for this table - de an threshold of 5 % related to the intake of all events , in which the allow@@ ance of allergi@@ es may occur a connection with P@@ emet@@ re@@ ins and C@@ is@@ pl@@ atin for possible .
* reference to National Cancer Institute C@@ TC version 2 for each toxic formation . * * related to National Cancer Institute C@@ TC ( v@@ 2.0 ; N@@ CI 1998 ) should be hair loss only as grade 1 or 2 reported .
&quot; &quot; &quot; 29 * P values &lt; 0,@@ 05 compared to P@@ ico re@@ formed / C@@ is@@ pl@@ atin and mix@@ cit@@ ab@@ ine / C@@ is@@ pl@@ atin , under use of &quot; &quot; &quot; &quot; Fisher Ex@@ act &quot; &quot; &quot; . * * * based on National Cancer Institute C@@ TC ( v@@ 2.0 ; N@@ CI 1998 ) to the National Cancer Institute C@@ TC ( v@@ 2.0 ) .
retinal @-@ relevant tox@@ icity , which were reported at &lt; 1 % ( occasionally ) the patients reported that ran@@ ge@@ - dom@@ ini@@ zed C@@ is@@ pl@@ atin and P@@ emet@@ re@@ ins were included :
analysis of the influence of the hist@@ ology on the effect effect of the effect effect on the overall survival of ALI@@ M@@ TA in patients with N@@ SC@@ LC were implemented at Gun@@ sten from Do@@ x@@ et@@ ax@@ el ( n = 172 , 6,@@ 2 versus 7.@@ 4 months ) , adapted HR = 1,@@ 56 ; 95 % CI = 1,@@ 08 @-@ 2,@@ 26 , p = 0,@@ 08 .
solve the contents of the 500 mg x 0.@@ 9 % of l@@ oride concent@@ rations ( 9 mg / ml ) without preser@@ v@@ atives , resulting a solution with a concentration of about 25 mg / ml P@@ emet@@ re@@ ins .
the resulting solution is clear and the col@@ oring is sufficient for colour@@ less to yellow or yellow , without breaking the product quality .
Pharma@@ ko@@ vi@@ gil@@ ance system The owner of the permission of the Office of the Office has taken care of that the pharmaceutical and ko@@ vi@@ gil@@ ance system , as described in version 2.0 , is ready for the transport , ready and ready to use as soon as the product is in circulation and during the product is in the market .
Risk Management Plan The owner of approval for the in@@ traffic is obliged to comply with the studies and additional costs of pharmaceu@@ ko@@ vi@@ gil@@ ance activities according to pharmaceutical management plan ( R@@ MP ) , presented in modules 1.@@ 8.@@ 2. the approval for the transport and all the following findings of the R@@ MP that were decided by CH@@ MP .
&quot; &quot; &quot; according to &quot; &quot; &quot; &quot; CH@@ MP Gui@@ deline on Risk Management Systems for Medic@@ inal products &quot; &quot; &quot; &quot; must be submitted to the next &quot; peri@@ odic Safety Update report &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
in addition , an updated R@@ MP has to be submitted if new information is submitted , which may have an influence on the currently security - specifications , pharmaceutical ko@@ vi@@ gil@@ ance plan or risk management activities • Within a major ( pharmaceu@@ ko@@ vi@@ gil@@ ance or risk management ) Meil@@ enst@@ one • On request by EME@@ A
ALI@@ M@@ TA 100 mg powder for the production of an in@@ fusion bucket - ALI@@ M@@ TA 500 mg powder for the production of a solvent
ALI@@ M@@ TA is used in patients who have no longer chem@@ otherapy , used to treat cancer patients with C@@ is@@ pl@@ atin in combination with C@@ is@@ pl@@ atin in combination with C@@ is@@ pl@@ atin in combination with C@@ is@@ pl@@ atin in combination with C@@ is@@ pl@@ atin in combination with C@@ is@@ pl@@ atin in combination with C@@ is@@ pl@@ atin .
if you have a kidney or previously , please contact us with your doctor or hospitals if you may not receive ALI@@ M@@ TA .
in case of you will be carried out before any in@@ fusion of blood tests , it will be checked whether your ne@@ sts and cir@@ rho@@ sis are sufficient and whether you have sufficient infl@@ ation@@ - to get ALI@@ M@@ TA to 49 .
your doctor may change the dose or to break the treatment if it requires your general condition and if your blood values are too low .
if you will also receive C@@ is@@ pl@@ atin , your doctor will ensure that your body contains sufficient water and you get the necessary medicine to avoid the break before and after the C@@ is@@ pl@@ atin gift .
if you are a liquid collection to get the lungs from the lungs , your doctor may get to eliminate this liquid before you get ALI@@ M@@ TA .
if you would like to spend a child in the first 6 months after treatment , please do not hesitate to contact your doctor or pharmac@@ ist .
exchange effects with other medicines Please tell your doctor if you are pregnant at pain or inflammation ( Schw@@ ell@@ in@@ - ) , such as such medication is called &quot; non ster@@ o@@ id@@ al anti @-@ log@@ is@@ tika ( N@@ SA@@ I@@ Ds ) .
depending on the planned situation of your ALI@@ M@@ TA In@@ fusion and / or extent of your kidney function , your doctor will tell you what other medicines you can take and when .
please inform your doctor or pharmac@@ ist if you have other drugs or have recently taken drugs , even if it is not authorised to prescription drugs hemp - d@@ elt .
a hospital , the patient care or a doctor will mix the ALI@@ M@@ TA powder with ster@@ ile 0.@@ 9 % of Nat@@ ri@@ um chl@@ oride @-@ injection solution ( 9 mg / ml ) before it is applied to you .
your doctor will send you cor@@ ti@@ son tablets ( according to 4 mg of D@@ ACH eth@@ anol two times daily ) that you need to take the day before and on the day after the application of ALI@@ M@@ TA .
your doctor will take you foli@@ c acid ( a vitamin ) for use or mul@@ tiv@@ it@@ amine , foli@@ c acid ( 350 to 1000 micro@@ g ) , writing which you need to take during the application of ALI@@ M@@ TA .
in the week before application of ALI@@ M@@ TA , and approximately all 9 weeks ( according to 3 cycles of the treatment with ALI@@ M@@ TA ) you will also receive a injection of Vi@@ - t@@ amin B@@ 12 ( 1000 micro@@ dosing ) .
in this use information , a side effect is described as &quot; very often &quot; means that they reported at least 1 of 10 patients .
a side effect is described as &quot; commonly referred to &quot; means that they reported at least 1 of 100 patients , but less than 1 of 10 patients reported .
if a side effect is described as &quot; occasionally &quot; described , this means that they reported at least 1 of 1,000 but less than 1 of 100 patients . this means that they reported from at least 1 of 10,000 but less than 1 of 1,000 patients .
fever or infection ( often ) : if you have a body temperature of 38 ° C or over , sweat or other signs of infection ( because you may have less white blood cells as normal , what is common often ) .
if you feel tired or weak , do not look like breathing in resp@@ ir@@ atory or b@@ ump@@ y ( because you probably have less hem@@ mo@@ glob@@ in than normal what is common often ) .
if you find a bru@@ te of the tooth , the nose or the mouth of the mouth or any other blood that doesn &apos;t come to a stand@@ still , or a r@@ öt@@ ter ur@@ ine or unexpected blu@@ eber@@ ries ( because you may have less blood flow than normal , what is very common ) .
occasionally ( occurs at least 1 of 1,000 patients ( but less than 1 of 100 patients ) increased pulse rate C@@ oli@@ tis ( inflammation in the intest@@ ine that can be linked with ble@@ eding in the intest@@ ine and end@@ othel@@ ium ) in the intest@@ ine ( ren@@ al of water in the tis@@ sues that leads to sw@@ ell@@ ings ) .
rare ( more than 1 of 10,000 patients , but less than 1 of 1,000 patients ) &quot; radi@@ ation Rec@@ all &quot; ( a skin r@@ ash is similar to a severe sun@@ burn ) , appearance on the skin that was subjected to the skin ( some days to years ) of a radi@@ otherapy regim@@ en .
occasionally , patients , the ALI@@ M@@ TA , usually in combination with other cancer - shake , an impact of stroke or stroke .
patients suffering from radiation during or after their ALI@@ M@@ TA treatment also causes a radiation treatment , caused the inflammation of the lung disease , which is caused by radiation treatment in connection ) .
52 Recomm@@ end@@ ation your doctor or pharmac@@ ist when one of the remaining side effects are exposed - or if you recognize side effects that are not present in this package .
the chemical and physical stability of th@@ inner and physical stability of th@@ inner and in@@ fusion solution at storage in the refrigerator or at 25 ° C for a period of 24 hours .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; we are looking forward to welcoming you ! &quot; &quot; &quot; &quot; &quot; &quot; &quot;
Tel : + 420 234 6@@ 64 111 Dan@@ mark El@@ i Lil@@ ly Dan@@ mark A / S T@@ l@@ f : + 45 45 6@@ 100 Germany Lil@@ ly Deutschland GmbH Tel . + 49@@ - ( 0 ) 6@@ 172 273 22@@ 22 E@@ est@@ i El@@ i Lil@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Du@@ ffy .
this paper investigates the impact of non @-@ take @-@ up for two hypothe@@ tical scenarios , namely increasing and decreasing the base amount of social assistance in Germany by € 100 per month .
Tel : + 39@@ - 0@@ 55 4@@ 25@@ 71 Ober@@ vi@@ ja El@@ i Lil@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Hol@@ ly Limited
Tel . : + 48 ( 0 ) 22 440 33 00 Portugal Lil@@ ly Portugal - Pro@@ d@@ ut@@ os Far@@ mac@@ ê@@ uti@@ cos , L@@ da Phone : + 351 @-@ 21 @-@ 4@@ 12@@ 6@@ 600 Rom@@ â@@ nia S.@@ R.@@ L .
Tel : + 421 220 6@@ 63 111 Su@@ omi / Finland O@@ y El@@ i Lil@@ ly Finland From Pu@@ h / Tel : + 35@@ 8@@ - ( 0 ) 8 7@@ 37@@ 8@@ 800 United Kingdom El@@ i Lil@@ ly and Company Limited Tel : + 44@@ - ( 0 ) 12@@ 56 3@@ 15@@ 999
solve the contents of the 100 mg x 0.@@ 9 % of l@@ oride concent@@ rations ( 9 mg / ml ) without preser@@ v@@ atives , which results in a solution with a concentrate of about 25 mg / ml P@@ emet@@ re@@ ins .
solve the contents of the 500 mg / ml fluid ounce with 20 ml 0.0@@ 9 % of l@@ oride concent@@ rations ( 9 mg / ml ) without preser@@ v@@ ative , which results in a solution with a concentrate - ration of about 25 mg / ml P@@ emet@@ re@@ ins .
the resulting solution is clear and the col@@ oring is sufficient for colour@@ less to yellow or green , without causing the Pro@@ - fra@@ ction quality .
it is applied to the important adult adults with a body mass index ( Body Mass Index - BM@@ I ) from ≥ 28 kg per square in connection with low cal@@ ories , o@@ bes@@ ity nutrition .
patients who take all@@ i take and after 12 weeks , they should contact their doctor or pharmac@@ ist .
if these enz@@ y@@ mes are cured , they may not be able to build some F@@ ette in the food , whereby a quarter of the food processor is un@@ mistak@@ able .
in a third study , all@@ i was don@@ ated in the third study all patients with a BM@@ I between 25 and 28 kg / m2 with plac@@ ebo .
in the two studies in patients with a BM@@ I from ≥ 28 kg / m2 , patients with all@@ i 60 mg showed a regular weight loss of 4,@@ 8 kg , compared to 2,3 kg during the intake of plac@@ ebo .
in the study with all@@ i in patients with a BM@@ I between 25 and 28 kg / m2 the patients could be observed a relevant weight loss .
the most common side effects of all@@ i ( observed in more than 1 of 10 patients ) are in@@ expensive spots at after , FLA@@ T@@ US ( wind turbin@@ es ) , di@@ still@@ ed secre@@ tion ( fan ) , flat@@ ul@@ ence ( wind ) , flat@@ ul@@ ence ( wind ) and soft chairs .
it must not be applied to patients who treated with C@@ ic@@ los@@ s ( for prevention of the organs of transplan@@ tation ) or with medicines such as war@@ far@@ in for prevention of blood cl@@ ots .
it may not be applied to patients who suffer an long @-@ term mal@@ evol@@ ence syndrome ( with no sufficient nutrients from intest@@ ine ) or cholesterol ( liver disease ) .
July 2007 , the European Commission shared the European Commission of G@@ lax@@ o Group has approved a permit for the transport of Or@@ ci@@ at GS@@ K in the entire European Union .
all@@ i is used for weight reduction of adults with over@@ weight ( Body @-@ Mass @-@ Index BM@@ I ≥ 28 kg / m2 ) and should be used in combination with a slight hypo@@ cal@@ or@@ ical , o@@ bes@@ ity nutrition .
all@@ i must not be applied by children and adol@@ esc@@ ents among 18 , since it is not sufficient data for effectiveness and security .
since or@@ list@@ at only minimal res@@ or@@ b@@ als , el@@ ders and patients with limited amount of liver and / or kidney dys@@ function does not require adaptation of the dosage .
• Over @-@ sensitive treatment with C@@ ic@@ los@@ por@@ in ( see Section 4.5 ) • Chron@@ ograph Mal@@ absorption • cholesterol ( see Section 4.6 ) • Equ@@ al treatment with war@@ far@@ in or other oral anti@@ o@@ ag@@ ul@@ ants ( see Sec@@ urities 4.5 und 4.8 )
the probability of the allocation of g@@ astro@@ intestinal symptoms ( see Section 8.2 ) may contain if all@@ i are taken with a low @-@ fat meal or low fat diet .
because the weight reduction in diabetes have to take control of diabetes , patients who take a medication against diabetes , before beginning of a therapy with all@@ i a doctor or pharmac@@ ist because the dosage of anti@@ di@@ abe@@ tic order must be adjusted accordingly .
patients , the all@@ i and drugs against high blood pressure or increased cholesterol , should take their doctor or pharmac@@ ist if the dosage must be adjusted accordingly .
it is recommended to meet additional qualifications in order to prevent that in case of severe di@@ arr@@ ho@@ ea possible failure of oral contra@@ ctor ( see Section 4.5 ) .
both in a study for exchange effects of medicines than also in several cases with simultaneous application of or@@ list@@ at and C@@ ic@@ los@@ por@@ a was observed .
with the application of War@@ far@@ in or other oral anti@@ o@@ ag@@ ul@@ ants in combination with or@@ list@@ at might affect the Quick values ( international norm@@ alities , in@@ r ) ( see Section 4.8 ) .
most patients who were treated in clinical studies up to 4 full years were treated with or@@ list@@ at , remained the concent@@ rations of vitamins A , D , E and K , and the beta @-@ car@@ ot@@ ene in the norm@@ alization .
however , patients should be recommended to ensure sufficient vitamin defici@@ ency ( see Section 4.4 ) .
after the gift of a single dose of A@@ mi@@ o@@ dar@@ on was received at a limited number of volunteers who received at the same at the same time or@@ list@@ at , a slightly decrease in A@@ mi@@ o@@ dar@@ on plasma concentration .
the experimental studies show no direct or indirect effects on pregnancy , embr@@ y@@ onic / f@@ ale development , birth or post@@ nat@@ al development ( see Section 5.3 ) .
side effects of or@@ list@@ at are mainly g@@ astro@@ intestinal nature and depend on pharmac@@ ological effects of the medicine , as the absorption of absor@@ bi@@ al fat is prevented .
the g@@ astro@@ intestinal effects were made from clinical studies with or@@ list@@ at 60 mg over a duration of 18 months until 2 years and were in general easily and temporarily .
most common types are defined as follows : very frequently ( ≥ 1 / 100 , &lt; 1 / 10 ) , occasionally ( ≥ 1 / 10,000 , &lt; 1 / 100 ) , rare ( ≥ 1 / 10,000 ) , not known ( ≥ 1 / 10,000 ) , not known ( ≥ 1 / 10,000 ) , not known ( ≥ 1 / 10,000 ) , not known ( ≥ 1 / 10,000 ) .
the frequency of the known adverse events which were established after the launch of the or@@ list@@ at , is not known because these events have been reported from a favourable magnit@@ ude .
when it is plau@@ sible that the treatment with all@@ i can lead to allergi@@ es with regards to possible and actual g@@ astro@@ intestinal effects .
individual cases of 800 mg or@@ list@@ at and multi @-@ way boxes of up to 400 mg three times a period of 15 days a period of 15 days a period of 15 days are given to significant clinical findings without significant clinical findings .
no side effects or other side effects were reported , either side effects or similar side effects such as the recommended dose of or@@ list@@ at .
based on investigations in humans and animals can be caused by a fast re@@ formation of system@@ ic effects that are due to the li@@ pas@@ sions of or@@ list@@ ations .
the therapeutic effect is mounted in the lum@@ ens of the Mag@@ ens and the upper thin @-@ fac@@ t@@ ms by kov@@ al@@ ente in the rest of the ga@@ stro @-@ rest of the ga@@ stro and p@@ ank@@ re@@ static li@@ pas@@ en .
due to clinical trials , 60 mg or@@ list@@ at , three times a three times daily , the absorption of about 25 % of the food is blo@@ cked .
two double blind , random@@ ized , plac@@ ebo controlled trials on adults with a BM@@ I ≥ 28 kg / m2 , the effectiveness of 60 mg Or@@ list@@ at , three times daily in combination with a hypo@@ cal@@ or@@ ical , o@@ bes@@ ity diet .
primary parameters , the change of body weight ( at the time of the boundary layer ) , as follows : as a change in the study course ( table 1 ) and as a share of those studies , which have lost more than 5 % or more than 10 % of their output weigh@@ s ( table 2 ) .
although in both studies , weight reduction over 12 months , the largest weight loss was observed in the first 6 months .
average change in the total of chol@@ est@@ ung was 60 mg -@@ 2.4 % ( output value 2.5 m@@ mo@@ l / l ) and with plac@@ ebo + 2,8 % ( output value 5,@@ 26 m@@ mo@@ l / l ) .
the average modification of the L@@ DL Chol@@ ester@@ ins was measured 60 mg -@@ 3.5 % ( output value 0.5 m@@ mo@@ l / l ) and with plac@@ ebo + 3.@@ 8 % ( output value 3,@@ 41 m@@ mo@@ l / l ) .
in the wa@@ ist , the average modification -@@ 4.5 cm with Or@@ g@@ at 60 mg ( output value 10@@ 3.@@ 7 cm ) and with plac@@ ebo -@@ 3.6 cm ( output value 10@@ 3.5 cm ) .
plasma concent@@ rations of non @-@ stimulation or@@ list@@ at were 8 hours after the oral gift of 360 mg or@@ list@@ at ( &lt; 5 ng / ml ) .
7 in general , in therapeutic dosage in plasma is only spor@@ adi@@ cally and in extremely low concent@@ rations ( &lt; 10 ng / ml or 0.@@ 02 µ@@ mo@@ l ) and without signs of a Kum@@ ulative basis .
in a study involving adi@@ p@@ ous patients , two main focus was administ@@ ered ( M1 after dischar@@ ging of the N @-@ For@@ my@@ l @-@ Leu@@ cin group ) , which is nearly 42 % of the total plastic surgery .
based on conventional studies on safety sp@@ har@@ mac@@ ology , tox@@ icity and re@@ productive data and re@@ productive data allow the pre@@ clinical data no special risk for humans .
Pharma@@ ko@@ vi@@ gil@@ ance system The holder of approval for the transport need to ensure that the pharmaceu@@ ko@@ vi@@ gil@@ ance system in accordance with the version of July 2007 as defined in module 1.@@ 8.@@ 1. the author@@ isation procedure , and works before and during the product on the market .
&quot; &quot; &quot; results appear ordered &quot; &quot; &quot; &quot; by relevance &quot; &quot; &quot; &quot; or &quot; &quot; &quot; &quot; by date &quot; &quot; &quot; &quot; ( publication date ) , &quot; &quot; &quot;
according to the CH@@ MP direc@@ tives , the updated R@@ MP has to be submitted to updated R@@ MP simultaneously with the next PS@@ UR ( peri@@ odic Safety Update Report ) .
furthermore , a updated R@@ MP should be submitted : • If new information are available , the current safety guidelines , the pharmaceutical ko@@ vi@@ gil@@ ance or risk management activities - within 60 days of consideration of an important , the pharmaceutical ko@@ vi@@ gil@@ ance or risk provisions of the European drug agency ( EME@@ A )
12 PS@@ UR@@ s The holder of approval for the use of approval for the use of approval for the use of approval for the all@@ i 60 mg hard r@@ att@@ les PS@@ UR@@ s all 6 months , then for two years , and then all three years .
don &apos;t use if you are under 18 , • if you are pregnant or bre@@ ast@@ feeding , • if you are sensitive to Or@@ g@@ los@@ s , if you suffer in@@ sensitive to or@@ list@@ at or any other blood puri@@ fication ( the liver , where you have problems with food intake ) , • if you have problems with the food intake ( chron@@ isches mal@@ evol@@ ence syndrome ) .
• take three times a day with every main meals , the fat contains , a capsule with water . • you should take a day before bed@@ time , a mul@@ tiv@@ it@@ am@@ int@@ abl@@ ette ( with Vitamin A , D , E and K ) . • You should not take longer than 6 months .
application : • take three times a day with every main meal of fat , a capsule with water . • You should not take any more than three capsules per day , once daily , before sleeping , a mul@@ tiv@@ it@@ am@@ int@@ abl@@ ette ( with the vitamins A , D , E and K ) . • You should not take longer than 6 months .
if you would like to read this later . • If you need more information or pharmac@@ ist if you need more information or advice , if you have any further information or advice , consult your doctor or pharmac@@ ist to advice .
possibly you need to stop the intake of all@@ i . • If one of the remaining side effects you are considerably affected or no side effects that are not specified in this utility information please refer to your doctor or pharmac@@ ist .
what do you need to apply before taking all@@ i ? • all@@ i may not be applied • For taking all@@ i with other medicines • To taking all@@ i with other medicines and drinks • pregnancy and down@@ time • transport and transport time and transport of machines 3 .
how is all@@ i appropriate ? • How can you prepare your weight stress ? O select your starting point of time ? O adults from 18 years ? how long should I take all@@ i in large quantities ? or if you forget all@@ i in large quantities , If you forget all@@ i in large quantities .
the adverse events are possible ? • serious adverse events • Very common side effects • Frequ@@ ent side effects • Incre@@ mental effects of blood tests • How can you control the nutritional defici@@ encies ?
how all@@ i contains • How all@@ i looks and content of the package • Pharmaceutical entrepreneurs and manufacturers • Other helpful information
all@@ i serves the weight reduction and will be applied for the required adults from 18 years with a body Mass @-@ Index ( BM@@ I ) of 28 or above . all@@ i should be used in combination with a low @-@ low and low cal@@ orie diet .
the BM@@ I will determine you if you have a normal weight or have been important .
even if these diseases often do not mean that you should feel un@@ well , you should ask your doctor in order to ask your doctor .
for each of 2 kg body weight you take in a diet , you can lose weight of extra kilogra@@ ms .
please inform your doctor or pharmac@@ ist if you have other drugs or have recently taken this medication even if it is not authorised to prescription drugs .
C@@ ic@@ los@@ por@@ in is used for organ transplan@@ t , severe inflam@@ matory illness , ar@@ thritis and certain serious skin diseases . • War@@ ent@@ in or other medicines that have a blood circulation .
oral care remedi@@ es and all@@ i • The effect of oral increasing means of oral care ( p@@ ill ) is separated under circumstances and if you have strong di@@ arr@@ ho@@ ea ( attack ) .
please consult your doctor or pharmac@@ ist if you take : • A@@ mi@@ o@@ dar@@ one to the treatment of heart rhythm disorders . • Ac@@ arb@@ age for treatment of diabetes .
ask your doctor or pharmac@@ ist if you take all@@ i and if you take drugs against high cholesterol levels , the dosage must be adjusted against high cholesterol levels because the dosage must be adjusted against too high cholesterol .
as you can set your cal@@ orie and surface effects , you can find out more helpful information on the blue pages in Section 6 .
if you leave a meal or a meal without fat , take no caps . all@@ i can only affect if the food contains fat .
if you take the capsule into connection with a meal , which contains lots of fat , risk @-@ conditioned sal@@ ts ( see section 4 ) .
in order to cure your body to the new eating habits , you start before the first capsule filling with a cal@@ ori@@ zation and o@@ bes@@ ity diet .
food and di@@ aries are effectively , as you can manage , what you eat as much you eat and it will probably be easier to change your eating habits .
to reach your target weight , you should select two daily targets : one for cal@@ ories and one for fat .
• Can you try to reduce the probability of nutritional benefits ( see Section 4 ) . • If you are looking to move more , before you begin with the intake of capsules .
remember your doctor if you are not used to exercise your doctor if you are physical activity of physical activity .
• all@@ i may not be taken longer than 6 months . • If you find out about twelve weeks application of all@@ i no reduction of your weight , please ask your doctor or pharmac@@ ist to advice .
under the circumstances you need to finish the intake of all@@ i . • If a successful increase , it is not about to return to the diet and then return to the old habits .
• If less than one hour since the last meal is passed , take the intake of caps after . • If more than one hour since the last meal is passed , take no cap .
( see section 1 ) ( see section 1 ) ( see section 1 ) .
heavy allergi@@ c reactions • Sch@@ were allergi@@ c reactions to the following changes : severe breathing protection , skin bur@@ ners , skin irrit@@ ations , sw@@ elling , sw@@ elling , sw@@ elling of the face , heart disease .
29 Very frequent side effects These can take longer than 1 out of 10 people who take all@@ i . • bl@@ ess@@ ings ( flat@@ ul@@ ence ) with and without gro@@ oves
frequent side effects This can take effect on 1 of 10 people who take all@@ i . • Mag@@ ical ( abdominal ) pain , • In@@ contin@@ ence ( chair ) • Incre@@ ased chair manual consult your doctor or pharmac@@ ist if one of these side effects or you are affected .
effects on blood tests Access is not known as often these effects arise . • an impact of certain liver enz@@ yme co@@ ag@@ ulation to patients , the war@@ far@@ es or other blood th@@ inners ( an@@ tik@@ o@@ ag@@ ulation ) treatment .
please inform your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
the most commonly adverse events occur with the active ingredients of capsules , and this means that more fat from the body is exhau@@ sted .
these side effects occur within the first weeks after treatment of the first few weeks after treatment , as you may have not yet reduced the fat content in the diet .
with the following basic rules , you can learn to minimize the nutritional quality of your favourite foods . • Learn more about the usual fat content of your favorite foods and through the size of por@@ tions you usually do normally .
if you know exactly how much you eat as much you eat , the probability that you exceed your fat content . • Can you give your recommended fat to the daily meal .
save the amount of cal@@ ories and fat that you may have to take a meal , not to take it in the form of a low main gr@@ ated , as you may have to control the weight reduction in other programs .
• This medication contains two white rever@@ sible containers to protect the content of moisture . • The bottle contains two white sealed containers with si@@ lic@@ agel that serve as a dry dry .
take this on no case . • You can specify your daily dose all@@ i in the blue transport box ( shuttle ) with itself that it is included in this package .
Fam@@ ar , 190 11 Av@@ l@@ ona , Greece Catal@@ ent UK Packaging Limited , S@@ edge Fonds , Hand@@ way , Great Oak@@ ley , Cor@@ by , North@@ amp@@ ton@@ shire N@@ N@@ 18 8@@ HS , United Kingdom
excess weight has increased impact on your health and increases the risk for the formation of various severe diseases such as : • hyper@@ tension , diabetes • heart disease • Oste@@ o@@ ar@@ thritis pain using your doctor about your risk for such diseases .
a permanent weight reduction , for example by improving the nutrition and more movement , the dis@@ sem@@ ination of serious diseases and has a positive influence on your health .
choose meals which contain a wide range of nutrients , and learn to eat health@@ ily healthy .
energy will also be measured in kil@@ o@@ jou@@ les that you can also find out on the packaging of food . • The recommended cal@@ orie intake should be considered as many cal@@ ories you should take a maximum of each day .
note the further below in this section of tables . • The recommended intake of fat is the maximum amount of fat which you should take with every meal .
what quantity for you are suitable for you at the below Information that indicates the number of cal@@ ories which is suitable for you .
if you take the same quantity of fat , such as before , this means that your body can not process these quantity of fat .
thanks to the recommended grease supply you can maxim@@ ize the weight reduction and at the same time the probability for serious accus@@ ations . • You should try , step and continuously .
34 This reduced cal@@ orie consumption should allow you to step up , and continuously dimin@@ ish approximately 0.5 kg per week to weight , without fru@@ strations and dis@@ appointment .
the active you are , the higher is your recommended cal@@ ori@@ en@@ ity . • &quot; straight physical activity &quot; means that you are not only little or not going , stairs in the garden , or other physical activities , e.g. through 3 km away , 30@@ - to 45 @-@ minute gardening work or 2 km running in 15 minutes .
• For a permanent weight loss , it is necessary to set realistic cal@@ orie and fat targets . • Sinn@@ ers are a nutrition book with information about the cal@@ orie and fat content of your meals .
the all@@ i program to support the weight loss combined the capsules with a nutrition plan and a large number of other information material which can help you to nour@@ ish cal@@ ori@@ zes and fat burning .
in conjunction with a customized program to support the weight gain , these information can help you develop a health@@ ier lifestyle and your target weight .
Alo@@ xi is applied to chem@@ otherapy , the strong rec@@ tor for exercise and vom@@ iting ( such as C@@ is@@ pl@@ atin ) , as well as chem@@ otherapy , the moder@@ ator for exercise and vom@@ iting ( like Cy@@ clo@@ phosph@@ ate , Do@@ x@@ or@@ ub@@ ic@@ in or Carb@@ op@@ l@@ atin ) .
the dosage of Alo@@ xi may be increased by the additional gift of a Cor@@ ti@@ co@@ ster@@ oids ( a drug which can be used as anti@@ em@@ e@@ opathy ) .
the application in patients with 18 years is not recommended because of the effects in this age group is not enough information .
this means that the active substance with a chemical substance in the body , 5 @-@ hydro@@ xy@@ cl@@ yp@@ t@@ amin ( 5@@ HT , also known as ser@@ ot@@ on@@ in ) , to prevent the recep@@ tors in the intest@@ ines .
Alo@@ xi has been studied in three main studies on 1 8@@ 42 adults who received a strong or uniform dis@@ appointment for exercise and vom@@ iting .
in chem@@ otherapy , the strong rec@@ t@@ angle for exercise and vom@@ iting , 59 % of patients who were treated with Alo@@ xi ( 132 of 223 ) , compared to 57 % of patients with On@@ dan@@ set@@ ron treated patients ( 126 of 221 ) .
at the chem@@ otherapy of chem@@ otherapy , the moder@@ ator for exercise and vom@@ iting , 81 % of patients who were treated with al@@ chem@@ otherapy were treated with the blood cells ( 153 of 189 ) , compared with On@@ dan@@ set@@ ron treated patients ( 127 of 185 ) .
in comparison with Dol@@ as@@ et@@ ron , these values at 63 % for Alo@@ xi ( 119 of 189 patients ) and 53 % for Dol@@ as@@ et@@ ron ( 101 of 191 patients ) .
in March 2005 , the European Commission divided the European Commission to Denmark Bi@@ rex Pharmaceuticals Ltd . a permit for the transport of Alo@@ xi in the entire European Union .
Alo@@ xi is indi@@ rectly : the prevention of acute inflam@@ matory and vom@@ iting at strong chem@@ otherapy and vom@@ iting , and vom@@ iting , due to cancer patient and vom@@ iting , due to cancer patient .
the eff@@ ic@@ acy of Alo@@ xi leads to prevention of evil and vom@@ iting , which is induced by a highly em@@ eto@@ genic chem@@ otherapy , can be strengthened by adding one before the chem@@ otherapy of the Cor@@ ti@@ co@@ ster@@ oids .
since Pal@@ on@@ os@@ et@@ ron may extend the col@@ on ass@@ ass@@ ment , patients should be monitored with an@@ am@@ n@@ eling Ob@@ sti@@ p@@ ation or signs of a subtle I@@ le@@ us after injection .
as with other 5@@ HT@@ 3 Ant@@ ag@@ ul@@ ators , however , caution is offered at equal gift of Pal@@ on@@ os@@ et@@ ron with medicines that increase the Q@@ T Inter@@ v@@ all or in patients with whom the Q@@ T Inter@@ v@@ all is extended or that is extension to such extension .
besides the connection with a further chem@@ otherapy of the trumpet shall be used to treat al@@ chem@@ otherapy in the days after chem@@ otherapy or dis@@ arm@@ ing the treatment of evil and vom@@ iting .
deprecated : function ereg _ replace ( ) is deprecated in / www / htdocs / w00cec0c / webEdition / we / include / we _ modules / object / we _ listview _ multiobject.class.php on line 296
in a clinical trial , there was no significant phar@@ ma treatment effect between one single intra@@ ven@@ ous dose of Pal@@ on@@ os@@ et@@ ron and a Ste@@ ady concentration of met@@ oc@@ lo@@ pra@@ mi@@ ds , a CY@@ P@@ 2@@ D@@ 6 inhib@@ itors .
in one population based pharmac@@ ological analysis was shown that the simultaneous increase of CY@@ P@@ 2@@ D@@ 6 @-@ In@@ du@@ bit@@ in ) as well as of CY@@ P@@ 2@@ D@@ 6 @-@ In@@ du@@ bit@@ in , C@@ im@@ eti@@ din , C@@ im@@ eti@@ din , Par@@ ox@@ ine , Par@@ ox@@ ine , Par@@ ox@@ ins , Ser@@ ra@@ avi@@ r , Ser@@ ra@@ iny and Ter@@ bin@@ af@@ ine , are no significant impact on the clearing of Pal@@ on@@ os@@ et@@ ron .
experience in the application of Pal@@ on@@ os@@ et@@ ron due to human pregnancy , however , pal@@ on@@ os@@ et@@ ron should not be applied to pregnancy , unless it is necessary from the treatment doctor as necessary .
clinical studies were the most common with a dose of 250 micro @-@ gram effects ( total of 6@@ 33 patients ) , which were at least with al@@ titudes in connection , head@@ aches ( 9 % ) and Ob@@ sti@@ p@@ ation ( 5 % ) .
very rare cases ( &lt; 1 / 10,000 ) of over@@ flow reactions and reactions to the previous performance ( boo@@ bs , dis@@ cip@@ itation , complaints and pain ) were given in post @-@ marketing .
in the group with the highest dosage , similar to the highest dos@@ es of un@@ desired events like in the other field groups ; there were no dose of drug relationships .
the analysis particularly foc@@ usses on the hetero@@ geneity of regional dynamics and the spati@@ ally structured inter@@ dependency between locations . IAB @-@ Bibliothek 354 Archive Info@@ bereich . online Survey of the IAB web presence
in two random@@ ised double blind studies , a total of 1,@@ 132 patients who received a moder@@ ated chem@@ otherapy with ≤ 50 mg / m2 C@@ is@@ pl@@ atin , ≤ 1,500 mg / m2 C@@ is@@ pl@@ atin ( semi @-@ value ( half hours ) or 100 mg Dol@@ as@@ et@@ ron ( semi @-@ value @-@ 1 hours ) or 100 mg Dol@@ as@@ et@@ ron ( semi @-@ value 2,@@ 3 hours ) , which was given to day 1 without a D@@ BB eth@@ ni@@ ble intra@@ ven@@ ous .
in a random@@ ised double @-@ blind study , a total of 6@@ 67 patients with ≥ 60 mg / m@@ 2@@ C@@ is@@ pl@@ atin , &gt; 1,500 mg / m2 Cy@@ clo@@ phen@@ ols and 250 or 750 micro@@ g Pal@@ on@@ os@@ et@@ ron , with patients compared to 32 mg On@@ dan@@ set@@ ron , which were received in day 1 intra@@ ven@@ ous .
results of studies with moder@@ ately positive chem@@ otherapy and the study with highly em@@ eto@@ genic chem@@ otherapy are summar@@ ized in the following tables .
in clinical studies to indications chem@@ otherapy @-@ induced stress and vom@@ iting ( C@@ IN@@ V ) were the effects of Pal@@ on@@ os@@ et@@ ron on blood pressure , heart rate and EC@@ G parameters including the Q@@ t@@ c Inter@@ v@@ alls with the corresponding effects of On@@ dan@@ set@@ ron and Dol@@ as@@ et@@ ron .
after successful clinical studies , Pal@@ on@@ os@@ et@@ ron has the ability to block the vent@@ ri@@ cular de@@ - and rep@@ ol@@ ar@@ isation of I@@ on@@ enk@@ an@@ isation and the duration of the shar@@ eholder .
the study of 221 healthy subjects in the study was the assessment of the EC@@ G effects of the E@@ KG procedure in individual cases of 0.25 , 0.@@ 75 and 2.@@ 25 mg .
Res@@ or@@ ption With intra@@ ven@@ ous tissue follows an initial decrease of plasma concent@@ rations from a slow Eli@@ min@@ ation from the body with an average termin@@ ating time of about 40 hours .
the average maximum plasma concentration ( C@@ max ) and the area under the concentration of concentration camps ( AU@@ C@@ 0@@ - Method ) are generally employed in general D@@ os@@ is@@ ies of 0.@@ 3- 90 , g / kg for singing and cancer patients dos@@ is@@ tica .
after intra@@ ven@@ ous gift of Pal@@ on@@ os@@ et@@ ron 0.25 mg every second day for a total of 3 cans were found in the Pal@@ on@@ os@@ et@@ ro@@ ar@@ thritis between day 1 and day 5 measured mean ( ± SD ) increase in Pal@@ on@@ os@@ et@@ ron plasma concentration in 42 ± 34 % .
from Ph@@ armac@@ ok@@ ine@@ tic simul@@ ations , that which resulted in once a daily intra@@ ven@@ ous gift of 0.25 mg Pal@@ on@@ os@@ et@@ ron on 3 consecutive days . however , the C@@ max was measured by 0.@@ 75 mg .
about 40 % are eliminated by the kidney and approximately 50 % in two primary met@@ abo@@ lit@@ es , which are compared to Pal@@ on@@ os@@ et@@ ron over 1 % of the ant@@ agon@@ ist effect on the 5@@ HT@@ 3 recep@@ tor .
in @-@ vitro diagnostics for Met@@ aboli@@ sm , the CY@@ P@@ 2@@ D@@ 6 and the I@@ so@@ enz@@ yme CY@@ P@@ 3@@ A4 and CY@@ P@@ 1@@ A2 are involved in the Met@@ aboli@@ sm of Pal@@ on@@ os@@ et@@ ron .
Eli@@ min@@ ation after a intra@@ ven@@ ous single dose of 10 micro @-@ gram / kg &#91; 14@@ C &#93; -@@ Pal@@ on@@ os@@ et@@ ron were found approximately 80 % of the dose within seconds , Pal@@ on@@ os@@ et@@ ron , as un@@ modified drug made about 40 % of the given dose .
after a single intra@@ ven@@ ous Bol@@ us@@ in@@ ite , the total body composition was ± 73 ml / min and the ren@@ ale stem@@ ance 53 ± 29 ml / min .
patients with severe liver dys@@ function calls the termin@@ ale Eli@@ min@@ ation@@ sh@@ orten time and the average household object with Pal@@ on@@ os@@ et@@ ron increases the reduction of dosage is therefore non @-@ justified .
in pre @-@ clinical studies , effects were observed only after ex@@ positions which indicates a significant relevance for clinical use of clinical use .
10 The higher clinical studies indicate that Pal@@ on@@ os@@ et@@ ron is in very high concent@@ rations of I@@ on@@ ary channels , which may be involved in the vent@@ ri@@ cular de@@ - and rep@@ ol@@ ar@@ isation .
high dos@@ es Pal@@ on@@ os@@ et@@ ron ( any dose anti @-@ inflam@@ matory exposure in humans ) , which were given daily over two years , led to a increased frequency of liver and tum@@ ours ( in thy@@ ophy@@ sis , pan@@ cre@@ as , secondary tum@@ ours ) and skin @-@ tum@@ ors , but not at mice .
the underlying mechanisms are not yet known but due to the high dos@@ es and da Alo@@ xi , the relevance of these results will be the relevance of these results as for humans .
the owner of this authorization for the transport , the European Commission has to inform the plans for domestic demand within the framework of this decision .
• If one of the listed side effects are affected or no side effects that are not specified in this utility information please refer to your doctor .
• Alo@@ xi is a clear , color@@ less injection solution for injection in a v@@ ene . • The active substance ( Pal@@ on@@ os@@ et@@ ron ) belongs to a group of medicines , which may cause body and vom@@ iting . • Alo@@ xi is used for preventing corrosion and vom@@ iting , which occur in connection with chem@@ otherapy due to cancer .
21 In application of Alo@@ xi with other medicines please let your doctor if you take other drugs or have taken this medication even if it is not authorised to prescription drugs .
pregnancy such as you are pregnant or believe , your doctor will not give you Alo@@ xi , unless it is clearly required .
ask for your doctor or pharmac@@ ist for advice if you are pregnant or believe , pregnant .
in some very rare cases , it came to allergi@@ c reactions to Alo@@ xi or to Br@@ ushed or p@@ ains to the penetration .
the Alo@@ xi photo and content of the package al@@ xi injection solution is a clear , color@@ less solution and is available in a package with 1 cur@@ l bottle made of glass , which contains 5 ml of the solution .
К@@ в@@ ар@@ ти@@ р@@ а ст@@ у@@ д@@ ия С@@ К@@ в@@ ар@@ ти@@ р@@ а ст@@ у@@ д@@ ия для 4 че@@ л .
Lat@@ vi@@ ja pharmaceu@@ ticals Latvia SIA 54 @-@ 5 Res@@ ear@@ ing of the Street Riga , L@@ V @-@ 10@@ 11 Tel : + 37@@ 16@@ 750@@ 2@@ 185 Li@@ et@@ u@@ va U@@ AB pharmaceutical Swiss Coalition
United Kingdom Business Park Ch@@ ester Business Park Ch@@ ester CH@@ 4 9@@ Q@@ Z - UK Tel : + 44 124@@ 4 625 152
in June 2006 , the Committee for Human@@ izing Human Rights ( CH@@ MP ) is a negative Approach which is recommended for the treatment of hep@@ atitis C recep@@ tors in the treatment of hep@@ atitis C recep@@ tors ( CH@@ MP ) .
this means that Alph@@ eon a biological medicine called Ro@@ fer@@ on @-@ A with the same effect is similar to the EU ( also &quot; reference values &quot; ) .
Alph@@ eon should be used for the treatment of adult patients with chronic ( long periods ) hep@@ atitis C ( one by a viral infection infection ) .
in case of micro@@ sc@@ opic examination the liver tissue damage is increased , the values of the liver enz@@ y@@ ms of Al@@ an@@ ine Amin@@ ot@@ ran@@ s@@ fer@@ ase ( AL@@ T ) in the blood increases .
it is produced by a yeast where a gene ( DNA ) was brought to the formation of the drug .
the manufacturer of Alph@@ eon analyzed data from Alph@@ eon with Ro@@ fer@@ on @-@ A ( active structure , composition and purity of the drug tested , active , security and eff@@ ic@@ acy of hep@@ atitis C ) .
in the study on patients with hep@@ atitis C the eff@@ ic@@ acy of Alph@@ eon was compared with the eff@@ ic@@ acy of the reference .
in the study , it was measured as many patients after 12 of 48 treatment weeks and 6 months after adjusting the treatment to the medicine .
( 44 @-@ 20 ) 74 18 84 23 E @-@ mail : mail @ em@@ e@@ a.@@ eu@@ .@@ int htt@@ p : / / www.@@ em@@ e@@ a.@@ eu@@ .@@ int © EME@@ A 2006 Re@@ p / www.@@ em@@ e@@ a.@@ eu@@ .@@ int © EME@@ A 2006 Re@@ p / www.@@ em@@ e@@ a.@@ eu@@ .@@ int © EME@@ A 2006
&quot; &quot; &quot; &quot; &quot; &quot; &quot; furthermore , concerns did not represent concerns that data on stability of the drug and the market @-@ market research means not sufficient . &quot; &quot; &quot;
the number of patients with hep@@ atitis C , which was similar to the treatment with Alph@@ eon and Ro@@ fer@@ on @-@ A , was similar to the clinical study .
after setting up the treatment with Alph@@ eon @-@ ret@@ te the disease in more patients came back to the reference treatment ; also Alph@@ eon more side effects .
in the study of the study , the study conducted an immune response ( i.e. the body is anti@@ body - specific proteins - against the medicine ) , not sufficiently vali@@ dated .
it can be applied to the treatment of im@@ pe@@ zo@@ u ( one with cr@@ ushes ) and small in@@ fusion Laz@@ er@@ ations ( Ris@@ ks or chi@@ cks ) , di@@ ced and chopped wo@@ unds .
Al@@ tar@@ go should not be used to treat infections caused by meth@@ ic@@ ill@@ in@@ co@@ cc@@ us au@@ re@@ us ( MR@@ SA ) because Alar@@ go has not been caused by such kind of infections .
Al@@ tar@@ go can be applied in patients with the age of nine months , but at the age of 18 , the surface of the skin surface is no longer than 2 % of the body surface .
in the case of the patient after two or three days , the doctor should examine the patient once again and alternative alternative treatments .
a block@@ ade of the bacter@@ i@@ amino acids ( the parts of the bacter@@ ium , in which proteins are produced ) , and the growth of the bacteria .
the main indi@@ ator of the eff@@ ic@@ acy was in all five studies of the patients , whose infection was carried out after the treatment .
119 ( 8@@ 5.6 % ) of 139 patients under Al@@ tar@@ go and 37 ( 5@@ 2.@@ 1 % ) of the 71 patients under plac@@ ebo
in the treatment of infected skin disorders , Al@@ tar@@ go and C@@ ef@@ es@@ in similar response rates : if the results of both trials were taken in skin disorders , some 90 % of patients were able to treat both groups on the treatment .
in these two studies , Al@@ tar@@ go has been established that Al@@ tar@@ go has been discovered in the treatment of ab@@ sc@@ esses ( ei@@ ght@@ filled ca@@ vi@@ ties in the body tissue ) or from infections which have been proven or probably caused by MR@@ SA not effective .
the most common side effect with Al@@ tar@@ go ( which was observed at 1 to 10 of 100 patients ) is an irrit@@ ation at the order .
as a result , the Committee for Human@@ ar@@ z@@ ards ( CH@@ MP ) became the conclusion that the benefits of Al@@ tar@@ go at the following the sl@@ ing treatment of the following super@@ ficial skin infections due to risks : • Im@@ pe@@ as , • infected small fam@@ ations , de@@ duc@@ tions or gen@@ ital wo@@ unds .
&quot; &quot; &quot; May 2007 the European Commission shared the European Commission to G@@ lax@@ o Group Ltd. was an authorization for the transport of Al@@ tar@@ go in the entire European Union . &quot; &quot; &quot;
the patients with which can be considered within two or three days , should be considered once and an alternative therapy can be taken into consideration ( see Section 4.4 ) .
in the case of sensitivity or severe local Ir@@ rit@@ ation , the treatment of Ret@@ ap@@ am@@ ulin sal@@ be should be broken off , the sal@@ be carefully checked and an appropriate alternative therapy of infection can be started .
Ret@@ ap@@ am@@ ulin is not applied to treat infections while MR@@ SA is known or suspected ( see section 5.1 ) .
clinical trials with secondary open wo@@ unds was the effectiveness of Ret@@ ap@@ am@@ ulin at patients with infections caused by a meth@@ ic@@ ill@@ in @-@ resistant Stap@@ hy@@ lo@@ co@@ cc@@ us au@@ re@@ us ( MR@@ SA ) .
an alternative therapy is to be taken into consideration when after a 2- and 3 days treatment there is no possibility of a deteri@@ oration of in@@ active function .
the effect of the simultaneous application of Ret@@ ap@@ am@@ ulin and other top@@ ical means of the same skin surface is not investigated and the simultaneous application of other top@@ ical medicine is not recommended .
due to the low plasma concent@@ rations which have been achieved when people after top@@ ical use are achieved , a clinical @-@ relevant inhib@@ itor is not expected ( see Section 5.2 ) .
3 . early oral dosage of 2 @-@ times daily 200 mg K@@ eto@@ con@@ az@@ ol increased the mean Ret@@ ap@@ am@@ ulin AU@@ C ( 0 @-@ 24 ) and C@@ max after top@@ ical application from 1 % Ret@@ ap@@ am@@ ulin Sal@@ be on shiel@@ ding skin from healthy adult males by 81 % .
due to low system@@ ic exposure to patients , D@@ os@@ is@@ omet@@ rics is not necessary for patients when top@@ ical Ret@@ ap@@ am@@ ulin is applied during an system@@ ic treatment with CY@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ory inhib@@ itors .
veter@@ inary studies have shown a reproduction of reproduction after or@@ aler and are in@@ adequate in relation to a statement on the birth and the f@@ öt@@ ale / post@@ nat@@ ale development ( see Section 5.3 ) .
Ret@@ ap@@ am@@ ulin sal@@ be should only be applied when pregnancy is only applied when an top@@ ical anti@@ bacterial therapy is clear , and the application of Ret@@ ap@@ am@@ ulin of the gift of a system@@ ic anti@@ biotic .
in the decision whether the bre@@ ast@@ feeding / output or therapy with Al@@ tar@@ go will be continued / ended , is between the benefit of the inf@@ ant and the benefit of Al@@ tar@@ go therapy for women .
in clinical studies at 2@@ 150 patients with super@@ ficial skin inf@@ ec@@ tions , the Al@@ tar@@ go was the most frequently reported side @-@ to @-@ trial of the previous studies that occurred about 1 % of the patients .
active ret@@ ap@@ am@@ ulin is a semi @-@ synthetic deriv@@ atives of P@@ leu@@ ro@@ mu@@ ti@@ lin , a substance which is isolated by fer@@ mentation of C@@ lit@@ op@@ il@@ us pass@@ eri@@ anus ( previously Ple@@ ur@@ ot@@ us pass@@ eri@@ anus ) .
the active mechanism of Ret@@ ap@@ am@@ ulin is based on sel@@ ective inhib@@ itor of bacterial protein synthesis by interaction to a specific binding agent of the bacter@@ ium of other ri@@ bos@@ om@@ al inter@@ ag@@ ic anti@@ bacterial tox@@ ic@@ ological substances .
data indicate that the binding location ri@@ bos@@ om@@ ales protein L@@ 3 is involved in the region of the ri@@ bos@@ om@@ al P @-@ Bin@@ ary station and the Pep@@ ti@@ d@@ yl@@ transfer@@ ring Centre .
due to the binding of this binding agent , the Pep@@ ti@@ d@@ yl@@ mu@@ ti@@ line of the Pep@@ ti@@ d@@ yl@@ lion , block partial P @-@ binding activity and prevent the normal formation of active 50@@ S ri@@ bos@@ om@@ ic sub@@ units .
due to the local pre@@ val@@ ence of the we@@ arer , the application of Ret@@ ap@@ am@@ ulin at least some infection processes can be understood , should be advis@@ able by experts .
there were no differences in the in @-@ vitro activity of Ret@@ ap@@ am@@ ulin opposite p.@@ au@@ re@@ us , regardless of whether the isol@@ ate is sensitive or resistant to meth@@ ic@@ ill@@ in .
in the case of a non @-@ catching approach on the treatment at S.@@ au@@ re@@ us , the presence of tribes can be taken into consideration by additional viral factors ( such as PV@@ L = Pant@@ on @-@ axis Leu@@ co@@ ci@@ din ) .
Res@@ or@@ ption In a study with healthy adults was 1 % Ret@@ ap@@ am@@ ulin sal@@ be daily under oc@@ las@@ sion on intact skin for up to 7 days .
of 5@@ 16 patients ( adults and children ) , the 1 % Ret@@ ap@@ am@@ ulin sal@@ be twice daily for 5 days for the top@@ ical treatment of secondary trau@@ mati@@ sm , individual plasma were obtained .
the sample iter@@ ation was performed by the days of 3 or 4 in the adult patients before medi@@ ation and in children between 0 @-@ 12 hours after the last application .
however , maximum individual system@@ ic recording on humans according to top@@ ical application of 1 % Sal@@ be on 200 c@@ m2 Separ@@ ated skin ( C@@ max = 22 ng / ml ; AU@@ C ( 0 @-@ 24 ) = 238 ng · h / ml ) 660 @-@ times lower than the Ret@@ ap@@ orama IC@@ 50 for P@@ GP shirts .
Met@@ aboli@@ sm in vitro oxid@@ ative Met@@ aboli@@ sm in human liver micro@@ som@@ es was primarily by CY@@ P@@ 3@@ A4 , under the lower participation of CY@@ P@@ 2@@ C@@ 8 and CY@@ P@@ 2@@ D@@ 6 ( see Section 4.5 ) .
toxic tox@@ icity of rats ( 50 , 150 or 450 mg / kg ) , there were signs of adap@@ tive liver and thy@@ ro@@ id resistance .
in @-@ vitro diagnostics based on Gen@@ mut@@ ation and / or chrom@@ osom@@ al effects in the mouse @-@ ly@@ m@@ ph@@ oma type or in cultures of human peripheral blood ly@@ mp@@ ho@@ cy@@ tes and rats @-@ core test test for in @-@ vivo investigation of chrom@@ osom@@ al effects .
there was neither a male nor female ext@@ inc@@ tion of limited dos@@ ages of 50 , 150 or 450 mg / kg / day , whereby one up to 5 @-@ times higher exposure was achieved than the highest overall exposure in people ( top@@ ical application to 200 c@@ m2 ) .
in an embr@@ y@@ oto@@ x@@ iz@@ ation study at rats were established by ≥ 12 mg / kg / day ( according to ≥ 3 units of estimated human exposure ( see above ) ) , development sto@@ x@@ iz@@ ations ( reduced body weight of the F@@ öt@@ d and delayed Os@@ si@@ fication ) and mat@@ ern@@ al tox@@ icity .
the owner of the permission of the author@@ isation is to ensure that a pharmaceutical ko@@ vi@@ gil@@ ance system will be presented as defined in the module 1.@@ 8.1 of author@@ isation .
the owner of approval for the in@@ traffic is obliged to perform further detailed studies and additional pharmaceutical ko@@ vi@@ gil@@ ance activities , as they are accepted in the 1 of the Risk Management Plan ( R@@ MP ) and the additional actu@@ ations of the R@@ MP which shall be agreed with CH@@ MP .
&quot; &quot; &quot; as in the CH@@ MP &quot; Gui@@ deline on Risk Management Systems for Medic@@ inal products &quot; &quot; &quot; , &quot; is intended to update the updated R@@ MP simultaneously with the next peri@@ odic Safety Update report . &quot; &quot; &quot;
travel or other signs and symptoms in the treated area are intended to quit the application of Al@@ tar@@ go and speak to your doctor .
please contact usi@@ f , cre@@ ams or lot@@ ions on the area that will be treated with Al@@ tar@@ go if it is not explicitly prescribed by your doctor .
it must not be applied in eyes , at the mouth or on the lips , in the nose or in the female gen@@ ital area .
if the sal@@ ads can be seen on one of these surfaces , wash the place with water and ask your doctor if complaints arise .
according to the sal@@ ute of the sal@@ be , you can cover the affected area with a ster@@ ile area or a Gaz@@ ever@@ band , unless you do not cover the surface , do not cover the surface .
it is offered in an aluminum tube with a plastic clasp , which contains 5 , 10 or 15 grams of sal@@ be , or in an aluminum bag , 0.5 g of Sal@@ be .
ambi@@ rix becomes the protection against hep@@ atitis A and hep@@ atitis B ( diseases that affect the liver ) in children aged between a and 15 years that are not im@@ it@@ ated against these two diseases .
ambi@@ ente will be applied in the framework of a two dos@@ es existing vacc@@ ination , whereby a protection against hep@@ atitis B may also be achieved after finishing the second dose .
for this reason , Ambi@@ ent can only be used when during immun@@ isation a low risk of hep@@ atitis B infection is and ensured that the effects of two dos@@ es can be brought into existing vacc@@ ination plan .
when a continuous dose of hep@@ atitis A or B is wishes , ambi@@ rix or another hep@@ atitis B or B vacc@@ ine .
vacc@@ ines , by strengthening the immune system ( the natural se@@ wage of the body ) , how it can happen against a disease .
once a child obtained the vacc@@ ine , the immune system recogni@@ zes the viruses and surface anti@@ gens as a &quot; foreign body &quot; and produces anti@@ bodies .
ambi@@ ente contains the same components as the use of the Twin@@ rix adults and since 1997 approved the vacc@@ ine Twin@@ rix children since 1997 .
the three vacc@@ ines are applied to protect the same diseases , Twin@@ rix adults and Twin@@ rix children .
since Ambi@@ rix and Twin@@ rix adults have been included , some of the data that uses the use of Twin@@ rix adults , also as a cover for application of Ambi@@ ent .
the main indi@@ ator for the effectiveness was the proportion of mental children that had developed a month after the last injection .
in an additional study with 208 children the eff@@ ic@@ acy of the vacc@@ ine was compared with a six @-@ month distance between the two inj@@ ections and a 12 @-@ month distance between the two inj@@ ections .
Ambi@@ ent led between 98 and 100 % of the mental sons a month after the last injection for the development of the anti@@ body concent@@ rations against hep@@ atitis A and B .
the additional study showed that the degree of the protective case of ambi@@ rix at a se@@ k - and at a 12 @-@ month distance between the inj@@ ections was similar .
the most common side effects of ambi@@ rix ( observed in more than 1 of 10 vacc@@ ines ) are head@@ aches , app@@ liqu@@ eur of appetite , pain at the inj@@ ector , rigi@@ dity ( ti@@ red@@ ness ) as well as friction .
Ambi@@ ent may not be sensitive ( allergi@@ c ) to the active substances , one of other ingredients or Ne@@ om@@ yc@@ in ( anti@@ biotic ) cannot be applied .
August 2002 , the European Commission issued the European Commission of G@@ lax@@ o@@ S@@ mith@@ K@@ line Bi@@ olog@@ y@@ s.@@ a. a permit for the use of ambi@@ ente throughout the entire world .
the standardis@@ ation schedule for the Grun@@ berg consists of two vacc@@ ine , with the first dose of the choice and the second dose consists of six and twelve months after the first dose .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
anti @-@ hep@@ atitis virus ( anti @-@ H@@ B@@ s@@ A@@ g ) , anti @-@ hep@@ atitis virus ( anti @-@ H@@ B@@ s@@ A@@ g ) and anti @-@ hep@@ atitis virus ( anti @-@ H@@ B@@ s@@ A@@ g ) and anti @-@ hep@@ atitis values are in the same size as after the vacc@@ ination with the respective mon@@ ov@@ al@@ ants .
it is not entirely secured by immun@@ ity persons who need to protect against a hep@@ atitis @-@ A vacc@@ ination , as it is no longer need to be identified by immun@@ ological investig@@ ators .
3 How to all inj@@ ecting imp@@ air@@ ments should be available for the rare case of an an@@ ap@@ hy@@ l@@ act@@ ate reaction after the gift of vacc@@ ination , the appropriate possibilities of medical treatment and monitoring is immediately available immediately .
if a faster protection against hep@@ atitis B , the standardi@@ zation is recommended , the 360 @-@ SA units form@@ al@@ in@@ in@@ activated hep@@ atitis B virus and 10 µ@@ g re@@ combin@@ ant hep@@ atitis B surface .
with hem@@ isph@@ eric pressure and persons with distur@@ ban@@ ces of the immune system , no sufficient anti @-@ H@@ AV@@ - and anti @-@ H@@ MP anti@@ bodies limit that in these cases , the gift of other vacc@@ ine can be needed .
since an intra@@ ocular injection or intra@@ mus@@ cular surgery in the Ges@@ mold could lead to a subtle vacc@@ ine success , these inj@@ ectors should be avoided .
ambi@@ ente could be loos@@ ened by th@@ rom@@ bo@@ cy@@ top@@ ie or blood cl@@ auses disorders , ambi@@ ente could occur in these cases , as it may occur in these cases after intra@@ mus@@ cul@@ ari@@ zation of blood .
when ambi@@ rix in the second life of a separate inj@@ uri@@ tion at the same time with a combined Di@@ ph@@ th@@ eri@@ zation , Tet@@ an@@ us@@ ei@@ tis , in@@ activated police const@@ ants ( DT@@ PA @-@ IP@@ V / Hi@@ b ) , the immune response was administ@@ ered for all anti@@ gens ( see section 5.1 ) .
patients with immun@@ os@@ upp@@ res@@ sive therapy or patients with immun@@ ity must be assumed that there may not be sufficient immune response .
in a clinical trial , involving 3 imp@@ air@@ ments of this form@@ ulation , the frequency of pain , pig@@ ment , sw@@ elling , sw@@ elling , sw@@ elling , sw@@ elling , oral cancer , and fever and fever .
20@@ 29 vacc@@ ines were administ@@ ered by a total of 10@@ 27 vacc@@ ines in the age of 10@@ 27 vacc@@ ine at the age of 1 to 15 years .
in a study with 300 participants at the age of 12 , including 15 years , the remedi@@ ation of ambi@@ rix with the 3 @-@ h@@ osen @-@ combination imp@@ air@@ ments are compared .
only exceptions were the higher frequency of pain and mat@@ ernity on a calculation basis for Ambi@@ es@@ dose Ambi@@ rix , but not on a calculation basis for people .
pain was observed after the gift of ambi@@ rix at 50.@@ 7 % of subjects , compared with 39.@@ 1 % in patients after the gift of a dose of 3 dos@@ es .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
the frequency of mat@@ urity was compar@@ atively high ( i.e. , between the entire vacc@@ ine cycle of 39.@@ 6 % of the subjects , the ambi@@ ente were compared with 36,@@ 2 % of the subjects that received the 3 @-@ h@@ osen @-@ combination imp@@ air@@ ments ) .
the frequency of preventive pain and mat@@ urity was very low and comparable to administration of the combination of the combination imp@@ air@@ ments with the 3 @-@ D@@ osen vacc@@ ine ema .
in a comparative study with 1 @-@ 11 @-@ year vacc@@ ine , the occurr@@ ence of local reactions and general reactions in the ambi@@ ri@@ x@@ group was comparable to the following use with the 3 @-@ axis units form@@ al@@ in@@ activated hep@@ atitis @-@ A virus and 10 µ@@ g re@@ combin@@ ated hep@@ atitis B surface .
for troubleshooting , feature requests and general help contact Customer Support at . make sure to include details on your browser , operating system , jQuery Slider version and a link ( or relevant code ) .
the proportion of vacc@@ ine substances , which are caused by heavy side effects during the 2 @-@ dos@@ es vacc@@ ination of the three @-@ dos@@ es vacc@@ ination with the combination imp@@ urities and 10 µ@@ g re@@ combin@@ ated hep@@ atitis B and 10 µ@@ g re@@ combin@@ ant hep@@ atitis B and 10 µ@@ g re@@ combin@@ ant hep@@ atitis B .
clinical studies which were conducted in imports from 1 to 15 years were conducted for anti @-@ HA@@ V 9@@ 9.@@ 1 % to one month after the first dose and 100 % a month after the second month for the month 6 months .
the Ser@@ o@@ Converter rates for anti @-@ H@@ ire were 7@@ 4,@@ 2 % to one month after the first dose and 100 % a month after the second , to the month 6 months . ( h . in month 7 ) .
3.7 Repair &amp; Maintenance Output Forecast 3.4 New Construction Output Forecast by Cost Type
with the 289 persons , their immune system was valuable , were the Ser@@ op@@ rot@@ ational rates ( SP in the table below ) against hep@@ atitis B in the month 2 and 6 after the gift of 3 @-@ D@@ os@@ en@@ gin@@ ine significantly higher than with ambi@@ ente .
the immune system respond to a clinical trial study with 1 to 11 @-@ year @-@ olds a month after finishing the full import series ( i.e. in month 7 ) , are listed in the following table .
in both studies the vacc@@ ine received either a 2 @-@ h@@ osen vacc@@ ination with three ELI@@ SA units form@@ al@@ in@@ able hep@@ atitis B , and 10@@ µ@@ g re@@ combin@@ ated hep@@ atitis B and 10@@ µ@@ g .
for persons who were at the time of the pri@@ cel@@ er@@ isation between 12 and 15 years old , the Per@@ consistency of anti @-@ H@@ AV@@ - and anti @-@ H@@ MP anti@@ bodies could be detected at least 24 months after immun@@ isation with ambi@@ rix in 0 @-@ 6 months vacc@@ ination .
in this study observed immun@@ ity reaction to both anti@@ gens was comparable to a combination of 3 cans with a combination imp@@ eding according to the vacc@@ ination of 3 cans and 10 µ@@ g re@@ combin@@ ant hep@@ atitis B and 10 µ@@ g re@@ combin@@ ant in a D@@ os@@ is@@ ex volume of 0.5 ml .
in a clinical trial of 12@@ - up to 15 @-@ year @-@ old , the Per@@ consistency of anti @-@ H@@ AV@@ - and anti @-@ H@@ MP anti@@ bodies are comparable to the 0 @-@ 6 months vacc@@ ination .
the first dose of ambi@@ ente in the second year at the same time with the collecting of a combined Di@@ ph@@ th@@ eri@@ ac , Tet@@ an@@ us@@ her , in@@ activate Poli@@ om@@ yel@@ i@@ tis@@ - and 8 Ha@@ em@@ op@@ hil@@ us ( DT@@ PA @-@ IP@@ V / Hi@@ b ) or with the first dose of a combined Mas@@ ers @-@ R@@ umps .
the clinical trial , which was conducted with 3 cans of the present wording of adults was shown for the current form@@ ulation of Ser@@ op@@ rot@@ ational and Ser@@ o@@ conver@@ tor , such as the previous wording .
the vacc@@ ine is used both before and after the res@@ us@@ ement of a oph@@ thalm@@ ologic and / or physi@@ c@@ ised visible changes .
according to Article 114 of the Directive 2001 / 83 / EC @-@ changed version , State Charter is made up from one state laboratory or one to this purpose .
14 AN@@ CH@@ ED AN@@ NE RE@@ GU@@ LA@@ TION 1 Production sy@@ ringe WITH NA@@ DEL 1 Production sy@@ ringe WITH NA@@ DEL 10 Production sy@@ ringe WITH Nad@@ ine 50 finished injection holes WIT@@ HO@@ UT Nad@@ ine
suspension for injection moulding machines with needle 10 free sy@@ ringe with needle 10 pre@@ injection moulding with Nad@@ ine 50 pre@@ injection moulding without need@@ les 1 dose ( 1 ml )
EU / 1 / 02 / 224 / 002 1 finished injection with needle EU / 1 / 02 / 002 / 003 10 pre@@ injection moulding with Nad@@ ine EU / 1 / 02 / 224 / 005 50 pre@@ fabricated sy@@ ring@@ es without need@@ les
the hep@@ atitis B virus is usually transmitted by vir@@ gin@@ ity foods and beverages , but can also be transmitted through other ways , such as through bathing in through the drainage of contam@@ inated waters .
you can feel very tired , have a dark ur@@ ine , a bub@@ ble face , yellow skin and / or eyes ( yel@@ low@@ ish ) and other symptoms that might need a stationary treatment .
as with all vacc@@ ines , ambi@@ ente cannot be complete prior to an infection with hep@@ atitis B or hep@@ atitis B virus , even if the complete vacc@@ ination series was completed with 2 cans .
if you are infected with hep@@ atitis B and hep@@ atitis B virus ( although you are infected with hep@@ atitis B or hep@@ atitis B virus , if you do not feel the imp@@ air@@ ment of the disease .
protection against other infections caused by the liver or symptoms that are similar to those in hep@@ atitis B or hep@@ atitis B infection can not be taught .
• If you have an allergi@@ c reaction to ambi@@ rix or any part of this vacc@@ ine , including Ne@@ om@@ yc@@ in ( anti@@ biotic ) .
if you have an allergi@@ c reaction , breathing or sw@@ elling of the face or the tongue ? • If you have an allergi@@ c reaction to an earlier imp@@ air@@ ment against hep@@ atitis A or hep@@ atitis B .
• if you would like to have a protection against hep@@ atitis B ( i.e. , within 6 months and prior to the completion of the second vacc@@ ination ) .
a possible risk of infection with hep@@ atitis B between the first and second vacc@@ ination is the doctor / your child of a vacc@@ ination with ambi@@ ente .
instead , he will advise you / your child 3 inj@@ ections of a combined hep@@ atitis B / hep@@ atitis B and 10 micro@@ g units of a form@@ al@@ in@@ activated hep@@ atitis B virus and 10 micro@@ instruments of a re@@ combin@@ ant hep@@ atitis B @-@ surface surface .
the second vacc@@ ination of this vacc@@ ination is usually given a month after the first dose and is likely to give you a vacc@@ ine protection against end of the vacc@@ ination .
sometimes breathing with persons who suffer from severe blood cl@@ auses , under the skin and not in the muscle tissue , if you are pregnant with illness or treatment in your / her body .
ambi@@ rix can be given in these cases , but the immune response of these people can be sufficient to see that a blood test can be necessary to see how strongly the reaction to the vacc@@ ination is .
21 With@@ draw@@ al your doctor if you have a child more medicines ( including those that you have received without justi@@ fication may be ) or if you have / your child recently been spirit@@ ually ( anti@@ bodies ) have been given or refused in the near future .
but it can be that in this case the immune response is not sufficient and the person is not protected against one or both hep@@ atitis A and B viruses .
&quot; &quot; &quot; &quot; &quot; &quot; &quot; if another vacc@@ ine has to be given with ambi@@ rix , it should be separated to separate fields and as possible as possible as possible . &quot; &quot; &quot;
when ambi@@ rix at the same time or shortly before or after a injection of pol@@ ym@@ phs , it is likely that the reaction to the vacc@@ ine is nevertheless sufficient .
as a result , ambi@@ en or nursing women are not administ@@ ered but it is urg@@ ently necessary that they are both against hep@@ atitis A as well as hep@@ atitis B .
please inform your doctor if your child has already shown a allergi@@ c reaction to Ne@@ om@@ yc@@ in ( anti@@ biotic ) .
if you miss the agreed date for the second vacc@@ ination , talk to your doctor and arrange a new appointment as soon as possible .
20 ♦ Executive Big Bed Room ( 1 ) Apply filter : pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain , pain and pain .
20 ♦ Airport ( up to 1 case per 10 st@@ imp@@ ed@@ D@@ osen ) : • sw@@ elling of the injection rate • Fi@@ eber ( over 38 ° C ) • Ben@@ chmark • Ga@@ ther@@ m complaints
other side effects , the days or weeks after vacc@@ ination with comparable combination or individual combination of hep@@ atitis B and hep@@ atitis B is very rare ( less than 1 case per 10,000 caps ) were reported :
these include public limited or broad acceptance , ju@@ ices or bl@@ acks , sw@@ elling of the ey@@ enne , and the facial , sw@@ elling of eye , or swal@@ lowing , sudden blood pressure , and loss of consciousness .
influ@@ enza @-@ similar complaints , including Schüt@@ ze , mus@@ cular , and car@@ cin@@ ogen@@ ic disorders , multiple s@@ clerosis , diseases of tend@@ ons , loss of tend@@ ons , loss of movement and movement . many body parts , strong head@@ aches and sti@@ cking of the neck , inter@@ ruption of normal brain functions
diseases caused some blood vessels , appetite , paraly@@ sis , paraly@@ sis and abdominal pain , ly@@ m@@ ph@@ ate sw@@ elling disease ( blue spots ) , caused by waste of blood pressure ( blue spots ) , caused by waste of blood pressure .
23 consult your doctor or pharmac@@ ist if one of the remaining side effects or side effects or side effects that are not specified in this package .
ambi@@ rix is available in packing 1 and 10 with or without need@@ les and in pack@@ ets to 50 without need@@ les .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
as Ambi@@ ent , however , only in a member state ( in the Netherlands since May 2003 ) , the available safety data for this medicine is limited due to the low patient facilities .
Am@@ mon@@ aps also can also be used for patients at the age of a month with a complete end defect or hyper@@ am@@ mon@@ ic enc@@ ephal@@ opath@@ ie ( bra@@ in@@ opathy of high am@@ mon@@ ia concent@@ rations ) in the history of history .
Am@@ mon@@ aps - split into several types of meals - p@@ aired , under the food of food , or via a guest of the abdominal wall ( through the abdominal wall in the stomach @-@ shaped tube ) or a nose end ( through the nose in the stomach &apos;s edge ) .
it was not a comparable study , since Am@@ mon@@ ica cannot be compared with another treatment or plac@@ ebo ( a spotlight media that could be compared with active ingredient ) .
Am@@ mon@@ ium can also lead to appetite loss , a ab@@ rup@@ tible acid content in blood , depression , irrit@@ ability , rice disorders , flav@@ on@@ oids , vom@@ iting , vom@@ iting , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , irrit@@ ability , skin care .
pdf @-@ Datei per E @-@ Mail , Enter@@ pris@@ e@@ wide Price ( Global Site License ) * * * , versandkostenfrei
Am@@ mon@@ g has been approved under &quot; exceptional circumstances because of the disease of disease at the time of approval of the disease only limited to this medication .
the use is used in all patients , in which a complete oral defici@@ ency is already manifest@@ ed in the new bor@@ eh@@ an age ( within the first 28 days age ) .
in patients with an delayed form ( in@@ set in@@ z@@ ym@@ eter , which is manifest@@ ed after the first living mon@@ at ) , there is a indication for use when in which An@@ am@@ n@@ ese has a hyper@@ am@@ mon@@ emia of enc@@ ephal@@ opath@@ ie .
for babies , for children who are not able to swal@@ low , tablets of swal@@ lowing or for patients with swal@@ low dys@@ function , AM@@ MON@@ A@@ PS is also available in gran@@ ulate form .
the daily dose is calculated individually under consideration of the protein toler@@ ance and the growth required for the growth and development of the patients .
after the recent clinical experiences , the normal daily dose of Nat@@ ri@@ um@@ ster@@ oids : • 450 - 600 mg / kg / day with children with a body weight of less than 20 kg • 9,@@ 0 g / m ² / day with children with a body weight over 20 kg as well as with herd and adults .
in patients who suffer an early lack of Carb@@ am@@ yl phosph@@ ate syn@@ th@@ et@@ ran@@ ate or or@@ ni@@ th@@ int@@ ran@@ sc@@ arb@@ or@@ las@@ e , the sub@@ stitution of Cit@@ rul@@ line or ar@@ gin@@ ine in a dose of 0.@@ 17 g / kg / day or 3,@@ 8 g / m ² / day .
patients with a Ar@@ gin@@ in@@ os@@ u@@ cc@@ in@@ at@@ ogen@@ ic syndrome have to have ar@@ gin@@ ine in a dose of 0.@@ 4 - 0,7 g / kg / day or 8,@@ 8 - 15,@@ 4 g / m ² / day .
AM@@ MON@@ A@@ PS tablets may not be administ@@ ered to patients with swal@@ lowing disorders , as a risk for the emergence of Ö@@ kon@@ c@@ anti@@ bacterial , if the tablets are not immediately stored in the stomach .
each tablet AM@@ MON@@ A@@ PS contains 62 mg ( 2,@@ 7 m@@ mo@@ l ) so@@ dium , according to 2.5 g ( 108 m@@ mo@@ l ) Nat@@ ri@@ um per 20 g Nat@@ ri@@ um@@ ph@@ yl@@ but@@ yl , which corresponds to the maximum dose of the maximum dose .
AM@@ MON@@ A@@ PS should therefore lead to patients with cont@@ ingent heart failure or severe kidney disease , as well as with Nat@@ ri@@ pen@@ er and Ö@@ de@@ mb@@ il@@ ateral clinical trials only with caution .
since Met@@ aboli@@ tion and Met@@ aboli@@ tion of Nat@@ ri@@ um@@ ster@@ oids on the liver and the kid@@ neys , AM@@ MON@@ A@@ PS should only be applied only with the utmost caution .
the importance of this results in reference to pregnant women is not known ; the use of AM@@ MON@@ A@@ PS during pregnancy is therefore compliant ( see 4.3 ) .
in sub@@ cut@@ aneous gift of phen@@ yl@@ acet@@ at on young rats ( 190 - 4@@ 74 mg / kg ) , it came to a slow@@ down of neur@@ onal closure and increased loss of neur@@ ons .
this paper investigates the impact of non @-@ take @-@ up for two hypothe@@ tical scenarios , namely increasing and decreasing the base amount of social assistance in Germany by € 100 per month . IAB @-@ Discussion Paper 20 / 2015
it could not be established if phen@@ yl@@ acet@@ at present in the wom@@ b milk , and out of this reason is the use of AM@@ MON@@ A@@ PS during the stand@@ still contra@@ ctor ( see 4.3 ) .
in clinical trials with AM@@ MON@@ A@@ PS , 56 % of the patients had at least an un@@ desired event ( AE ) and at 78 % of these unwanted events , they were not out with AM@@ MON@@ A@@ PS in conjunction with AM@@ MON@@ A@@ PS .
the frequency response is defined as follows : very frequently ( ≥ 1 / 100 , &lt; 1 / 10 ) and occasionally ( ≥ 1 / 1.000 , &lt; 1 / 100 ) .
an prob@@ ation of toxic reaction to AM@@ MON@@ A@@ PS ( 450 mg / kg / day ) was reported by a 18 years old abnormal disease in conjunction with l@@ eni@@ potenti@@ ary , severe hy@@ po@@ ol@@ emia , peripheral neu@@ rop@@ ath@@ ic and pan@@ cre@@ atitis .
a case of over@@ dose occurred in a 5 months old small child with an acci@@ dental average dose of 10 g ( 13@@ 70 mg / kg ) .
these symptoms are associated with the accumulation of phen@@ yl@@ acet@@ at which showed intra@@ ven@@ ous administration to in@@ ven@@ tions up to 400 mg / kg / day a dos@@ is@@ limitation of ne@@ oto@@ x@@ emia .
phen@@ yl@@ acet@@ at is an enz@@ yme active connection developed by acet@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine con@@ ju@@ g@@ ated that ex@@ its the kid@@ neys .
they saw phen@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine with har@@ n@@ ene ( both connections contain 2 Nit@@ rogen at@@ oms ) ; phen@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine is therefore ideal as alternative medicine for ex@@ cre@@ ed nitrogen .
5 patients with dis@@ rup@@ tions of the ur@@ inary cycle can be assumed that each gram is made Nat@@ ri@@ um@@ ph@@ yl@@ but@@ yl phosph@@ ate between 0.@@ 12 and 0.@@ 15 g phen@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine nitrogen .
it is important to realize that diagnosis earliest and treatment can immediately start immediately to improve the survival of survival and the clinical outcome .
the pro@@ g@@ nosis of early symptoms associated with occurr@@ ence of the first symptoms in Neu@@ kirchen @-@ old was almost always inf@@ low , and the illness brought to treatment with per@@ it@@ one@@ al@@ di@@ aly@@ sis and essential amino acids or with their sti@@ cking @-@ free analogue within the first previous year .
due to hem@@ at@@ aly@@ sis , the use of alternative approaches of nitrogen oxide ( Nat@@ ale ben@@ zene compounds ) , prot@@ ector , and possibly sub@@ stitution of essential amino acids , it was possible to increase the survival rate of Neu@@ born in post@@ part@@ al ( but within the first lifetime ) .
in patients , the disease was diagnos@@ ed at the course of a hyper@@ am@@ mon@@ emia of enc@@ ephal@@ opath@@ ie , the survival rate of 100 % , but even in these patients the survival rate was 100 % , but even in these patients the survival of other neuro@@ logical defic@@ its or other neuro@@ logical defic@@ its .
patients with a late @-@ recur@@ rence type of disease ( including female patients with hetero@@ dy@@ es form of the Or@@ ni@@ th@@ int@@ ran@@ s@@ las@@ e @-@ Man@@ gels ) , which were treated by a hyper@@ am@@ mon@@ emia of the Or@@ ni@@ th@@ int@@ ran@@ y@@ rat and a protein reduced diet , was the survival rate 98 % .
neuro@@ logical defic@@ its , even in treatment hardly re@@ balanced and in some patients may cause further deteri@@ oration of neuro@@ logic signals .
phen@@ yl@@ acet@@ y@@ rat is oxi@@ di@@ zed to phen@@ yl@@ acet@@ at , which is produced in liver and kid@@ neys , with phen@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine .
concent@@ rations of phen@@ yl@@ but@@ y@@ rat and its Met@@ aboli@@ sm in plasma and ur@@ ine , after injection of a single dose of 5 g Nat@@ ri@@ um@@ ster@@ oids and with liver cir@@ rho@@ sis , and with liver cir@@ rho@@ sis , and with liver cir@@ rho@@ sis of up to 20 g / day ( not controlled trials ) .
the behavior of phen@@ yl@@ but@@ y@@ rat and its met@@ abo@@ lit@@ es were also examined for cancer patients after intra@@ ven@@ ous tissue of Nat@@ ri@@ um@@ ster@@ oids ( up to 2 g / m ² ) or phen@@ yl@@ acet@@ at .
after a or@@ ating single dose of 5 g Nat@@ ri@@ um@@ ster@@ oids in tablet form , 15 minutes after taking brass plasma concent@@ rations from phen@@ yl@@ but@@ yl alcohol .
in the majority of patients with Har@@ n@@ ym@@ ph@@ oma or hem@@ mo@@ glo@@ bin@@ opathy ( 300 @-@ 650 mg / kg / day up to 20 g / day ) at the next morning after nights are no phen@@ yl@@ acet@@ at in plasma .
for three of six patients with cir@@ rho@@ sis of cir@@ rho@@ sis ( 20 g / day ) were treated with so@@ dium acet@@ yl@@ but@@ y@@ rat ( 20 g / day ) were treated in the plasma levels at the third day five times higher than after the first gifts .
the medication is processed within 24 hours and 100 % in the form of con@@ ju@@ g@@ ated product phen@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine over the kid@@ neys .
after the results of the Mic@@ ron@@ u@@ cle@@ us tests , Nat@@ ri@@ um@@ phen@@ yl@@ but@@ yl alcohol had no k@@ la@@ sto@@ er@@ ous effects ( examination 24 and 48 h according to or@@ char@@ itable response to a single dose of 8@@ 78 to 2800 mg / kg ) .
AM@@ MON@@ A@@ PS Gran@@ ul@@ at will be taken either with oral ( m@@ ous@@ ins and children that can not swal@@ low tablets , or patients with swal@@ lowing disorders ) or a so@@ dium finish or a nose end .
after the recent clinical experiences , the normal daily dose of Nat@@ ri@@ um@@ ster@@ oids : • 450 - 600 mg / kg / day with a body weight of less than 20 kg • 9,@@ 0 g / m ² / day with children with a body weight over 20 kg as well as with herd and adults .
the concentration of am@@ mon@@ ia , ar@@ gin@@ ine , essential amino acids ( especially bran@@ ching amino acids ) , car@@ ni@@ tin and ser@@ um protein in plasma should be kept inside the normal range .
in patients who suffer an early lack of Carb@@ am@@ yl phosph@@ ate syn@@ th@@ et@@ ran@@ ate or or@@ ni@@ th@@ int@@ ran@@ sc@@ arb@@ or@@ las@@ e , the sub@@ stitution of Cit@@ rul@@ line or ar@@ gin@@ ine in a dose of 0.@@ 17 g / kg / day or 3,@@ 8 g / m ² / day .
AM@@ MON@@ A@@ PS Gran@@ ul@@ at contains 124 mg ( 5.@@ 4 m@@ mo@@ l ) Nat@@ ri@@ um per gram Nat@@ ri@@ um@@ ster@@ oids per 20 g ( 108 m@@ mo@@ l ) Nat@@ ri@@ um per 20 g Nat@@ ri@@ um@@ ph@@ yl@@ but@@ yl , which corresponds to the maximum dose of the maximum dose .
if R@@ atten@@ uation is exposed to phen@@ yl@@ acet@@ at ( active Met@@ aboli@@ sm of phen@@ yl@@ but@@ y@@ rat ) , it came to L@@ ä@@ s in the pyramid cells of the brain rin@@ se .
an prob@@ ation of toxic reaction to AM@@ MON@@ A@@ PS ( 450 mg / kg / day ) was reported by a 18 years old abnormal disease in conjunction with l@@ eni@@ potenti@@ ary , severe hy@@ po@@ ol@@ emia , peripheral neu@@ rop@@ ath@@ ic and pan@@ cre@@ atitis .
they saw phen@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine with har@@ n@@ ene ( both connections contain 2 Nit@@ rogen at@@ oms ) ; phen@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine is therefore ideal as alternative medicine for ex@@ cre@@ ed excess of surplus value .
on the basis of exam@@ inations over phen@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine for patients with distur@@ ban@@ ces of the ur@@ inary cycle may be assumed that each gram is made Nat@@ ri@@ um@@ ph@@ yl@@ but@@ yl phosph@@ ate between 0.@@ 12 and 0.@@ 15 g phen@@ yl@@ acet@@ yl@@ gl@@ ut@@ amine nitrogen .
neuro@@ logical defic@@ its , even in treatment hardly re@@ treated , and in some patients may cause further deteri@@ oration of neuro@@ logic signals .
after a or@@ ating single dose of 5 g Nat@@ ri@@ um@@ ph@@ yl@@ but@@ yl phosph@@ ate in gran@@ ulate form , 15 minutes after taking brass plasma concent@@ rations from phen@@ yl@@ but@@ yl phosph@@ ate .
during the duration of the durability , the patient can save the finished product in a period of 3 months for a period of 3 months at a temperature of 25 ° C .
in this approach , the small measuring spo@@ ons 0,@@ 95 g , the mean value spo@@ on 2,@@ 9 g and the large measuring spo@@ ons 8,@@ 6 g Nat@@ ri@@ um@@ ster@@ oids .
if a patient has to receive the medication about a probe , AM@@ MON@@ A@@ PS can be dissolved in water ( the sol@@ ves of Nat@@ ri@@ um@@ osa but@@ yl but@@ yl is up to 5 g in 10 ml water ) .
in patients with these rare diseases are missing certain liver enz@@ yme , so that they can accum@@ ulate the sti@@ ck@@ able waste products that are unable to accum@@ ulate proteins in the body .
in case of laboratory tests , you need to take the doctor to take the doctor that you can take the AM@@ MON@@ A@@ PS to affect the results of specific laboratory tests .
taking advantage of AM@@ MON@@ A@@ PS with other medicines please inform your doctor or pharmac@@ ist if you have other drugs or have recently taken this medication even if it is not authorised to prescription drugs .
AM@@ MON@@ A@@ PS is not going to take the medicine in the mother &apos;s milk and may damage your baby .
in rare cases , confusion , head@@ aches , fla@@ vor@@ less dys@@ function , dys@@ function , anxiety disorders , memory dys@@ function , and a deteri@@ oration of existing neuro@@ logic states .
if you find one of these symptoms , please contact your doctor or with the emergency recording of your hospital .
if you forget the intake of AM@@ MON@@ A@@ PS please take the appropriate dosage as soon as possible with the next meal .
changes in blood cells ( red blood cells , white blood bo@@ ils , depression , irrit@@ ability , depression , vom@@ iting , vom@@ iting , puri@@ fication , irrit@@ ability , kidney dys@@ function , weight gain , kidney dys@@ function , weight gain and an@@ om@@ ale laboratory values .
please inform your doctor or pharmac@@ ist if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
&quot; &quot; &quot; you may not use AM@@ MON@@ A@@ PS after processing up to &quot; &quot; &quot; &quot; Ver@@ tex &quot; &quot; &quot; &quot; or &quot; &quot; &quot; &quot; Ver@@ sion@@ able up to &quot; &quot; &quot; . &quot; &quot; &quot; &quot;
as AM@@ MON@@ A@@ PS looks and content of AM@@ MON@@ A@@ PS tablets are made of high @-@ quality colour and oval shape , and they are equipped with &quot; U@@ CY 500 . &quot;
30 If you take the laboratory tests , you need to take the doctor to take the doctor that you may have AM@@ MON@@ A@@ PS , since Nat@@ ri@@ um@@ phen@@ yl@@ but@@ y@@ ate may affect the results of specific laboratory tests .
taking advantage of AM@@ MON@@ A@@ PS with other medicines please inform your doctor or pharmac@@ ist if you have other drugs or have recently taken this medication even if it is not authorised to prescription drugs .
you should have AM@@ MON@@ A@@ PS is distributed in identical single @-@ boxes ( hose , which runs through the abdominal wall directly into the stomach . ) or a nose end ( hose which is led by the nose in the stomach . ) .
31 • Make an inclined measuring spo@@ on gran@@ ulate . • St@@ range of a straight edge , e.g. a knife through the upper edge of the measuring head to remove excess Gran@@ ul@@ at . • Meas@@ ure the recommended amount of measuring spo@@ ons gran@@ ulate from the container .
An@@ gi@@ ox is applied for adult patients with &quot; acute cor@@ on@@ ary syndrome ( ACS , reduced blood supply ) , for example at the unstable dro@@ pping ( a form of pain in the breast basket with different thickness ) or m@@ yo@@ cardi@@ al inf@@ ant ( heart attack ) without &quot; ST@@ - Heb@@ ung &quot; ( an an@@ om@@ ination measuring value during the electro@@ kar@@ di@@ ers or EC@@ G ) .
the toxic effect of blood cl@@ ots in patients who are applied to a PCI a higher dose , and in@@ fusion can continue to be continued until four hours after the procedure .
this may contribute to patients with tick or cardi@@ an@@ isation to maintaining the blood flow to the heart and increase the effectiveness of a PCI .
approximately 14 000 patients took part in the main study about the treatment of ACS , which was compared with a gly@@ cop@@ rot@@ ein @-@ II@@ b / II@@ I@@ a inhib@@ itor ( G@@ PI ) with conventional combination treatment with He@@ par@@ in ( another anti@@ o@@ ag@@ ul@@ ans ) and one G@@ PI compared .
during the PCI , the patients often have a st@@ ent ( a short cut ) , which in the Ar@@ ter@@ ie remain in order to prevent a clasp and in addition other drugs to prevent blood cl@@ ots , such as Ab@@ ig@@ xim@@ ab and A@@ spir@@ in .
in the treatment of ACS , An@@ gi@@ ox - with or without the gift of G@@ PI - when the prevention of new events ( death of death , heart disease or Rev@@ isi@@ ae ) after 30 days or a year , as effective as the conventional treatment .
in patients who under@@ went with a PCI , An@@ gi@@ ox was in terms of all indications like He@@ par@@ in , except for severe ble@@ eding , in which it was considerably more effective than He@@ par@@ in .
An@@ gi@@ ox must not be applied to patients who may have sensitive ( allergi@@ c ) against Bi@@ val@@ ir@@ u@@ din , others sh@@ ud@@ ine or any other ingredients .
it may not be applied to patients who had recently had a blood pressure , as well as people with high blood pressure or severe kidney diseases or a heart infection .
pdf @-@ Datei per E @-@ Mail , Enter@@ pris@@ e@@ wide Price ( Global Site License ) * * * , versandkostenfrei
&quot; &quot; &quot; &quot; &quot; &quot; &quot; in September 2004 the European Commission divided the European Commission to provide a permit for the transport of An@@ gi@@ ox in the entire European Union . &quot; &quot; &quot;
for the treatment of adult patients with acute cor@@ on@@ ar@@ syn@@ dro@@ mes ( inst@@ ab@@ ile An@@ gina / non @-@ ST @-@ Hebrew inf@@ ant ( IA / N@@ STE@@ MI ) ) in emergency exit or when an early intervention is planned .
the recommended initi@@ al@@ dose of angi@@ oma in patients with ACS is an intra@@ ven@@ ous bol@@ us@@ ation of 0.1 mg / kg followed by an in@@ fusion of 0.25 mg / kg / h .
in case of the patients in another consequence a PCI has been carried out , a additional bolt from 0.5 mg / kg , and the in@@ fusion for the duration of the intervention to 1.@@ 75 mg / kg / h will be increased .
after the PCI can be processed after clinical trials , the reduced in@@ fusion dose of 0.25 mg / kg / h for 4 to 12 hours .
immediately prior to the procedure , a stud of 0.5 mg / kg , followed by an in@@ fusion of 1,@@ 75 mg / kg / h for the duration of intervention .
the recommended dosage of An@@ gi@@ ox for patients with a PCI consists of an initi@@ ating intra@@ ven@@ ous bol@@ ts of 0.@@ 75 mg / kg body weight and an increasing intra@@ ven@@ ous in@@ fusion with a dose of 1,@@ 75 mg / kg body weight / h at least for the duration of intervention .
the safety and eff@@ ic@@ acy of an all@@ number Bol@@ us gift was not investigated and is not recommended , even if a short PCI procedure is planned .
this value ( ACT after 5 minutes ) is short@@ ened to 225 seconds , a second bolt connection is 0,3 mg / kg / body weight .
in order to reduce the occurr@@ ence of lower ACT should be carefully mixed and dil@@ uted medicines before application carefully mixed and the bol@@ us@@ dose is quickly administ@@ ered .
once the ACT is more than 225 seconds , a further monitoring is not required , provided under 1.@@ 75 mg / kg , in@@ fu@@ sion@@ ary dose is correct .
patients with medium @-@ severe kidney dys@@ function ( G@@ FR 30 @-@ 59 ml / min ) , which are treated with Bi@@ val@@ ir@@ u@@ din against ACS , or not ) , a lower in@@ fusion rate of 1.4 mg / kg / h should be used .
is the ACT value under 225 seconds , a second Bol@@ us@@ dose of 0,3 mg / kg and to check the ACT 5 minutes after the second Bol@@ us@@ dose .
patients with medium @-@ severe kidney damage caused in the phase II@@ I@@ - PCI @-@ study ( RE@@ PLA@@ CE @-@ 2 ) which led to approval , was the ACT value 5 minutes after gift of Bi@@ val@@ ir@@ u@@ din @-@ Bol@@ us without any d@@ os@@ is@@ cation at average 366 ± 89 seconds .
3 In patients with severe kidney damage ( G@@ FR &lt; 30 ml / min ) and also di@@ aly@@ sis ( see Section 4.3 ) .
the treatment with angi@@ oma can be seen 30 minutes after end the intra@@ ven@@ ous gift of un@@ fra@@ ction of He@@ par@@ in or 8 hours after finishing the sub@@ cut@@ aneous gift of the molecular he@@ par@@ in .
• Well @-@ sensitive use due to the active ingredient or other ingredients or against her@@ ud@@ ine • active ble@@ eding or increased blood risk , due to inflammation of the hem@@ isph@@ ere , and / or mis@@ cell@@ aneous health risk . • severe kidney disease ( G@@ FR &lt; 30 ml / min ) and di@@ aly@@ se@@ wage treatment
patients are carefully checked during treatment with symptoms and signs of a blood , especially if Bi@@ val@@ ir@@ u@@ din is administ@@ ered with another anti@@ o@@ ag@@ ul@@ ans ( see Section 4.5 ) .
in case with PCI @-@ patients under Bi@@ val@@ ir@@ u@@ din , most ble@@ eding may occur in ar@@ ter@@ ial cells can occur in patients who occur in a perc@@ ut@@ aneous cor@@ on@@ ary intervention ( PCI ) , while treatment can occur everywhere .
patients to be treated with Bi@@ val@@ ir@@ u@@ din , a monitoring of In@@ r @-@ Wer@@ ts should be treated with bi@@ val@@ ir@@ u@@ din , to ensure that the value is achieved after treatment with bi@@ val@@ ir@@ u@@ din .
arising from the knowledge of anti@@ o@@ ag@@ ul@@ ants ( He@@ par@@ in , War@@ far@@ in , Th@@ ro@@ mb@@ oly@@ tic or Th@@ rom@@ bo@@ cy@@ tes Risiko ) may be assumed that these compounds may increase blood circulation .
with the combination of Bi@@ val@@ ir@@ u@@ din with Th@@ rom@@ bo@@ cy@@ ten@@ sions techniques or anti@@ o@@ ag@@ ul@@ ants provide the clinical and biological hem@@ ophi@@ lic parameters in each case regularly .
the experimental investigations are in@@ adequate in terms of impact on the pregnancy , the embr@@ y@@ onic / fat development , which in@@ adequate or the post@@ nat@@ al development in@@ adequate ( see Section 5.3 ) .
46@@ 12 were random@@ ised to Bi@@ val@@ ir@@ u@@ din alone , 4@@ 604 were random@@ ised to Bi@@ val@@ ir@@ u@@ din plus G@@ PI@@ I@@ b / II@@ I@@ a inhib@@ itor and 4@@ 603 were random@@ ised to either un@@ fra@@ ction of He@@ par@@ in or E@@ no@@ x@@ apar@@ in plus G@@ PI@@ I@@ b / II@@ I@@ a inhib@@ itor .
both in the bi@@ val@@ ir@@ u@@ din group as well as in patients with he@@ par@@ in treated groups were more frequently to un@@ desirable events than in male or younger patients .
heavy blood tests were defined according to AC@@ U@@ ITY and tim@@ i dimensional stability , such as in the foot@@ notes of the table 2 .
both light and heavy blood tests were significantly lower than in groups with He@@ par@@ in plus G@@ PI@@ I@@ b / II@@ I@@ a inhib@@ itor and Bi@@ vali@@ dator plus G@@ PI@@ I@@ b / II@@ I@@ a inhib@@ itor ( see table 2 ) .
a AC@@ U@@ ITY of blood was defined as one of the following events : intra@@ cran@@ ial blood , retro@@ per@@ it@@ one@@ al , intra@@ ocular blood , intra@@ ocular blood of ≥ 12 g / dl with well @-@ obvious blood circulation , prevention of breast cancer , re@@ operation due to a blood flow , use of blood products to trans@@ fusion .
other , less often observ@@ ations , with more than 0.1 % ( occasionally ) , &quot; other &quot; points , retro@@ per@@ it@@ one@@ al , g@@ astro@@ intestinal , ear , nose or neck .
the following information on side @-@ effects are based on the data of a clinical trial with Bi@@ val@@ ir@@ u@@ din at 6000 patients who under@@ went a PCI .
both in the Bi@@ val@@ ir@@ u@@ din Group as well as in patients with he@@ par@@ in treated groups were more frequently to un@@ desirable events than in male or younger patients .
both light and heavy blood tests were significant less often than in the comparative group of He@@ par@@ in plus G@@ PI@@ I@@ b / II@@ I@@ a inhib@@ itor .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
in case of over@@ dosing the treatment with bi@@ val@@ ir@@ u@@ din can break instantly and to monitor the patient with regard to signs of blood .
An@@ gi@@ ox contains Bi@@ val@@ ir@@ u@@ din , a direct and specific Th@@ ro@@ mb@@ in@@ hi@@ kers , which is bound both on the cat@@ amar@@ an centre of Th@@ ro@@ mb@@ in bin@@ ds , regardless of whether Th@@ ro@@ mb@@ in in the liquid phase or at the field is bound .
the binding of Bi@@ val@@ ir@@ u@@ din to Th@@ ro@@ mb@@ in , and thereby his effect is rever@@ sible because Th@@ ro@@ mb@@ in himself part the binding of Bi@@ val@@ ir@@ u@@ din @-@ Ar@@ g@@ 3 @-@ Pro@@ 4 slowly , whereby the function of the active centre of Th@@ ro@@ mb@@ in re@@ generates .
moreover , Bi@@ val@@ ir@@ u@@ din carried out by Bi@@ val@@ ir@@ u@@ din with ser@@ um of patients , where it was done in past @-@ induced Th@@ rom@@ bo@@ cy@@ top@@ ie / he@@ par@@ in@@ ulin syndrome ( H@@ IT / H@@ IT@@ TS ) , no Th@@ rom@@ bo@@ zy@@ ten aggreg@@ ation reaction .
&quot; &quot; &quot; results appear ordered &quot; &quot; &quot; &quot; by relevance &quot; &quot; &quot; &quot; or &quot; &quot; &quot; &quot; by date &quot; &quot; &quot; &quot; ( publication date ) , &quot; &quot; &quot;
in case of the patients , a PCI has been carried out , a further Bol@@ us from 0,@@ 5mg / kg Bi@@ val@@ ir@@ u@@ din , and the in@@ fusion for the duration of the intervention at 1.@@ 75@@ mg / kg / h .
in the arm A of AC@@ U@@ ITY study was un@@ fra@@ c@@ apped he@@ par@@ in or E@@ no@@ x@@ apar@@ in according to the relevant guidelines for the treatment of acute cor@@ on@@ ary syndrome ( ACS ) in patients with unstable m@@ gina / non @-@ ST defici@@ ency ( IA / N@@ STE@@ MI ) .
patients in arm A and B have been random@@ ised to obtain a G@@ PI@@ I@@ b / II@@ I@@ a inhib@@ itor either prior to the angi@@ ography ( at the time of the boundary conditions ) or in the PCI .
in the AC@@ U@@ ITY by the AC@@ U@@ ITY study , the characteristics of high risk op@@ sy , which are required by angi@@ ography within 72 hours .
about 77 % of patients had a recur@@ ring isch@@ emia , 70 % had dynamic EK@@ G@@ - changes or increased cardiovascular biom@@ ar@@ ker , 28 % had diabetes and about 99 % of all patients under@@ gone within 72 hours of an angi@@ ography .
primary analysis and results from the AC@@ U@@ ITY study for the 30 @-@ trial and the 1 year @-@ end point for the overall population ( IT@@ T ) and for the patient who received A@@ spir@@ in and Clo@@ pi@@ ti@@ bles according to the Protocol ( before the An@@ gi@@ ography or before the PCI ) , tables 7 and 8 .
AC@@ U@@ ITY study ; 30 @-@ day and 1 year risk differences for the combined end@@ point and its components for patients who received A@@ spir@@ in and Clo@@ pi@@ anos
&quot; &quot; &quot; patients , A@@ spir@@ in and Clo@@ pi@@ anos , according to the protocol &quot; arm &quot; arm &quot; arm &quot; arm &quot; arm &quot; &quot; &quot; , &quot; C U@@ FH / E@@ no@@ x Bi@@ val B@@ - A Bi@@ val + G@@ PI@@ I@@ b / II@@ I@@ a + G@@ PI@@ I@@ b / II@@ I@@ a risk of Di@@ ff . &quot; &quot; &quot;
the frequency of blood tests both in AC@@ U@@ IT@@ Y@@ - as well as in tim@@ i extent up to day 30 for the total population ( IT@@ T ) and for patients who received A@@ spir@@ in and Clo@@ pi@@ anos .
patients , A@@ spir@@ in and Clo@@ pi@@ ous total population ( IT@@ T ) according IC@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b / II@@ I@@ a G@@ PI@@ I@@ b
* Clo@@ pp@@ boards are defined as one of the following events : intra@@ cran@@ ial blood , retro@@ sp@@ inal hem@@ or@@ rh@@ age , intra@@ ocular blood pressure , intra@@ ocular blood flow of ≥ 12 g / dl with well @-@ obvious blood circulation , prevention of blood and blood tests , re@@ produ@@ ci@@ bility due to a blood flow , use of blood products to trans@@ fusion .
the 30 @-@ day Results , based on square and triple @-@ end points of a random@@ ised double @-@ blind trial with more than 6,@@ 000 patients receiving a PCI @-@ controlled ( RE@@ PLA@@ CE @-@ 2 ) are shown in table 10 .
clinical studies with a small number of patients compl@@ ained about the application of angi@@ oma in patients with H@@ IT / H@@ IT@@ TS .
Ph@@ armac@@ ok@@ ine@@ tic properties of Bi@@ val@@ ir@@ u@@ din were identified in patients who under@@ went a perc@@ ut@@ aneous cor@@ on@@ ary intervention ( PCI ) , as well as patients with ACS .
it is expected that Bi@@ val@@ ir@@ u@@ din as Pep@@ ti@@ d &apos;s Pep@@ ti@@ d offers a cat@@ ar@@ act in its amino acids .
primary met@@ abo@@ lit@@ es from the split of the Ar@@ g@@ 3 Pro@@ 4 binding of the N @-@ termin@@ ology sequence due to Th@@ ro@@ mb@@ ity , is not effective due to the loss of its affili@@ ates to the cataly@@ tic center of Th@@ ro@@ mb@@ in .
the Eli@@ min@@ ation takes place in patients with regular kidney function after a process first order with a terminal piece of 25 ± 12 minutes .
based on conventional studies to safety sp@@ har@@ mac@@ ology , tox@@ icity , or reproduction process , the pre@@ clinical data could not be no particular haz@@ ards for humans .
tox@@ icity of animals in recur@@ red or continuous exposure ( 1 day to 4 weeks at a exposure to 10 @-@ fold of the clinical ste@@ ads ) limited to excessive pharmac@@ ological effects .
adverse effects caused by a long @-@ term physi@@ ological stress as a reaction to a non @-@ hom@@ est@@ ost@@ atic co@@ ag@@ ulation , after short @-@ term exposure were comparable to those in clinical application , even at very much higher dos@@ es .
the use of the ready @-@ to @-@ use solution is not controlled under controlled and vali@@ dierung as@@ ep@@ tic conditions , this is not longer than 24 hours at 2 ° C to 8 ° C .
An@@ gi@@ ox is a fri@@ ghtened powder in single dose of type @-@ 1 glass to 10 ml , which sealed with a but@@ yl rubber mixing , and sealed with a cap from moul@@ ded aluminium sealed .
5 ml ster@@ ile water for injection moulding can be given in a continuous bottle , and easily be completely dissolved and the solution is clear .
5 ml are taken out from the balance sheet and continue with 5 % glu@@ cos@@ ity solution for injection or with 9 mg / ml ( 0.@@ 9 % ) Nat@@ ri@@ um chl@@ oride in a total volume of 50 ml to obtain a final concentration of 5mg / ml Bi@@ val@@ ir@@ u@@ din .
the owner of the approval of approval for the in@@ traffic is based on the studies and pharmaceutical ko@@ vi@@ gil@@ ance activities which are represented in the pharmaceu@@ ko@@ vi@@ gil@@ ance Plan , as well as in version 4 of the risk management plan ( R@@ MP ) , as well as every subsequent changes of the R@@ MP , which has been agreed by CH@@ MP .
as a result of the CH@@ MP Gui@@ deline to Risk Management Systems for Human@@ izing R@@ MP is to be submitted at the same time with the next peri@@ odic Safety Update report ( PS@@ BE ) .
• patients with chest pain due to a heart disease ( acute cor@@ on@@ ar@@ gic - ACS ) • patients who operate the treatment of caps in the blood vessel ( An@@ gi@@ oplas@@ tie and / or or perc@@ ut@@ aneous coral on@@ ary syndrome - PCI ) .
• You are pregnant or susp@@ ect that you might pregnant should be pregnant . you are currently bre@@ ast@@ feeding .
no exam@@ inations are carried out on the traffic conditions and the ability to serve machinery , but one knows that the effects of this drug may be short @-@ term .
if a blood occurs , the treatment with dent@@ ox has broken . • Before the beginning of injection or in@@ fusion , you will inform your doctor about the possible signs of an allergi@@ c reaction .
such reactions are sel@@ dom ( they occur in less than 1 of 1000 patients . • A particularly careful monitoring is carried out if you get a radiation therapy for the vessels , which can obtain the heart with blood ( this treatment is referred to as beta or gam@@ ch@@ y@@ therapy ) . • The dose you get obtained from your body weight and the type of therapy that you get received .
• 0.1 mg / kg body weight , followed by an in@@ fusion ( tropical solution ) with 0.25 mg / kg body weight per hour ( 0.1 mg / kg body weight per hour means a quarter of a milli@@ liter of medication per hour ) .
prob@@ able if An@@ gi@@ ox is administ@@ ered with other afflic@@ tions in combination with other afflic@@ tors ( see Section 2 &quot; In Application of An@@ gi@@ ox with other medicines . ) .
these are occasional side effects ( with less than 1 of 100 patients ) . • Th@@ ro@@ mb@@ ose ( blood cl@@ ause ) that could lead to serious complications such as a heart attack .
this is a occasional side effect ( with less than 1 of 100 patients ) . • pain , blood flow and high blood flow at the punk station ( after a PCI treatment ) .
please inform your doctor if one of the remaining side effects are considerably affected or no side effects that are not specified in this utility information .
An@@ gi@@ ox shall not be applied to the label on the label and can not be applied to the expi@@ ration date of the expi@@ ration date .
Pol@@ ska The Medic@@ ines Company UK Ltd . : + 800 8@@ 43 6@@ 33 26 Lu@@ b + 41 61 5@@ 64 13@@ 20 Se@@ asons : + 30 210 5@@ 28@@ 1700 E @-@ mail :
A@@ pi@@ dra is used for treatment of adults , young people and children aged six years with diabetes that require treatment with ins@@ ulin .
A@@ pi@@ dra is sub@@ cut@@ aneous ( under the skin ) into the abdominal wall , the th@@ igh@@ s or the upper arm or as a continuous in@@ fusion with an ins@@ ulin pump .
diabetes is a disease in which the body is not sufficient ins@@ ulin to regulate the gluten @-@ free ins@@ ulin ( sugar ) in blood , or ins@@ ulin is not effective .
ins@@ ulin lu@@ li@@ ine differs very low of human ulin , and the change indicates that it has a shorter time effective than a short @-@ effective human life .
A@@ pi@@ dra was used in combination with a long @-@ effective ins@@ ulin in patients with a total of 1 5@@ 49 adults and in a study with a total of 1 5@@ 49 adults and in a study with 5@@ 72 children aged between four and 17 years .
in type 2 diabetes , A@@ pi@@ dra was studied in a study with 8@@ 78 adults .
the main organ@@ izer for the effectiveness was the change of the substance of the substance of the substance ( H@@ b@@ A@@ 1@@ c ) in blood that shows how good the blood sugar is set .
in the first study with adults with type 1 diabetes after six months , a reduction of 0.@@ 14 % ( 20 % to 7,@@ 46 % ) compared to a reduction of 0.@@ 14 % in ins@@ ulin defici@@ ency .
for adults with type 2 diabetes , the reduction of H@@ b@@ A@@ 1@@ c concentration 0.0@@ 46 % after six months with A@@ pi@@ dra was compared to 0.@@ 30 % at the norm .
A@@ pi@@ dra is not applied to patients who may suffer in@@ sensitive ( allergi@@ c ) against ins@@ ulin lu@@ li@@ ine or one of the other ingredients , or in patients who suffer from a hypo@@ vol@@ emia .
the cans of A@@ pi@@ dra can possibly be adjusted if it is administ@@ ered together with a number of other drugs that can affect blood glu@@ cose levels .
&quot; &quot; &quot; in September 2004 the European Commission shared the &quot; &quot; &quot; &quot; San@@ of@@ i @-@ Av@@ enti@@ s Germany GmbH a permit for the transport of A@@ pi@@ dra in the entire European Union . &quot; &quot; &quot;
A@@ pi@@ dra is as a sub@@ cut@@ aneous injection either in the field of the abdominal belt , the th@@ igh@@ s or the del@@ ist@@ em@@ els or sub@@ cut@@ aneous by continuous in@@ fusion in the field of the abdom@@ en .
due to reduced glu@@ con@@ gen@@ esis capacity and decreased tox@@ oplas@@ tics , the ins@@ ulin needs to be reduced to patients with a limitation of the liver function .
any change of the active ingredient is ( normal , N@@ PH , z@@ ink@@ ed ) , etc . ) , the type of ins@@ ulin ( animal feed ) and / or the manufacturing method can cause a change of ins@@ ulin .
3 A in@@ adequate dosage or the decrease of a treatment , especially in patients with ins@@ ulin defici@@ ency , can lead to a hyper@@ gl@@ yc@@ emia and di@@ abe@@ tic K@@ eto@@ capac@@ itance .
the provision of a patient to other ins@@ ulin type or ins@@ ulin of a different manufacturer should be carried out under str@@ ingent dental supervision and can make a change of dosage required .
the point of the place of a hy@@ po@@ gl@@ yc@@ emia depends on the drug profile of the ins@@ ulin and can therefore change the treatment of the treatment .
to the substances that increase the blood sugar and the tendency to hypo@@ id ar@@ thritis , An@@ gi@@ ot@@ ens@@ in @-@ Conver@@ ting Enzy@@ me ( ACE ) -@@ inhib@@ itors , mon@@ o@@ amine oxi@@ di@@ ase ( MA@@ O ) -@@ inhib@@ itors , mon@@ o@@ amin @-@ oxi@@ di@@ ase ( MA@@ O ) -@@ Hem@@ mer , Pent@@ oxide , S@@ aliz@@ yl@@ ate , S@@ aliz@@ yl@@ ate and Sul@@ fa drugs .
in addition , under the effect of sympath@@ oly@@ sis , Cl@@ oni@@ din , Cl@@ oni@@ din , Gu@@ ane@@ thi@@ din and reserves the symptoms of ad@@ ren@@ al effects .
the experimental studies on re@@ productive studies showed no differences between In@@ su@@ - ling@@ lu@@ li@@ ine and Human@@ ins@@ ulin in terms of pregnancy , the embr@@ y@@ onic / fat development , birth and post@@ nat@@ al development ( see Section 5.3 ) .
it is not known whether ins@@ ulin lu@@ li@@ ine occurs in the human mother &apos;s milk , but in general , ins@@ ulin is neither in the mother &apos;s milk nor will it be res@@ umed for or@@ eb@@ ral application .
the name of clinical trials are listed in terms of clinical studies , group@@ ed after system organ@@ izer ( very often : ≥ 1 / 100 , &lt; 1 / 100 ; rare : ≥ 1 / 10,000 , &lt; 1 / 100 ; rare : ≥ 1 / 10,000 ; very rare : &lt; 1 / 10,000 ) ;
cold - silent , cool and so@@ othing skin , ti@@ red@@ ness , nerv@@ ousness , or tre@@ ach@@ er@@ ous , anxiety , concentration , concentration , concentration of tend@@ ons , head@@ aches , exercise regim@@ ent and heart kno@@ bs .
Li@@ pod@@ yst@@ rop@@ hi@@ e Does Not to change the inj@@ ections within the injection system , it may occur in a result of a Li@@ pod@@ yst@@ rop@@ hi@@ e to the inj@@ ector .
heavy hy@@ po@@ is@@ ex works with consciousness can be treated using an intra@@ mus@@ cular or sub@@ cut@@ aneous injection of glu@@ cose ( 0.5 to 1 mg ) that can be treated by a doctor or intra@@ ven@@ ous gift of glu@@ cose through a doctor .
after a glu@@ cos@@ ity object , the patient should be monitored to a hospital to determine the ur@@ - cause for serious hy@@ po@@ gl@@ yc@@ emia and to avoid unwanted effects .
ins@@ ulin lowers the blood glu@@ cose level ( especially through sk@@ el@@ iness and fat ) as well as inhib@@ itor of glu@@ cose production in the liver .
studies with healthy volunteers and patients with diabetes have shown that at a sub@@ cut@@ aneous ga@@ stro of ins@@ ulin lu@@ li@@ ine of the efficiency is shorter and the active ingredients are shorter than at the hu@@ - man@@ em normal functioning .
in a study with 18 male individuals aged 21 to 50 years , ins@@ ulin lu@@ li@@ ine showed ins@@ ulin lu@@ li@@ ine in the therapeutic dosage of 0.@@ 0@@ 75 to 0.@@ 15 E / kg , the glu@@ cose effect of glu@@ cose effect , and at 0.3 E / kg or more a disp@@ rop@@ or@@ tion@@ ate effect of glu@@ cose effect , exactly like Human@@ ic ulin .
ins@@ ulin lu@@ li@@ ine has a double high efficiency , such as norm@@ ales in@@ ulin and achieved the full glu@@ cose effect on about 2 hours earlier than Human@@ ic ulin .
data coverage : market sizes ( historic and forecasts ) , company shares , brand shares and distribution data . why buy this report ?
ins@@ ulin lu@@ li@@ ine 2 minutes ahead of the meal &apos;s meal was achieved a better post@@ erior control than with human@@ ly normal , the 2 minutes before the meal was achieved .
is ins@@ ulin lu@@ li@@ ine 15 minutes after the beginning of the meal , a comparable gem control like in human@@ ly normal , the 2 Mi@@ - n@@ age before the meal ( see Figure 1 ) , reached .
ins@@ ulin lu@@ li@@ ine at the beginning of the meal compared to human@@ ly normal , the 30 minutes ( NOR@@ MAL - 30 min ) before the start of the meal ( Fig@@ 1A - 30 min ) before the start of the meal ( Figure 1A ) was given before a meal ( Figure 1@@ B ) in the beginning of the meal ( Figure 1@@ B ) .
ins@@ ulin lu@@ li@@ ine at the beginning of the meal in comparison to human Nor@@ - mal@@ ins@@ ulin , 2 minutes ( NOR@@ MAL - before ) before the start of the meal ( Figure 1@@ C ) before the beginning of the meal ( Figure 1@@ C ) .
